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Abstract 
 
Enteric pathogens form a large part of infectious diseases which contribute to a bulk of the healthcare 
costs. Enteric infections are usually contracted via the faecal-oral route or through contact with 
contaminated surfaces. Treatment by antibiotics is becoming increasingly ineffective due to the 
growing number of antibiotic resistant strains. Anti-microbial resistance poses a serious threat to the 
future of healthcare worldwide and necessitates the search for alternate forms of therapy. 
Bacteriophages (phages), are viruses which specifically infect and lyse bacteria. To introduce phages 
as a viable form of therapy, route of administration needs to be considered carefully. Model phages 
with broad host ranges are ideal for therapy however oral delivery to the lower gastro-intestinal (GI) 
poses several challenges. The acidic stomach environment can be detrimental to phages, rendering 
them inactive during passage. To overcome this challenge and improve the stability of phage during 
encapsulation and storage, this PhD research has been conducted. pH responsive polymers, Eudragit 
and alginate were used to develop composite microparticles which protected phage from acidic pH 
(pH 1-3). A novel method of acidifying oil was developed for crosslinking droplets in vitro to avoid the 
use of harsh solvent systems that can cause phage inactivation. Platform microfluidic technology was 
employed for phage encapsulation for the first time. Monodispersed droplets and particles were 
produced, offering fine-tuning of droplet diameter to tailor the release and pH protection of 
encapsulated phage. Process scale-up was attempted using membrane emulsification (ME) to produce 
larger volumes of encapsulated phage. In vitro and in-situ models investigated the efficacy of 
encapsulated phage-bacterial killing. Industrial scale method of spray drying, and electrospinning 
were also used to demonstrate the versatility of the formulation. Tableting dry powder phage, showed 
an effective method for producing solid dosage forms for therapy. Additionally, electrospun phage 
fibres also showed the potential use of pH responsive formulations in addressing wound infections. 
Improvement in encapsulated phage storage stability was observed with the addition of trehalose in 
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the formulation. This research underpins the need for testing phage encapsulation for site-specific 
delivery and offers insight into the potential use of commercially available technologies.  
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Chapter 1: Introduction  
 
Research exploiting bacteriophages (phages) which are viruses that infect bacteria, as alternatives to 
antibiotics has risen in the past decade as the use of antibiotics as a conventional method to treat 
infectious diseases has reached a plateau with increased antibiotic resistance. Pathogens associated 
with enteric infections and diseases have all been reported to develop some degree of antibiotic 
resistance (Holmes et al., 2016). Phage are self-amplifying and specifically lyse their host bacterial 
strains without harming the natural gut flora. Unlike antibiotics, phages can target bacteria by 
penetrating through biofilms and attack strains which have evolved antibiotic resistance. Combining 
phage and antibiotics may be an effective treatment for infection (Lu & Koeris, 2011). Phages are 
largely composed of nuclei acids  occur naturally rendering them relatively low in toxicity (Loc-Carrillo 
& Abedon, 2011). Phages being the next generation for treatment (Housby & Mann, 2009) it is 
important to address their site specific delivery in order for the phages to work at their optimum.  
 
Studies have already been undertaken to encapsulate drugs and other active agents for colon targeted 
delivery. The significance of this lies in the complex and harsh environment instigated by the gastro-
intestinal tract. The ability of the GI tract acid and enzymes to inactivate microbes and chemical agents 
reduces the ability of the active agent to reach the site of infection and provide curative processes 
(McConnell et al., 2008). With this in mind many methods have been developed and are commercially 
used for encapsulating drugs and active agents to improve their viability (Amidon et al., 2015). As well 
the healthcare industry, encapsulation for controlled release is also an important part of the food, 
cosmetic and pharmaceutical industries.  
 
Control over size of microparticles has been a highlight in the encapsulation discipline and has 
encouraged the diversity in the techniques for production of these products. The properties of the 
active agent such as its water solubility, chemical topology etc. poses a challenge in encapsulation 
process. Modifications and variation in encapsulation techniques serve to improve the stability, safety 
and controlled release of the encapsulated agent (S. Zhang et al., 2011). In addition to that the 
uniformity of droplets on a micro or nano scale has also led improvements and development in the 
methods for product production.  
 
So far, phage encapsulation has not been investigated extensively, limited studies on encapsulation 
discuss techniques and formulations (Colom et al., 2017b; Dini et al., 2012; S. S. Y. Leung et al., 2016; 
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S. S. Y. Leung et al., 2017; Yongsheng Ma et al., 2008, 2012; Stanford et al., 2010b; Tang et al., 2013; 
Tang et al., 2015). Phage encapsulation for enteric delivery specifically, poses challenges, especially 
since the acidic environment of the stomach can render many phages inactive (Yongsheng Ma et al., 
2008, 2012; Stanford et al., 2010b). This impacts the dose of the phage delivered to the site of infection, 
which is crucial in arresting bacterial growth. 
 
Modern techniques such as microfluidics are platform technologies for the development of novel 
formulations and applications. Precision control over process parameters provide a useful tool when 
developing encapsulated biologics. Versatility of polymers such as Eudragit can be tested on different 
techniques including membrane emulsification which offers a useful platform for scaling up 
microfluidic formulations. Spray drying, and electrospinning are both contrasting techniques which 
may be employed to test polymer applications in hosting phages for therapy further. 
 
Aims and Objectives 
 
This report will look at different methods and techniques available for microencapsulation of phages, 
with emphasis on improving stability of phages. It will assess the various parameters that contribute 
to successful encapsulation of phages. An optimised encapsulation formulation will be developed, 
which will protect the phages against changes in gastrointestinal pH. Encapsulation will be optimised 
to produce uniform sized droplets and particles using a glass capillary microfluidic device. The process 
will then be translated to a commercially available microfluidic chip pushing the boundaries of the 
formulation. This will then be upscaled for bulk production using membrane emulsification technology 
once again investigating the optimising process parameters. In contrast, dry powder phage will be 
produced using spray drying to demonstrate the efficacy of the formulation. The formulation will be 
further probed by producing encapsulated phage in electrospun fibres for wound dressing application. 
 
This research will aim to formulate and develop a viable encapsulation system intended to delivery 
bacteriophages to the colon. The components for encapsulation will be studied to produce a robust 
shell to protect the bacteriophage from hostile environments. The formulation for encapsulation will 
be subjected to a technique for producing monodispersed droplets and particles which enable control 
over release kinetics. Downstream processes (after encapsulation) will be used to confirm the 
efficiency of the encapsulation system.  
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To synthesise microparticles a glass microfluidic device with two different geometrical variations will 
be used. This will enable the study of size of variation of droplets and particles with its subsequent 
effect on encapsulation efficiency. The performance of the flow-focussing microfluidic device will be 
observed in its ability to produce microparticles and determine the optimum device conditions for 
microparticle synthesis. This technique will be studied for its ability as a proficient system to produce 
microdroplets/particles. Mathematical analysis will determine the amount of phage captured in each 
particle.  
 
The effect of each element of the emulsion on the viability of bacteriophage will be carried out. 
Survival of the bacteriophage in each of the encapsulation elements will determine the suitability of 
the polymer to encapsulate the bacteriophage adequately. The bacteriophage survival will be 
observed over a period and reduction in titre recorded. With statistical analysis, it will be possible to 
conclude the suitability of the system before it is run via microfluidic device to produce droplets and 
particles.  
 
Stability of the microfluidic device on producing monodispersed droplets over an extended period will 
be studied. Droplet size analysis over the period of 6 hours of droplet production will be analysed to 
determined coefficient of variance. This analysis will determine the stability and robustness of the 
device over a period. Droplet to particle transition will be observed by processing particles through 
isolation, rinsing and drying. SEM analysis will be used to study the morphology of the particles. The 
process will be replicated in a commercial chip, with a different geometry. Probing the formulation to 
push the efficacy of encapsulation and protection against SGF will be investigated. Impact of particle 
size on acid protection will be examined. 
 
The process will be up-scaled using membrane emulsification technology, highlighting the challenges 
encountered during scale-up. The process parameters will be studied and optimised to produced 
particles encapsulating phage providing SGF protection. Efficacy of the formulation will be further 
probed by using conventional spray drying method to produce dry powder encapsulated phage. Here, 
emphasis will be on the long-term storage stability of phage under different conditions. Further 
investigation into the production of tablets from dry powder will be studied. The ability of these 
tablets to conform to pharmaceutical standards will be examined. To further investigate the 
formulation, electrospinning phage into fibres will be performed to produce a novel matt of fibres for 
wound dressing applications.  
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Multiple phages with varying hosts will be studied in the encapsulation system to conclude the 
suitability of the formulation and production. This will confirm the novel approach to producing 
microparticles containing phages produced via multiple devices. Downstream processes will be 
improved for better retention and purification of product. Modification to the formulation and the 
geometry will be analysed for enhancing production rate, stability and efficiency of the microparticles.  
 
Particles will be exposed to simulated gastric and intestinal fluids to observe the release of 
bacteriophages over a period of 6 hours. The particles will be analysed for their ability to protect and 
deliver the bacteriophage to a pH simulated colon environment. Differences in phage titre will 
represent the survival of phage in each simulated environment. The ability of release phages on 
arresting bacterial growth will also be analysed to determine the efficacy of the encapsulation. Further 
analysis will involve in-situ experiments to observe the three-way interaction of phage infection 
(released from a particle) of C. difficile in the presence of human epithelial cells.   
Research Novelty 
 
Microfluidics has been used extensively over the past few decades to produce emulsion droplets and 
has been exploited for lab-on-chip research. There have been studies into using microfluidics for 
discovery and drug delivery however the use of microfluidics for bacteriophage encapsulation has 
never been exploited before. Encapsulation of bacteriophage has been studied very little; literature 
search has revealed only a handful of studies into the formulation for encapsulation and the use of 
spray drying as a method for producing particles encapsulating phage. There is a lot of research that 
is still required in this field due to the promise of using phages as alternative therapeutics.  
 
There are also no reports of phage encapsulation where scale-up, on a commercial scale has been 
reported. Here, up-scaling the phage encapsulation process has been investigated for the first time. 
Spray drying of phage in sugars has previously been reported with only one paper showing the use of 
polymer for site specific delivery. This project reports the encapsulation of phage in a pH responsive 
polymer using spray drying with subsequent tableting for the first time. Electrospinning phage in 
nanofibers has also been reported however, this work shows a novel formulation for the production 
nano and micro fibres carrying phage with a pH triggered release.  
 
Overall, this study provides a one-stop platform exploiting the use of multiple technologies for phage 
encapsulation. Advantages and limitations are addressed for phage encapsulation and impact on 
stability. A further emphasis on the use of encapsulated phage in situ is also addressed providing useful 
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insight into the efficiency of the system. Phage encapsulation processes have been optimised with the 
importance of dosage and site-specific delivery in mind. Work has been performed in different phages 
against various pathogens to show the transferable nature of the encapsulation process.  
 
The novel formulation and approaches taken for phage encapsulation fill many gaps in literature such 
as the need for sufficient acid protection from pH 2. This work is one of the first to provide a useful 
insight into the little explored world of phage application for therapy. This work provides a starting 
point for exploring avenues and pushing boundaries for phage encapsulation.  
Thesis structure 
 
Chapter 1 Introduction. The first chapter of the thesis explains the overall aims and objectives of the 
research. It includes discussing and reasoning the use of multiple techniques for phage encapsulation. 
It further elaborates on the research novelty and purpose.  
 
Chapter 2 Literature review. Discusses the problem of enteric infections and associated pathogens. 
Introduction to phage, properties, life cycle and their potential as alternative form of therapy is given. 
A literature review on the different encapsulation technologies present and their mode of action in 
producing encapsulated active agents is included. Focussing on their potential use for phage 
encapsulation and possible advantages and shortfalls. A further insight into the pH of human 
gastrointestinal tract, and potential polymers for phage encapsulation is discussed.  
 
Chapter 3 Clostridium difficile specific bacteriophage encapsulation using microfluidic glass capillary 
devices for colon delivery. Introduces the use of in-house made glass microcapillary device for 
producing tuneable microparticles carrying C. difficile phage CDKM9. Developing a formulation with 
phage CDKM9 that causes minimal impact on phage viability for a stimulus triggered function and 
protection against stomach acid pH 2  
 
Chapter 4 Microfluidic encapsulation of bacteriophages in a commercial chip with high precision 
control. The use of commercial microfluidic chips to produce high precision phage encapsulated 
particles with focus on process parameters, acid protection at pH 1, arresting bacterial growth and 
storage stability.  
 
Chapter 5 Scaling-up bacteriophage microencapsulation using membrane emulsification technology 
in a pH responsive polymer. Purposing the use membrane emulsification technology to scale up the 
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process of phage encapsulation. Investigating the influence of experimental parameters on the 
production of microparticles. Following the stability of encapsulated phage and analysing the three-
way interaction of phage, bacteria and mammalian cells.  
 
Chapter 6 Microencapsulation of Felix O1 in pH responsive polymers using spray drying for tableting 
and improved storage. Demonstrating the use of a well-established technique; spray drying for phage 
encapsulation. Using Eudragit and trehalose to produce pH responsive dry powder particles. 
Producing tablets from powder for ease of use, storage and manufacture. Investigating the storage 
stability in powder and tablet form under different conditions.  
 
Chapter 7 Electrospun pH responsive nano and micro fibres for bacteriophage encapsulation. 
Demonstrating the versatility of Eudragit in delivering phage at site of infection by electrospinning in 
fibres ranging from nano to micron size. Showing a novel technique to produce phage encapsulated 
fibres to be used for wound dressing or oral delivery.  
 
Chapter 8 Overall conclusion of the research carried out in each chapter. Focussing on the key findings 
and its impact on phage research to the scientific community. Recommendations and plans for future 
work is discussed. 
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Chapter 2: Literature review 
 
2.1 Enteric pathogens 
 
Gastrointestinal infection is an umbrella term covering various pathogen related to illnesses starting 
from the stomach all the way to the colon. This covers infections caused through food poisoning, poor 
hygiene related transmission and opportunistic pathogens (Wikswo et al., 2015). Due to the vast array 
of bacterial species involved, it is difficult to target just one since all pathogens have shown anti-
microbial resistance which poses a serious healthcare challenge. Some clinically relevant pathogens 
that cause gastrointestinal infections include: Clostridium difficile, Clostridium perfringens, 
Helicobacter pylori, Bacillus cereus, Yersinia, Salmonella spp., Staphylococcus spp (Wikswo et al., 2015).  
Mechanism of action and transmission of infections differs for each pathogen and usually are 
indicative of the possible route of transmission. A key symptom common for all gastrointestinal 
infections is the onset of diarrhoea, which may be short lived or in severe cases lead to dysentery 
(Viswanathan et al., 2009). Usually pathogens related to food contamination can follow one of two 
routes in being ingested, one, high dose of the microbial agent is taken in with food or secondly, the 
toxins are produced in the food prior to ingestion. Once the contaminated food is ingested, damage 
to the lining of gastrointestinal tract begins leading to the onset of symptoms (Wikswo et al., 2015).  
Poor hygiene when handling food can increase risk of contamination, which includes poor hand 
washing practice and non-sanitised work surfaces. Awareness about heating food is a crucial factor, 
cooked foods are recommended to be heated to 60°C and raw meats should be heated at much higher 
temperatures to avoid growth of bacteria and toxins. Staphylococcus aureus food poisoning occurs 
due to malpractice of food handling, which leads to S. aureus producing enterotoxins which are then 
ingested via food. There are up to 21 enterotoxins associated with Staphylococcus known to cause 
food poisoning (Loir Yves Le, 2003). These toxins are pH and heat resistant proteins which can survive 
the acidic stomach conditions and remain stable under heat as high as 100°C. Therefore, despite the 
bacteria being destroyed, the enterotoxins can still cause vomiting and diarrhoea (Loir Yves Le, 2003).  
Similarly, Shigella a rod-shaped, Gram Negative bacterium also causes gastrointestinal infection 
resulting in bacillary dysentery and shigellosis. Transmission can be from contaminated food and 
water but most commonly through the faecal-oral route. Once ingested the bacteria invades the 
epithelial cells and resides in the cytoplasm of cells by entering through phagosomes. As the bacterium 
multiplies and spreads throughout the Peyer’s patch, the epithelium of M cells (immune-modulatory 
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cells) becomes ulcerated leading to the onset of symptoms such as stomach cramps, fever and 
diarrhoea (Niyogi, 2005). Shiga toxin produced by S. dysenteriae type 1 invades endothelial cells of the 
small blood vessels of the small intestine by binding to glycosphingolipid. Here, cell functions are 
interrupted due to the toxin binding to the large ribosomal subunit responsible for protein synthesis 
leading to haemorrhaging and lesions in the colon. Treatment of severe cases requires the use of 
antibiotics such as ciprofloxacin and azithromycin, however due to high incidence of resistance use of 
these antibiotics needs to be carefully considered (Niyogi, 2005).  
Salmonellosis known as Salmonella gastroenteritis is caused by the rod-shaped, Gram Negative 
bacterium Salmonella. Although several species are associated with infection most common to cause 
infection in humans is S. enterica and more specifically serotypes (subgroups) Enteritidis and Typhi. 
Salmonella is part of poultry’s microbiota, therefore handling raw eggs and poultry increases the risk 
and spread of the infection. Salmonella is also part of intestinal microflora in some individuals, so 
infections depends on factors such as host health, dose and type of inoculum. Infection is easily 
preventable by handwashing and maintaining good hygiene practice when handling food. Like Shigella, 
once ingested hypersecretion and elicitation of inflammatory processes is triggered by evasion 
through M cells in the epithelial mucosa. Intoxication may also occur because of some Salmonella 
strains producing enterotoxin inside the body (Velge et al., 2012). Although the symptoms such as 
fever, nausea cramps and vomiting usually subside after a few days or with the help of oral rehydration 
therapy, in more severe cases antibiotics are prescribed. Some antibiotics used for treatment include: 
fluoroquinolones, cephalosporins and ampicillin, but reports are emerging Salmonella has developed 
resistance against these front-line antibiotics (WHO, 2014). 
Typhoid fever associated with S. typhimurium is a more serious form of salmonellosis, causing 
mortality in up to 10% of cases. Infected individuals shed S. typhi through their faeces and precautions 
need to be taken to avoid infecting others, especially during the use of antibiotic treatment with 
fluoroquinolones, ceftriaxone, and azithromycin (WHO, 2014). Mortality occurs due to perforation 
and ulceration of the intestine, which is brought on by infected macrophages lysing and releasing the 
bacteria into the bloodstream and lymphatic system (Gal-Mor, Boyle, & Grassl, 2014). Pneumonia and 
jaundice are commonly observed during dissemination of the disease.  
Gastrointestinal infections can also be caused by strains of Escherichia coli although it is also a 
commensal bacterium. Pathogenic E. coli strains carry virulence factors, such as type 1 fimbriae which 
promotes colonization of the colon and produces toxins. Strains acquire their virulence factors 
through horizontal gene transfer, four of six pathogenic strains are transmitted via food and water. 
Enterotoxigenic E. coli (ETEC) is known to cause travellers’ diarrhoea, commonly related to travel to 
9 
 
less developed countries. ETEC produces enterotoxin which may be heat labile and adhesins which 
help the bacteria attack the intestinal wall (Nataro & Kaper, 1998). Enteroinvasive E. coli (EIEC) shows 
similar pathogenesis to shigellosis due to its intracellular invasion of intestinal epithelial tissue (Van 
Den Beld & Reubsaet, 2012). Enteropathogenic E. coli (EPEC) causes life-threatening diarrhoea leading 
to severe dehydration, especially in infants and in less developed countries. Mode of action is through 
the injection of Tir protein which attaches to the surface of the intestinal epithelial cells and triggers 
rearrangement of host cell actin from microvilli to pedestals (Nataro & Kaper, 1998). 
Enterohemorrhagic E. coli (EHEC) is by far the most dangerous of the E. coli strains as it can cause 
epidemics. Several outbreaks have been reported due to the epidemic strain O157:H7, where the O 
and H stand for the antigens that contribute to the pathogenicity (Nataro & Kaper, 1998). Like EPEC 
and EHEC this strain causes the formation of pedestals in the mucosal lining and produces a shigella 
like toxin. Severe cases display symptoms leading to haemorrhagic colitis and profuse bleeding. 
A serious gastrointestinal disease associated with contaminated water and food can be elicited by 
Vibrio cholera. It is a Gram Negative, flagellated curved rod-shaped bacteria sensitive to stomach acid 
therefore high bacterial concentrations (~109 CFU/ml) are required to establish infection. Once the 
bacteria enter the intestine due to their motility there can travel between the mucosal layer and 
attach to epithelial cells to release cholera enterotoxin. Changes to the adenylate cyclase results in 
cAMP levels rising, which activates the chloride channels, releasing ions into the intestinal lumen, 
causing the influx of ions into the intestinal lumen. Water enters the lumen from the osmotic pressure, 
resulting in water and electrolytes being depleted from the body bringing the onset of dehydration 
and electrolyte imbalance (Viswanathan et al., 2009). In severe, disseminated disease tetracyclines 
are recommended but other antibiotics may also be used. Prevention of disease is usually through 
good sanitation practice, since the bacteria are killed by heat, proper heating of food and water is 
important.  
Campylobacter jejuni a Gram Negative, spiral shaped bacterium causes gastroenteritis. It is contracted 
from poultry which becomes contaminated during slaughter (Connerton et al., 2011) or through 
unpasteurised milk and contaminated water are other potential routes of transmission. Amongst 
other pathogenic bacteria similar symptomatic profile is observed and treatment of severe cases 
usually require administration of antibiotics.  
Clostridium difficile (CD) is a gram positive bacterium first isolated in 1935 from normal intestinal flora 
of neonates by Hall and O’Toole (Ananthakrishnan, 2011). It has been associated with hospital 
acquired infections throughout Europe and America (Heinlen et al., 2011). It is accountable for 15 % 
to 25% of C. difficile-associated diarrhoea (CDAD) sometimes also referred to as toxin mediated 
10 
 
diarrhoea, one of the leading causes of infectious diarrhoea. Onset of clinical symptoms occur after 
24 hours to 72 hours include fever, abdominal pain and leucocytosis (Ramesh et al., 1999).  
There is a risk of Clostridium difficile infection (CDI) accompanying antibiotic treatment. However, it 
can also be transmitted via the faecal-oral route in areas with poor hygiene practices. Poor hygiene in 
healthcare has triggered many outbreaks of CDI epidemics. Studies show the ratio of hospitalised 
patients with CD colonisation is higher compared to healthy adults. However, more recently, 
community acquired CD infection is also becoming of concern. With rise in community acquired CDI it 
is likely that an increase in hospital CDI cases is imminent (Heinlen et al., 2011).  
CD is an obligate anaerobe and in unfavourable conditions (i.e. nutrient deprivation) forms spores. CD 
spores are thick walled resting cells and can remain viable on inanimate surfaces for up to five months 
(Ananthakrishnan 2011). Precautions in hospitals such as alcohol hand rubs are ineffective at killing 
spores. Therefore, hospitalisation can bring the onset of CDI in patients where the ingested spores 
germinate into vegetative cells, causing infection (Meader et al., 2010). 
During infection CD colonises in the colon where it can actively grow in its vegetative form. Antibiotic 
associated CDI results from changes in gut micro-flora due to antibiotics depleting the microflora and 
suppressing the immune response against CDI (Burke & Lamont, 2014). As a result, opportunistic CD 
can colonise the colon causing CDI and CDAD. The natural microflora of the gut forms a barrier against 
CD colonisation in healthy conditions. 30 % of antibiotic associated diarrhoea cases are linked to C. 
difficile (Lyerly et al., 1988). Highest risk of CDI is amongst patients over the age of 65 years, who have 
been recently exposed to antibiotics. CD is also found asymptomatically in up to 15 % of the adult 
population. Colonisation in infants is more common and is present at a rate of approximately 35 % 
falling to 15 % after the 1st year of life (Eyre et al., 2013). Non-healthcare related cases are also coming 
forward which includes individuals who are suffering from inflammatory bowel disease, children and 
pregnant women (Ananthakrishnan, 2011). 
For the above-mentioned pathogens of the gastrointestinal tract and many more, antimicrobial 
resistance is increasingly being reported (WHO, 2014). Many infections are cleared by the body’s 
immune system, in other cases antibiotics are required to prevent further spread and damage. It is 
due to the complexity of the infection that sometimes antibiotics are unable to fully clear the bacteria, 
giving bacteria the opportunity for evolving resistance mechanisms. In other cases, resistance genes 
are transferred through horizontal gene transfer, equipping pathogens before exposure to 
antimicrobials. Full reviews on mechanisms and intervention of antimicrobial resistance is discussed 
in detail by Roca et al., (2015); Holmes et al., (2016). 
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2.2 Bacteriophages 
 
Antibiotic resistance is causing a major concern in healthcare. With a rise in the number of antibiotic 
resistant pathogens, development of new therapeutics is of utmost importance. The rate at which 
pathogens develop resistance is also on the rise. The mechanisms that aid this process include; 
interconnected travel, overuse of antibiotics, non-compliance, transduction of genes and bacterial 
evolution. The development of new antibiotics is challenging and currently does not look promising in 
terms of supply of new classes of antibiotics. Therefore, in the arms race against antibiotic resistance 
and development of new therapeutics, bacteriophages have once again become an area of interest 
(Lu & Koeris, 2011). Phages are abundant in the natural environment usually found close the source 
of host. They were first discovered in 1915 by Frederick Twort and Félix D’Hérelle in 1917. They were 
used as therapeutics shortly after, however, were soon swept away by the introduction of antibiotics 
after World War II (Alisky et al. 1998; Nobrega et al. 2015). Phage research has been continuing since 
their discovery in Eastern Europe particularly at the Eliava Institute of Bacteriophage, Microbiology 
and Virology, Georgia since 1923 (Merril et al., 2003). 
A $25 billion a year antibiotic industry by far over shadows the advancement of phage therapy which 
was the reason for ceasing research into phage therapy in France in 1970 (Merril et al., 2003). Lack of 
knowledge about phages, their efficacy and pharmacokinetics have been the reasons why phages 
were not considered fit for therapeutic use. Side effects from using phages in previous studies led to 
failures during clinical trials, mainly due to the lack of knowledge on purifying phages (Housby & Mann, 
2009). Method to purify phages such as chromatography have been developed (Adriaenssens et al., 
2012) although large pharmaceutical companies are still reluctant to invest in phage therapy research. 
This is largely due to the struggle of gaining intellectual property rights for phage products (Nobrega 
et al., 2015). 
Developing new antibiotics against pathogenic bacteria may be ineffective as the process can take up 
to ten years or more and resistance may still develop (Centres for Disease Control and Prevention 
2013). Nevertheless, alternative antibiotics are being investigated and the research into phage 
therapy has also risen. 
Bacteriophages have been functional in nonclinical applications. Phage mixtures are applied to food 
products to reduce the number of potentially harmful bacteria that can result in food associated 
infections. Some of these have also passed FDA approval in the USA and are sold commerically 
(Abuladze et al., 2008). Phages have also been used to detect bacterial infections as diagnostics, such 
as Methicillin-resistant Staphyloccocus aureus is detected by an infection of phage in the blood culture 
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test (Hagens & Loessner, 2007). These approved applications show the potential use of phages as 
therapeutics and diagnostics.  
Many animal models have effectively shown the positive attributes of phages being able to clear their 
target bacteria, minimal disruption of normal flora and no side-effects. For example an hamster model 
study showed phage therapy prevented CD induced iliocecitis (Ramesh et al., 1999). There are many 
advantages of phage therapy. Phages are highly specific and have narrow host ranges. This allows 
specific targeting of the pathogen producing an infection. Infections of the colon and rectum where 
the microflora is under the threat of elimination by antibiotics can easily be targeted whilst keeping 
natural flora intact. The self-replicating process of phages after infection of the suitable host is ideal 
when targeting a population with a specific dose. The phage replication will be amplified in relation to 
the amount of host present. An inflamed colon during infection can process and eliminate consumed 
substance at a faster rate. This results in lower bioavailability of drugs; therefore ability of the phage 
to replicate rapidly is a great advantage in this scenario (Rea et al., 2013).  
Phages unlike drugs are non-toxic and are unable to attack mammalian cells or tissue. As a result, 
there is minimal tissue damage and inflammation is significantly low. Studies have shown the use of 
phage therapy in controlling Psuedomonas aeruginosa infection in a mouse model. P. aeruginosa 
associated with the condition cystic fibrosis causes many hurdles in treatment with antibiotics due to 
the development of a biofilm. However, Alemayehu and colleagues have demonstrated that 
administration of a phage combination significantly reduced bacterial numbers by 4-log10 and phages 
could penetrate through the biofilm (Debebe Alemayehu et al., 2012; Rea et al., 2013) 
Nevertheless, like any therapeutic option there are challenges associated with phage therapy. 
Resistance is the key issue when it comes to antibiotics and similarly, bacteria are able to evolve and 
alter their surface receptors specific for phage binding and render them ineffective. Sulakvelidze and 
Alavidze (2001) showed bacteria that developed resistance to the phage initially administered were 
retargeted by a different phage able to infect the bacteria. They found overall 92% of the treatments 
showed success. This study showed that although the bacteria were able to develop resistance they 
could be targeted using a different phage (Sulakvelidze and Alavidze 2001). One way to move forward 
from this knowledge is to target bacteria with a mixture of phages and subsequently increase the host 
range of the phages used. Alternatively, phage screening to isolate a phage with the most extensive 
host range may also be beneficial (Tiwari et al 2014) 
Alternatively, Betts et al., (2013) and colleagues have demonstrated the concept of phage evolution 
with increased effectiveness against the host. Psuedomonas aeruginosa strain PAO1 resistant to the 
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phages in study was effectively infected and killed by evolved phages. Through continuous passage 
(adding to exponentially growing host) of phages varying from one to six rounds (Betts et al., 2013) 
and colleagues were able to demonstrate the effect of evolution on increasing host range and impact 
on host population. The findings in this study show a potential alternative to counteract phage 
resistance in addition to isolating new phages with wider host ranges.   
2.2.1 Bacteriophage life cycle 
 
There are two types of life cycles a phage can undergo; lytic and lysogenic cycle (Figure 2.2.1). Phages 
approach and adsorb onto a bacterium cell wall where they attach using phage receptors. Lytic phages 
inject their DNA into the host and hijack the bacterial metabolism. The bacterial machinery is 
manipulated by the phage DNA to produce more phage progeny. As result of producing more phage, 
the bacterial cell metabolism comes to a halt rendering the bacteria weak. Phage progeny disrupt and 
break the bacterial cell wall to release mature phage into the surrounding environment which goes on 
to infect more bacterial cells (Campbell et al., 2006). Lysogenic (temperate) phages also attach and 
adsorb on bacterial cell walls injecting their DNA. They can initiate the lytic cycle but can also integrate 
their DNA into the bacterial genome (prophage) and exist as plasmids. As the bacterial cell replicates 
so does the incorporated prophage; causing the inheritance of phage DNA in all daughter cells 
(Sulakvelidze and Alavidze 2001; Merril et al. 2003). The prophage will remain dormant until certain 
conditions cause it to revert to the lytic cycle. Conditions that cause this change could be the bacterial 
state or the addition of antibiotics which causes the excision of prophage (J. Y. Nale et al., 2012).  
Lysogenic phages can integrate their DNA into the bacterial genome due to the presence of the 
integrase gene. Integrase enables the phage to catalyse site-specific integration allowing 
incorporation into the bacterial genome. This gene is not present in lytic phages (Fogg et al., 2014). To 
prevent integration the gene can be excised from the phage DNA to only allow for the lytic cycle to 
take place (Goh et al., 2007). This will enable the use of lysogenic phages in phage therapy as currently 
only lytic phages are researched in therapeutic use (Nobrega et al., 2015).  
One of the issues with using lysogenic phages for therapy is that they may carry bacterial virulence 
factors and antimicrobial-resistance genes which can be transferred via transduction (Nobrega et al., 
2015). An example of this is studied by Goh et al. (2013) where a CD phage ɸC2 transduced the 
antibiotic resistance gene against erythromycin. Other risk factors that phages can transduce include 
toxin genes such as the Shiga toxin gene stx. Echerichia coli strains that produce Shiga toxin is encoded 
by prophages (Imamovic & Muniesa, 2012).  
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2.2.2 Structure and classification of phages  
 
The structure of phages consists of an icosahedral head also known as the capsid, this protects the 
genome (nucleic acid) that can be in the form of RNA or DNA (Figure 2.2.2). The genome of phages 
can be single stranded RNA (ssRNA), double stranded RNA (dsRNA), ssDNA or in 90% of sequenced 
phages dsDNA. Visualisation of phages via transmission electron microscope (TEM) and properties of 
the nucleic acid has enabled the classification of phages (Clokie & Kropinski 2009; Monk et al. 2010).  
The structure of phages within one family is similar, however between families the tail length, phage 
size and genome length can vary between 24 nm to 400 nm and 18 kb to 400 kb respectively. 
Caudavirales comprise 96 % of the phage population and consist of tailed phages. This group is further 
phylogenetically divided into Siphoviridae, Myoviridae and Podoviridae. 61% of the tailed phages are 
Siphovridae, which are characterised by their non-contractile tails. Myoviridae comprise 25 % of the 
 
Figure 2.2.1 A schematic to show the steps in a phage infection cycle. Phages can follow the lytic cycle 
which leads to the lysis of bacterium or the lysogenic cycle where the phage DNA is incorporated in the 
bacterial genome. 
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population with contractile tails and Podoviridae characterised by their short non-contractile tails 
make 14 % of the population of tailed phages.  
The capsid is attached to the tail via an adaptor (Figure 2.2.2), which connects the capsid to the tail. It 
serves to pack dsDNA in the capsid and take part in release of DNA into the host upon detecting a 
signal from the tail. The DNA is delivered via the tail to the host cell after the tail fibres and needles 
have specifically bound to the corresponding bacterial receptor. The phage genome is released as the 
connector opens into the host cell (Ackermann 2009).  
Upon successful replication of phage inside the host cell, phage is released via bacterial cell lysis 
(Figure 2.2.1). Bacterial cell wall is lysed by the actions of holin which produces pores in the 
cytoplasmic membrane alongside endolysin, which produces hydrolytic enzymes that cleave bacterial 
cell wall (Schmelcher & Loessner, 2014).  
  
 
 
2.2.3 The need for phage encapsulation 
 
Phages are a protein and like all biologically active ingredients, is susceptible to environmental stresses. 
When considering its use for therapy, formulating the delivery of phage in its optimum form and 
dosage are important parameters. However, considering this it is imperative to identify and 
understand the possible stresses the phage is prone to and may be subjected to during delivery for 
Figure 2.2.2. Schematic to show the overall structure of a single phage. 
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therapy. In addition to that phage and bacterial population dynamics give useful insight into how 
phage can be utilised as a useful therapeutic tool to combat and minimise the problem of antimicrobial 
resistance.  
Lysis of bacteria by phage is dependent on the adsorption of phage virions to the surface of a their 
target bacterial cells (Cairns, Timms, Jansen, Connerton, & Payne, 2009). Phage amplifies in proportion 
to the concentration of the bacteria present, in a first order process. Several studies have modelled 
phage and bacterium kinetics during different stages of growth and concentration with consideration 
of the immune system also playing a part in eradicating infection (Levin & Bull, 2004; Malik et al., 2017; 
Payne & Jansen, 2001; Yasunori Tanji et al., 2005). These models are useful tools in helping determine 
the dose required, rate at which the phage is released at the site of infection, which can be pivotal 
factors in deciding whether infection can be eradicated before mutants emerge (Cairns et al., 2009). 
For high bacterial loads (109 CFU/ml), a high dose of phage shows an early arrest of bacterial 
population with no reappearance of bacterial growth (Malik et al., 2017; Yasunori Tanji et al., 2005).  
Efficacy of phage therapy is dependent on the phage dose and release rate. Therefore, to prevent loss 
of phage viability due to formulation, storage or through in vivo parameters (acid and digestive 
enzymes) is important for phage therapy. Furthermore, phage cocktails are thought to be a promising 
approach in combating infection and emergence of resistant mutants (Chang et al., 2017a; J. Nale et 
al., 2018). Tailoring formulations for each phage may be an option to maintain viability at its optimum.  
2.2.3.1 Environmental stresses and phage stability 
 
During phage formulation there are several parameters both mechanical and chemical, which can 
impact on the viability of a phage. Phages have previously been reported to be sensitive to organic 
solvents, temperature, pH and ionic concentration (Briers et al., 2008; Knezevic et al., 2011; S. W. Lee 
& Belcher, 2004; Puapermpoonsiri, Spencer, & van der Walle, 2009). Similarly, mechanical stress has 
also been reported to effect phage viability- during encapsulation the technique employed to capture 
the phage may use shear or agitation, which can physically render the phage inactive. A more popular 
technique for producing encapsulated phage; spray drying uses high temperatures, desiccation and 
atomisation a combination which has been reported to effect phage titre (S. S. Y. Leung et al., 2016; 
Tang et al., 2014). Electrospinning for example, uses current and solvents to produce nanofibers 
entrapping phages, both of which impact on the phage titre (R. Korehei & Kadla, 2013). To contest the 
effect of these stresses on phage viability, suitable excipient carriers or bulking agents need to be 
carefully considered for optimisation to minimise the loss of phage titre. 
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Another aspect that needs to be investigated when considering the use of phage for therapy, is the 
storage stability. Phages are generally propagated and stored (4°C) in growth media such as brain 
heart infusion (BHI) for short-term, and in 50 % glycerol at -80°C for long-term storage. Storage of dry 
powder containing phage is usually done by incorporating a sugar, such as trehalose and freeze drying 
the phage. Clark, (1962) found that freeze drying phage showed the highest loss of phage titre 
between 1-2-log during lyophilization but produced the most stable phage over a two-year storage 
period in comparison to storing phage in the fridge. All conditions investigated showed decline in 
phage titre after two years with storage in the fridge showing better results than storage at room 
temperature and in glycerol (Clark, 1962). 
A study by Knezevic et al., (2011) demonstrated the effect of external factors on four P. aeruginosa 
phages. The study found phages to be highly sensitive to pH 1.5 with complete loss of titre after 30 
mins, however at pH 7 they remained viable. All phage lost viability upon exposure to silver nitrate, 
other factors such as temperature and polysaccharides and rat serum were also examined for their 
effect on these phages. The results reveal that there are some similarities on phage responses (such 
as loss in titre upon acid exposure) to external factors, but differences were also observed (the degree 
of titre loss) indicating each phage may react differently to external environmental factors. This 
directly influences the formulation ingredients that may or may not be used for encapsulation of 
phages and need careful evaluation if encapsulating a cocktail of phages.  
 
2.2.4 Bacteriophages against enteric pathogens 
 
Phages are ideal for treating enteric infections due to their specificity as mentioned previously which 
will prevent disruption of the surrounding microbiota in the gut as seen with the use of antibiotics 
(Meader et al., 2013). For therapy, lytic phages are ideal to prevent phage entering the lysogenic cycle 
and remaining dormant inside the bacteria. Experimentally lytic phages can prevent the growth and 
colonisation of enteric bacteria. Therefore, phages have been approved by the FDA for their use on 
produce such as salads and leafy vegetables, where enteric bacteria may be present. Phages against 
E. coli O157:H7, Salmonella spp. and Listeria monocytogenes are shown to be effective in reducing 
bacterial loads in vegetables to prevent food poisoning (Sharma, 2013).  
To date, no lytic phages have been isolated for C. difficile however Ramesh et al., (1999) showed the 
use of temperate CD specific phages in vivo to treat hamster models with CDI induced by clindamycin. 
The results showed the clearance of infection and survival of 14 out of 18 hamsters given phage doses 
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in comparison to the control where all hamsters died.  Nale et al., (2016) also showed reduction in C. 
difficile carriage 36 hours post administration of phage in a hamster. Further delay in symptoms was 
also observed in comparison to control (J. Y. Nale et al., 2016). 
In other studies, artificial human colon and fermentation models have been employed to observe the 
effects of phages to treat CDI. Results show a promising decline in CD population with phage therapy 
(Meader et al., 2010, 2013).  Despite these promising results research on CD specific phages in therapy 
is challenging due to the need for anaerobic conditions for bacterial growth (Hargreaves & Clokie, 
2014). 
2.3 Encapsulation techniques 
 
In this section different encapsulation techniques currently used to encapsulate active agents are 
discussed. The review will focus mainly on colon targeted delivery and wound dressing applications. 
Examples included for each method are obtained from a literature search in the following order:  
>name of encapsulation method > microencapsulation >colon drug delivery. 
This review will provide an insight into the advantages and disadvantages of using each system for 
encapsulation of bacteriophages for colon delivery.  
The review is divided into different sections as described in Table 2.3.1. 
Table 2.3.1 Different encapsulation techniques 
Physio-chemical 
processes 
Physio-mechanical 
processes 
Coacervation Fluidized bed 
Solvent Evaporation Spinning disk 
Gelation Interfacial polymerisation 
Sol-gel 
Interfacial 
polycondensation 
Liposomes Spray Drying 
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 Microfluidics 
 Membrane Emulsification 
 Electrospinning 
  
2.3.1 Physio-chemical processes 
 
2.3.1.1 Coacervation and phase separation 
 
Coacervation is the separation of a mixture of one or two colloid liquids into two phases; one phase 
containing the coacervate (colloid particles electrostatically held together) and the second phase 
consisting of an aqueous solution. It is sometimes referred to as phase separation. Coacervation was 
the first industrially adapted method for microencapsulation and was reported by Bungenberg de Jong 
and Kruyt in 1929 (Jong, 1929). 
The process of coacervation is shown schematically in Figure 2.3.1 below. There are two types of 
coacervation methods, known as simple and complex coacervation. The process for 
microencapsulation in both methods is alike; the only difference is in the way the phase separation is 
carried out. Firstly, the material that will form the wall/coat is solubilized in a solution (a), (b) Figure 
2.3.1. Then an active agent (to be encapsulated) is suspended in the solution containing the previously 
dissolved wall forming material (c) Figure 2.3.1. The wall material is induced out of the solution at 
stage (d) Figure 2.3.1. This induction in simple coacervation is propagated by the addition of a 
desolvation agent such as acetone or ethanol. Once out of solution, the wall material adsorbs onto 
the droplets and is cross-linked (e) Figure 2.3.1 to form a coat around the active agent as 
demonstrated in (f) Figure 2.3.1.  
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In complex coacervation on the other hand, the polarity of two oppositely charged polymers in the 
Step (d) Figure 2.3.1 in complex coacervation is propagated by adding an oppositely charged polymer 
to that of the wall material. This difference results in charge-mediated induction of the wall material 
out of solution. Cross-linking of polymer in the last step is usually induced by altering properties that 
would render the polymer capable of forming chemical links between molecular chains. This is usually 
prepared by changing properties such as pH and salinity (Yin & Sto, 2003), solubility or adding cross-
linking agents such as formaldehyde (Y.-I. Huang et al., 2007). A classic example of this technique that 
has been exploited for many years is gum-arabic and gelatin. Positively charged gelatin (at pH <8) 
forms a complex coacervate when it is counterbalanced with negatively charged Gum Arabic. This 
system can be used for phage encapsulation since both gelatin and gum-arabic are derived from 
natural resources. Dispersing phage in gelatin which can form the wall material whilst the process of 
coacervation may initiated by guar gum which then further coats the microparticles leading to phage 
encapsulation. Another polymer combination that can employ coacervation for encapsulation is 
Figure 2.3.15 Schematic representation of the steps in the coacervation process. (a) The wall material 
is added to an aqueous solution. (b) Heat is applied to dissolve the wall material. (c) The active 
ingredient is suspended in the solution and stirred at a rate that produces the required droplet size. 
(d) The suspended wall material is induced to come out of solution by adding a desolvation agent. (e) 
The wall material adsorbs on the surface of droplets and (f) crosslinks to form a shell around the active 
ingredient. 
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alginate and chitosan, both are oppositely charged essential for the formation of microparticles (Y.-I. 
Huang et al., 2007). 
Particle sizes using coacervation technique range from 2-1200 µm (Ghosh, 2006) although smaller size 
particles have been reported. Coacervation is a highly conventional method however; the importance 
of oppositely charged phases can limit the use of the system for applications involving non-charged 
substances such as an uncharged polymer. The system requires a specific formulation without which 
the formation of microspheres is challenging. It is also limited to the application of external stimulus 
(heat, pH etc.) for specific stages for the coacervation to progress. The size of droplets is also 
dependent on the agitation rate, which gives a large coefficient of variation (CV).  
2.3.1.2 Solvent evaporation 
  
Frequently used to encapsulate drugs (Carreras et al., 2012; Doan et al., 2011; Y. Wang et al., 2013) 
solvent evaporation is a straight forward method involving two or three phases. The core material 
carries the active agent surrounded by a coat material, which acts as a barrier for site specific delivery. 
The third phase is usually the manufacturing vehicle in the form of a liquid. The agent to be 
encapsulated is dissolved with the polymer in a volatile solvent and this is known as the dispersed 
phase. This phase is then emulsified using a stirrer in an aqueous phase in other words the continuous 
phase to generate droplets. Subsequent solvent extraction takes place from the dispersed phase via 
the continuous phase. This process results in the formation of solid particles, which is then subjected 
to further drying to remove residual solvent.  
Solvent evaporation for single oil-in-water (O/W) emulsion is frequently used for insoluble or poor 
water-soluble drugs. The drug to be entrapped (e.g. Salmon calcitonin a hormone for the treatment 
of osteoporosis) is dispersed in the inner phase containing a volatile solvent (i.e. methanol) and 
polymer (i.e. PLGA which acts as the coating material), which is emulsified in an aqueous phase 
comprising a dissolved surfactant (i.e. sodium oleate) (Jeyanthi, Thanoo, Metha, & Deluca, 1996). The 
drug-polymer and solvent are emulsified in the aqueous phase using shear to generate droplets. The 
methanol is soluble in water and therefore leaches into it by diffusion followed by evaporation from 
the free surface of the aqueous phase (being more volatile than water). Solvent extraction results in 
the formation of solid particles that contain the encapsulated drug. 
During the process of solvent removal, the solubility characteristics of the composition are considered 
which directly affect the rate of removal. Elevated temperature results in a higher solvent removal 
leading to the formation of highly porous particles. This is not ideal because in controlled systems it 
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leads to undesirable drug release profiles (Jeyanthi et al., 1996). Double emulsion methods can be 
applied to situations where the drug to be encapsulated is hydrophilic, therefore it is immiscible with 
the organic inner phase and will likely diffuse out to the aqueous phase. In these circumstances water-
in-oil-water (W/O/W) emulsions stabilise the entrapment of the drug whilst utilising removal of 
solvent as a method of creating microspheres. An example of double emulsion solvent evaporation 
was demonstrated by Doan et al., (2011) for the encapsulation of inhalable antibiotic rifampicin (RIF) 
in PLGA microspheres. The inner water phase contained the RIF along with buffer which was 
emulsified in an organic solution containing PLGA (PLGA is a polymer) and later added to the outer 
aqueous phase containing PVA (Doan et al., 2011).  
The variation in microsphere sizes that can be obtained via this method can vary from couple of 
microns to hundreds of microns. Although, solvent evaporation is an effective method, it is limited in 
its criteria to using volatile solvents to obtain particles which is not suitable for phage encapsulation. 
Phage are not compatible with an organic solvent which form an important parameter in 
encapsulation by solvent evaporation (Matsubara et al., 2007). Additionally, like coacervation the CV 
of particle sizes is largely dependent on the rotary motion of a homogenizer, which gives low control 
of droplet size.  
2.3.1.3 Gelation (Ionotropic gelation) 
 
Gelation for encapsulation is usually used when alginate is the main component of the formulation. 
Alginate is linear, non-branched polysaccharide composed of varying ratios of 1, 4-linked β-D-
mannuronic acid (M) and α-L-guluronic acid (G) residues. Alginate is water soluble and forms a 
reticulated structure which can be crosslinked to form an insoluble meshwork. It has a distinctive 
ability to form a gel when it encounters divalent cations i.e. Ca2+ (Liu, Yu, et al., 2002). When divalent 
ions (i.e. from CaCl2) diffuse into an aqueous alginate solution they bind and induce guluronic acid 
residues to crosslink, causing internal gelation (C. M. Silva et al., 2006). Several studies have used 
gelation of alginate as a carrier for phage to protect from low pH (Colom et al., 2017b; Cecilia Dini et 
al., 2012; Yongsheng Ma et al., 2012; Stanford et al., 2010b; Tang et al., 2013; Yongsheng et al., 2008) 
In addition to alginate there are other polymers which are utilised for encapsulation via the gelation 
method. Fermentation by aerobically submerging Sphingomones Eloda produces gellan gum. This is 
an exopolysaccharide of bacteria which is usually prepared commercially. Increasing the temperature 
of a concentrated aqueous solution of gellan gum induces gelation. Subsequently lowering the 
temperature, gellan chains form double helices forming junction zones through sol-gel transition. This 
feature gives a thermos-reversible hydrogel (Patil et al., 2012).   
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Chitosan is another naturally occurring poly-amino-saccharide; it is non-toxic and is easily bio-
absorbable. Other properties include its ability to tolerate acid and has anti-ulcer characteristic 
preventing irritation that results from drug administration (C.-X. Zhao, 2013). Therefore, Chitosan is 
considered an attractive polymer for drug delivery  and phage formulations (Tang et al., 2015; 
Yongsheng et al., 2008). Carboxymethyl cellulose and pectin are also used in the gelation process. 
These polymers are naturally occurring with properties that allow cross-linking/ gelation by altering 
chemical bonds (Patil et al., 2012).  
Polymer and crosslinking electrolyte concentration, temperature, pH of solution, drug concentration 
and gas forming agents influence ionotropic gelation. These factors can determine the efficiency of 
crosslinking between units because in order for crosslinking to commence the optimal conditions need 
to be present (Patil et al., 2012). Not being able to control these factors results in poor gelation and 
therefore a decline in the number of microspheres formed. The size of particles depends on the 
manual agitation applied by a stirrer as well as proficiency of gelation. The sizes can be varied greatly 
from a couple of microns to hundreds. The control over size determination of particles is limited and 
dependent on the factors influencing cross-linking. Encapsulation by gelation has been effectively 
proven and is on the rise due to the use of eco-friendly compositions and avoidance of toxic organic 
solvents. It is however limited by its own mechanism of action as the availability of natural 
polysaccharides with the ability to crosslink is limited. In addition to that the encapsulation efficiency 
is low and the controlled release of the loaded agent is poor due to problems with porosity (Martins 
et al., 2007). 
2.3.1.4 Liposomes 
 
Liposomes are used to encapsulate aqueous solution with a membrane of phospholipids. 
Phospholipids form a barrier between the aqueous phase and the oil phase, the polar head pointing 
towards the aqueous phase and non-polar tail towards the lipid phase. This method encapsulates a 
hydrophilic drug in the aqueous inner phase and can also encapsulate lipophilic drugs in the lipid 
bilayer. The interactions of the membrane bilayer with the hydrophilic and lipophilic properties of the 
drug directly affect the encapsulation efficiency (Kulkarni et al., 1995 Barenholz, 2003). The 
preparation of the liposomes can also contribute to encapsulation efficiency; some of the factors 
include the volume of aqueous phase, surface area and membrane robustness (Kulkarni et al., 1995).  
The process for preparation of liposomes is referred to as microencapsulation vesicle, starting with 
water-in-oil emulsion. The drug to be encapsulated may be water or oil soluble. Regardless, of the 
solubility of the drug the primary emulsion is water-in-oil. The primary emulsion is then dispersed in 
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another water phase to generate drug loaded liposomes. This double emulsion is subjected to shear 
force which breaks up the emulsion into homogenous droplets. The process is described by Nii & Ishii 
(2005).  
Liposomes have been successfully applied to encapsulate drugs; one such example is outlined in the 
U.S. Pat. No. 3,993,754, by inventors Rahman Yueh-Erh, Elizabeth (1976). Here, they described the use 
of encapsulating anti-tumour drugs provided for chemotherapy of malignant tumours using liposomes. 
The liposomes encapsulating the drug are administered intravenously, penetrating the tumour cells 
to induce death. Similarly, further patents including US 4515736, method for encapsulating materials 
into liposomes (Deamer, 1985) and patent US 4485054 A.  
Several patents on the process exist and have shown the use of liposomes as an effective method for 
drug encapsulation. Phages have also been encapsulated in liposomes for oral delivery and release in 
the gastrointestinal tract (Colom et al., 2015; Nieth et al., 2015; S. Singla et al., 2016; Singla et al., 
2016). The size of the liposomes produced is usually very small ranging from nanometres to a few 
micrometres. Due to the small size of liposomes it is difficult to separate non-encapsulated phage from 
encapsulated phage. 
2.3.1.5 Sol gel 
 
The precursor is the initiator of the sol gel process; it undergoes hydrolysis by the addition of water 
and presence of a catalyst which can be a base, acid or a metal alkoxide. The commonly used 
precursors are tetraethyl orthosilicate (TEOS), alkoxymetallate and, or alkoxysilane which form 
hydroxyl derivatives such as silica acids and hydroxysilanes etc. The hydroxylated monomers produced, 
undergo polymerisation followed by phase separation generating either a semi-metal oxide or a 
hydrated metal hydrogel. As the aqueous phase is removed from the hydrated gel, the formation of 
pores occurs producing a porous xerogel (Gill & Ballesteros, 2000).  
Silica alkoxides are prone to hydrolysis and form silica (SiO2), subsequent condensation causes the 
bridging of two oxygen atoms causing silicon atoms to come together. Continuation of this reaction 
causes the silica atoms to be added and grow the polymeric chain, Figure 2.3.2. This type of reaction 
can occur at different location growing the silicon oxide or alkoxide particles. The term ‘sol’ refers to 
the stage where these particles are dispersed in a colloid system with solvent. As the particles continue 
to grow they start to interlink with chains from other locations forming a ‘gel’ network that 
encompasses pores of trapped fluid. Aerogels are formed from the aqueous phase being replaced by 
gas in such a way that its solid network is retained, with only slight shrinkage in the gel. Originally this 
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was achieved under super critical conditions. However, it is now possible to carry out the process in 
ambient drying conditions.  
 
 
 
 
The common sol-gel matrixes are comprised of silica, metallosilicates and titanium, zirconium and 
aluminium oxides. The matrixes formed from these materials are in a hard-transparent glass form and 
can be further modified to be applied for different applications one of which is for biosensors. 
However, they have also been successfully applied for the encapsulation of bioactive materials such 
as enzymes, proteins, antibodies and cells (Avnir et al., 1994).  
The process eliminates any harsh conditions which can easily denature and destroy bioactive material. 
Sol-gel is carried out at room temperature which is suitable for many bioactive agents without any 
rigorous applications. Sol-gel compared to conventional polymers is durable, strong and highly 
resistant to mechanical, biological and chemical degradation. Manufacturing and engineering of 
products desires such properties for efficient, viable and scale-up purposes. The disadvantage of this 
technique is that ceramics can be frail; the presence of pores reduces the rate of chemical interaction. 
Further to this, following polycondensation the hydrogel ages causing it to shrink through loss of liquid 
phase. Although used in the food industry as an anti-caking agent, it is not ideal for oral phage therapy 
due to the use of metal oxides.  
 
2.3.2 Physio-mechanical processes 
 
2.3.2.1 Interfacial polycondensation 
 
Interfacial polycondensation is the process of polymerisation between two immiscible phases. Two 
different monomers (reactive when brought together) are dispersed in each phase of the 
heterogeneous system. These monomers react at the interface of the two phases leading to the 
Figure 2.3.2. A schematic of the sol gel process in the formation of a dense ceramic. 
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formation of a polymeric membrane around the inner face. Figure 2.3.3 shows the generic steps; first 
water-in-oil emulsion is prepared. The inner phase carries one of the two monomers and the agent to 
be encapsulated in dissolved or dispersed in the inner phase. The outer phase contains the surfactant 
and the second monomer. Mechanical agitation results in the formation of droplets. Figure 2.3.3 (a) 
shows a single droplet representing the elements acting upon all droplets in the emulsion (Benita, 
2006).  
The monomers in the inner and external phase Figure 2.3.3 (b) are particularly reactive. The two 
monomers react at the interphase of water and oil to form a polymeric membrane around the droplets 
Figure 2.3.3 (c).The microcapsules are usually obtained from water-in-oil or oil-in-water emulsions 
although oil-in-oil emulsions have also been used for interfacial polycondensation (K. Bouchemal et 
al., 2003). Solubility and partition co-efficient determine the localization of the reaction Figure 2.3.3 
(c), (d). The reaction can take place at the outside of the droplet or in the inner wall.  
 
 
 
 
 
Figure 2.3.3. Schematic representation of polymeric membrane formation in the interfacial 
polycondensation process. (a) Enlarged single droplet from water-in-oil emulsion with monomer in 
the water phase and surfactant in the oil phase. (b) Second monomer added to oil phase resulting in 
a reaction (c) with the water phase monomer at the water-in-oil interface. Alternatively, the reaction 
may take place at the inner surface of the droplet (d). 
The reaction only commences when there is a sufficient concentration of monomers in each phase 
which determines the partition coefficient. The solubility of the monomers determines where the 
reaction takes place which can result in either microspheres (in droplets) or microcapsules (outside 
droplets). The size of the droplets is hugely influenced by the initial emulsion step with the properties 
of both phases and the choice of surfactant. The duration and input of energy from mixing via 
mechanical stirring, homogenization or ultrasonication also determine the droplet size. The thickness 
of the wall is dependent on the concentration of monomers. 
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Polyurethane is a polymer already utilized in various fields of medicine due to its mechanical 
properties and biocompatibility. Polyurethane can undergo gradual biodegradation in the human 
body, making it a suitable candidate for microparticle preparation. Kim et al., (2006) encapsulated an 
anti-tuberculosis drug, isoniazid in polyurethane using interfacial polycondensation. This water-in-oil 
emulsion was made by adding the water phase to the oil phase whilst stirring. The water phase 
contained isoniazid, poly(ethylene glycol) (PEG) (monomer one) in water. This was gradually added to 
a solution of Toluene and surfactant Tween 20. Once the emulsion was complete Tolylene 2,4-
diisocyanate (TDI) the second monomer is added. The addition of the second monomer results in a 
rapid reaction with PEG causing crosslinking at the water/toluene interface and subsequent 
encapsulation of drug (M. D. Kim et al., 2006). Applying this method for phage encapsulation can be 
challenging due to the limited use of polymers and need for organic solvents.  
 
2.3.2.2 Interfacial polymerisation 
 
Although sometimes difficult to distinguish from interfacial polycondensation, interfacial 
polymerisation performs in a slightly unique way. The presence of a monomer in this case is also 
essential however the mechanism of crosslinking differs somewhat from polycondensation. In the 
case of interfacial polycondensation when two monomers come together the reaction produces a 
molecule like water as a by-product hence the term polycondensation. On the contrary, for interfacial 
polymerisation the double bond between two carbon atoms of a monomer open during an addition 
reaction and form a polymer chain. This phenomenon is also referred to as addition polymerisation. 
During addition polymerisation the chain can be extended by addition of any number of monomers. 
The three steps in this process are; initiation, propagation and termination (Figure 9.1 appendix). 
During initiation a double bonded monomer is activated by a free radical. The activated monomer 
radical interacts with other monomers and attaches during propagation as the chain grows. The 
termination of the reaction takes place when two radicals come together to reform a double bond 
and stabilise. The length and other properties of polymers can be precisely controlled for synthetic 
polymers. Figure 9.1 (appendix) demonstrates the process using an example of the polymer, 
polyethylene.  
The formation of polymer around an active agent seals it and therefore encapsulates the agent for 
site specific delivery. Interfacial polymerisation is commonly used in synthetic polymer industry 
however it can also be applied for drug encapsulation. Kobaslija et al encapsulated Coumarin-1 (model 
encapsulant) in polyuria microcapsulaes. Polyethylemine was the polymer used for this study. 2,4-
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Tolylene Diisocyanate was added to initiate solution polymerisation and an immediate reaction 
resulted in formation of solid polymer. In this case mechanical stirring was applied to obtain small 
microcapsules (Kobašlija & McQuade, 2006). As previously stated, mechanical agitation does not give 
narrow size distribution of particles. Interfacial polymerisation can produce particles sizes ranging 
from a 1 to a couple of hundred micrometres. 
2.3.2.3 Extrusion  
 
Extrusion is a common technique used for the formation of microcapsules of a hydrocolloid solution. 
It is used extensively in the food industry for the encapsulation of microorganisms aimed to improve 
gut health by replenishing and maintaining a rich micro-biota. This method utilises the properties of a 
hydrocolloid solution to generate a shell around a bioactive agent. Alginate is the polysaccharide of 
choice for this method due to its ability to form a gel, in conjugation with calcium chloride as explained 
in the gelation section above.  
To form droplets, a cell suspension (e.g. at concentration 106) is added to a mixture of sodium alginate 
solution. The mixture is passed through a syringe, where droplets are formed when they are pushed 
through needle. The diameter of the needle determines the size of the droplet as well as the distance 
of the fall into the setting solution. Once droplets are formed they fall into a solution of calcium 
chloride, as mentioned previously this causes the alginate to harden and form a shell around the 
bioactive material Figure 2.3.4. This method is preferred due to its low cost, ease of use and the 
general mild conditions necessary for retaining viable cell concentration (Krasaekoopt et al., 2003).  
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The size of beads obtained from this method is usually bigger than what most techniques can generate. 
The beads are in millimetres and in some cases a couple of hundred micrometres. The large size of 
beads is usually desirable especially when capturing probiotics for the likes of yogurt or yogurt drinks.  
The principle of extrusion has been applied with other methods to obtain droplets and subsequently 
particles. One such method is the double capillary method, two immiscible phases; inner (core 
substance) phase and outer (wall material or polymer) phase. The two phases are passed separately 
through the inner capillary (core substance) and outer capillary (polymer). The two phases meet at 
the tip to form a jet and break downstream to form droplets. Similarly, the same principle is applied 
to a centrifugal extrusion device. Except the break-up into droplets is mediated by rotating motion 
which breaks up the stream of wall material coating the inner phase (Madene et al., 2006).  
2.3.2.4 Spinning disk 
 
As the name suggests spinning disk produces particles with the use of a rotating disk at a certain speed. 
It is also referred to as spinning disk atomization and is similar to the extrusion technique. The feed 
comprises of a liquid which undergoes disintegration when exposed to the spinning disk at the centre 
of the chamber. The shear forces exerted by the speed of the disc cause the liquid to form a thin film 
on the disc. As the feed is continuously introduced into the chamber, the droplets are released via 
centrifugal forces exerted at the edge of the disk and collected (Figure 2.3.5). The droplets undergo 
further processing by cooling to solidify droplets into particles (Ghosh, 2006). The size of the droplets 
is dependent on the rotational speed of the disk. The size of microspheres produced can vary from 5-
1500 micrometres, although with a multistep process nanoparticles can also be generated (Huanbutta 
et al., 2013). The simplistic approach of this technique is scalable with a production capacity of tons 
per day, usually using a multi-disk system.  
Figure 2.3.4. A schematic of the extrusion process. Bacteria are suspended in a solution of sodium 
alginate which is transferred into a needle with a defined size needle. The droplets formed by the 
syringe are collected in a solution of calcium chloride which solidifies the droplets into particle or 
beads. 
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This technique was utilised by Huanbutta et al., (2013) to encapsulate diclofenac sodium (an anti-
inflammatory drug). The group showed successful production of nanoparticles encapsulated in 
poly(methyl acrylates)-coated chitosan. Eudragit S100 and L100 (co-polymers) were also utilised to 
increase colon targeted drug delivery efficiency. Similarly, gelation (previously mentioned) can also be 
applied to the spinning disk method to produce particles of a narrow size distribution. Senuma et al 
(2000) encapsulated yeast in a alginate microspheres. The principal of encapsulation in general terms 
remained the same (as shown in Figure 2.3.5) where the alginate and yeast were fed by a peristaltic 
pump into the rotating disk reactor. The resulting droplets were collected in a bath of calcium chloride 
to convert droplets into particles.  
There are several applications of this method due to its simplicity and ease of use. It is inexpensive 
and produces products on a large scale. However, the encapsulation efficiency and product size 
distribution are marginally better than other conventional methods. The range of product particle size 
shows a significant range from nanometres to several hundred micrometres.  
 
2.3.2.5 Fluidized bed 
 
Figure 2.3.5. Schematic of a spinning disk reactor 
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Fluidized bed technology has been commercialised and well established to produce industrial 
polymers amongst many other applications. The reactor can carry out multiphase chemical reactions, 
a porous plate (distributor) at the bottom of the chamber supports the solid substrate (usually a 
catalyst which coats the fluid and undergoes chemical reactions) through which the fluid is forced into 
the chamber under high velocity. The high pressure keeps the solid substrate suspended and it 
behaves like a fluid a process known as fluidization. At this stage the contents of the reactor swirl 
around much like a tank of water under agitation. This technique can be used to achieve a shell layer 
of any kind around solid particles. Double coatings or a mixture of coatings can be challenging when 
working with other technologies to produce double layer shells. This is because to achieve double shell 
layers the emulsion is aqueous requiring stabilisers. In this case however, solid particles can undergo 
further coating; an example of this would be chitosan particles encapsulating a drug undergoing 
Eudragit enteric coating in a fluidized bed (Kaur and Kim 2009).  
There are several steps of this technology including; drying, agglomeration (granulation or spray 
drying), spray granulation, micro-encapsulation and coating. The positions of the spray nozzle (e.g. 
bottom or top spray) refer to Figure 2.3.6 determine the process type. Bottom spray (also known as 
Wurster’s coater) position of the nozzle is better applied in granulation or agglomeration process 
where as the top spray position is better suited for coating purposes. Batch size, air velocity, inlet 
temperature, humidity, nozzle diameter and position, viscosity, surface tension, spray rate, 
atomization and air pressure are all major variables in fluidized bed process. 
Particles are sprayed with a liquid coating; the process of solvent evaporation aids the formation of a 
coat around the particle. By controlling rate, concentration and flow of the coat material and particles 
in the chamber the thickness and formulation can be changed according to preference. Gravity force 
compensation is the basic concept of fluidization of particles. Top spray bed introduces the coat 
material downwards, encapsulating particles with high efficiency as they move up the chamber 
towards the coat spray. The originally developed bottom spray coater sprays the coat material 
towards the top. The particles are introduced into the chamber via a perforated plate, from the 
bottom of the chamber; the air flow from the bottom ensures the complete fluidization of particles. 
There are many modifications that can be made to enhance the process and increase the efficacy of 
atomization and fluidization, such as a rotating drum to enhance fluidization of particles (Gouin, 2004).  
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The applications of fluidized bed can range significantly; food industry and pharmaceutical industry 
have adapted the method. Preparation of pellets containing Glipizide (drug) for type II diabetes (Yadav 
et al., 2011), Oxytetracycline (OTC) antibiotic against various bacteria (Kleinubing et al., 2014), salmon 
calcitonin for treating osteoporosis (Yang et al., 2012) are all drugs which have been encapsulated 
using fluidized bed technology. The pH responsive methyl-methacrylate Eudragit co-polymer with 
alginate/chitosan was used to encapsulate the drug OTC by Kleinubing et al. 2014 for gastro-resistant 
controlled release. The size of the particles produced via fluidized bed usually ranges from 
micrometres to millimetres. In some cases, nano-sized particles may be produced but the process are 
challenging, and the impact of electrostatic forces needs to be considered.  
2.3.2.6 Spray drying 
 
This technique uses the flow of hot dry air moving through a chamber to nebulise a solution into a 
spray to form particles. It is widely used in the food, chemical, biochemical and pharmaceutical 
industry. A hot gaseous drying medium converts the feed from a fluid state to a dry form. There are 
three stages in spray drying, the first is the atomization which largely determines the particle size, 
second is solvent evaporation and finally particle collection. Atomisation is the initial stage of the 
entire process; here the phases are fed into a specific atomizer for conversion of the phases into 
droplet form. There are different atomization systems available and usually vary in their nozzle design. 
Figure 2.3.6 Schematic of a fluidized bed showing (a) a bottom nozzle spray (b) Top nozzle spray 
coater.  
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The purpose of this stage is to increase the surface for heat transfer between the liquid and dry air to 
elevate heat and mass transfer. The nozzle design can be rotary, pressure or two-fluid atomization. 
There are further modifications available to these designs. Nevertheless, the feed is fed through these 
nozzle systems and the type of design determines how the droplets are formed (Walters et al., 2014).  
Atomization with a rotary atomization nozzle the feed is sprayed via a spinning disk or wheel into the 
drying chamber creating droplets. Pressure atomization introduces the feed into the chamber under 
high pressure causing the fluid to break into droplets. The two-fluid nozzle carries the feed and 
atomization air via two separate nozzles which come to together, the air causes disruption of the fluid 
into droplets producing a spray. Each system has a direct impact on the particle size produced and 
each is useful for a different type of feed. For example, more viscous feeds benefit from the rotary 
nozzle system producing particles of up to 200 µm. The other two nozzle systems can produce particles 
less than 10µm dependent on the diameter of the nozzle. The size of the particle is affected by the 
viscosity as well as the surface tension of the initial feed, with high viscosity and surface tension the 
particle size increases (Benita, 2006).  
Temperature plays a vital role in a spray drying system. The hot air contact marks the start of the 
drying stage; this is usually instantaneous resulting in solvent evaporation. There are two flow 
arrangement that can be used to introduce hot air to cause drying, the flow of hot air can be co-current 
or counter current. Feed is sprayed in the same direction as the hot air in a co-current set-up. 
Temperature between 150-200˚C of the hot air in-let causes rapid solvent evaporation. A much lower 
temperature is kept for dried powder to maintain the integrity of particles. However, in the counter-
current flow the feed is fed at the opposite side of the hot air in-let resulting in a much higher 
temperature contact. The dried particles remain exposed to elevated temperature causing some 
constraints to its applications when requiring thermo-sensitive particles. The water in the droplets 
diffuses from the core to the surface due to the surface evaporation rate. This is determined by the 
heat and water vapour partial pressure which causes the water to diffuse away from the droplet and 
heat is transferred to the droplet. Because of these forces the crust of the droplet solidifies and forms 
a particle. This process is instantaneous especially given the higher surface area to volume ratio of 
droplets which increases the rate of solvent removal (Gharsallaoui et al., 2007). 
The product is collected in a cyclone located outside the dryer chamber. This helps trap fine particles 
from the humid air to avoid product loss. The denser particles are usually recovered from the bottom 
of the drying chamber. Some spray dryers also contain bag houses which are filters capable of 
retaining the finest of powders (Walters et al., 2014). The typical process of spray drying is 
demonstrated by (Dobry et al., 2009) in Figure 2.3.7.  
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Spray drying has been used in various applications including encapsulation of drugs. Inventors Thomas 
E. Waddell et al (2013) have described the use of spray drying to encapsulate bacteriophages in the 
pH sensitive polymer Eudragit S100 and L100 for site specific delivery in the patent CA 2463827 C  
(Thomas E. Waddell, Roger Johnson, 2013). The successful encapsulation via this method has proven 
the diversity of its application in various industries.  
2.3.3 Membrane emulsification 
 
Membrane emulsification was proposed in 1988 by Nakashima and Shimizu as a new emulsification 
system. Before this, conventional methods included shaking, injecting, stirring, and ultrasonic, aerosol, 
spray drying, homogenizing etc. This method is suitable for any emulsion for particle production 
(Nakashima et al., 2000). It can produce droplets sizes of 1 micrometre and above with coefficient of 
variance less than 10 %. Membrane emulsification allows better control over droplet size production 
than other conventional methods. This technique is simple and allows production of narrow size 
distribution droplets with low shear stress with lower energy consumption. The well-defined 
Figure 2.3.7 A typical spray drying process showing key equipment involved (Dobry et al., 2009). The 
feed is mixed and prepared before being added to the atomization chamber. Once the feed is added 
formation of droplets and drying takes place. The product is passed through a cyclone and a bag house 
to separate the particles from the humid which is then eliminated via a condenser. 
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production of droplets is dependent on the type of membrane used. This technique has the potential 
to be scaled from a laboratory to an industrial production process.  
There are several types of membranes categorised as surface or sintered membranes. The most 
commonly used membranes are the Shirasu-porous-glass (SPG) and microsieve membranes. SPG 
membranes offer a uniform, flawless surface. They can have pore sizes ranging from 0.05-20µm and 
are commercially available. The surface of the SPG membrane can be further modified to suit the 
emulsion system. Microsieve membranes are essentially microfiltration membranes with a controlled 
pore geometry and spatial arrangement. These membranes are popular when requiring low 
transmembrane pressure but a high transmembrane flux.  
There are several factors that can influence the size of droplets including; membrane microstructure, 
wetting properties, spore shape and size, spatial distribution of pores etc. In addition to these, forces 
that act upon the phases also contribute to droplet size. Transmembrane flux and shear stress acting 
at the surface of the membrane control the movement of the droplets. Viscosity of the dispersed and 
continuous phase, surfactant type and the concentration also contribute to droplet size. Droplets can 
further be processed during or after membrane emulsification to produced solidified particles. 
Particles sizes are directly dependent on the droplet size and the chemistry of the transition process. 
There are various particle morphologies that can be achieved via this process including porous and 
core-shell particles. The most common application of membrane emulsification is the synthesis of 
particles. Particles are applied in various fields including drug delivery. Advantage of using membrane 
emulsification for particle production is that organic, inorganic, metal, hydrogels, carbon, polymer etc. 
can be used.  
Holdich et al., (2010) describe the use of oscillating and stationary membranes for the production of 
droplets with a narrow size distribution. They describe the shear-based detachment of the droplets in 
a stirred and oscillating membrane system. The study describes the application of shear at the 
membrane surface that can reduce the breakup of previously formed droplets. In one case the shear 
is applied in the direction of injected phase, by an oscillating membrane surface (frequency 10 to 90 
Hz). The frequency is kept low to allow comparison with a stationary membrane (same material) with 
a shear applied by a stirrer in the dispersion cell. The method allows comparison of droplets above 
30µm produced in a controlled manner to allow for industrial scale-up. In conclusion, oscillating 
membrane system produced smaller more uniform droplets than the stirring dispersion cell. This study 
highlights the robustness of using membrane emulsification to produce droplets with a controlled 
result. In addition to that it shows promise for industrial scale up by simply increasing the membrane 
surface area. To allow, for a better controlled final product membrane can be exploited in many ways 
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such as by surface treatment or physical modifications to change rates of forces being applied during 
the process.  
 
 
 
Direct membrane emulsification systems are depicted in Figure 2.3.8 a-e. The dispersed phase (red) is 
injected into the immiscible continuous phase (white) forming droplets. The membrane can be 
hydrophilic or hydrophobic depending on whether water-in-oil or oil-in-water emulsion is required. 
Droplets can be formed in the absence of shear at the membrane surface relying only on the interfacial 
tension (Kukizaki 2009; Kosvintsev 2008). From a commercial standpoint this method is not viable as 
the production rate is low therefore; shear force may be applied at the membrane surface. Droplet 
detachment at the membrane surface can be aided by applying shear stress via cross-flow geometry 
of the feed fluid or stirring Figure 2.3.8 a-c.  
Figure 2.3. 8.16 Membrane emulsification systems (G. T. Vladisavljević et al., 2012) 
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Membrane emulsification can also be used for premixes Figure 2.3.8 f, which give the advantage of 
producing double emulsions such as water-in-oil-in-water or oil-in-water-in-oil. The primary water-in-
oil or oil-in-water emulsion is fed through the membrane into another immiscible phase. This 
technique is useful to produce smaller droplets in a big drop but more importantly for encapsulation. 
A model water soluble drug (blue dextran) was encapsulated with 100% efficiency in poly(D,L-lactic-
co-glycolic) (PLGA) microparticles using membrane emulsification by Gasparini et al., (2008). 
Preparation and characterization of PLGA particles for subcutaneous controlled drug release by 
membrane emulsification was demonstrated. 
Depending on the pore size of the membrane (5 to 50 µm) droplets with controlled size are produced. 
Membrane emulsification is a useful platform to produce microparticles with drug encapsulation with 
the potential to upscale. For double emulsions, required for many encapsulation procedures 
membrane emulsification has also proven useful. Van der Graff et al discusses the use of double 
emulsions for encapsulation of food, medicines and other high value products. Due to the increased 
shear sensitivity of double emulsions surfactants (lipophillic and hydrophilic) are used. The primary 
emulsion (w/o or o/w) is usually subjected to high shear stress to allow formation of droplets. When 
the external phase (water or oil) is added the high shear, stress can cause the inner droplets to break 
further into smaller droplets which are not desirable. High shear also results in elongation of internal 
droplets increasing coalescence and areas for drug release. Therefore, it is ideal to use membrane 
emulsification due to its low shear stresses on the system without compromising droplet 
monodispersity (Van Der Graaf et al., 2005).  
Morelli et al., (2017) showed the use to this technique for yeast encapsulation in gelatin and or 
chitosan microparticles coated with Eudragit S100. The results demonstrated the use of this technique 
and formulation as an effective way for encapsulating active agents for colon delivery. It is therefore 
a promising method even for microbial cell encapsulation and certainly for bacteriophages in phage 
therapy.  The particles produced can vary from a couple of microns to hundreds of microns.  
 
2.3.4 Microfluidics 
 
Microfluidics is a technology which exploits properties of various liquids to attain an enhanced 
application. In other words, it is a platform to perform meticulous testing, assaying, and diagnosis on 
a higher scale with attention to every droplet. Microfluidics has gained much recognition in every field 
due to its controllability.  
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There are different variations of microfluidic devices which suit different purposes but essentially form 
monodispersed droplets Figure 2.3.9. Simplest microfluidic device is the T-junction device, where 
droplet formation is a result of its structure. Made in a T-shape where the main channel is 
perpendicular to the horizontal channel Figure 2.3.9 a and b. The dispersed phase flows through the 
main channel and the continuous phase from one end of the horizontal channel. The dispersed phase 
flows down into the continuous phase while the continuous phase flow across the horizontal channel. 
The formation of droplets occurs at a short distance from where the two phases meet due to shear 
stresses and upstream pressure (Thorsen et al., 2001).  
Using the same principals as the T-junction device of formation of droplets, a cross junction device is 
also available Figure 2.3.9 f and g. The cross-junction device has 3 entry channels and one outlet 
channel for collecting formed droplets. All channels are perpendicular to each other in geometry. The 
dispersed phase is introduced into the device between two inlets of the continuous phase. This 
geometry configuration allows full ‘engulfment’ of the dispersed phase which at a short distance after 
encountering the continuous phase forms droplets in the outlet channel. As the jet from the dispersed 
phase becomes too thin when entering the continuous phase, it forms a droplet. With another cross 
junction connected downstream of the droplets collection channel can produce core/shell particles 
and with further extension to this principal more complex emulsions can be produced (triple, 
quadruple, quintuple) (A. R. Abate et al., 2011;  a. R. Abate & Weitz, 2009). 
Y-junction microfluidic devices are also applied to produce droplets. The geometry of the channels is 
in the shape of a ‘Y’ where the dispersed phase is fed through one of the two channels on the same 
side Figure 2.3.9 h and i. The continuous phase enters through the channel next to the dispersed phase 
and both flow into an outlet channel at the opposite end. The droplet size is independent of the flow 
rate or the viscosity in this geometry which we observe in the case of T-junction devices. This type of 
device can generate a stream of two distinct fluids when the Reynolds numbers are low. This type of 
process has a different purpose such as forming crystals in a continuous line or to etch the inner wall 
of the outlet channel (Kenis, 1999).  
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Figure 2.3.9. Schematic of different microfluidic devices (G. T. Vladisavljević et al., 2012). 
Microfluidic flow focusing device, combines the flow of two phases in the same direction entering into 
a small orifice focussing hydrodynamically to produce droplets (Q. Xu & Nakajima, 2004). The inner 
phase flows through an orifice surrounded by the outer phase, the device developed by Anna et al 
2003 demonstrates this concept Figure 2.3.10 a. Core shell particles, with double emulsions can be 
generated with these devices, however depending on the properties of the liquids three coaxial 
streams (Figure 2.3.10 b) (Nie et al., 2005) or a consecutive flow focusing device can be used.  
Consecutive flow focussing device offer the alteration of wettability at the orifice surface (Seo et al., 
2007). As shown by Figure 2.3.10 d, the throughput of the product can be increased by running several 
channels in parallel and collecting in the same outlet (M. Hashimoto et al., 2008).  
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Figure 2.3.1017 Schematic of different microfluidic flow focussing devices (G. T. Vladisavljević et al., 
2012). 
Droplets are formed by the pressure and shear stress exerted on the dispersed phase to form a narrow 
jet which breaks near or downstream the orifice. As the inner and outer phase (liquid A and liquid B) 
it is seen that during focusing into the orifice the walls of the orifice are not wetted by the inner phase. 
Therefore, the wall is pre-treated either hydrophilic or hydrophobic to produce O/W or W/O 
emulsions, respectively. This step is important because if the inner phase wets the wall, then outer 
phase droplets will be formed and vice versa.  
Microfluidic devices, whether they are junction or flow focusing, are usually devised by lithography 
and are commonly made of poly(dimethylsiloxane) (PDMS). Although other polymeric materials can 
also be used, PDMS provides good protection from contact between walls of the channels and the 
forming droplets. Also, the clear appearance of the PDMS device aids the visualisation during particle 
generation. It also helps prevent the problem of wetting by the dispersed phase and protecting 
droplets from shear and adhesion to the wall which can damage the droplet conformation. The 
shortfall of using PDMS devices however is that, the user is restricted from using organic solvents as 
the material is prone to swelling. In addition to that, the flexibility of the material means that the 
device is easily deformed with minimal pressure.  
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Glass capillary devices are also popular due to their tolerance to organic solvents and can be surface 
treated to make it hydrophilic or hydrophobic. Glass capillary devices are less prone to swelling and 
other changes due to chemical therefore are preferred over PDMS and other materials. The durability 
and surface treatment options for the use of organic solvents have made this a preferred choice.  
Glass capillary devices are used in various geometric arrangements, from planar, T-junction, Y-junction, 
cross junction and 3 phase devices. In all arrangement the meeting of different streams of fluids form 
different channels at a specific region cause the formation of droplets that are collected in the 
converging channel (outlet). The idea behind droplet formation rests on regimes such as squeezing, 
dripping and jetting. In the squeezing regime, the dispersed phase occupies a large area of the capillary 
whilst being surrounded around the edge of the capillary by a thin continuous phase. As the 
continuous phase approaches the tip of the capillary the pressure exerted increases along the capillary 
forcing the continuous phase to squeeze and break at the neck of the capillary. As the break occurs 
the dispersed phase is surrounded by the continuous phase as a droplet rather than a continuous 
stream. In this regime the size of the droplet is dependent on the difference in flow rate of the two 
phases. It is not highly affected by the value of interfacial tension or viscosities of the two fluids (De 
Menech et al., 2008). The squeezing regime is commonly seen is T-junction and Y-junction. 
In the dripping regime, the formation of a droplet is dependent on the interfacial tension that opposes 
the elongation at the neck and the drag force applied by the continuous phase on the emerging droplet 
Figure 2.3.11 b. The balance of these two forces determines the breakup and hence the size of the 
droplet. Here, the fluid flow rate is low, inertial and viscosity forces are dominated by interfacial 
tension.  
The jetting regime on the other hand can occur in one of two ways; narrowing (Figure 2.3.11 c) or 
widening (Figure 2.3.11 d). In the narrowing jetting regime Figure 2.3.11 c, the high velocity of the 
continuous phase increases the velocity gradient at the interface and leads to high shearing. The 
velocity force exceeds the interfacial force.  As a result of these forces a long narrow jet is produced 
which breaks up into droplets downstream. In the case of widening jetting the opposite occurs, the 
high velocity gradient at the interface is created by the high flow rate of the dispersed phase causing 
a long, wide jet which forms droplets downstream. The size of droplets formed in narrowing jetting 
are smaller than those formed by widening jetting. 
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Figure 2.3.1118 Image of dripping and jetting regimes (Utada et al., 2007). 
The capillary number (Ca) (a dimensionless quantity), can be used to predict the prevailing mechanism 
of droplet formation in a microfluidic device. It represents the relative effect of viscous forces against 
surface tension present at an interface between two immiscible liquids. For Cac  <0.002 is within 
squeezing regime, 0.01 < Cac  < 0.3 is within dripping regime (J. H. Xu et al., 2008). As the capillary 
number further increased, the point at which the droplets breaks will move further downstream, 
shifting the regime from dripping to jetting. Low capillary numbers tend to result in formation of 
droplets closer to the junction (capillary tip) and high capillary number further downstream of the 
junction Figure 2.3.11. Capillary number is calculated by the equation below: 
Equation 1 
Ca =
μ𝑣
σ
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Where, Ca is Capillary number, µ is dynamic viscosity (Pa.s), v is fluid flow rate (ms-1), σ is surface or 
interfacial tension (Nm-1). 
The capillary number for a microfluidic device envisages the relative effect of different forces such as 
inertial, interfacial, viscosity and velocity. It enables users to predict and understand the nature of the 
flow and droplet formation in relation to these forces and be able to predict changes when one force 
is altered. 
Another dimensionless number is Reynolds number (Re), which shows the association between inertial 
and viscous forces in a microfluidic device. It is represented by the equation below: 
Equation 2 
Re =
𝜌𝑉𝐿
μ
=  
𝑉𝐿
𝑣
 
 
Where ρ (kgm-3) is the density of the fluid, V (ms2) is the characteristic flow rate, and L (m) is the 
characteristic length scale of flow, μ (Pas) is the dynamic viscosity of fluid and v (m2s) is the kinematic 
viscosity. 
At low Reynolds numbers, laminar flow occurs because viscous forces are dominant and is 
characterised by smooth fluid motion. High Reynolds number results in turbulent flow due to 
dominant inertial forces. In microfluidic devices the Reynold number must be low to achieve smooth 
linear flow. Reynolds number is further affected by Newtonian and non-Newtonian fluid dynamics. 
Weber number is another dimensionless number which define the relationship between inertial forces 
and surface tension of two fluids in a microfluidic device. It is collaboration of the Capillary number 
and Reynolds number and is given by the equation below: 
Equation 3 
We = ReCa =
ρ𝑉2l
σ
 
 
The Bond number identifies the importance of gravitational force in microfluidics in relation to 
interfacial tension and is given by the equation below: 
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Equation 4 
Bo =
∆pgl2
σ
 
 
Where, Δp is density difference between fluids (kgm-3), g is acceleration due to gravity (ms-2), l is the 
length (m), σ is the interfacial tension between fluids (Nm-1). 
As demonstrated by the dimensionless number above, there are many contributors to the formation 
of droplets via a microfluidic device. Forces such as inertial, surface and interfacial tension, shear 
stress, viscosity, all play a part. However, there are other influential measures that also need to be 
addressed. Surfactants play a vital role in stability of an emulsion therefore should be considered when 
considering droplet sizes. Surfactants can also change the viscosity of fluids and consequentially 
influence flow rates. In addition to that, it is important to also address capillary treatment; wetting 
can result in increased variance in droplet size as well as the instability of the device.  
Orifice size in microfluidic devices plays a key role in determining droplet size. As one would imagine 
with a large orifice size the volume of dispersed fluid passing through will increase hence result in 
larger droplets and vice versa. However, it is a combination of all these forces and geometrical 
arrangements that produce a given droplet size. Microfluidic devices therefore, are highly meticulous 
down to one drop at a time. This fine-tuning offers users the control over all aspects involved in final 
product generation such as particles. By changing one aspect it is possible to view the change in 
droplet generation in real-time.  
Core shell particles can also be generated using microfluidic devices. Three dimensional axisymmetric 
microfluidic devices enable this and produce multiple emulsion droplets. Co-flow, counter-current 
flow, three phase glass capillary devices are all types of microfluidic devices which can produce 
droplets with multiple phases with specific properties. In Co-flow devices the two phases flow the 
same direction and form droplets on encountering a tapered capillary. Counter-current flow devices 
introduce the phases in opposite direction towards a tapered capillary forming droplets. A three-phase 
glass capillary device forms droplet from three phases which has a geometric combination of co-flow 
and counter-current device mechanism.  
It is imperative to highlight the importance of microfluidics in influencing the rapid growth of lab-on-
chip technology in industry. It is highly desirable in the healthcare sector as well as many others to 
reduce time, cost and improve sensitivity and sustainability. Keeping this in mind microfluidics offers 
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the ideal platform to replace or improve current methods for point of care testing. Rapid diagnostics, 
screening microbial libraries, viability studies are all examples of bioassay miniaturisation using 
microfluidics. A full review is discussed by (Ríos & Zougagh, 2015).  
 
2.3.5 Electrospinning 
 
2.3.5.1 Mechanism 
 
Stemming originally from electrospraying where droplets are formed, electrospinning produces fibres. 
Electrospinning is a process which utilises high voltage to charge a polymer solution that is extruded 
through a metal needle or capillary towards an oppositely charged collector. During extrusion in the 
presence of charge, instead of formation of a round droplet, a cone is formed otherwise known as the 
Taylor cone. This is due to the attraction between the oppositely charge solution and collector but 
also the electrostatic repulsions between like charges of the polymer solution. Once the electric field 
surpasses the surface tension of the polymer solution a fibre jet in ejected from the nozzle. As the jet 
travels through air to the collector, solvent evaporates depositing solid polymer fibres on the collector. 
The onset of bending instability during acceleration of the fibre from the ejector to the collector 
increases the path length and time which aids fibre thinning and solvent evaporation (Yarin et al., 
2001). 
Fibres can range from nanometres to micrometres depending on several experimental parameters. 
The collector can vary in geometry depending on the required state of fibres, these vary between 
immobile plate, rotating mandrel or aqueous solution. A schematic of electrospinning setup is shown 
in figure 2.3.12 with a stationary flat collector plate. 
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Figure 2.3.12 Schematic of electrospinning setup with a stationary collector plate. 
 
2.3.5.2 Processing parameter 
 
Formation of continuous defect free fibres is dependent on several factors which influence the overall 
size and morphology. It is therefore imperative to investigate the optimal conditions for each system 
to obtain the desired results. Parameters that impact the formation and structure of fibres include, 
voltage, flow rate of solution and the spinneret to collector distance.  
The strength of the applied voltage can change the fibre diameter from nanometre to micrometres. 
At suboptimal levels, production of beaded fibres is usually observed or a failure to form a jet 
altogether.  With increasing voltage Deitzel et al., (2001) found that the shape from which the Taylor 
cone formed changed from the tip of a drop to the tip of the spinneret (Figure 2.3.13) in a polyethyene 
oxide (PEO) and water system. At very high voltages the taylor cone is ejected from inside capillary 
which often results in beaded fibres (Figure 2.3.13). A separate study by Meechaisue et al., (2006) 
demonstrated fibres produced below the applied voltage of 20kV produced mostly beaded fibres as 
opposed to fibres produced above 20 kV which showed smooth fibres. Additionally, they also 
observed an increase in fibre diameter upon increasing the applied voltage from 2.5 µm at 10 kV to 
5.4 µm at 25 kV. From these studies one can conclude that for every polymer and solvent system there 
lies an optimal electric field to produce defect free fibres.  
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Figure 2.3.13 Influence of applied voltage on the creation of the Taylor cone. Source (Sill & von Recum, 
2008) 
Flow rate of the polymer solution in the syringe influences the diameter of the fibre as well as its 
porosity and shape. Lower flow rates fail to promptly replace the fluid at the tip of the spinneret as 
the polymer solution transitions into a fibre jet producing discontinuous fibres (Taylor, 1969). On the 
other hand, high flow rates can result in the formation bigger fibres with increased pore sizes. It can 
also show increased beading and flattened ribbon like structure of the fibres due to shortened time 
for solvent evaporation to take place (Megelski, 2002).  
The distance between the spinneret tip to the collector can impact the diameter of the fibres. 
Increasing the distance results in thinner fibre diameter as opposed to shorter distances which 
produced thicker fibres. A study by Jaeger et al., (1998) found that PEO fibre diameter decreased from 
19 µm to 9 µm by changing spinneret to collector distance from 1 to 3.5 cm.  
2.3.5.3 Solution properties 
 
Although each polymer and solvent system will differ in their properties for producing smooth fibres, 
some aspects can be controlled to reach an optimised process. Solution properties that influence the 
production of smooth fibres include polymer concentration, solvent volatility and conductivity.  
Polymer concentration determines whether fibre spinning, and therefore fibre formation, will occur 
or not. Both viscosity and surface tension of the solution are influenced by the polymer concentration. 
Within the optimal range, polymer concentration will be enough for chain entanglement. In dilute 
polymer solutions fibre does not form continuous threads due to effects of surface tension and instead 
breaks up into droplets before reaching the collector. At too high concentrations of polymer the 
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viscosity of the solution is increased, and the solution fails to electrospin altogether due to the lack of 
control on the flow rate. However, once am optimal range has been established one may observe an 
increase in fibre diameter upon increasing the polymer concentration (Megelski, 2002).  
In electrospinning to form fibres it is important that the solvent of choice is volatile for solvent 
evaporation to occur, leaving polymer fibres on the collector. If the solvent is too volatile or not 
enough it can affect fibre morphology by increasing pore density with volatility increases and vice 
versa. During solvent evaporation, a phase separation occurs in the transiting jet which may be 
induced by vapor induced (Megelski, 2002). Conductivity of the solvent influences the fibre diameter. 
Highly conductive solvents have a greater capacity to carry charge as opposed to low conducting 
solvents. Fibre jet produced from a high conductive solvent will be exposed to a greater tensile force 
during fibre formation than a solvent with low conductivity. Although a study by Hayati, Bailey and 
Tadros, (1987) showed that solutions with high conductivity were unstable under electric field 
resulting in bending instability and polydisperse fibre diameter. Low conductivity solvents can be 
mixed with high conductive solvents given that polymer solubility is not affected. To increase 
conductivity (C. Zhang & Yuan, 2005) added sodium chloride ions to PVA and water solution at 
concentrations 0.05 to 0.2 %. Conductivity of the solution increased from 1.53 to 10.5 mS/cm and the 
fibre diameter reduced on average from 214 nm to 159 nm respectively.  
 
2.3.5.4 Types of electrospinning 
 
Since the establishment of electrospinning a 100 years ago, several modifications to the design of the 
electrospinning process have been done. Depending on the type and configuration of the spinneret; 
mono with and without emulsion, parallel or coaxial different results are obtained. Simplest 
configuration of the spinneret is the mono spinneret where only one solution is ejected. This produces 
single or sometimes composite fibres if polymer(s) dissolve in the single solvent system. On the other 
hand, if two different polymers or solutions are to be used an emulsion may be used and electrospun 
in a single spinneret system. Alternatively, a parallel configuration may be employed to spin two 
immiscible polymer solutions in parallel (Figure 2.3.14). However, differences in solvent conductivity 
in each system may result in two Taylor cones being formed and in other cases the ratio of each 
polymer may vary (Gupta & Wilkes, 2003).  
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Figure 2.3.14 Schematic of spinneret configurations a) parallel b) coaxial. Source (Sill & von Recum, 
2008) 
Coaxial configuration is relatively new to electrospinning. Here two different polymer solutions flow 
simultaneously via separate capillaries with one smaller capillary inside a bigger capillary (Figure 
2.3.14) . This configuration is popular for drug delivery application due to its ability to form fibre within 
a fibre otherwise termed core-shell. Biologicals prone to inactivation via electric charge or 
incompatible with solvents can now be encapsulated in fibres via this mechanism. For instance, 
fluorescein isothiocynate conjugated bovine serum albumin was encapsulated with poly (ethylene 
glycol) (PEG) in poly(Ꜫ-caprolactone) (PCL) fibres using coaxial electrospinning. The resulting fibres 
showed prolonged release as opposed to burst release previously observed (Y. Z. Zhang et al., 2006). 
2.3.5.5 Applications 
 
Tissue engineering has benefited from electrospinning application due to its ability to form scaffolds 
with desirable mechanical and biological properties.  Several factors need to be considered carefully 
including material, application, orientation and porosity. Natural, synthetic or a combination of both 
materials can be used to achieve optimal fibre properties.  
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2.4 Polymers for drug delivery  
 
Overview 
Site specific delivery of drugs and other active agents is highly desirable yet challenging. A 
biocompatible carrier is required to overcome hurdles posed by the natural processes of the biological 
system. To be more specific, colon-targeted drug delivery is studied across the world to improve and 
find novel methods for site specific delivery. The harsh environment of the digestive system renders 
many drugs and active agents inactive when administered alone (Amidon et al., 2015; Choonara et al., 
2014; Philip & Philip, 2010). 
One of the key constraints for colon targeted drug delivery is the change in pH. Other factors are also 
contributors such as temperature, osmotic pressure, transition times, enzymes etc. It is important for 
a drug carrier system to withstand these changes and successfully deliver the drug to its site. It is also 
highly desirable for the drug carrier to release the drug in a time specific manner when encountering 
the appropriate trigger (Ibekwe et al., 2008).  
Table 2.4.2. pH and transition times through the GI tract (McConnel et al., 2008). 
 
 
 
 
The pH of the stomach can range from pH 1.2 to pH 3 depending on the fed or fasted state. The low 
acidic pH renders many biological agents inactive including bacteriophages. It is expected during fed 
state the transition from the stomach to the small intestine takes up to 2 hours (Vandamme, Lenourry, 
Charrueau, & Chaumeil, 2002). Pepsin and Lipases also contribute to cleaving biologically active 
compounds in the stomach. Small intestinal pH ranges from pH 5.4 to pH 7.5 with a longer transition 
time. Here many digestive enzymes (i.e. maltase, lactase and enterokinase) further degrade 
endogenous substrates (Jose et al., 2009). Further along the gastrointestinal tract (GI tract) at the 
cecum, increase in mucus layer is observed with high absorption capability. This would prevent any 
active agents targeted for the colon being delivered. On approach to the large intestine (colon) the pH 
increases ranging between pH 5.6 to pH 7.7. As well as the change in pH, enteric bacteria, residual 
food and gases (Carbon dioxide and methane) are found which can all influence the delivery and 
  Stomach Small intestine Jejunum  Ileum  
Large 
intestine 
Proximal 
colon Distal colon 
pH 1.0-3.0 5.5-7.4 6.0-7.4 5.7 6.8-7.2 6.8 7.2 
Time 
(hours) 1 to 2 3 to 4 6-72 hours 
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release of an active agent (Amidon et al., 2015). Therefore, for colon targeted delivery a robust 
polymer which can withstand the changes of the upper GI tract and show controlled release in the 
colon would be ideal. 
2.4.1 Gut physiology during disease 
 
The pathophysiology of the GI-tract is subject to further change due to the action of the infecting 
bacterial species. The intestinal barrier provided by the mucosal surfaces is disabled by distortions and 
ulcers. Mucus production is increased, and infiltration of inflammatory cells trigger an inflammatory 
response which initiates the onset of infection associated symptoms. 
2.4.1.1 Transit time and microflora 
 
A common change associated with GI diseases is the dysbiosis of the microbiome in the colon. During 
infection the reason for this is usually associated with administration of antibiotics which wipes out 
commensal species. The transit time during diseased state is also faster due to the onset of diarrhoea 
which increases the expulsion of fluid from the body. Further to this, the decreased osmotic gradient 
between the colon and the epithelia means increased leakage of fluid with minimal reabsorption 
which decreases viscosity and dilutes the action of enzymes present (Van Citters & Lin, 2006). This 
directly affects the transit time which can alter the way conventional dosage forms are delivered to 
the colon.  
2.4.1.2 pH and volume 
 
Owing to the nature of the infection (colon related), fluctuation in the stomach and small intestine pH 
has been little investigated. The pH of the colon however, is observed to be significantly lower than in 
healthy adults. Under normal conditions the pH of the colon between the proximal and distal colon is 
6.8 and 7.2 respectively. However, in diseased state the pH drops below 5.5 (Hua et al., 2015; 
McConnell et al., 2008). The change in pH affects the microbial population in the colon which can 
directly affect the transit time, preventing encapsulation formulations from releasing the drug.  
2.4.1.3 Mucosal integrity 
 
The purpose of the epithelial barrier in the colon is to control movement of molecules in and out of 
the lumen to the underlying tissues. This regulation is aided by transmembrane protein complexes 
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referred to as tight junctions (TJ). The transport of cytokines, ions and glucose etc. is due to multi-
protein complexes which act downstream to selectively move substances in an out depending on 
appropriate stimuli. The epithelial layer is surrounded by a tightly attached mucus layer, which lacks 
the presence of bacteria. This firmly attached mucus layer is surrounded by another mucus layer which 
is attached less compactly and is colonised by bacteria. The main mucin (glycoproteins) that comprises 
the mucus in the intestine is MUC2. MUC2 protects the epithelial barrier from bacterial interaction 
and is continuously shed to reduce host-bacterial interactions. If the bacteria are successful in 
penetrating the outer mucus layer, they will be able to interact with MUC1 which is attached to the 
epithelial cells via a transmembrane domain. The mucus layer not only acts as a barrier but also 
provides food sources for commensal bacteria to maintain their niches. There are many sugars such 
as oligosaccharides, galactose and fucose which are attached to the mucin glycoproteins available for 
bacteria. It is found that in CDI patients produced higher amounts of galactose which is known 
receptor for toxin A in animal models ((Voth & Ballard, 2005). 
Although these properties make good pharmacological targets, they become dysfunctional during the 
diseased state. Bacterial toxins enter the cytosol via receptor mediated endocytosis; the endosome 
used for transport is acidic. Upon reaching the cytosol these toxins exhibit their enzymatic actions by 
glycosylating the Rho resulting in actin condensation, membrane blebbing and eventually apoptosis 
of cells (Voth & Ballard, 2005). Toxin receptors for some bacteria in humans have not been identified 
therefore better understanding of pathogenesis is required for therapeutic development.  
A study by Engevik et al. (2014) showed the production of acidic mucin is largely composed of MUC1. 
The decreased production of MUC2 indicated a disabled barrier system for preventing bacteria 
crossing the epithelial barrier. The ‘leaky’ mucosal gel layer alters the viscosity which affects the 
permeability of mucoadhesive drug formulations (Keely et al., 2009).  
2.4.2 Drug Delivery  
 
Polymers can be natural or synthetic and have been exploited as drug carriers due to their 
biocompatibility. Polymers offer diversity in topology, chemistry, biodegradability, flexibility and 
resilience. Polymers also show controlled and sustained release at a specific site as they have proven 
to overcome being metabolised by pancreatic enzymes. Such polymers are used to carry drugs for the 
treatment of ulcerative colitis, Crohn’s disease, colorectal cancer inflammatory bowel disease and 
many more (Dubey et al., 2010; Souza et al., 2013). 
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There are many advantages of colon drug delivery systems (CDDS). The colon has a long transit time 
and is the optimal absorption site for proteins and other molecules. It offers prolonged drug 
absorption and release which can be desirable for treatment of diseases that show symptoms during 
specific times. Alternatively, abrupt release can also be triggered with certain polymer formulations. 
Also, CDDS reduces toxicity, incidence of adverse effects and lowers the conventional dosage required 
(Choonara et al., 2014).  
There are many drug carrier systems for site specific drug delivery such as poly(lactic)acid, chitosan, 
PEG, sodium alginate, dendrimers and Eudragit series. All these polymers respond to different stimuli 
at the target site. Types of stimuli from the environment can vary from temperature, ionic strength, 
pH, osmotic pressure and glucose levels. Therefore, it is important to consider the site delivery and 
purpose of the encapsulated drug when deciding which polymer to use. Release mechanisms play a 
vital role in delivering drugs and should be evaluated for changes in diseased states (McConnell et al., 
2008).  
Properties of the polymer including hydrophilicity, lubricity and surface energy direct the 
biocompatibility of the polymer with blood and tissue. These properties help decide the suitability of 
a polymer for a site-specific delivery.  Permeability, degradability and durability also influence the 
physical properties. Hydrogels which undergo hydrolytic degradation and swelling are influenced 
greatly by their surface properties (Angelova & Hunkeler, 1999). It is now also possible to graft active 
agents (enzymes, proteins, antibodies) to the surface of the polymer for targeting of specific organs 
and cells (Pillay et al., 2013). 
The number of bacteria in the upper GI tract is approximately 103-104 CFU/ ml, largely composed of 
Gram positive facultative anaerobic bacteria. In the colon however, this increases significantly to 1011-
1012 CFU/ml (Sekirov et al., 2010) and is largely composed of anaerobes such as Bacteriodes, 
Bifidobacteria, Eubacteria, Clostridia, Enterococci and Enterobacteria. To survive this, bacteria utilise 
undigested substrates from the small intestine. Carbohydrates like di- and tri-saccharides and 
polysaccharides are fermented by these organisms (Nicholson et al., 2012). Microbes produce 
enzymes such as β-glucoronidase, α-arabinosidase, β-xylosidase, β-galactosidase, nitroreductase and 
urea dehydroxylase. (Mountzouris et al., 2007). These enzymes metabolise polysaccharides which the 
body is unable to produce enzymes against. 
Colon drug delivery strategies can also vary depending on the mechanism that is exploited such as pH, 
time dependent and biodegradability. Prodrugs use the strategy of cleavage of bonds between the 
drug and carrier by reduction or hydrolysis using enzymes present in the GI tract. pH dependent 
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systems utilise a combination of polymers to withstand the pH changes of the GI tract. However, due 
to certain pH overlaps between the small intestine and colon, site specificity can be affected. However, 
time dependent systems can survive through the transit times of each segment of the GI tract and 
only released upon reaching the colon. This approach can somewhat be unpredictable due to variation 
in transit times influenced by various inter/intra factors (McConnell et al., 2008). Microflora-activated 
systems depend on the microbial presence in the colon for the fermentation of polysaccharides 
present in the coat material of the encapsulated drug. Although this approach is positive, the 
enzymatic process can take several hours (approx. 12 hours) for complete degradation. Other 
strategies include osmotic systems and peristaltic pressure which is also subject to variation and 
instability, decreasing the site-specific response.  
2.4.3 Natural polymers 
 
Natural polysaccharides are widely used for drug encapsulation and colon targeted drug delivery. 
These polysaccharides are desirable due to their biodegradability, hydrophilicity, and limited swelling 
characteristics in acidic environment. The diverse population of microbes in the colon metabolise 
these polysaccharides by hydrolytic cleavage of the glycosidic bonds (Jose et al., 2009). They are 
inexpensive, low cost and available in a variety of structures and properties (Hovgaard and Brondsted 
et al 1996; Vandamme et al., 2002). Examples of polysaccharides in drug delivery include; Pectin, 
Chitosan, Guar gum and dextrans. 
Chitosan is a cationic aminopolysaccharide co-polymer of glucosamine and N-acetylglucosamine 
extracted by alkaline deacetylation of chitin (Garcia-Fuentes & Alonso, 2012) (Figure 9.2 appendix). 
Chitosan is soluble at low pH and therefore for effective use in colon targeted drug delivery it requires 
an enteric layer for protection against acidic environment. The enteric layer is stripped off in the 
intestine where the pH increases, releasing the chitosan coated core. Microbes in the colon act on the 
chitosan by degrading it and releasing the drug (Sinha & Kumria, 2001).  
Chitosan microcores have been shown to encapsulate sodium diclofenac using the spray-drying 
method. These microcores were then further encapsulated within a methacrylate polymer Eudragit. 
Eudragit is the enteric layer which protects the chitosan from dissolving in the presence of low pH. 
Upon entering the intestine the enteric layer is stripped off which is also pH triggered causing the 
chitosan microcores to swell and subsequently release the drug upon entering the colon (Lorenzo-
Lamosa et al., 1998).  
55 
 
Pectin is a non-starch, linear polysaccharide obtained from plant cell walls (Figure 9.3 appendix). It is 
effective in delivering both water soluble and insoluble drugs however due to its poor ability to form 
a film it is often used in combination with other polymers. Curcumin was encapsulated in pellets 
consisting of pectin and hydroxypropyl methycellulose (HPMC) showed effective protection against 
premature drug release and efficient release in the intestine (Kumar et al., 2009). 
Guar gum is a polysaccharide composed of two sugars, galactose and mannose (Figure 9.4 appendix). 
It can be used for colon targeted drug delivery due to its release retarding property and susceptibility 
to microbial degradation. Fluoruracil (drug) was encapsulated in pellets consisting of guar gum and 
Eudragit. It was observed that the guar gum acted as a retardant and worked in a time-controlled 
manner. Eudragit also help protect the drug in the acidic environment. Due to microbial aided 
degradation of guar gum the drug was released in the proximal colon (Ji, Xu, & Wu, 2009). 
Alginate is a linear polymer (Figure 9.5 appendix) which is commonly used for its ability to gel in the 
presence of calcium ions. This gelation results in the formation of calcium alginate beads which are 
capable of encapsulating drugs. Ma et al., (2008) and Ma et al., (2012) showed the encapsulation of 
phage Felix O1 against Salmonella enterica into chitosan and alginate microspheres. Upon exposure 
to simulated gastric fluid 2-log reduction was observed, but full release was obtained in intestinal fluid. 
Similarly, there are other polysaccharides namely, amylose, lectins, inulin, dendrimers and pullulan 
which all have been exploited for their ability to encapsulate drugs for colon targeted delivery and can 
be applied for phage encapsulation. 
The mechanism in all polysaccharide-based polymers is the same in that they are degraded by the 
diverse population of microbe produces enzymes which target different chemical bonds. However, 
this process is constrained by the changing environment of the GI tract which can dissolve, swell or 
essentially inactive the polysaccharide ability to protect the drug. Therefore, as seen in many cases 
they are almost always used in combination with synthetic polymers such as the Eudragit series which 
is pH responsive.  
2.4.4 Eudragit S100 
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Figure 2.4.1 Monomer of Eudragit S100 
 
Eudragits are a family of polymethacrylate polymers (Figure 2.4.1); Eudragit S100 (ES100) and L100 
are the most commonly used pH-dependent methcrylic acid copolymers. Dew et al. (1984) developed 
the first pH-responsive colon targeted delivery system. Eudragit L100 dissolves at pH 6 and Eudragit 
S100 at pH 7. Therefore, it is commonly found that anionic ES100 is used in combination with other 
polysaccharide polymers for colon targeted drug delivery due to its ability to bypass acidic 
environment (low pH) of the upper GI tract. These polymers are commercially available (Evonik, 
Darmstadt, Rohm Pharma Germany) and are widely used in the preparation of microspheres.  
The ES100 mechanism of action is largely based around the COOH group of its chemical structure. In 
its raw powder form, the polymer is anionic and remains that way unless a hydroxyl group is present 
for its neutralisation and subsequent dissolution. The common solvents used are ethanol, isopropanol, 
methanol, DCM etc. It does not dissolve in water; however, in the presence of hydroxyl ions in the 
water it has the capability to dissolve. The phenomenon is the essence of its pH triggering response. 
When the pH increases the hydroxyl ion concentration increases therefore, prompting the dissolution 
of the polymer. The mechanism of action is demonstrated in Figure 2.4.2.  
 
 
Figure 2.4.2 Schematic to show the mechanism of pH responsive polymer. 
 
Eudragit have been successfully used for the production of microspheres encapsulating drugs for colon 
delivery (Chawla et al., 2012; de Arce Velasquez et al., 2014; Jain et al., 2005; Kietzmann et al., 2010; 
C. M. Silva et al., 2006). As ES100 has a response to the highest pH (pH 7) it is ideal for colon targeted 
Eudragit® S100 
Bacteriophage 
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delivery. By combining this copolymer with other biodegradable polymers (mentioned above), it 
makes a promising delivery system of phages to the colon. Bacterial infection of cattle can be 
detrimental; phages are an alternative to antibiotic treatment. (Stanford et al. 2010) has shown the 
use of ES100 for Escherichia coli specific phage encapsulation for cattle treatment. Here, they show 
the high sensitivity of the phage to the acid in the gastric environment. However, encapsulated phage 
showed higher viability and the aptitude to reduce bacterial population at the site of infection. The 
potential of ES100 in encapsulation can also be observed in the patent CA 2463827 C (Waddell et al. 
2013). 
Other, synthetic polymers are also available that have been FDA approved for food additive, 
pharmaceutical ingredients and as drug system carriers. Examples of this include Pluronics® and 
Tetronics®, they present a sol-gel transition at varying temperatures. The drug release is temperature 
and diffusion triggered (Escobar-Chavez, 2006). However, the application of such system is not 
suitable for colon targeted drug delivery. Poly(ethylene glycol) (PEG), poly(ethylene oxide) (PEO), 
poly(acrylic acid), poly(vinyl pyrrolidone) (PVP) and Boronate-containing polymers are all synthetic 
polymers. Semi-synthetic polymers which are derivates of cellulose are also used. 
2.4.5 Combination of polymers for colon targeted drug delivery 
 
2.4.5.1 Eudragit and chitosan 
 
Polysaccharides are an effective way to encapsulate bioactive agents but on their own they are weak 
delivery systems. In most cases, enteric coating is required to protect the polysaccharides from the 
gastric environment. Chitosan for example, is a cationic, hydrophilic, crystalline polymer with the 
ability to undergo gelation but in the presence of acid it dissolves. Therefore, to keep chitosan intact 
during transition through the GI-tract until it reaches the colon where it undergoes hydrolysis of its 
glycosidic bonds, an enteric coating with synthetic polymer such as Eudragit is usually applied 
(Lorenzo-Lamosa et al., 1998).  
Chitosan is an approved food ingredient; therefore it is an acceptable excipient for oral administration. 
It possesses a mucoadhesive character and is cleavable by lysozyme, produce by intestinal bacteria in 
the mucosa. Although efforts have been made to crosslink this polysaccharide using aldehydes, the 
toxicity remains a concern. Therefore, by applying an enteric coating it is possible to target drug 
delivery in the colon. Chitosan microspheres containing the drug are usually produced by one of the 
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encapsulation techniques, which is followed by the addition of the enteric coating by solvent 
evaporation. This ensures encapsulation efficiency and stability of the two polymers.  
Delivery of mesalamine (drug) in Eudragit S100 coated chitosan microspheres for the treatment of 
ulcerative colitis was demonstrated by Badhana et al., (2013). The mechanism behind its delivery relies 
on the ability of the enteric coating to protect the encapsulated drug during transition from the 
stomach and small intestine. Upon reaching the colon where the pH increases, the enteric layer strips 
off exposing the chitosan to the local mucosal environment to be natural degraded by lysozymes. At 
colonic pH (pH > 7.2) the chitosan sphere swells but do not dissolve. This prompts the release of the 
drug into the local environment where the site-specific action commences.  
A similar study by Lorenzo-Lamosa et al., (1999) showed the encapsulation of sodium diclofenac (anti-
inflammatory drug) is chitosan cores, coated with either Eudragit S100 or L100. Release profiles show 
faster release with enteric coating Eudragit L100 due to its response to lower pH in comparison to 
Eudragit S100 (pH 7). The swelling of chitosan cores was observed with water diffusion resulting in 
drug dissolution and release. Protection against gastric pH was seen with a total release time between 
8 to 12 hours. The chemical properties of the polysaccharide and the enteric coating are compatible, 
in that infrared analysis showed ionic crosslinking between the amine groups of the chitosan with the 
carboxyl groups of Eudragit. 
2.4.5.2 Eudragit and PLGA 
 
Eudragit® has been used to coat poly(lactide-co-glycolide) (PLGA) particles (Figure 9.6 appendix). For 
similar reasons to chitosan microspheres, PLGA particles require protection from gastric pH due to its 
susceptibility to dissolution. Enteric coating provides this protection until colon pH is reached where 
the dissolution of the enteric coating triggers swelling of the PLGA core encapsulating the drug. PLGA 
chains undergo cleavage into smaller low molecular weight fragments upon hydration. These undergo 
further erosion and degradation releasing the drug in the colon site (Y. Wang et al., 2013).  
In vivo models analysing the efficacy of PLGA and Eudragit nanoparticles in a trinitrobenzenesulfonic 
acid (TNBS) colitis rat model was investigated by Makhlof et al., (2009). The investigation highlighted 
the bioavailability of budesonide (anti-inflammatory drug) in the proximal region of the colon with 
specific adhesion of the nanoparticles to the inflamed mucosal tissue. It is found that smaller particle 
sizes demonstrate better attachment to the mucus layer and penetrate through the disrupted, 
ulcerated mucosal barrier site during inflammatory colitis (J. Stein et al., 1998; A. Lamprecht et al., 
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2005). Inflammatory cells such as macrophages engulf these nanoparticles which further contribute 
to their accumulation at the site of inflammation (H. Nakase et al., 2001).  
2.4.5.3 Eudragit and sodium alginate 
 
Alginate is another polysaccharide regarded safe by the FDA and is widely used in the food industry as 
an emulsifier and stabiliser. It is an anionic polymer with carboxyl end groups giving it mucoadhesive 
properties which are reported to be higher than any other polysaccharide polymer such as chitosan. 
This property means the drug bioavailability due to localisation at absorptive surfaces is increased. In 
response to low pH alginate does not release the encapsulated drug but shows shrinkage with porous 
morphology. As the pH is increase sodium alginate converts into a soluble viscous layer, giving it a pH 
responsive property. However, it is noted that pH changes result in burst release which can easily 
denature the bioactive agent encapsulated. Mechanism of release is dependent on the porous 
network through which the bioactive agent can diffuse out or due to the polymeric degradation. The 
pore size of sodium alginate is between 5 nm to 200 nm. 
Thus, to protect alginate microspheres during passage through the GI tract enteric coating can be 
applied to protect shrinkage in low gastric pH. Crosslinking sodium alginate with calcium chloride 
whilst encapsulating the drug is a common procedure. This can be followed by Eudragit coating for 
protection. Naproxen (anti-inflammatory drug) was encapsulated in sodium alginate and Eudragit 
S100 for colon targeted delivery (Chawla et al., 2012). Sodium alginate has demonstrated to be 
biocompatible with phages. Encapsulation of phages has been demonstrated with this polysaccharide 
with positive results showing site specific delivery (Cecilia Dini et al., 2012; Yongsheng Ma et al., 2008, 
2012). 
Dextran is another polysaccharide prone to ester cleavage by dextranase produced by microflora in 
the colon. It is hydrophilic with a reactive hydroxyl group which can react with other carboxyl groups 
on co-polymer or drugs. 
2.4.6 Commercially available technologies  
 
There are various systems that are widely used to further coat microspheres into pellets. Coat 
technologies for colon targeted drug delivery such as CODESTM are used for this application. CODESTM 
technology is comprised of a three-layer system; the core containing the drug is surrounded by the 
inner acid soluble layer (Eudragit E), the middle layer is made of HPMC which acts as barrier, and the 
outer enteric layer. The core is comprised of a polysaccharide which is hydrolysed by enzymes 
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produced by bacteria in the colon. The enteric coating protects the drug from the stomach acid but 
dissolves in the small intestine along with HPMC where the pH is 6 or above. Eudragit E (inner layer) 
dissolves at pH less than pH 5, it is only slight permeable and swellable in the small intestine. On arrival 
in the colon the polysaccharide core diffuses and dissolves through the inner coating to be broken 
down into organic acid by enzymes. Because of this the microenvironment pH is reduced causing the 
dissolution of Eudragit E and release of the encapsulated drug. The purpose of this technology is to 
reduce the variability associated with pH and time during drug delivery.    
Another tableting technology called COLALTM employs a simpler method with a two-layer coating. The 
inner coating is made of a polysaccharide which is prone to degradation by colonic bacteria and the 
outer layer is the enteric coating to protect degradation during passage through acid pH in the 
stomach and small intestine. The enteric coating dissolves at pH above 7 in the colon exposing the 
polysaccharide layer. Enzymatic action of the bacteria in the colon degrades this slowly releasing the 
drug. Ethylcellulose and amylose blend as the polysaccharide inner coating was researched by Wilson 
and Basit (2005) for mesalazine (anti-inflammatory drug for ulcerative colitis) release. It was found 
that the system was susceptible to colonic bacterial induced degradation. The formulation is now 
available as COLAL®, which is used to coat tablets containing corticosteroid prednisolone sodium 
metasulphobenzoate (COLALPRED®; Alizyme Therapeutics Ltd, Cambridge UK). It is currently in phase 
III clinical trial for the treatment of ulcerative colitis. To delay release until reaching the colon Eudragit® 
coating dispersion has been used (Thompson et al., 2001; Basit & Ibekwe 2007). 
The third technology known as the multimatrix system (MMXTM) utilising a combination of pH 
triggered and diffuse based method. This technology is designed to release the drug in the colon. The 
drug is dispersed in a lipophilic matrix which is surrounded by a hydrophilic matrix. The third outer 
layer is comprised of a pH-dependent coat which prevents release in stomach acid. As the enteric 
coating is removed in the colon, fluid is absorbed into the remaining layers causing swelling and 
eventually formation of a gel. Bacterial fermentation breaks of the gel in fragments allowing the drug 
to diffuse out into the colon (Sandborn et al., 2007).  
Single coat tabletting technology, PHLORALTM combines pH responsive polymer Eudragit S100 with 
polysaccharide (resistant starch). Eudragit S100 prevents drug release and swelling of starch in the 
stomach and small intestine. The ‘resistant’ starch is capable of resisting degradation by amylase 
produced by the pancreas but is susceptible to colonic enzymes. In the colon at the ileocaecal junction 
due to increase pH Eudragit S100 dissolves, exposing the starch to both enzymatic and pH triggered 
degradation (Ibekwe et al., 2008).  
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2.4.7 Chemical modification of polymers 
 
2.4.7.1 Aliphatic polyesters 
 
Synthetic polymers are widely used in industry for various applications from plastics, grafts, drug 
delivery and many more. Biopolymers with reactive groups offer the advantage of manipulating its 
chemical structure to suit the purpose it is used for. Biopolymers are used to protect drugs to enable 
them to reach the site of infection intact. Aliphatic biopolymers such as poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(ε-caprolactone) (PCL) and their copolymers are synthetically produced 
using one naturally occurring substrate for example lactic acid produced by bacteria in PLA. These 
polymers are biodegradable, biocompatible and bio-absorbable making them good candidates to be 
studied for biomedical applications. Modification of their reactive groups alters their end use, some 
of the features include, hydrophilicity, rate of biodegradation, bioadhesion, targeting moiety 
attachment. These features are activated by adding chemical groups like carboxyl, hydroxyl, amino, 
ketal, bromo, chloro, carbon-carbon double to triple bonds to the polymer. To allow for the addition 
of these reactive groups either homopolymerization or copolymerisation process can be applied. The 
most common application of aliphatic polyesters is in clinical devices. 
2.4.7.2 Polycarbonate and Poly (amino acids)  
 
Polycarbonate is also a biopolymer with side chains (OH, NH2, COOH) that can be tuned to meet the 
requirements of biomaterials. They have good biodegradability, low toxicity and biocompatibility. 
Peptides and drug molecules can be attached to free functional side chains of the polymer for specific 
drug delivery and tissue engineering. Drug attachment through esterification of 4-
isobutylmethylphenylacetic acid (non-steriodal anti-inflammatory drug (NSAID)) to the copolymer was 
studied by Grinstaff et al., (2003). Poly (acidic amino acids) such as poly(L-glutamic acid) (PLG) is 
produced by linking amide bonds from naturally occurring L-glutamic acid and active carboxyl bonds. 
This too can be modified by changing functional side chains by esterification, polymerisation, 
condensation or aminolysis.  
- Biopolymers with responsive activities  
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Biopolymers that are responsive to specific stimuli have gained increased attention. Transition to their 
physical-chemical properties (conformation, polarity, phase structure and chemical composition) 
enables them to respond to small changes in the environment. Modifying synthetic biopolymers for 
smart function is vital in targeting constraints faced in biomedical research. At present they are being 
used in biomedical applications for drug delivery, tissue engineering and biosensor design.  
2.4.7.3 pH responsive  
 
pH in the body can vary from acidic to alkaline which can be challenging when targeting a drug to a 
specific site. Biopolymers responsive to pH exhibit this function through the addition ionisable groups 
which respond to changing pH. The polypeptides usually acidic or basic depending on the amino acid 
attached. Poly(histidine) for example gets protonated at the imidazole groups at pH 5 to 6.5. 
Hydrophobic groups can be incorporated into their structure to alter their pKa.    
2.4.7.4 Prodrugs 
 
Polymers with modifiable reactive groups, biodegradability and responsive characteristics have been 
studied for drug delivery. Drugs can conjugate to carboxyl groups on polymers like poly(α-malic acid) 
to form prodrugs (biodegradable macromolecules) to decrease the side effects encountered during 
free drug administration. As the polymer degrades in response to a stimulus (i.e. pH) the attached 
drug is also released. Prednisone acetate showed burst release at pH 7.4 in vitro as the polymeric 
micelle composed of poly(acrylic acid-b-DL-lactide) dissolved at this pH (Huang et al., 2009). Kim et 
al., (2009 and 2012) reported metronidazole prodrugs in two forms; (N-nicotinoyl-2-{2-(2-methyl-5-
nitroimidazol-1-yl)ethyloxy}-D,L-glycine (NMG)) and sulfate conjugated metronidazole. In both cases 
the prodrug was metabolised by nitoreductase present in the cecal contents of rats. Similarly, 
metronidazole-pectin prodrug was researched by Vaidya et al., (2012), results showed no release in 
acidic pH but subsequent release was observed at alkaline pH.  
 
Other prodrug designs include incorporation of the active agent to the carrier polymer which is 
susceptible to colonic enzymatic action. Here, azo-link is established by conjugating the drug for 
example 5-aminosalicylic acid (Mesalamine) (drug for ulcerative colitis) to the carrier example, 
sulfapyridine to form azo-linked prodrug, sulfasalazine (Azulfidine®). In the colon sulfasalazine is 
metabolised by reductase into 5-ASA and sulfapyridine. In the same way, addition of β-D-galactose 
to the active agent (5-ASA dexamethasone) via a glycoside bond will enable release of the drug by 
hydrolyses by glycosidases in the colon (Lautenschlager et al., 2014). Hydrogels formed by 
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crosslinking for example dextran to diisocyanate, show the ability to withstand conditions in the 
upper GI-tract with minimal swelling. In the colon however, the hydrogel swells to its maximum 
capacity exposing the crosslinks to enzymatic action, in this case by dextranase (Hovgaard and 
Brondsted 1994). 
 
2.4.7.5 Modifying size, charge and surface ligands 
 
Colonic drug delivery has significantly improved over the years with increased bioavailability and site 
specificity. However, challenges arise when infection of the colon results in physiology changes 
rendering conventional formulations ineffective. In diseased state they have poor specificity for the 
site of infection and reduced efficacy in comparison to healthy conditions (Hebden et al., 2000). 
Nanoparticle associated delivery systems are designed to target the site of infection through passive 
transport. The size of nanoparticles (nanometers) increases their efficacy and bioavailability at the 
target site with no adverse effects to the surrounding environment.  
2.4.7.6 Size, charge and PEGylation dependence 
 
Studies have found that by reducing the size of particles to nanoscale enhances their ability to reach 
deep routed site for targeted drug release. The residence time of nanoparticles is also higher 
compared to bigger particles, as bigger particles are more prone to peristaltic action and movement 
through the colon. Nanoparticles are able to present an epithelial enhance and retention (eEPR) effect 
enabling elective delivery of active molecules into the colitis tissue (Collnot et al., 2012; Xiao et al., 
2012). Conventional formulations lack this ability due to their size, causing deposition in regional areas. 
Smaller particle sizes are able to take advantage of endocytosis for internalisation into the epithelial 
cells of the colon. They attach to specialised epithelial M cells which are responsible for antigen 
transport form the lumen to the immune system. These M cells are also responsible for uptake of 
nanoparticles by transcytosis (Pichai et al., 2012). Microparticles demonstrate adherence to inflamed 
mucosal wall whereas nanoparticles absorbed across the epithelial barrier (Schmidt et al., 2013). 
The charge of the particles can also contribute to the deposition in the colon. Cationic delivery systems 
adhere to the negatively charged intestinal mucosa which promotes their cellular uptake and 
subsequent drug release (Coco et al., 2013). The mucins which comprise the mucosa are also known 
to be negatively charged. Anionic systems adhere to inflamed tissue via an electrostatic interaction, 
as the presence of positively charged proteins in the inflamed regions increases. Unlike cationic 
64 
 
particles which get immobilised on the mucus, anionic particles can interdiffuse through the mucus 
network due to decreased electrostatic interaction (Hua et al., 2015). 
Incorporating poly(ethylene glycol) (PEG) on the surface of particles builds a hydrophilic surface 
chemistry that allows an unobstructed diffusion of nanoparticles through the epithelium. The reason 
for this is that the surface modification prevents strong interaction of nanoparticles to the mucus 
which can prevent diffusion to the colitis tissue (Cu et al., 2008).  
2.4.7.7 pH dependence 
 
As previously mentioned the difference in pH through the GI tract is exploited by many formulations 
for targeted drug delivery. The most common pH-dependent coating used in oral delivery is 
methacrylic acid copolymers (Eudragit). By varying the number of carboxylate side chains, the polymer 
can be induced to dissolve at different pH. These polymers are usually used in combination to allow 
drug release within a range for example Eudragit S100 and L100 for release at pH between 6 and 7. 
This polymer series also exhibits mucoadhesive properties (Asghar and Chandran 2006). A study found 
that Eudragit coated liposomes in simulated gastric and intestinal fluids was not able to withstand the 
presence of bile salts. The instability of the enteric coating in bile salt can greatly affect the stability of 
drug in vivo (Barea et al., 2012). 
2.4.7.8 Biodegradable systems 
 
There are some aspects which are consistent amongst patients with IBD which can be exploited to 
formulated biodegradable systems for drug delivery. Laroui et al produced nanoparticles (400nm) 
encapsulating anti-inflammatory drug, tripeptide Lys-Pro-Val using calcium and sulfate ion cross-
linked chitosan and alginate. This hydrogel was prone to degradation by enzymes in the colon which 
subsequently released the drug. Similarly, poly(epsilon-caprolactone) (PCL) can be used to micro-coat, 
nanoparticles to protect degradation by acidic environment, adsorption by enzymes and proteins. The 
drug is released in the colon via the action of lipases which degrade PCL (Bhavsar and Amiji 2007). 
Hydrogels are susceptible to hydrolytic cleavage by colonic enzymes and can also be used for targeted 
biodegradable delivery systems (Han et al., 2008).  
 
2.4.7.9 Active targeting systems 
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Active targeting by surface imbedding ligands for selective drug accumulation at the site of 
inflammation can help reduce adverse effects and increase therapeutic efficiency. Monoclonal 
antibodies and peptides specific for target site are used to increase specificity and enhance 
mucopenetrative properties (Saltzman et al., 1994). It is thought that by incorporating ligands for 
receptors present at the site of infection will improve binding and intensify endocytosis. Possible 
receptors for target in the inflamed colon can include, ICAM-1 which is upregulated during 
inflammation, mannose receptors and macrophage galactose-type lectin (MGL) (expressed by 
activated macrophages). By combining the effect of small particle size, PEGylation and integration of 
mannose ligands an increased penetration ability of macrophage was observed (Xiao et al., 2012). 
The combined effect of different enhancement to specific targeting may be the future for colon drug 
delivery. It is important to understand the changing physiology of the colon from healthy to diseased 
state and to consider patient to patient variations. The gut microflora can also vary greatly between 
healthy individuals therefore biodegradable coatings should be formulated to cover the variability 
between individuals.  
2.4.8 Phage encapsulation for the treatment of enteric infections 
 
2.4.8.1 Phage and probiotic (2 in 1) delivery potential 
 
Probiotics (live microbial feed) are thought to be beneficial for host by improving and maintain the gut 
microbial population. Probiotics are approved by health authorities and require delivery to the colon 
for maximum effect. Encapsulation is seen to be the best way to avoid killing the live bacteria and 
deliver it to the colon (Albertini et al., 2010; Govender et al., 2015; Han et al., 2008). Probiotics may 
help in replenishing or repopulating the intestinal flora after an infection. Therefore, the most 
common bacterial species such as Bifodobacterium and Lactobacillus may be incorporated with the 
bacteriophage during treatment. The bacteriophage is self-replicating, if the host (bacteria) is present. 
During the process of treatment (with phages) to prevent further colonisation and improve recovery, 
incorporation of probiotics may be another approach to lower the number of sick days and 
subsequently cost associated with treatment, recovery and possible relapse.  
2.4.8.2 Phage and phosphatase 
 
In addition to that Alam et al., (2014) studied the effects of brush border enzyme intestinal alkaline 
phosphatase (IAP) in restoring the gut flora after infection. Streptomycin and clindamycin induced 
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infection in mice resulted infection with Salmonella Typhymurium and Clostridium difficile respectively. 
Administration of calf IAP (cIAP) showed protection against infection from S. Typhymurium and C. 
difficile. IAP is produced by enterocytes in the proximal region of the small intestine and is secreted 
into the lumen. It functions to detoxify bacterial toxins, dephosphorylates ATP, regulates host 
microbial interaction, guts mucosal defence, maintains gut immunity and preserves intestinal 
microbiotal homeostasis (Alam et al., 2012). IAP is another possible candidate which could be 
incorporate alongside bacteriophages to speed up recovery and repopulate colonic microflora. 
 
2.4.9 Mechanisms for testing encapsulation 
 
Studying the effect of encapsulation in vitro has often involved using buffers with varying pH values. 
This is a straightforward way to demonstrate resistance of the formulation to gastric pH and intestinal 
pH with subsequent dissolution in slightly alkaline pH mimicking the colon. However, it can be argued 
that although it is a great test to test the key constraint encountered in the GI tract but it lacks the 
ability to examine other factors present in vivo that may influence dissolution. pH responsive polymers 
that resist gastric pH, can be tested via this method however it is found that the presence of bile salts 
(Barea et al., 2010). Therefore, it is important to evaluate the influence of as many parameters seen 
in vivo, in vitro testing.  
For a better understanding of the GI tract environmental influence on the encapsulation formula, 
there are USP standards that state the composition of a simulated gastric and intestinal environment. 
Simulated gastric and intestinal fluids consider the presence of bile salts, surfactants and enzymes in 
the upper GI tract in addition to the pH. Presence of pepsin in the stomach and protease in the small 
intestine is considered. Simulated fluids give a better understanding of the possible interactions 
between the delivery system and the upper GI-tract. Simulation of the colon is difficult due to its 
complex network of microflora.  Nevertheless, studies have been undertaken to address this issue and 
develop better systems for understanding the physiology. 
To better test the dissolution of a delivery system in the colon presence of the microflora under certain 
pH conditions is seen to be important especially when evaluating pH responsive and biodegradable 
polymers. Efforts have been made to mimic the microflora in the human gut, in an in vitro model. 
Hamster (animal) models have been extensively employed to study CDI. It is found that the microflora 
of these animals is closely related to the gut microbiota of humans. This however is controversial, as 
the microflora fingerprint is thought to be distinct for everyone. Ex-germ free mice have been 
67 
 
inoculated with human micro flora (HFA) in order to better mimic the human gut physiology (Sekirov 
et al., 2010). 
Using human faecal emulsions from healthy and infected individuals it is possible to evaluate the effect 
of delivery systems in vitro without using invasive procedures (Best et al., 2012). Macfarlane et al. 
(1998) investigated validity of a three-stage compound continuous culture system. Here, the colonic 
material obtained from 4 sudden death victims at autopsy was divided into three vessels (V) 
representing the proximal (V1) and the distal (V2 and 3) of the colon. The fermentation system 
mimicked the spatial, temporal, nutritional and physicochemical characteristics of the human colon. 
The retention time could be controlled, and pH of each vessel could be monitored. It was found that 
the pH of the digestive material in the cecum and the ascending bowel was acidic but increased 
towards neutrality in the distal gut. Carbohydrate breakdown largely occurred in V1 and aromatic 
amino acid fermentation was shown to be affected by retention time.  Overall the correlation between 
in vivo chemical and bacteriological measurements to this vitro study was positive (Macfarlan et al., 
1997) suggesting that this three-stage fermentation system is a suitable model system to study 
dissolution of colon targeted delivery systems. 
The next step after in vitro testing is to apply the encapsulated active agent in vivo, using animal 
models. Hamsters especially Syrian hamsters are commonly used to study factors associated with CDI. 
This is because they share recognised features isolated form human samples and contract infection 
after administration of antibiotics as seen in humans (Best et al. 2012). Better understanding of the 
human gut under normal and diseased conditions is necessary to improve analysis of delivery systems. 
In addition to that further research to understand the effect of virulence factors produced by 
pathogens and receptors involved in colonisation is required to formulate active delivery systems.  
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Chapter 3: Clostridium difficile specific bacteriophage encapsulation using 
microfluidic glass capillary devices for colon delivery 
Abstract 
 
The prevalence of pathogenic bacteria acquiring multidrug antibiotic resistance is a global health 
threat to mankind. This has motivated a renewed interest in developing alternatives to conventional 
antibiotics including bacteriophages (viruses) as therapeutic agents. The bacterium Clostridium 
difficile causes colon infection and is particularly difficult to treat with existing antibiotics; phage 
therapy may offer a viable alternative. The punitive environment within the gastrointestinal tract can 
inactivate orally delivered phages. C. difficile specific bacteriophage, myovirus CDKM9 was 
encapsulated in a pH responsive polymer (Eudragit S100 with and without alginate) using a flow 
focussing glass microcapillary device. Highly monodispersed core-shell microparticles containing 
phages trapped within the particle core were produced by in situ polymer curing using 4-aminobenzoic 
acid dissolved in the oil phase. The size of the generated microparticles could be precisely controlled 
in the range 80 µm to 160 µm through design of the microfluidic device geometry and by varying flow 
rates of the dispersed and continuous phase. In contrast to free ‘naked’ phages, those encapsulated 
within the microparticles could withstand a 3 h exposure to simulated gastric fluid at pH 2 and then 
underwent a subsequent pH triggered burst release at pH 7. The significance of our research is in 
demonstrating that C. difficile specific phage can be formulated and encapsulated in highly uniform 
pH responsive microparticles using a microfluidic system. The microparticles were shown to afford 
significant protection to the encapsulated phage upon prolonged exposure to an acid solution 
mimicking the human stomach environment. Phage encapsulation and subsequent release kinetics 
revealed that the microparticles prepared using Eudragit S100 formulations possess pH responsive 
characteristics with phage release triggered in an intestinal pH range suitable for therapeutic purposes. 
The results reported here provide proof-of-concept data supporting the suitability of our approach for 
colon-targeted delivery of phages for therapeutic purposes. 
3.1 Introduction 
 
C. difficile is the most common cause of infectious antibiotic-associated diarrhoea (Burke & Lamont, 
2014) that occurs in the developed world (He et al., 2013). There is a significant cost associated with 
the treatment of C. difficile infection (CDI); a single CDI case in the UK costs ~£7,000 (Public Health 
England 2012) and the annual cost in Europe is ~€3 billion. In the USA, treatment for a single case 
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costs ~$12,800 with the annual additional cost to healthcare providers reaching ~$800 million (Bouza, 
2012; He et al., 2013). 
The clinical outcomes of CDI range from asymptomatic colonisation to mild diarrhoea and in severe 
cases, inflammatory lesions and formation of pseudomembranes in the colon (pseudomembranous 
colitis), bowel perforation (toxic megacolon), sepsis, shock and even death (Rupnik et al., 2009). C. 
difficile is only susceptible to three marketed antibiotics, Metronidazole, Vancomycin and Fidaxomicin 
and recurrence rates are high and indicate that spores surviving treatment results in re-infection 
(Vardakas et al., 2012). 
3.1.1 C. difficile biogeography 
 
CD is extensively distributed in the general environment and exposure to CD in healthcare facilities is 
high. A study by (Al Saif & Brazier, 1996) in South Wales found CD to be widespread in freshwater 
supply including taps, drainage channels, communal pools, rivers and lakes. In addition to freshwaters, 
CD was also found to exist in soil, produce and faeces of farmyard animals.  
Farmyard animals and laboratory animals are found to carry CD as an enteric pathogen. Spores of CD 
were also isolated from meat and poultry; contamination with spores could be a result of the 
slaughterhouse environment and processing (E. R. Dubberke et al., 2011). 
 
3.1.2 Prevalence of C. difficile 
 
Globally CD has caused significant concerns in healthcare over several decades (Kuijper et al., 2008; 
Wiegand et al., 2012). Statistics show that in the USA alone 250,000 cases with 14,000 deaths were 
reported due to CDI annually (Centres for Disease Control and Prevention 2012;Lessa et al., 2015). 
Different countries show the consistent prevalence of community acquired CDI ranging from 11 % to 
28 %.  According to the National Health Service (NHS) Trusts in England and Wales (effective April 2007) 
all CDI cases occurring in patients 2 years and above must be reported.  
The epidemiological study of CD is monitored by Public Health England (PHE) in England and Wales, 
who collect data every three months on CDI incidences in Healthcare settings. PHE publish surveillance 
reports monthly, quarterly and annually on CDI cases and data are available to the general public via 
the PHE website (Erik R Dubberke et al., 2015). A decline from 44,563 cases in 2004 to 13,785 in 2014 
was observed. The highest number of cases was recorded in 2006 (55,653).   
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Health Protection Agency (HPA) (previously known as Public Health England) in 2010 reported that 
decrease in CDI cases may be due to increased awareness of protocols for infection control in the 
healthcare environment. To further manage the reduction rate of CDI the HPA has put in several 
strategies such as mandatory reporting, financial penalties for CDI outbreaks in hospitals and antibiotic 
stewardship (Wilcox 2011; Hargreaves & Clokie 2014). Another reason may be due to variation in 
diagnostic tests across hospitals ( Wilcox & Smyth 1998; Goldenberg & French 2011). Under reporting 
may also contribute to the decline in cases of CDI. K. A. Davis et al., (2014) reported that in a study of 
428 hospitals spanning several European countries 23 % of CDI cases failed to report. Community 
associated CDI are not included in the report which will increase the numbers furthers.  
3.1.3 Antibiotic treatment of C. difficile  
 
Onset of CDI is often related to antibiotic treatment more commonly with clindamycin and 
fluoroquinolones. However, prescribing terminal doses of these antibiotics usually clear CDI (Burnham 
and Carrol 2013). If this is not successful then vancomycin or oral metronidazole is given, which has 
been the gold standard for over 30 years (Ivarsson et al., 2015). Metronidazole is able to clear 77.6 % 
and vancomycin 85.8% of cases however there is a 27.1 % and 24 % chances of reoccurrence 
respectively (Vardakas et al., 2012). The treatment therefore, is not permanent; relapses of infection 
are probable. Antibiotics do not work in all patients, in 55 % of cases relapse follows antibiotic 
treatment. Complications occur after antibiotic treatment which disrupts the function of the microbial 
flora of the intestinal tract predisposing patients to infection with other pathogens (Ramesh et al., 
1999; Rupnik et al., 2009). 
Fidaxomicin (Optimer Pharmaceuticals) a new antibiotic approved in 2011 by the US Food and Drug 
Administration (FDA) for the treatment of CDI. Comparatively, much lower levels of reoccurrence were 
observed with fidaxomicin but the use is limited by its high cost ($2800). Vancomycin ($680) is more 
expensive than metronidazole ($22) therefore the first recommended treatment is metronidazole 
(Ivarsson et al., 2015). 
The FDA has fast tracked the approval of Cadazolid (Actelion) and Surotomycin two other antibiotics 
currently in Phase III clinical trials (Cubist Pharmaceuticals) (Ivarsson et al., 2015). The development 
of antibiotic resistance is on the rise, the bacteria are able to infect and colonise in the presence of 
antibiotics (Rupnik et al., 2009). Vancomycin resistance is of great concern due to the microflora of 
the gut being wiped out and the emergence of vancomycin- resistant CD and enterococci as a 
consequence of this vancomycin is only prescribed in severe cases, as a last resort drug 
(Ananthakrishnan, 2011; Ramesh et al., 1999). 
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New treatment options are under investigation to counteract the problem of antibiotic associated 
infection and antibiotic resistance. Some of the new therapeutics include, vaccines containing 
monoclonal antibodies against toxin A and B, faecal microbiotic transplantation (Shields et al., 2015) 
which has demonstrated a success rate of almost 90 % and also the use of bacteriophages for the 
treatment of CDI (Hargreaves & Clokie, 2014). 
3.1.4 Subgrouping C. difficle strains 
 
In order to differentiate between prevailing strains of CD across the world, and to sub-group CD strains 
a common distinguishable method called PCR ribotyping is used (Goldenberg & French, 2011). The 
genome of CD contains an operon with many variations in copy sizes of the rRNA operon. This operon 
consists of intergenic spacer regions of 16S to 23S, which is used to characterise the CD strain by 
amplification and carrying out PCR. A pattern of bands between regions 238 to 566 base pairs is 
observable on an agarose gel which is used to distinguish CD into different ribotypes (Sadeghifard et 
al., 2006). This method enables discrimination between different subgroups and classifies similar 
banding patterns as the same ribotype. The use of different analysis software across laboratories 
showed difficulties in reproducibility so Indra et al., (2008) updated the PCR ribotyping method to a 
high-resolution capillary based gel electrophoresis. So far 350 ribotypes have been reported and the 
number is expected to rise (Fawley et al., 2008; Public Health England 2014).  
3.1.4.1 Prevalence of CD PCR ribotypes 
 
Healthcare outbreaks associated with ribotype 027 (R027) also referred to as North American pulsed-
field type 1 (NAP1) have been thought to a consequent from the excessive use of fluoroquinolones. 
The majority of reported CDI cases across North America, Canada and Europe have been due to R027 
(Fawley et al., 2008; Rupnik et al., 2009; Smits, 2013). R027 is capable of sporulation, which is likely a 
contributing factor to its widespread dissemination and persistence (Smits, 2013; Noren, 2010). The 
presence of the binary toxin and deletion of toxin repressor gene, tcdC in R027 may further lead to 
increased production of toxins A and B (Ananthakrishnan, 2011; Sirard et al., 2011). 
Another hypervirulent strain, ribotype 078 (R078) has also been associated with CDI worldwide, 
mainly due to excessive production of toxins A and B. In comparison to R027, R078 is known to cause 
more community acquired CDI cases (Cartman et al., 2010). It was first isolated in pigs and calves but 
now is the second most prevalent ribotype in the Netherlands increasing from 3 % to 13 % from the 
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year 2005 to 2008 respectively. Numerous CDI outbreaks have been, such as the outbreak in Ireland. 
Consequently R078 is the second most prevalent ribotype after R027 (Burns et al., 2010).  
A change in the R027 epidemiology has been observed with marked decrease in CDI associated with 
this ribotype. This may be explained by the control measures put in healthcare settings (Public Health 
England 2014) which may also be contributing to the increased prevalence of other ribotypes (Sutter 
et al., 2012). Other ribotypes seen in clinical settings are R001 in China and Korea, R002 in Japan and 
Hong Kong, R014/020 in European counties and the US, R017 in Northern Europe and R078 across 
Europe (Burke & Lamont, 2014; Goudarzi et al., 2014). 
In the U.K. PHE have been using the capillary-based gel electrophoresis method since 2007 to observe 
trends in the national prevalence of CD ribotypes. A recent report highlighting ribotype trends from 
2007 to 2013 and showed there wa a decline in ribotype R027 from 65 % to 5 % respectively. Smaller 
reductions were noted for ribotypes R001 decreasing from 10 % to 5 %, R106 from 8 % to 2 %, from 
years 2007 to 2013 respectively. The changes reflect the reduced cases of CDI and motility in England 
and Northern Ireland (Wilcox et al., 2012). Because of ribotype reduction rates, other less prevalent 
ribotypes have been on the rise. Some examples according to Public Health England (2014) include, 
R002, R005, R014/020, R015, R023 and R078. It is hoped that by identifying the ribotypes responsible 
for causing infection using the CDRN method would enable new control measures to be put into place 
to limit further spread of CDI across healthcare (Wilcox et al., 2012).  
 
3.1.5 Ribotype 076 a Model Strain 
 
The bacteriophage T9 was chosen as a model phage which can effectively infect C. difficile strain T6, 
ribotype 076. Although strain T6 was isolated from an environmental sample, it represents strains that 
have the potential for transmission to a clinical setting through community acquired infection. The 
ribotype 076 was found in several clinical studies during a prevalence study of ribotypes (Rotimi et al. 
2003; Huber et al. 2014). In healthcare settings (15-25 %) infections are predicted to occur due to 
transmission between patient to patient contact or transmission through the environment example 
surface to hand contact (Walker et al., 2012).  Whilst the presentation of ribotype 076 is small in the 
clinical setting, it highlights the transmission from environment to clinical setting. This therefore, 
makes it a clinically relevant strain suitable for studies. 
3.1.6 C.difficile phages 
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A lack of suitable C. difficile phages has limited research on phage therapy for CDI. A recent study (Nale 
et al., 2016) however, showed the potential of phages to treat CDI in a hamster model using 
combinations of C. difficile phages. A polyvalent cocktail containing between 2 to 5 phages covering a 
suitable host range was used; the phages delivered to the hamsters were given as simple phage 
suspensions and bicarbonate was administered to the animals prior to phage delivered orogastrically 
to reduce the stomach acidity. The phages used in this study all encoded integrases, and though they 
can infect lytically they can follow the temperate phage lifecycle and thus are not ideal phages for 
phage therapy. However no strictly virulent phages have been isolated for this pathogen and the 
phage cocktail demonstrated efficacy in multiple model systems suggests that they have significant 
potential to reduce the C. difficile burden in the gut environment. Data presented by Nale et al., (2016) 
showed that phages were effective both in vitro and in vivo versions of a relevant hamster infection 
model, where use of phages reduced colonisation and increased time of survival in the hamster model. 
Further work has shown that the same phage combinations can be used to prevent and treat infection 
in a biofilm and an insect model (Nale et al., 2016). 
3.1.7 Oral delivery of phage 
 
When free phages are delivered orally for phage therapy or for modulating microbiota (Young & Gill, 
2015), there is likely to be variable but significant losses of phage titre by the time phages reach the 
intended infection site. Potential reduction in phage titres due to phage inactivation attributed to 
stomach acidity may in part have been responsible for failure of a recent clinical trial aiming to show 
reduction in acute bacterial diarrhoea symptoms in children using phage therapy (Sarker et al., 2016). 
This is primarily due to the acidic conditions encountered in the stomach, and the presence of bile and 
digestive enzymes and other proteases in the intestinal tract and stomach (Choinska-Pulit et al., 2015; 
Yongsheng Ma et al., 2008; Tang et al., 2013). Therefore, there is a clear need to protect phages 
against these adverse gastrointestinal conditions by protecting them via encapsulation (S. Kim, Jo, & 
Ahn, 2015a; Yongsheng Ma et al., 2008; Tang et al., 2013), and to control their targeted release at the 
site of infection e.g. in the colon for CDI. The goal of encapsulation is to create a suitable micro-
environment to protect phages from the harsh environmental conditions found in the stomach, and 
also to protect the phages during processing and storage prior to use (Merabishvili et al., 2013). 
Encapsulation technologies are well established for many pharmaceutical drugs however, for phages 
such technologies may not be suitable. This is because the techniques suitable for conventional 
therapeutic compounds often involve the use of organic chemicals that may inactivate phages (S. W. 
Lee & Belcher, 2004; Puapermpoonsiri et al., 2009). To overcome this, recent phage encapsulation 
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strategies have used basic homogeniser and extrusion techniques that appear to be less harmful and 
they maintain phage viability to some extent (Yongsheng Ma et al., 2008, 2012; Puapermpoonsiri et 
al., 2009; Shi, Zheng, Zhang, & Tang, 2016; Tang et al., 2013). The lack of suitable encapsulation 
techniques that allow the precise control of phage encapsulation has been the motivation behind the 
present work discussed in this chapter where we have used microfluidic technology to encapsulate 
phages.  
Unlike homogeniser and extrusion techniques microfluidic based microencapsulation allows exquisite 
control over each droplet that allows the control of desirable properties (Brouzes et al., 2009) 
including precise loading of phage per particle and uniformity of the particle size and release kinetics. 
We suggest that combining microfluidic encapsulation with the possibility of being able to select a 
wide range of available stimuli responsive polymers will enhance the utility of phage encapsulation 
for a range of therapeutic applications. As such, the encapsulation strategy taken in this work was to 
microencapsulate C. difficile specific phages in a pH responsive polymer. 
The main desired feature of phage microencapsulation presented here is to protect the phages from 
the stomach acid, and then release them in the infected colon at the typical pH of 7 (Figure 3.1a). 
Previously published studies that have used Eudragit S100 as an enteric coating for colon targeted 
drug delivery in combination with alginate have shown promise (Chen et al., 2016). Alginate is a 
natural biopolymer which is biocompatible, in other words nontoxic to tissue, biodegradable and 
relatively cheap. The gelation of alginate may be achieved by addition of high molecular weight 
polycations such as chitosan, or the addition of low molecular weight polyvalent Ca2+ cations (K. T. Lee 
& Mooney, 2013). Eudragit S100 is an anionic copolymer composed of methyl methacrylate and 
methacrylic acid with monomers arranged randomly on a polymer chain (Figure 3.2ai). The presence 
of weakly acidic carboxyl groups in the polymer chain results in the pH responsive behaviour; in an 
acidic environment, the groups are uncharged whilst at pH values greater than their pKa (pKa ~ 4), the 
polymer chains begin to disentangle due to the electrostatic repulsion between the negatively charged 
carboxyl groups (Figure 3.2aii) (Nguyen & Fogler, 2005). The suggested mechanism of phage release 
is illustrated in Figure 3.2 b. Prolonged exposure to acid will enable the protonation of the carboxyl 
groups, allowing precipitation of the polymer. 
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Figure 3.1. Overview of the delivery of encapsulated phage through the GI-tract to the colon. (a) 
Schematic of the gastrointestinal tract, depicting transit of intact encapsulated phage-loaded 
microparticles through the stomach and their subsequent disintegration in the colon at pH 7 leading 
to the controlled release of phages from the microparticles; (b) Transmission Electron Microscopy and 
(c) schematic of bacteriophage Phi9CD-KM, Myovirus. 
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Figure 3.2. Mechanism of phage release from microparticles. Schematic of ai) the chemical structure 
of Eudragit S100, y:x = 2:1 aii) Eudragit S100 polymer chain separation due to dissociation of weakly 
acidic functional groups, electrostatic repulsion and polymer swelling; (b) Phage loading/release 
mechanism from pH responsive Eudragit S100 microparticles. 
Composite Eudragit S100 and alginate particles have been used to deliver 5-aminosalicylic acid (5-ASA) 
and curcumin (both model drugs) to the colon. Duan et al. (Duan et al., 2016) found that the Eudragit 
S100 coating enables resistance to the acidic environment of the stomach, whilst alginate provides 
muco-adhesive properties which prolong the residence time of the microparticles within the body. 
Similar investigations carried out by Sookkasem et al., (2015) showed the release of curcumin in 
simulated intestinal fluid at pH 7.4. Pleasingly, as predicted, the curcumin released from the beads 
was shown to be cytotoxic to the cell line HT-29, demonstrating the efficacy of encapsulation. Vemula 
et al., (2015) investigated the transit of Flurbiprofen to the colon in healthy volunteers through X-ray 
imaging. The composite tablets released the drug in the colon without disintegrating in the upper GI-
tract.  
A further novelty of the work reported here is the microencapsulation of phages using microfluidic 
technology which allows the manufacture of highly uniform micron-sized core-shell particles (G. T. 
Vladisavljević et al., 2012) and using acidified oil for the precipitation of Eudragit S100. The technique 
affords exquisite control over the morphology of the microparticles including their size and size 
distribution, shell thickness and thereby phage release kinetics, phage loading and encapsulation 
efficiency.  
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Aim of the study 
 
The aim of the study presented here was to demonstrate the application of microfluidics in 
encapsulation of bacteriophages for the first time. Microparticles with C. difficile phage CDKM9 in the 
core, surrounded by a shell of either Eudragit S100 or ES100 /alginate matrix were produced using this 
device. The pH sensitive microparticles were designed to survive the transition of phages delivered 
orally via the mouth, through the stomach and intestine with phage release in the colon. We 
demonstrate the ability to manufacture uniform phage entrapped particles for pH responsive site-
specific delivery.  
 
3.2 Materials and Methods 
3.2.1 Materials  
 
Eudragit S100 was purchased from Evonik, Germany. Miglyol 840, a propylene glycol diester of 
caprylic/capric acid, was obtained from Sasol, Germany and used as carrier oil for the continuous 
phase. Polyglycerol polyricinoleate (PGPR) soluble surfactant was purchased from Abitek, USA and 
used to stabilise the water/oil interface. 4-amino-benzoic acid, p-toluenesulfonic acid and sodium 
chloride (Acros Organics, UK) were purchased from Fisher Scientific, UK. The organic acids 4-amino-
benzoic acid and p-toluenesulfonic acid were used to trigger in situ curing of the droplets in the oil 
phase. Ethanol and n-hexane were of analytical grade (Fisher Scientific, UK). Ethanol was used to 
dissolve calcium chloride as the alginate crosslinking agent and n-hexane was used to remove oil from 
the emulsion respectively. 5(6)-Carboxyfluorescein was purchased from Sigma Aldrich, UK and used 
to visualize the generated particles. Ultrapure water was obtained from Millipore 185 Milli-Q Plus 
water filtration system. Sorensen’s buffer 0.2 M was used as a dissolution media for the microparticles 
and was prepared by mixing sodium phosphate (NaH2PO4) (for pH 7, 39 ml and for pH 6, ~88 ml) with 
sodium phosphate dibasic (Na2HPO4) (for pH 7 6, 1 ml and for pH 6, ~12 ml) (Fisher Scientific UK). Low 
viscosity alginate was purchased from Sigma Aldrich, UK.  
3.2.2 C. difficile strain and bacteriophage CDKM9 
 
Clostridium difficile strain CD105HE1 ribotype 076 was used to propagate the phage as per the method 
of Nale et al. (Nale et al., 2016) Bacteriophage CDKM9 is a myovirus previously isolated from an 
environmental water sample as described by Rashid et al. (Rashid et al., 2016) 
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C. difficile, CD105HE1, was cultured in brain heart infusion (BHI) (Oxoid, Ltd., UK) agar supplemented 
with 7% defibrinated horse blood (TCS Biosciences, Ltd., UK). Liquid cultures were grown in fastidious 
anaerobic (FA) broth and BHI broth. C. difficile was cultured anaerobically in an anaerobic chamber 
(Ruskinn Technology, UK) using an anaerobic environmental gas mixture composed of 10 vol % H2, 10 
vol % CO2 and 80 vol % N2. 
Phage CDKM9 was propagated on CD105HE1. Phage stocks were prepared as follows: 0.5 ml of an 
overnight culture of C. difficile was grown in FA broth was transferred to 50 ml of pre-reduced BHI 
broth and incubated in the anaerobic chamber at 37 ˚C. The optical density (OD550nm) was measured 
at hourly intervals until it reached 0.2, after which 100 - 300 µl (dependent on phage titre of stock) of 
phage stock was added. The 50 ml tube was incubated overnight in the anaerobic chamber at 37 ˚C 
for phage amplification to occur. The following day the tube was centrifuged at 2,000 x g for 10 min 
at 4˚C. The supernatant was filtered through a 0.2 µm filter (Millipore, USA), collected and stored at 
4˚C until further use. 
Plaque assays were carried out using the double layer agar method.(Clokie & Kropinski, 2009). Briefly, 
1.5 ml of 0.4 % BHI semi-solid agar and 1.5 ml of salt mixture (0.4 M MgCl2 and 0.1 M CaCl2, Oxoid Ltd. 
UK) were added to 250 µl of overnight C. difficile FA broth culture and poured onto 1 % BHI agar plates 
and set under a laminar flow hood. 10 µl of phage solution was spotted on the plate (in triplicate), left 
to dry and incubated in the anaerobic chamber at 37˚C overnight. The following day the resulting 
number of phage plaques was enumerated. 
The phage titre was determined by carrying out serial dilutions from the phage collected and each 
dilution (in triplicate) was spotted on host lawn (same as the propagation host). Phage titre was 
determined by counting plaques and expressed as plaque forming units (PFU) per ml. 
3.2.3 Phage sensitivity to pH 
 
Phage inactivation (sensitivity) to different experimental parameters used to encapsulate the phages 
was assessed as follows. The polymer solvents analysed were deionised water (dH2O), 0.2M NaCl and 
BHI broth. The polymer was dissolved in each of these by adjusting the pH to 7.4. Effect of pH on phage 
was analysed by adding phage to a 0.2 M solution of NaCl with pH adjusted to 2, 3, 4, 5, 6 or 7 by 
adding 0.1 M HCl or 0.1 M NaOH. To analyse the survival of phage in each parameter 270 µl of each 
solution was added to a 96 well plate (in triplicate), with BHI broth as positive control, 30 µl of phage 
stock (108 PFU/ml) was added to each well. At time points 0 h, 6 h and 24 h serial dilutions in BHI broth 
(270 µl) were performed for each test and spotted (10 µl) on host lawn (prepared as described in the 
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plaque assay section previously). 32 repeats of each dilution were performed for each time point. The 
spotted plates were dried for 5 min and then incubated in the anaerobic chamber at 37 ˚C overnight. 
The following day, plaques were counted and PFU/ml calculated. 
3.2.4 Experimental set-up of microfluidics 
 
The controlled production of microdroplets and microparticles was achieved using in house fabricated 
glass capillary devices. The experimental setup for drop microfluidic experiments is shown in Figure 
3.3a. Two SGE (1 ml and 5 ml) syringes were mounted on two 11 Elite syringe pumps (Harvard 
Apparatus, UK) to deliver the aqueous and oil phase to the inner and outer capillary respectively via 
separate medical tubes. The microfluidic device was positioned on the GXM XD63 optical inverted 
microscope (GX Microscopes, USA). Formation of droplets started when the dispersed phase reached 
the orifice of the collection capillary and was observed with a Phantom V9.0 high-speed camera (Vision 
Research, Ametek, USA) connected to the inverted microscope using x4 magnification lens. The 
camera was connected to the computer which allowed monitoring and recording of the droplet 
forming process at 2000 frames per second with a resolution of 576 by 288 pixels. The droplets and 
particles produced from the device were collected into a glass vial via the collection tube. Table 3.1 
summarises the compositions of the dispersed and continuous phases used for the experimental work 
reported here. 
Table 3.1. Compositions of dispersed and continuous phase. 
 
Dispersed 
phase 
D1 
0.2M NaCl pH 7.4 
5% (w/v) Eudragit S100  
107 PFU/ml 
D2 
0.2M NaCl pH 7.4 
5% (w/v) Eudragit S100  
5(6)-Carboxyfluorescein 50µM 
D3 
0.2M NaCl pH 7.4 
10% (w/v) Eudragit S100 
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2% (w/v) Alginate 
107 PFU/ml 
Continuous 
phase 
C1 
Miglyol 840 
2% (w/v) Polyglycerol polyricinoleate (PGPR)  
0.25% (w/v) p-toluenesulfonic acid  
C2 
Miglyol 840 
2% (w/v)Polyglycerol polyricinoleate (PGPR)  
1% (w/v) p-toluenesulfonic acid  
C3 
Miglyol 840 
2% (w/v) Polyglycerol polyricinoleate (PGPR)  
1% (w/v) 4-aminobenzoic acid  
C4 
Miglyol 840 
2% (w/v) Polyglycerol polyricinoleate (PGPR)  
0.75% (w/v) 4-aminobenzoic acid 
C5 
Miglyol 840 
2% (w/v) Polyglycerol polyricinoleate (PGPR)  
1% (w/v) 4-aminobenzoic acid 
~0.15% (w/v) CaCl2 
~3% (v/v) Ethanol 
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Figure 3.3. Microfluidic production of microparticles. a) Schematic of laboratory experimental set-up; 
b) Schematic of droplet production using a glass capillary microfluidic device followed by in situ 
gelation with 4-aminobenzoic acid dissolved in the oil phase; c) Schematic of the plug flow regime due 
to premature gelation of Eudragit S100 with p-toluenesulfonic acid resulting in a high viscosity of the 
aqueous phase during jet pinch-off. p-Toluenesulfonic acid, with a pKa of −2.8, is more than 10,000 
times stronger acid than 4-aminobenzoic acid, with a pKa of 2.38. 
3.2.5 Glass capillary device fabrication 
 
Experiments were performed using a microfluidic device with counter-current flow focusing (Figure 
3.3b). The device consists of a circular glass capillary tube (Intracel Electrophysiology and Biochemistry 
Equipment, St Ives, Cambs., UK) inserted into a square glass capillary tube (Atlantic International 
Technologies Inc., Rockaway, NJ, USA). The inner circular capillary has an internal diameter of 0.58 
mm and outer diameter of 1 mm. The outer square capillary has an inner diameter of 1.15 mm and 
outer diameter of 1.4 mm. 5 cm length of both capillaries was used. 
The inner round capillary was pulled using a P-97 Flaming/ Brown micropipette puller (Sutter 
Instrument Company, Novato, USA) by heating the central region of the capillary approximately 20s 
until it softens and separates into two parts leaving a sharp tip with a diameter of 20 µm at both ends. 
The orifice or the nozzle diameter was adjusted to the desired size by abrading the orifice with 
sandpaper (Black Ice Waterproof T402 Paper, Alpine Abrasives, UK). The orifice sizes used for the 
experiments were 100 µm and 200 µm. To confirm the inner diameter of the orifice of the inner 
capillary a Microforge MF-830 microscope (Intracel Electrophysiology and Biochemistry Equipment, 
St Ives, Cambs., UK) was used. After abrading, the inner capillary was cleaned by blowing compressed 
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air through the lumen and subsequently treated in order to create a hydrophobic inner surface using 
octadecyltrimethoxysilane (OTMS) (Sigma Aldrich, U.K.). 
The square capillary was placed on a square microscope slide (Sigma-Aldrich, UK) and firmly attached 
with cyanoacrylate glue. The inner round capillary was carefully inserted inside the outer square 
capillary and axially centred with the help of the microscope. Two syringe needles with plastic hubs 
(2.5 mm outer diameter and 0.9 mm inner diameter, B-D Precisionglide®, Sigma-Aldrich, UK) were 
placed at edges of the square capillary and firmly held together with two component epoxy glue (Five 
Minute ® Epoxy, ITW DEVCON Limited, UK). The aqueous and oil phase was supplied through medical 
delivery tubes (0.86 mm inner diameter and 1.52 mm outer diameter, Smiths Medical International 
Limited, UK), attached to syringe needles. The phases entered the square capillary from two opposite 
ends which were enclosed inside the plastic hubs of the syringe needle. The droplets were collected 
through a collection tube (1.58 mm inner diameter and 2.1 mm outer diameter, Sigma-Aldrich, UK) 
which was attached to the inner round capillary (protruding from the plastic hub). The plug flow 
regime where the formed drop adopts a plug shape and occupies the entire cross section of the 
collection tube is demonstrated in Figure 3.3c. 
3.2.6 Phage encapsulation 
 
The dispersed (aqueous) phase was prepared by dissolving Eudragit S100 powder (final working 
concentration of 5 % w/v) in either 0.2 M NaCl solution or BHI. 10 M NaOH solution was added 
dropwise until the solution turned clear and colourless indicating complete dissolution of Eudragit 
S100 polymer. To prepare composite particles, 2 % (w/v) alginate was dissolved with Eudragit S100 
over heat (~60 °C) stirring overnight (formulation D3 in Table 1). For phage encapsulation, the 
dispersed phase contained 1.6 x 107 PFU/ml of phages in formulation D1 and D3 (Table 3.1). For dye 
encapsulation, 10 mM solution of carboxyfluorescein in ethanol was added to 5 % w/v Eudragit® S100 
dissolved in 0.2 M NaCl to make a final dye concentration of 50 µM (formulation D2 in Table 3.1). 
The continuous (oil) phase was prepared by dissolving 2 % (v/v) of PGPR and 1 % (w/v) of 4-
aminobenzoic acid (formulation C3 in Table 1) or (0.25 % or 1 %) (w/v) p-toluenesulfonic acid in Miglyol 
840. The phases were introduced into the microfluidic device at different flow rates (Table 3.2), to 
ensure droplets formed at the entrance of the tapered inner capillary were monodispersed. The flow 
rates were kept constant throughout each experiment. The droplet formation was followed for 
periods more than 6 h as part to evaluate droplet stability over extended periods of operation. The 
droplet size was analysed using the Image J program (the National Institute of Health, Washington, 
U.S.). To evaluate droplet stability over prolonged periods of operation, the size of 20 droplets at each 
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time point was measured. The particles were collected in an empty glass vial. Air bubbles are a 
common issue in microfluidic droplet generation. Air bubbles were avoided by using high-quality gas-
tight glass syringes instead of plastic syringes. 
Table 3.2. Summary of samples prepared using different microfluidic experimental conditions. 
Experiments Orifice size / µm Dispersed phase flow 
rate, Qd / ml h-1 
Continuous phase flow 
rate, Qc / ml h-1 
F1 200 1.2 7.0 
F2 200 0.5 3.5 
F3 200 0.5 3.0 
F4 200 0.5 2.0 
F5 100 0.09 2.0 
 
Eudragit S100/Alginate composite microparticles were prepared as per the procedure above. The 
dispersed phase composition was 2 % (w/v) alginate and 10 % (w/v) Eudragit S100 (formulation D3 in 
Table 3.1). Formulation C5 was used for the continuous phase (Table 3.1). A 5 % w/v calcium chloride 
(Fisher Scientific, UK) solution in ethanol (reagent grade, Sigma Aldrich UK) was prepared and 
subsequently added to the Miglyol to make-up the appropriate composition of the continuous phase 
used for alginate crosslinking. The microparticles were left to crosslink overnight at room 
temperature. 
After collection, the sedimented microparticles were processed by pipetting off excess Miglyol oil. 
Residual oil was removed by rinsing the particles three times with n-hexane and gently centrifuging at 
10 g for 3 min at 4˚C. Residual hexane solvent was removed by vacuum drying the particles for 15 min 
at room temperature. 
3.2.7 Scanning electron microscopy (SEM) 
 
20 µl of washed microparticles prepared as outlined above, were pipetted and placed on 13 mm filter 
disks (0.2 µm pore size, Millipore Ltd. UK). The filter disks with the samples were placed in a -20˚C 
freezer for 24 h. The frozen particles were then placed in a glass freezer dryer jar and connected to a 
freeze dryer machine at 1 bar pressure and -50˚C. The particles were freeze dried for 24 h to allow 
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removal of any residual liquid. The particles were viewed using a benchtop Scanning Electron 
Microscope (Hitachi TM3030 Table-top Microscope). 
3.2.8 Transmission electron microscopy (TEM) 
 
To identify the purity of the phages used for encapsulation was confirmed using transmission electron 
microscopy (TEM) analysis was conducted. 1 ml of phage stock was centrifuged at 4,500 x g for 1 hour 
at 4˚C and the pellet was washed two times with 0.1 M ammonium acetate (Fisher, UK) and re-
suspended in 100 µl of ammonium acetate. 4 µl of sample suspension was placed on glow discharged 
pioloform/ carbon coated copper grids which were allowed to stand for 5 min for bacteriophage to 
bind, 1% w/v uranyl acetate was added to stain the sample. 10µl of deionised water was used to rinse 
the sample and the prepared sample was left to dry for 24 h. The grids were examined using a JEOL 
1220 electron microscope with an accelerating voltage of 80 kV. Digital images were captured using 
SIS Megaview III digital camera with associated analysis software. 
3.2.9 Confocal microscopy 
 
Carboxyfluorescein encapsulated microparticles were viewed using a Confocal Laser Scanning 
Microscope (CLSM) (BioRad Radiance 2000 MP with a Nikon Eclipse TE300 inverted microscope).  
3.2.10 Encapsulated phage release 
 
2 % (w/v) of washed particles were suspended in prewarmed 10 ml simulated intestinal fluid, 10 
mg/ml pancreatin in 0.05mM KH2PO4 at pH 6 or 7 (Sigma Aldrich, UK) under agitation conditions at 
37°C. For acid exposure 2 % (w/v) of washed particles were suspended in prewarmed 10 ml simulated 
gastric fluid, 3.2 mg/ml pepsin in 0.2 M NaCl at pH 2 (Sigma Aldrich, UK) for an exposure period of 3 h 
(reported mean gastric emptying times in human subjects is typically less than 3 hours for both pre-
fed and fasted states (Ibekwe et al., 2008)), under agitation conditions at 37°C. Particles were 
subsequently centrifuged at 2,000 g for 15 min and re-suspended in simulated intestinal fluid (pH 7) 
under agitation conditions at 37°C until complete dissolution of particles. For enumeration of phage 
released, plaque assays were used (as described previously section 3.2.2) by removing 10 µl of sample 
at hourly intervals, serially diluting in BHI broth and spotting on a host bacterial lawn. The PFU/ml was 
determined the following day at each time point. 
3.2.11 Statistical analysis 
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Comparison of sample means using 2 sample t-tests and evaluation of 95 % confidence intervals for 
data was carried out using the statistical software Minitab 18. 
3.3 Results 
3.3.1 Encapsulated phage (Ephage) microparticle production 
 
Highly monodispersed core-shell Eudragit S100 droplets were produced under optimised 
hydrodynamic conditions using 0.75 % (w/v) 4-aminobenzoic acid to precipitate the polymer by ion 
exchange (a process termed polymer curing). Stable production of uniform droplets required 
optimisation of the hydrodynamic conditions. Microfluidic devices can be controlled in situ by direct 
microscopic observation. Hydrodynamic conditions were optimised in real-time by adjusting fluid flow 
rates during each experiment until uniform droplets were produced. Three different droplet 
generation regimes were observed depending on the relative magnitude of the shear, inertial and 
interfacial tension forces acting during droplet formation. These forces were modulated by changing 
the formulation of the phases introduced into the device and the flow rates of the continuous and the 
dispersed phases. 
One regime which was found to be unsuitable for stable microparticle formation was ‘jetting’. ‘Jetting’ 
is characterised by the long jet created inside the collection capillary away from the orifice resulting 
in unstable breakup of the droplets at various positions along the jet. Jet widening (Figure 3.4ai) 
occurred due to the high velocity of the dispersed phase compared to the continuous phase causing 
the velocity of the dispersed phase in the collection capillary to decrease until eventually the jet breaks 
into large drops due to the Rayleigh-Plateau instability. The transition from ‘dripping’ to ‘widening 
jetting’ occurs at the critical Weber number of the dispersed phase. The Weber number is a measure 
of the relative magnitude of inertial forces compared to the interfacial tension forces, 𝑊𝑒 = 𝜌𝐿𝑉2 𝛾⁄ , 
Where ρ (kgm-3) is the density of the fluid, V (ms2) is the characteristic flow rate, and L (m) is the 
characteristic length scale of flow and   is the interfacial tension. In Figure 3.4aii, the inner phase is 
stretched into a longer and narrower jet due to the higher flow rate ratio, 
dc Q/Q  compared to that 
in Figure 3.4ai, but the drops are still formed in ‘widening jetting’ regime. Alternatively, when the 
velocity of the outer phase in the collection capillary is much larger than the velocity of the inner 
phase, a narrowing jet is formed that produces relatively small droplets. The transition from ‘dripping’ 
to ‘narrowing jetting’ occurs at the critical Capillary number (Utada et al., 2007), but this transition 
was not observed in this study. In either case, the droplet breakup remained unstable due to the 
imbalance of forces brought on by the high flow rate; either due to the inner or the outer phase. The 
viscosity of the phases also plays a significant role (Figure 3.4). 
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Figure 3.4. Production of W/O emulsions composed of 5 % (w/v) Eudragit S100 dispersed in Miglyol 
840 with 2 % (w/v) PGPR and 0.75 % (w/v) 4-aminobenzoic acid. ai) Widening jetting at Qc 3 mlhr-1 and 
Qd 0.9 mlhr-1. The jet length is approximately 9 times the orifice diameter and the drop diameter was 
400 m; aii) Narrowing jetting Qc 6 mlhr-1 and Qd 0.5 mlhr-1. The jet length was approximately 11 times 
the orifice diameter and the drop diameter is 280m; b (i-iv) Stages of droplet formation in the 
dripping regime; ci) The dripping regime during experiment F3 (Table 3.2); cii) The dripping regime 
during experiment F5 (Table 3.2); ciii) The plug-flow regime at the orifice diameter of 200 µm, Qc = 
0.06 mlhr-1and Qd = 0.3 mlhr-1. The curing was achieved using 1 % (w/v) p-toluenesulfonic acid. The 
average drop diameter is ~700 µm; di) Droplets produced in (ci), average droplet size is 135 µm; dii) 
Droplets produced in (cii), average droplet size is 80 µm. 
To enable better control of the droplet generation process and to reliably produce monodispersed 
droplets, the ‘dripping regime’ worked best. Here, the droplets were formed closer to the orifice of 
the collection capillary (Figure 3.4b) because the interfacial tension forces dominated over the inertia 
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of the dispersed phase and the viscous stress forces from the continuous phase. Droplet formation 
began as the dispersed phase entered the tapered collection capillary (Figure 3.4bi). The dispersed 
phase did not encounter the capillary wall due to repulsion from the hydrophobic surface of the 
treated capillary wall which resisted wetting by the aqueous phase. The continuous phase forced the 
dispersed phase to elongate axially (Figure 3.4bii), collapsing the dispersed phase and producing a 
neck behind the forming droplet. As the elongation progressed further, the neck thinned into a thread 
(Figure 3.4biii), eventually breaking the dispersed phase and releasing the droplet (mother plug). 
Following retraction, the process restarted with the dispersed phase protruding at the orifice of the 
collection capillary (Figure 3.4biv). In this dripping regime, the formation of one droplet took 4.5 ms-1, 
thus 222 droplets were formed each second and subsequent droplets were produced at the same 
position as the previous droplets (Erb et al., 2011; Fu et al., 2012). The balance between the drag force 
and interfacial tension and negligible shear in the collection capillary after drop formation resulted in 
uniform droplets. The dripping regime occurs when the Weber number of the dispersed phase and 
the Capillary number of the continuous phase are both below their critical values. The Capillary 
number (Ca) represents the ratio between the viscous forces and interfacial tension across an 
interface between the two phases (Ekanem et al., 2015; Erb et al., 2011; Utada et al., 2007). The 
Capillary number of the continuous phase is given by: 𝐶𝑎 = 𝜇𝑣 𝜎⁄ , Where, Ca is Capillary number, µ 
is dynamic viscosity (Pa.s), v is fluid flow rate (ms-1), σ is surface or interfacial tension (Nm-1). For 
experiments conducted using the dispersed phase flow rate of 0.5 ml h-1 and the continuous phase 
flow rate of 3 ml h-1, Figure 3.4ci, Ca was below 0.1 leading to a dripping regime (Erb et al., 2011). The 
viscosity of the dispersed phase depended on the concentration of Eudragit S100 and alginate in the 
different formulations investigated and varied between 5 - 50 mPas.   
Changing the droplet size is an important feature of microfluidics enabling control over phage loading 
and particle size. Droplet generation in the dripping regime was optimised over a range of flow rates 
thereby enabling control of the droplet size whilst maintaining a high degree of the size uniformity. 
This was done in real-time whilst observing (using the microscope camera) the change in the resulting 
droplet size. When increasing the flow rate of the inner phase relative to the outer phase, the size of 
the droplets increased; this trend was well documented and observed in many experimental and 
numerical studies (Ekanem et al., 2015). Typically, the following relationship exists between the drop 
diameter, 
dropd , the orifice diameter, orificed , and the flow rate ratio (Goran T. Vladisavljević et al., 
2012): ddrop /dorifice = x(Qc/Qd)-y where x and y are derived from the line of best fit from a plot of drop 
diameter against flow rate. In accordance with this equation, when the flow rate of the outer phase 
was increased, the size of the droplets decreased. This was due to the increased pressure and shear 
stress exerted by the outer phase to break-up the inner phase into droplets. 
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Droplet size was also controlled by changing the orifice size of the collection capillary (Figure 3.4ci and 
cii). The plug flow regime occurred due to the high potency of the acid (p-toluenesulfonic acid) in the 
oil phase resulting in precipitation of the polymer at the water/oil interface during droplet formation. 
p-toluenesulfonic acid, is a significantly stronger acid (compared with 4-aminobenzoic acid) and 
resulted in premature polymer curing and a rapid increase in the interfacial tension and the viscosity 
of the dispersed phase. Because of this phenomenon droplets/particles produced were bigger than 
the orifice size (Figure 4ciii). The dripping regime could not be established, irrespective of the fluid 
flow rates, and the droplet production rate was very low. 
Orifice diameters of 200 µm and 100 µm produced an average droplet size of 135 µm and 80 µm 
respectively (Figure 3.4d) for experiments using formulation D1 (Table 3.1) and microfluidic 
experimental conditions F3 and F5 (Table 3.2). In both cases, the overall droplet size was smaller than 
the diameter of the orifice minimising the likelihood of contact between the dispersed phase and the 
orifice walls and associated wetting. The flow rates were reduced when the orifice diameter was 
changed from 200 µm to 100 µm, to prevent the transition to the ‘jetting regime’ which would occur 
due to the high velocity of the two phases entering the collection capillary. Droplets produced by 
varying the experimental parameters (as described above) resulted in highly uniform droplets with a 
coefficient of variation of their sizes of less than 2 % (Figure 3.4d). 
To test the reliability of the device, the microparticle generation experiment was run for 6 h (using 
experimental conditions F1, Table 3.2) whilst examining the device integrity and droplet generation 
behaviour. Visually, the device remained stable over the 6 h period (Figure 3.5a). There was no wetting 
of the collection capillary which is usually observed when the aqueous phase comes in contact with 
the capillary wall resulting in polydispersed drops or even the inversion of the emulsion from a water-
in-oil to an oil-in water emulsion (Seo et al., 2007). Therefore, pre-treating the collection capillary prior 
to device setup allowed the aqueous phase to resist encountering the capillary wall. At all times, the 
dispersed phase remained at the centre of the continuous phase stream due to the 3D geometry of 
the device and perfect coaxial alignment of the two capillaries. 
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Figure 3.5. Long term stability study of a glass capillary microfluidic device in generating water-in-oil 
droplets. Aqueous phase: 1 % (w/v) Eudragit S100 and oil phase: 2 % (w/v) PGPR in Miglyol 840. (a) 
Snapshots of droplet generation over six hours (b) Device function over six hours with corresponding 
droplet size and coefficient of variation (CV) (Dd = ; CV= ). Qd = 1.2 mlh-1, Qc = 7 mlh-1, orifice size 
= 200 µm). Error bars represent one standard deviation (20 droplets counted per time point). 
Throughout the microparticle generation process, no air bubbles were seen in the device which can 
affect the size of the droplets, by restricting the flow of the dispersed phase. A stable flow pattern was 
observed without interruption or change in phase behaviour. The device remained functional and 
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identical throughout the six hours of droplet generation; this demonstrated that the device was a 
reliable means of phage encapsulation contained in the aqueous phase. The stability of the droplet 
size over the six-hour period is shown in Figure 3.5b. The variation of the droplet size was less than ± 
4µm. The coefficient of variation (C.V., a standardized measure of the dispersion of the particle size 
distribution) measuring the ratio of the standard deviation to the mean droplet size was less than 2 
%; it is generally accepted that a C.V. value below 3 % for a particle size distribution is considered 
highly monodispersed as demonstrated here; thus the glass capillary device was able to produce highly 
uniform droplets. All experiments were replicated three times; in each case the flow rate and droplet 
diameter remained consistent. All post-processing was carried out in the same tube resulting in <1 % 
loss of particles due to processing. The particle sizes were reproducible after all post-processing steps.   
3.3.2 Carboxyfluorescein labelled microparticles 
 
Several formulations using carboxyfluorescein as the encapsulated agent were evaluated to find 
formulations suitable for encapsulation of phage in microparticles formed using the microfluidic 
device. Carboxyfluorescein encapsulated particles were generated using optimised flow rates of the 
inner and outer phase; F2, F3, F4 (Table 3.2). The average droplet diameter increased with decreasing 
Qc, from 109 µm (F2), to 131 µm (F3) to 170 µm (F4); this was expected due to a decrease in shear and 
pressure forces acting on the dispersed phase jet with decreasing Qc (Table 3.2). The change in particle 
size during curing was observable in real-time using confocal laser scanning microscopy (CLSM) (Figure 
3.6). The encapsulation efficiency of the fluorescent dye was 100 %, as no emission was detected in 
the oil phase. 
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Figure 3.6. Microscopy images of carboxyfluorescein encapsulated particles cured in acidified oil, dried 
on a microscope slide. (ai-iii) production of droplets in microfluidic device at different Qc flow rates; 
(bi-iii) corresponding confocal images of particles cured for 24 hours and 48 hours (ci-iii) produced in 
(ai-iii); (di-iii) scanning electron microscope images of 24 hours cured particles. 
The influence of curing time on particle size was investigated for microparticles cured using 4-
aminobenzoic acid. A significant difference was observed between the mean droplet size in the 
collection capillary just after formation (discussed above and shown in Figure 3.6a) and the mean 
particle size in the collection vial for samples F2 (104 µm), F3 (113 µm), F4 (155 µm). There was no 
significant difference between the mean particle sizes for samples F2 - F4 precipitated for 0 h, 24 h or 
48 h. Shrinkage of particles was observed after being left to dry on a glass slide and a similar change 
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in diameter was observed with the SEM analysis, which was due to the loss of water from the particle 
core and associated shrinkage/collapse of the gel network (Figure 3.6). 
To mimic the strong acidic environment encountered during digestion, a 0.1 M hydrochloric acid 
solution was added to the Eudragit S100 particles loaded with carboxyfluorescein (a surrogate 
hydrophilic model drug). The time lapse imaging showed no release of the dye into the surrounding 
environment (Figure 3.7a). This suggested that Eudragit S100 microparticles can retain the dye and 
maintaining the integrity of the particles in an acidic environment. 
 
Figure 3.7. Confocal Images showing pH responsive behaviour. Time lapse snapshots (in milliseconds, 
ms) of carboxyfluorescein (50 µM) encapsulated particles composed of 5 % (w/v) Eudragit S100 
(Formulation D2, Table 3.1). a) exposure of ~170 µm particles to 0.1M HCl; b) dissolution of ~170 µm 
particles in 0.1M NaOH. Snapshot time series in milliseconds (ms). 
The particles were then subjected to an alkaline environment using a 0.1 M solution of sodium 
hydroxide, thereby increasing the pH to basic. Leaching of the dye into the surrounding environment 
was observed and the particles completely lost their structural integrity (Figure 3.7b). The pH response 
a) 
b) 
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of the Eudragit S100 was almost immediate and a burst release of the dye was observed starting from 
40 ms. The ionisation of the polymer chains when exposed to sodium hydroxide was immediate with 
a burst release of the dye as expected due the increased concentration of hydroxyl ions. These results 
demonstrated the feasibility of encapsulating a water-soluble agent in pH responsive microparticles 
using formulations that allowed microfluidic fabrication of microparticles. 
3.3.3 Transmission electron microscopy (TEM) 
 
TEM analysis confirmed that the CDKM9 bacteriophage belonged to the myoviridae family. Typical 
features revealed a capsid head of approximately 70 nm attached to a tail and baseplate of 
approximately 200 nm (Figure 3.1b). Myoviridae phages contain dsDNA in a non-enveloped capsid; 
their tails are contractile enabling host cell penetration. The six tail pins and fibres are also 
characteristic of this type of phage (Figure 1b, c). The host range analysis for this phage has previously 
been reported by Rashid et al., (2016) 
3.3.4 Phage sensitivity to formulation parameters  
 
The effect of different formulation parameters on free phage viability and therefore their impact on 
phage encapsulation was evaluated. Little work has been done to date on formulation of C. difficile 
specific phages showing the effect of physical and chemical environmental factors on phage viability. 
Free phage in BHI alone were used as a control and compared with phage preparations subjected to 
different formulations. Firstly, the effect of pH on phage viability was tested for phages that were 
suspended in a 0.2 M sodium chloride solution at different pH. The phage lost nearly all activity after 
10 min of exposure to pH 2 (Figure 3.8a). Phage viability was significantly improved when the solution 
pH was above pH 3. Although there was a statistically significant reduction in phage viability for phages 
exposed to solutions at pH 6 and pH 7 the 95% confidence intervals for the means do overlap 
suggesting a modest difference in means and not dissimilar to data observed for phages exposed to 
BHI over a 24 h period (Figure 3.8a). Phage titres reduced by about one log at pH 4 and pH 5 (Figure 
3.8a). 
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Figure 3.8. Influence of formulation parameters on free phage viability at various exposure times. a) 
effect of pH on free phage viability in 0.2 M NaCl solution. * indicates significantly different phage 
titres using a 2-sample t-test at each condition compared with phage in BHI (controls) at T0 (p < 0.05). 
Error bars indicate 95% confidence intervals for means.; b) effect of polymer solvent on free phage 
viability. T0 point denotes time between 0 – 10 min, T6 exposure to solution for 6h and T24 exposure 
a) 
b) 
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for 24h. * indicates significantly different phage titres using a 2-sample t-test at each condition 
compared with phage at T0 for each composition (p < 0.05). Error bars indicate 95% confidence 
intervals for means. 
Phages are usually stored in broth (e.g. BHI broth used here), however, dispersing phage in a polymer 
solution may adversely impact phage viability. The effect of different dissolution media used to 
dissolve Eudragit S100 on phage activity was investigated (Figure 8b). The greatest loss of phage titre 
was in a polymer solution where the polymer was dissolved in water, and the pH adjusted to pH 7, a 
3- log reduction in phage titre was observed. Water was therefore not used for phage formulation. 
Eudragit S100 was also dissolved in 0.2 M sodium chloride solution (Figure 3.8b) as this has been 
previously shown to help protect phages from osmotic shock (Leibo & Mazur, 1966). Phage viability 
over 24 h of exposure to 0.2 M solution of sodium chloride showed that the phage titre was reduced 
by ~1 log (Figure 3.8b). DNA may be lost from phage capsids under high osmotic pressure and 
therefore the presence of salt is an important consideration for phage stability and receptor binding 
(S. Huang et al., 2008; Leibo & Mazur, 1966). Phage viability in 5 % (w/v) Eudragit S100 dissolved in 
BHI broth was tested showing around ~1 log reduction in phage titre like results for 0.2 M sodium 
chloride. 
Phage stocks stored in BHI broth at 4°C showed no greater than ~1 log reduction in phage viability 
stored over a period of 2 months. Storage temperature between 4˚C and 20˚C had no significant effect 
on the phage titre for phages stored in BHI broth (data not shown). 
3.3.5 Phage release in simulated fluids 
 
Following washing and removal of Miglyol, encapsulated phage particles were added to shaking 
solutions containing simulated intestinal fluid. The release of phages in simulated intestinal fluid was 
assayed over 24 h at two different pH values (Figure 3.9a). Eudragit S100 is a pH responsive polymer, 
known to dissolve at around pH 7. Near 100% (typically > 95%) encapsulation of phages was observed 
following the entire encapsulation and washing procedures. For pure Eudragit S100 microparticles, an 
initial burst release (around 10 % of the phage loading) was observed at pH 7 suggesting phages were 
rapidly able to permeate across the porous microparticle shell. Initially, there is a large phage 
concentration gradient due to the concentration of phages in the microparticle compared with the 
outside solution. This gradient drives phages to diffuse into the external solution. The concentration 
gradient gradually reduces, and the phage release slows down over time. Release of phage at pH 7 
may be attributed to polymer shell swelling as polymer chains begin to disentangle upon exposure to 
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the buffer and ion exchange occurs between the counter ions H+ replaced by Na+ and dissociation of 
the carboxylic acid groups (Nguyen & Fogler, 2005). Phage release in pH 7 was fast (burst release) with 
most release taking place within an hour of exposure to buffer. Even over a 24 h exposure period to 
SIF at pH 6 phage only ~ 10% of encapsulated phage was released. 100% release of phage at pH 7 
corresponded with a calculated phage dose of ~3.1 x 108 PFU ml-1. 
Pure Eudragit ES100 microparticles exposed to simulated gastric fluid (pH 2) for 3 hours resulted in 
complete inactivation of phage with no detected phage release in simulated intestinal fluid (Figure 
3.9b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Release of encapsulated phage from microparticles. a) Phage release kinetics from Eudragit 
S100 (ES100) and ES100/Alginate microparticles exposed to Simulated Intestinal Fluid (SIF) at pH 6 and 
a) 
b) 
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pH 7 and from ES100/Alginate microparticles exposed to Simulated Gastric Fluid (SGF, pH 2, 3 h 
exposure) followed by release in SIF at pH 7; b) Quantitative titres of phages released at 24 h in Fig 9a 
above. Samples labelled pH 2 were exposed to SGF (pH 2, 3 h exposure) followed by release in SIF at 
pH 7. * indicates significantly different phage titres (p < 0.05) for a 2-sample t-test of each sample 
compared with phage release from ES100/Alginate (SIF pH 7). Summary statistics for data are 
presented in Table 3.3. 
Table 3.3 Summary of microencapsulated CDKM9 release results (2-sample t-test for means). 
Sample ID Mean / 
PFU ml-1 
StDev /  
PFU ml-1 
Lower 95% 
CI 
Upper 95% 
CI 
p-
value 
Sample 
size 
(n) 
Null 
hypothesis 
ES100/Alg (SIF) 2.1 x106 4.5 x 105 1.4 x 106 2.8 x 106 - 4 NA 
ES100/Alg 
(SGF) 
1.1 x 105 1.8 x 104 7.6 x 104 1.3 x 105 0.000 4 Mean = 2.1 x 
106 
ES100 (SIF) 3.1 x 106 7.6 x 105 1.3 x 106 5.1 x 106 0.121 3 Mean = 2.1 x 
106 
ES100 (SGF) 0 NA NA NA NA 4 NA 
Notes: Reported mean values are after 24 h exposure to simulated intestinal fluid; CI = confidence 
interval; p < 0.05 indicates rejection of null hypothesis; 
Phage encapsulated in pure alginate microparticles were completely inactivated following acid 
exposure to simulated gastric fluid (see supplementary information, S1 FIG). With the addition of 
alginate to Eudragit S100 particles, significant protection of phage against acidic pH in simulated 
gastric fluid was achieved (Figure 3.9b). There was around ~1 log reduction in phage titre in 
comparison with encapsulated phage not exposed to simulated gastric fluid. The calculated dose for 
100% release of phage at pH 7 in SIF following SGF exposure was ~ 1.1 x 107 PFU g-1. 
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Figure 3.10. Storage stability of encapsulated CDKM9 phage in ES100/Alginate microparticles 
refrigerated at 4C. Phage titre was evaluated by exposing microparticles to simulated intestinal fluid.  
* indicates significance as compared with sample at week 0 (p < 0.05) using a 2-sample t-test. 
3.3.6 Storage of Ephage 
 
ES100/Alg microparticles stored over the course of 4 weeks under refrigerated conditions (at 4C) 
showed a modest drop in phage titre (Figure 3.10). Phage titre dropped from ~ 4 x 106 PFU ml-1 (4 x 
108 PFU g-1 of microparticles) at week 0 to 1 x 106 PFU ml-1 (1 x 108 PFU g-1 of microparticles) after 1 
week of storage. Thereafter, the titre remained stable up to week 4. 
3.4 Discussion 
 
A limited range of microencapsulation techniques have previously been employed for bacteriophage 
encapsulation, with extrusion based droplet formation the most frequently used method (Colom et 
al., 2017a; C Dini et al., 2012; S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012; Samtlebe et al., 
2016; Tang et al., 2014; Wall et al., 2010). None have employed microfluidic fabrication techniques 
used here. The principle driver for encapsulation has been to protect phages from the stomach acidity. 
In a considerable number of previously published studies, the sizes of phage encapsulated 
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microparticles have tended to be considerably larger than those reported here (an order of magnitude 
bigger). Little consideration has previously been given to the control of the particle size distribution, 
the phage loading per particle and the resulting heterogeneity of the release kinetics from each 
particle (S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012, Tang et al., 2013, 2014). A key 
advantage of the microfluidic fabrication process used here is the precision with which uniform small 
droplets (mean size ~100 µm) containing encapsulated phage may be prepared under low shear 
conditions resulting in near 100 % phage encapsulation efficiency. 
The importance of establishing a stable dripping regime means that each droplet was produced at the 
same position; it may therefore be assumed that the disruptive forces of the same magnitude acted 
on each individual droplet and these forces became negligible after pinch-off. This is a rare occurrence 
because in conventional bulk emulsification systems, the droplets are continuously being subjected to 
shear which typically varies widely across the mixing container or valve (Egidi et al., & Kosvintsev, 
2008; Stillwell et al., 2007); this is true when encapsulation is carried out using conventional 
homogenisation or atomisation techniques (Jain et al., 2005; Sağlam et al., 2011; Un & Lements, 2007). 
Continuous excessive exposure to shear results in the droplets breaking further into smaller droplets 
resulting in emulsions with a high polydispersity index (Kong et al., 2012). The microfluidic fabrication 
process provides a highly controlled uniform shear environment resulting in monodispersed 
microparticles. 
It is well known that phage are sensitive to physical and chemical stresses including shear (S. S. Y. 
Leung et al., 2016; Vandenheuvel et al., 2013a), temperature (Vandenheuvel et al., 2013a), pH (Briers 
et al., 2008), ionic strength (Knezevic et al., 2011), exposure to organic solvents (S. W. Lee & Belcher, 
2004; Puapermpoonsiri et al., 2009) etc. Formulations used for phage encapsulation require careful 
selection of constituents and encapsulation conditions. Phage CDKM9 was shown to be highly 
sensitive to acidic pH. Similar results have been reported previously for a number of other therapeutic 
phages including a Salmonella phage Felix O1 (a myovirus) (Yongsheng Ma et al., 2008), a 
Staphylococcus aureus bacteriophage K (also a myovirus) (S. Kim et al., 2015a; Yongsheng Ma et al., 
2012) and for an E. coli specific phage exposed for 5 min at pH 2 (S. Kim et al., 2015a). This loss of 
phage activity highlights the need to protect the phage from the harsh acidic environment of the 
stomach if controlled doses of phage are to be reliably delivered at the infected colon. Our results 
show that phage CDKM9 may be acceptably formulated in a low molarity salt solution containing 
mixtures of dissolved polymers alginate and Eudragit. The observation that pH conditions typically 
found in the colon do not detrimentally affect phage activity is promising as viable phages need to be 
released at the site of infection in the colon (where the environmental pH may vary from neutral to 
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alkaline) and remain viable after release. Previously McConnell et al., (2008) reported that the pH of 
the colon can fall during bacterial infection to around or just below pH 7; in such a case, the released 
phage should remain viable and capable of lysing the infecting C. difficile bacteria causing CDI. Osmotic 
damage to phage during phage processing and storage is an important consideration (Davies & Kelly, 
1969). Governal and Gerba (1997) reported activity of an E. coli phage dropped by 2 log upon exposure 
to ultrapure water. Our results also suggest that phage CDKM9 titre drops upon exposure to deionised 
water. Phages from the Myoviridae family, are known to be one of the most stable types of phages 
however, a number of studies suggest considerable variation in phage stability exposed to identical 
stress conditions (Vandenheuvel et al., 2013a). We have shown that phage CDKM9 may be formulated 
with Eudragit in a 0.2 M salt solution. Merabishvili et al., (2013) showed that an S. aureus phage (from 
the Myoviridae family) formulated in ~2 mM salt solution may be stored under refrigerated conditions 
for up to 3 months without loss of phage titre. Generally, BHI broth is the storage medium of choice 
for phage stocks; it is known to keep phages stable whilst stored over long periods of time (Jończyk et 
al., 2011). Although phage CDKM9 may be formulated with Eudragit in BHI, we decided to avoid 
working with a complex broth medium since both saline and broth showed similar phage viability 
results. 
A number of previous studies have used alginate as the main encapsulating agent either on its own 
(Colom et al., 2017a; Yongsheng Ma et al., 2012; Wall et al., 2010) or in combination with whey protein 
(Samtlebe et al., 2016; Tang et al., 2013, 2014) or chitosan (S. Kim et al., 2015a; Yongsheng Ma et al., 
2008). Phages encapsulated in crosslinked pure alginate microparticles were found to be susceptible 
to acid damage following exposure to simulated gastric fluid (C Dini et al., 2012; Yongsheng Ma et al., 
2008, 2012). Alginate hydrogel pores tend to be in the 5-200 nm range depending on the degree of 
crosslinking (George & Abraham, 2006). The porosity of the alginate gel microparticles affects phage 
susceptibility to acid damage due to diffusion of acid. A number of studies have added CaCO3 within 
the microparticles to protect phage from acid damage (Colom et al., 2017a; Yongsheng Ma et al., 
2012). Other studies have shown that by combining alginate with chitosan (S. Kim, Jo, & Ahn, 2015b; 
Yongsheng Ma et al., 2008) or whey protein (Samtlebe et al., 2016; Tang et al., 2013, 2014), better 
acid protection may be achieved. We have shown that by combining the pH responsive character of 
Eudragit with alginate, phage CDKM9 was significantly protected from exposure to simulated gastric 
fluid at pH 2 and could thereafter be readily released upon exposure to pH 7. Furthermore, the 
microparticles were stable upon storage under refrigerated conditions for up to 4 weeks. The 
combination of small particle size and pH responsive character of the encapsulating polymer resulted 
in rapid release of phage within the first hour upon exposure to pH 7 whereas release was negligible 
at pH 6. Previous studies on phage encapsulated in large microparticles (~ 1mm) have reported slower 
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sustained release kinetics for alginate encapsulated phage (S. Kim et al., 2015a; Yongsheng Ma et al., 
2008). Colom et al., (2017a) reported faster release from small alginate microparticles containing 
CaCO3 as antacid (mean size ~ 100 µm). However, exposure to simulated gastric fluid (pH 2.8 for 60 
min) resulted in between 2 log and 3 log reduction in Salmonella phage titre suggesting that even with 
the addition of CaCO3, phage were highly susceptible to SGF. Particle size was found to be an important 
factor influencing phage protection from SGF for acid permeable beads (Tang et al., 2014). Alginate-
whey protein microparticles having the same composition but different mean sizes showed larger 
particles protected phage better compared with smaller microparticles (Tang et al., 2014). The 
diffusion path length of acid is increased with particle size thereby affording protection to phage 
further away from the bead surface. We have shown that encapsulation of phage in Eudragit/alginate 
microparticles (mean size ~ 100 µm) may permit rapid burst release of phage cargo without significant 
acid damage. In future studies, it may be possible to tailor phage release kinetics through controlling 
the microparticle size and the shell composition (e.g. Eudragit to alginate ratio); this work is currently 
underway in our laboratory. 
A number of in vivo animal studies have shown dose dependent phage therapy outcomes, with high 
doses of phage resulting in better clinical results (Biswas et al., 2002; Cerveny et al., 2002; Smith et al., 
1987; Wills et al., 2005). Accurate control over the phage dose delivered at the site of infection and 
the timing of the delivery are important considerations (Sarker et al., 2016). Careful formulation and 
microfluidic loading of phage (resulting in uniform particle size) would facilitate control over the phage 
release dynamics and accurate delivery of the phage dosage. This has so far received little attention 
in the published literature. We have demonstrated that even after exposure of phage encapsulated 
microparticles to simulated gastric fluid at pH 2 for 3 hours, the released phage dose corresponds to 
~ 1 x 107 PFU g-1 of phage microparticles. The encapsulated dose was ~ 2 x 108 PFU g-1 of phage 
microparticles. One gram of microparticles would therefore deliver a ~107 PFU dose which is similar 
to therapeutic doses given in a number of animal studies (Smith et al., 1987; Barrow and Lovell, 1998; 
Chibani-chennoufi et al., 2004; Abdulamir, Sabah and BakarFatimah;, 2014; Nale et al., 2016; Yen et 
al., 2017). Nale et al., (2016) in their hamster C. difficile infection model delivered an unformulated 
phage suspension at a dose of ~ 108 PFU/hamster. The actual dose delivered to the site of infection 
would have been considerably lower. Failure of the recently concluded phage trial for the treatment 
of E coli diarrhoea in children was attributed to the lack of clinical host range coverage of the employed 
E.coli phages to the disease-causing bacteria (faecal phage titres were not higher in patients 
harbouring a phage sensitive E. coli colony in the stool; around 50% of all patients). A drop in phage 
titre due to phage exposure to stomach acidity may also have been a factor in the consequent lack of 
in situ phage amplification (Sarker et al., 2016). Stanford et al., (2010) previously used Eudragit S100, 
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for phage encapsulation and enteric delivery targeting E. coli infection in cattle. A spray dryer was 
used to encapsulate phages into a dry powder, which was administered either as a bolus or added to 
the feed directly. The method was not optimised to protect the phage from the stomach acidity. Some 
protection of phages from stomach acidic pH was seen with phage replicating in vivo and a lower E. 
coli faecal shedding rate was observed in phage treated cattle. We have demonstrated much improved 
acid protection of phage encapsulated in highly uniform Eudragit/alginate microparticles; a significant 
step forward compared with previously published work. 
Delivery systems and their formulation require consideration of the bioavailabity of the active agent 
at the site of infection. The size of microparticles may play an important role by ensuring it is minimally 
affected by the conditions of the diseased state. The small intestine and the colon are connected via 
a junction known as the ileum; while C. difficile infection has been reported to occur and cause disease 
in the small intestine (Navaneethan & Giannella, 2009), in most patients the bacterium mainly affects 
the colon. Nevertheless, release of phage in the small intestine as microparticles transit towards the 
colon may prove beneficial in eradicating CDI for a wide range of patients. Other considerations for 
colon targeted delivery of active agents include the changes in transit times during infection. Increased 
loss of fluid from the colon due to symptoms such as diarrhoea result in observed shortened mean 
transit times. Dilution of phage due to the high fluid environment may be a particular challenge. Larger 
particles (~ mm size range) may be more prone to the influence of short transit times. Smaller particles 
may be predisposed to non-specific mucoadhesion (Alhnan et al., 2010; Kietzmann et al., 2010) which 
may aid in phage retention and sustained release over a signficant time period. Colom et al., (2017a) 
showed better phage retention (for animals treated with encapsulated phage versus those treated 
with free phage) in the caecum of chickens and a significant reduction in Salmonella colonisation, 
attributing these results to the mucoadhesiveness of the small alginate microparticles (~ 100 µm) used 
for encapsulating phage. Wittaya-areekul et al., (2006) showed differences in mucoadhesion 
properties of chitosan coated alginate microparticles using an in vitro assay using porcine gut tissue 
samples. 
Gastrointestinal infections can affect different parts of the gut. In future different phage fomulations 
may need to be developed targeting phage release in the appropriate intestinal region perhaps using 
more specific infection related triggers e.g. enzymes or toxins released by the bacterium causing the 
infection (Bean et al., 2014). 
 A limitation of phages for therapeutic use (C. difficile phages such as CDKM9 are no exception) is their 
narrow host range. Most phages only infect a small number of prevalent strains, thereby necessitating 
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the use of phage cocktails to provide adequate therapeutic coverage. Phages incorporated in the 
cocktail may require tailored formulations to ensure adequate stability (Malik et al., 2017). 
Microfluidic systems such as the one described in the present work have the potential to enable 
precise control of the particle size and loading of the phages within the microparticles. Here, we have 
demonstrated for the first time, proof-of-concept data in support of this platform technology for the 
production of encapsulated phage in a pH responsive polymer suitable for targeted intestinal phage 
delivery. An eight week study on the use of Eudragit coated mesalazine tablets in patients with mild 
to moderately active ulcerative colitis (Gibson et al., 2006) showed that the tablets were well tolerated 
suggesting Eudragit® based microencapsulation of phages may be safe for use in humans. 
3.5 Conclusions 
 
Highly uniform small microparticles (mean size ~ 100 µm) of Eudragit S100 or Eudragit S100/alginate 
were generated using a flow-focussing glass capillary device. A novel mechanism of microparticle 
formation was demonstrated using acidified medium-chain triglycerides in a water-in-oil emulsion 
system. Solid core-shell microparticles were produced with a low polydispersity index enabling control 
over phage loading and their subsequent pH triggered release. Encapsulation of carboxyfluorescein in 
Eudragit S100 particles was visualised using confocal laser scanning microscopy and examined under 
different conditions elucidating the effect of different formulation and microfluidic experimental 
parameters on particle size. Phage encapsulation and subsequent release kinetics revealed that 
microparticles prepared using Eudragit S100 formulations possess pH responsive characteristics with 
phage release triggered in an intestinal pH range suitable for therapeutic purposes. The encapsulated 
phages were shown to be significantly protected upon prolonged exposure to an acidic environment 
without the addition of an antacid in the formulation. We have also demonstrated the storage stability 
of the encapsulated phage under refrigerated conditions over a 4-week storage period. Future work 
will investigate the efficacy of the encapsulated phages by controlling phage loading and release rates 
on bacterial inactivation in suitable in vitro chemostat type systems as well as in tissue culture models 
and long term in relevant animal infection models. 
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Chapter 4: Microfluidic encapsulation of bacteriophages in a commercial chip 
with high precision control 
 
Abstract 
 
A Salmonella specific bacteriophage Felix O1 (Myoviridae) was microencapsulated in a pH responsive 
polymer formulation. The formulation incorporated a commercially available pH responsive polymer 
Eudragit S100 (10 % w/v), with the addition of the biopolymer sodium alginate whose composition 
was varied (0.5 % w/v - 2 % w/v). The microencapsulation process employed a commercially available 
microfluidic droplet generation device. A key feature of the microfluidic process was the exquisite 
control over the uniformity of the droplet size, phage dose and high encapsulation efficiency (~100%). 
Monodispersed droplets were subsequently crosslinked into highly uniform spherical gelled 
microparticles containing viable encapsulated phages. A novelty of the work reported here is that the 
size of the generated monodispersed droplets could be precisely controlled in the range 50 µm to 200 
µm by varying the flow rates of the dispersed and continuous phases. Consequently, alginate 
concentration and microparticle size were shown to influence the phage release profile and most 
importantly the degree of acid protection afforded to phages upon exposure to simulated gastric fluid 
(SGF). Bigger microparticles (~100 µm) showed better acid protection compared with smaller beads 
(~50 µm) made from the same formulation. Increasing the alginate composition resulted in improved 
acid protection of phages, however, high viscosity formulations containing 2 % (w/v) alginate 
negatively affected ease of droplet generation in the microfluidic device thereby posing a limitation in 
terms of process scale-up. Optimisation of microcapsule size and alginate composition was carried out. 
Felix O1 encapsulated in 10 % (w/v) ES100 and 1 % (w/v) alginate showed excellent protection upon 
exposure of the gelled microparticles to SGF at pH 1 for 2 h without the use of any antacids in the 
encapsulation matrix. Encapsulated phages previously exposed to SGF at pH 1 for 2 h were released 
at elevated pH in simulated intestinal fluid (SIF) and arrested bacterial growth in the log growth phase. 
The significance of our research is in demonstrating the use of microfluidic microencapsulation of 
phages to produce solid dosage microcapsule forms providing a high level of acid protection with a 
rapid pH triggered release profile suitable for targeted delivery and controlled release in the 
gastrointestinal tract. 
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4.1 Introduction 
 
It is estimated that Salmonella alone accounts for 1.2 million foodborne illnesses in the United States, 
with 23,000 hospitalisations and 450 deaths costing an estimated 365 million dollars in medical costs 
each year (Scallan et al., 2011). Increasing centralisation and industrialisation of food supply enhances 
the probability of distribution of these hardy organisms. Antimicrobial resistance to ‘first-line’ drugs is 
increasingly common among Salmonella worldwide (Hohmann, 2001). In animals, decolonisation of 
the gastrointestinal tract from Salmonella may be beneficial for biocontrol to reduce dissemination of 
harmful bacteria through the food chain e.g. lairage associated Salmonella transmission in pigs (Wall 
et al., 2010). Ensuring delivery and subsequent release of a precise high dose of phages to the site of 
infection in the gastrointestinal tract remains an important challenge to ensure that phage therapy 
develops its full potential as a therapeutic or prophylactic antimicrobial agent (Malik et al., 2017). 
Encapsulation may help protect phages from loss of activity during manufacturing and storage and 
during transit through the stomach en route further downstream in the gastrointestinal tract. 
Encapsulation in solid dosage forms e.g. microcapsules may also permit easy oral dose application 
allowing phage administration through feed instead of administration via oral gavage. 
When free phages are delivered orally for phage therapy or for modulating microbiota, there is likely 
to be variable but significant losses of phage titre by the time phages reach the intended infection site 
(Young & Gill, 2015). Oral application of phages exposes them to stomach acidity, digestive tract 
contents (e.g. enzymes such as pepsin and pancreatin) which can inactivate phages (Denou et al., 
2009). A recent in vivo study in chickens (phage were added to animal feed) using alginate 
microencapsulated Salmonella Felix O1 phages showed a significant reduction in levels of phage titre 
(3 log reduction compared to the dose given) found in the gastrointestinal tract (Yin-hing Ma et al., 
2014). Potential reduction in phage titres due to inactivation attributed to stomach acidity may in part 
have been responsible for failure of a recent clinical trial treating acute bacterial diarrhoea symptoms 
in children using phage therapy (Sarker et al., 2016). Acidic conditions encountered in the stomach 
and the presence of bile and digestive enzymes and other proteases in the intestinal tract and stomach 
may inactivate unformulated phages (Choinska-Pulit et al., 2015; Yongsheng Ma et al., 2008; Tang et 
al., 2013). Use of antacids may increase the risk of gastroenteritis and its use was not permitted in a 
recent clinical trial (Sarker et al., 2016). In a separate study, mice were given an oral dose (T4 
coliphages in drinking water) of 109 PFU/g gut contents which resulted in a 1000-fold lower titer, 
indicating a sizable loss in phage activity (Denou et al., 2009). Therefore, there are clear drivers to 
protect phages against adverse gastrointestinal conditions by encapsulating them and to control their 
targeted release at the site of infection e.g. in the lower gastrointestinal tract (GIT) i.e. ileum, cecum 
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and colon for Salmonella and other enteric infections (S. Kim et al., 2015a; Yongsheng Ma et al., 2008; 
Tang et al., 2013). 
Previous phage encapsulation strategies have used basic homogeniser and extrusion techniques and 
have employed formulations that are gentle in terms of avoiding use of organic solvents that would 
inactivate phages (Yongsheng Ma et al., 2008, 2012; Puapermpoonsiri et al., 2009; Shi et al., 2016; 
Tang et al., 2013). These studies have shown modest protection of phages when the capsules were 
exposed to simulated gastric fluid at pH values in the range 2 – 2.5, for up to 2 h exposure duration. 
(Vinner et al., 2017) recently showed for the first time the potential of microfluidic encapsulation for 
a C. difficile specific phage using an in-house developed microfluidic device (Vinner et al., 2017). In-
house built microfluidic droplet generation devices are highly versatile however they require a high 
level of fabrication expertise including access to specialist micro-forging equipment, the devices are 
fragile, difficult to handle, prone at times to leakages and ingress of air bubbles causing contamination 
and production issues especially for processing of biological materials.  
Aims and objectives 
 
The aim of this study was to use commercially available low-cost glass microfluidic droplet generation 
systems to microencapsulate phage. Additionally, in the previous chapter the phage titre for the 
encapsulated C. difficile specific phage was rather low (107 PFU ml-1), the formulation was not 
optimised, and acid protection was limited to pH 2. The objectives here were to precisely control 
microparticle size and hence investigate the effect of particle size and formulation parameters 
(alginate concentration) to prepare pH responsive microparticles that were able to withstand 
significantly low gastric acidity (as low as pH 1 for 2 h) without appreciable loss in phage activity at 
high encapsulated phage titres. 
4.2 Materials and Methods 
4.2.1 Chemical reagents 
 
A methyl methacrylate co-methacrylic acid copolymer Eudragit S100 was purchased from Evonik, 
Germany. Miglyol 840, a propylene glycol diester of caprylic/capric acid, was purchased from Sasol, 
Germany and used as carrier oil for the continuous phase. Polyglycerol polyricinoleate (PGPR), an oil 
soluble surfactant, was purchased from Abitek USA. Para-toluenesulfonic acid and sodium chloride 
were purchased from Fisher Scientific, UK. Sorensen’s buffer 0.2 M was used as a dissolution media 
for the microparticles and was prepared by mixing sodium phosphate (NaH2PO4) with sodium 
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phosphate dibasic (Na2HPO4) (for pH 7) (Fisher Scientific UK).  Alginate was purchased from Sigma 
Aldrich, UK.  
4.2.2 Salmonella strain and bacteriophage Felix O1  
 
Salmonella enterica ATCC19585 was purchased from LGC standards, EU (Figure 9.9 appendix). Phage 
Felix O1 was kindly donated by Dr Cath Rees, University of Nottingham, UK (Siqueira, Dodd, & Rees, 
2006). S. enterica strain was used to propagate and enumerate Felix O1 (Figure 9.10 and 9.11 
appendix). Brain heart infusion broth and agar (Oxoid UK.) were used for all bacterial work. A single 
colony from a streaked overnight culture on a BHI agar plate was used to inoculate fresh BHI broth 
and left shaking overnight at 37˚C. The culture was diluted and regrown to log phase at 0.2 O.D. 
(550nm) for all phage work.  
Table 4.1. Compositions of formulations and operating parameters for microfluidic device used to 
prepare emulsion droplets. 
 
 
Formulation ID D1 D2(s) D2(b) D3 
Composition 
10 % (w/v) 
ES100 
2 % (w/v) 
Alginate 
~109 PFU/ml 
10 % (w/v) 
ES100 
1 % (w/v) 
Alginate 
~109 PFU/ml 
10 % (w/v) 
ES100 
1 % (w/v) 
Alginate 
~109 PFU/ml 
10 % (w/v) 
ES100 
0.5 % (w/v) 
Alginate 
~109 PFU/ml 
Dispersed phase 
flow rate, Qd / µl 
h-1 
50 25 100 50 
Continuous phase 
flow rate, Qc / µl 
h-1 
1000 1000 1000 500 
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Felix O1 was propagated by infecting a log phase culture of S. enterica at MOI 0.01. Once the culture 
had cleared the lysate was centrifuged at 2000 g for 15 mins at 4˚C and filtered using a 0.2 µm pore 
size filter (Millipore, USA). All phage stocks were stored at 4˚C until further use. 
To titre the phage stocks, 10 µl of phage stock was serially diluted (10-fold) to 10-8 in 90 µl of BHI broth. 
This was spotted in triplicate on a double layer agar plate containing 10 µl of overnight culture of host, 
S. enterica. The plate was dried near a flame and then incubated overnight at 37˚C. The following day 
plaques were counted to determine the phage titre and expressed as plaque forming units (PFU) per 
ml. 
4.2.3 Free phage sensitivity at different pH values 
 
Phage sensitivity to different pH values was tested in 0.2 M NaCl with pepsin at 3.2 mg/ml for solutions 
of pH 2, 2.5 and 3. For pH solutions 4 to 7, 0.2 M Sorensen’s buffer was used with the addition of 10 
mg/ml pancreatin. Time points were taken at 0 min, 30 min, 1 hour, 3 hours, 6 hours and 24 hours. 
For pH 2 and 2.5 exposure time points were also taken every minute for the first 10 mins. 10 µl was 
removed at each time point and serially diluted 10-fold to 10-8 as described above. The samples were 
spotted in triplicate on a lawn of the host bacteria introduced via the double layer agar method. The 
plates were incubated at 37˚C overnight and checked for PFU the following day. 
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Figure 4.1 Schematic of experimental setup to produce water-in-oil emulsion for phage 
microencapsulation. Microscope stage with mounted microfluidic chip connected to two syringe 
pumps suppling aqueous (containing phage and polymer formulation) and oil phase. High speed 
camera connected via computer to microscope for visualisation of drop formation. 
4.2.4 Felix O1 encapsulation using microfluidic droplet generation system 
 
Eudragit S100 (ES100) was dissolved in deionised water (dH2O) by dripping 4 M NaOH until the solution 
was clear. The solution pH was adjusted to pH 7 using 0.1M HCl. To this solution different 
concentrations (0.5 %, 1 %, 2 % (w/v)) of alginate was added and dissolved by stirring at 60°C overnight 
in 50 ml Duran bottles with a top equipped with a magnetic stirrer to aid mixing. The solution was left 
to cool before phage stock was added. Felix O1 stock was concentrated by centrifuging in Amicon 
tubes (Millipore, UK) with a 0.2 µm filter for 15 min and 2,000 g. This concentrated phage was added 
to the dispersed aqueous phase solution to make the final concentration of phage of ~108-109 PFU ml-
1. The continuous oil phase was made of a 50:50 mixture of Miglyol 840 and Castor oil (Elf Foods, 
Loughborough, UK), with 5 % (w/v) PGPR. The emulsion was collected in acidified oil, consisting of 
0.05 M p-toluenesulfonic acid in Miglyol with 5 % (w/v) PGPR. 
Eudragit-alginate droplets were prepared by using a hydrophobic quartz droplet junction chip with an 
etch depth of 190 µm purchased from Dolomite, UK (Figure 4.1). The dispersed aqueous phase was 
introduced through the inner/middle channel and the continuous phase from the two outer channels. 
The phases were pumped via 10 ml syringes (BD Plastipak, UK) mounted on syringe pumps (Harvard 
Apparatus, UK). The two phases were delivered and collected through medical delivery tubes (0.86 
mm inner diameter and 1.52 mm outer diameter, Smiths Medical International Limited, UK). As the 
two phases met at the interface, the oil phase causes the aqueous phase to pinch and form droplets. 
The flow rates for all formulations were kept constant and maintained to keep the dripping regime. 
The droplet formation was observed via a high-speed camera (Micro C110 Phantom Ametek, UK), 
connected to an inverted microscope (Nikon Eclipse E200) using x 4 magnification objective lens. The 
camera was connected via computer allowing recording of the droplet formation at around 3000 
frames per second. The forming droplets were collected in acidified oil and allowed to crosslink for a 
minimum of 2 hours. 
The acidified oil was removed by pipetting off the oil layer after gentle centrifugation at 300 g for 5 
mins to settle the acidified microparticles. An excess of 0.1 M CaCl2 was added to the microparticles 
to crosslink the alginate for 1 hour. Microparticles were collected by centrifuging at 2000 g for 5 mins 
and removing the CaCl2 solution using a pipette. The gelled particles were stored hydrated at 4oC. 
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The drop and particle size were analysed using the Image J program (National Institute of Health, 
Washington, U.S.) by counting 10 drops or particles per sample. The particle sizes for gelled 
microcapsules were measured using Coulter LS series 130 (Beckman Coulter Inc.), employing a 
Fraunhofer optical model for data regression (Figure 9.7 appendix). 
4.2.5 Scanning electron microscope (SEM) 
 
Gelled particles were frozen on filter paper (0.2 µm pore size, Millipore Ltd. UK) at -20˚C overnight. 
The particles were freeze dried (VirTis Wizard 2.0) for 24 hours at 50 Pa pressures and -20˚C. The 
particles were put on viewing stubs using double sided carbon tape, sputter coated with gold and 
viewed using a table top SEM (Hitachi TM3030 Microscope). 
4.2.6 Encapsulated phage release in SGF and SIF 
 
100 mg of Felix O1 encapsulated particles (approximate) were suspended in 10 ml prewarmed 
simulated intestinal fluid (SIF) containing 10 mg/ml pancreatin in 0.2 M Sorensen’s buffer at pH 7 
(Sigma Aldrich, UK). All dissolution experiments were carried out at 37oC, shaking. For acid exposure 
to pH 1, 2, 2.5 and 3, 0.1 g particles were suspended in 10 ml prewarmed simulated gastric fluid (SGF) 
containing 3.2 mg/ml pepsin in 0.2 M NaCl at pH 2 (Sigma Aldrich, UK). After 2 hours exposure to SGF 
at each pH, the particles were centrifuged at 2000 g for 10 min, SGF removed and microparticles re-
suspended in SIF (10 ml) for dissolution and phage release. Phage release was monitored over 4 hours, 
by taking samples to enumerate phage release kinetics at hourly time points. To do this, plaque assays 
were performed as described previously by taking 10 µl samples, serially diluting and spotting on a 
bacterial lawn using double overlay agar method. The plates were counted the following day for 
plaques. 
4.2.7 Encapsulated phage Salmonella killing 
 
Salmonella was cultured from a single colony with a starting O.D. (550nm) of <0.001, shaking at 37oC 
overnight. 60 ul of overnight culture was added to 60 ml of BHI. 2 ml of this starter culture was added 
to 24 well tissue culture plates. Approximately 0.2 g of microparticles were added to multiple wells 
(for hourly time points) to evaluate in vitro phage release, amplification and arresting of bacterial 
growth (samples were shaken to allow mixing). Microparticles used were either virgin or previously 
exposed to pH 1 for an exposure period of 2 hours. At hourly intervals 1 ml aliquots were withdrawn 
and the O.D. measured of the controls (bacteria only), pH 1 exposed particles and non-pH 1 exposed 
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particles. An additional 1 ml aliquot per well was transferred to an Eppendorf tube for each sample 
and centrifuged at 2000 g for 3 mins for plaque assays. 10 µl was removed from the supernatant to 
enumerate for phage using the double-layer agar method as described previously. The pellet was 
separated and re-suspended in fresh BHI broth, this was serially diluted and plated on BHI agar plate 
to enumerate residual bacteria concentration. The control was also serially diluted and plated to 
determine the bacteria concentration. The plates were incubated overnight at 37oC and checked for 
plaques and colonies the following day. The results were presented as the mean of three repeats. 
4.2.8 Statistical analysis  
 
Statistical analysis was carried out using the statistical software Minitab 18. 
4.3 Results 
4.3.1 Production of phage encapsulated ES100-alginate microparticles 
 
Highly monodispersed droplets were produced for 0.5 % (w/v) (viscosity, 25 cP) and 1 % (w/v) alginate 
(64 cP) compositions (all solutions had 10 % (w/v) ES100). Droplet generation was stable for 0.5 % 
(w/v) and 1 % (w/v) alginate formulation over extended periods with drops collected for several days 
without interruption. Formulations with alginate compositions higher than 1 % (w/v) were highly 
viscous, (2 % (w/v) alginate solution having a measured viscosity of 574 cP) and this resulted in 
difficulties in maintaining uniformity of droplet generation for prolonged periods due to flow 
instabilities causing disruption in droplet generation and observation of jetting phenomena discussed 
elsewhere (Vinner et al., 2017). Stable production of uniform droplets required at-line optimisation of 
the hydrodynamic conditions. Microfluidic droplet generation devices can be controlled in situ by 
direct microscopic observation. Hydrodynamic conditions were optimised for each formulation in real-
time by adjusting fluid flow rates during each experiment until uniform droplets were produced. 
Thereafter only slight changes to these values were needed to achieve droplets of similar sizes 
ensuring batch-to-batch uniformity of droplets. 
To enable better control of the droplet generation process and to reliably produce droplets with low 
polydispersity, the ‘dripping regime’ worked best. Here, the droplets were formed closer to the orifice 
of the collection capillary because the interfacial tension forces dominated over the inertia of the 
dispersed phase and the viscous stress forces from the continuous phase. Droplet formation began as 
the dispersed phase entered microfluidic flow focusing zone. The dispersed phase did not meet the 
capillary wall due to repulsion from the hydrophobic surface of the collection capillary wall which is 
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designed to resist wetting by the aqueous phase (Figure 4.2a and b). The continuous phase forced the 
dispersed phase to elongate axially, collapsing the dispersed phase and producing a neck behind the 
forming droplet. As the elongation progressed further, the neck thinned into a thread, eventually 
breaking the dispersed phase and releasing the droplet. Following retraction, the process restarted 
with the dispersed phase protruding at the orifice of the collection capillary. In this dripping regime, 
the formation of one droplet took ~95 ms, thus ~10 droplets were formed each second and 
subsequent droplets were produced at the same position as the previous droplets. The balance 
between the drag force and interfacial tension and negligible shear in the collection capillary after 
drop formation resulted in uniform droplets. 
 
Figure 4.2 Production of pH responsive microparticles using a microfluidic droplet generation system. 
(a) in situ imaging showing generation of small droplets in the microfluidic chip using formulation D2(s) 
and (b) large droplets using formulation D2(b); (c) collected small droplets with formulation D2(s) 
(mean drop size 73 µm  11 µm); (d) collected large droplets with formulation D2(b) (mean drop size 
190 µm  5 µm); (e) collected small droplets with formulation D1 (mean drop size 64 µm  12 µm); (f) 
collected big droplets with formulation D3 (mean drop size 164 µm  19 µm); (g) particle size 
distributions for gelled microparticles using with formulation D2(s) and D2(b); (h) scanning electron 
micrograph of freeze dried big microparticles prepared using formulation D2(b). 
Changing the droplet size is an important feature of microfluidics enabling control over phage loading 
and particle size. Droplet generation in the dripping regime was optimised over a range of flow rates 
113 
 
for alginate formulations of differing viscosities thereby enabling control of the droplet size whilst 
maintaining a reasonably high degree of the size uniformity (Figure 4.2 c and d). This was done in real-
time whilst observing (using the microscope camera) the change in the resulting droplet size. 
Increasing the flow rate of the inner phase relative to the outer phase resulted in increased size of the 
droplets e.g. for 1 % alginate formulation. 
Droplet formation in the microfluidic droplet generation chip was followed by curing in acidified oil, 
removal of acidified miglyol and gelling of alginate in 0.1M CaCl2. This resulted in distinct gelled 
microspheres (Figure 4.2 e and f). The gelling process resulted in significant shrinkage in the size of 
the final microparticles as shown by the Coulter measurements (Figure 4.2) and the freeze-dried SEM 
image (Fig 4.2h). 
  
Figure 4.3. Effect of pH on free phage Felix O1 viability in 0.2 M NaCl solution. * indicates significantly 
different phage titres using a 2-sample t-test at each condition compared with phage exposed to pH 
7 at the corresponding time point. Time point 0 hours denotes time between 0-10 minutes for phage 
exposed to all pH values except pH 2.5 where phage titre reduced rapidly, and data is plotted 10 
seconds post exposure. 
4.3.2 Effect of acid exposure on Felix O1 viability 
 
The effect of acidic pH on Felix O1 phage viability was tested. Phages were suspended in 0.2 M sodium 
chloride solutions with varying pH. The phage lost nearly all activity after 10 min of exposure to pH 2 
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and lost activity progressively upon exposure to pH 2.5 over a period of 6 hours (Figure 4.3). Phage 
viability was significantly improved when the solution pH was above pH 3. 
Phage Felix O1 was found to be stable and retain titre upon formulation in 10 % (w/v) ES100 containing 
between 0.5 % (w/v) to 2 % (w/v) alginate upon storage under refrigerated conditions at 4 oC (for up 
to 1 week) and for several days in syringes mounted in microfluidic pumps used during droplet 
generation at room temperature. 
4.3.3 Microencapsulated phage exposure to simulated gastric fluid (SGF) and phage 
release in simulated intestinal fluid (SIF) 
 
Near 100 % (typically > 95%) encapsulation of phages was observed following the entire encapsulation 
process. Gelled microparticles were added to shaking solutions containing SGF with pH adjusted to pH 
1, pH 2, pH 2.5 and pH 3 and microparticles were exposed for 2 hours followed by phage release in 
SIF. Small 1 % (w/v) alginate microbeads (mean size 50 µm) were able to protect Felix O1 phage up to 
acidic pH 2.5 (Figure 4.4a). However, further lowering pH resulted in titre drop from 1x109 PFU ml-1 to 
4 x 107 PFU ml-1 (at pH 2) and complete loss of phage titre upon exposure to pH 1. Using the same 1 % 
(w/v) alginate formulation and increasing the size of microparticles (mean size ~100 µm) resulted in 
significant improvement in phage viability with no measured loss in phage titre for microparticles 
exposed to pH 1 (Figure 4.4b). The release profile also changed from burst release for small 
microbeads to slow release for the larger microbeads with around 20 % of encapsulated phage dose 
released after 1 hour and near complete release after 2 hours of exposure to SIF. Increasing the 
alginate composition from 1 % (w/v) to 2 % (w/v) for small microbeads significantly improved phage 
acid protection with phage surviving exposure albeit with titre reduction upon exposure to SGF at pH 
1 (Fig 4.4c). For larger microbeads lowering the alginate composition reduced acid protection with 0.5 
% (w/v) alginate samples showing acid protection down to pH 3 with significant drop in phage titres 
at pH 2.5 (Fig 4.4d). 
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Figure 4.4. Protection of encapsulated Felix O1 bacteriophage from SGF and release of phages upon 
exposure to SIF. (a) acid protection and phage release kinetics for small microparticles, formulation 
D2(s); (b) acid protection and phage release kinetics for big microparticles, formulation D2(b); (c) acid 
protection and phage release kinetics for small microparticles, formulation D1; (d) acid protection and 
phage release kinetics for big microparticles, formulation D3. * indicates significance in comparison to 
pH 7 for each time point (p < 0.05) in a two sample t-test. 
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4.3.4 Microencapsulated phage release and Salmonella killing 
 
Large 1% (w/v) alginate microbeads pre-exposed to SGF (pH 1) rapidly released phage with the phage 
titre rising to 1 x 106 PFU ml-1 shortly after addition (Fig 4.5 c). Optical density measurements showed 
a clear deviation in Salmonella growth in cultures at time point 3 hours post microparticle addition for 
small and large microparticles that had previously been exposed to SGF at pH 1 for 2 hours (Fig 4.5 a). 
For big particles the CFU counts dropped sharply after 3 hours with concomitant amplification of 
phage titres (Fig 4.5 b, c). Exposure to SGF at pH 1 resulted in considerably lower phage titres in the 
small 1% (w/v) alginate microparticles, therefore phage release from the small microbeads resulted in 
much lower phage titre (1 x 103 PFU ml-1). This resulted in a significant delay in both Salmonella CFU 
reduction (~ 4 hours) and subsequent phage amplification (Fig 5.5 b, c). 4 hours post microparticle 
addition both sets of cultures had arrested Salmonella growth and considerable phage amplification 
was noted with phage titre rising to ~ 1 x 1010 PFU ml-1 however, the time taken to arrive at this level 
differed significantly for the two 1% (w/v) alginate samples indicative of the effect of phage dose on 
phage-bacterium population dynamics. 
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Figure 4.5 Dynamics of phage killing of S. enterica (serovar Typhimurium) bacteria with 
microencapsulated Felix O1 bacteriophage. (a) Optical density curves; (b) CFU data showing bacteria 
killing in the presence of added microencapsulated phage (big and small beads prepared using 
formulation D2) pre-exposed to simulated gastric fluid (exposure period of 2 hrs at pH 1) prior to 
addition to bacterial cultures; * indicates significance in comparison to the control ( p< 0.05) (c) Phage 
amplification in the presence of Salmonella. * indicates significance in a 2-sample t-test (p < 0.05) n=3. 
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4.3.5 Storage stability of encapsulated phage 
 
10 % (w/v) ES100 containing 1% (w/v) Alginate microparticles stored over the course of 4 weeks under 
refrigerated conditions (at 4C) showed a modest drop in phage titre (Figure 4.6). Phage titre dropped 
from ~ 4 x 108 PFU ml-1 microparticle at week 0 to 1 x 108 PFU ml-1 microparticles after 1 week of 
storage. Thereafter, the titre remained stable up to week 4. 
a) 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
Figure 4.6. Storage stability of Felix O1 phage in (a) formulations D1-D3 and (b) microencapsulated in 
microparticles prepared using formulation D2 (~100 µm beads) refrigerated at 4o C. Phage titre was 
evaluated by exposing microparticles to simulated intestinal fluid (pH 7). * indicates significance as 
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compared with sample at week 0 (p < 0.05) using a 2-sample t-test. All measurements were done in 
triplicate with three biological repeats and three technical repeats. 
4.4 Discussion 
 
Fabrication of bacteriophage encapsulated microparticles using microfluidic technology allows precise 
control over the particle size, phage dose per particle and tailoring of the release profile for targeted 
delivery and controlled release of phages. The low controlled shear in the microfluidic droplet 
generation unit allows 100% phage encapsulation and production of highly uniform droplets. Previous 
published works on phage microencapsulation have employed a limited range of microencapsulation 
techniques with extrusion based droplet formation the most frequently used method (Colom et al., 
2017a; C Dini et al., 2012; S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012; Samtlebe et al., 2016; 
Tang et al., 2014; Wall et al., 2010). The significant potential of microfluidic microencapsulation for 
phages is relatively unexplored with only two previous published papers to date including one from 
our group (Boggione et al., 2017; Vinner et al., 2017). Motivation for research into solid dosage forms 
for oral application of phages is driven by the need to protect phages from the harsh gastrointestinal 
tract environment. Phage mediated reduction of bacterial levels in vivo requires high tires of viable 
phages delivered precisely at the site of infection that are able to target the host and arrest bacterial 
growth (Malik et al., 2017). In vitro phage stability experiments exposing phages to solutions of 
different acidic pH may be useful predictors of in vivo phage survival and a prerequisite during 
formulation development prior to testing in animal models (Watanabe et al., 2007). In a considerable 
number of previously published studies, the sizes of phage encapsulated microparticles have tended 
to be considerably larger than those reported here (an order of magnitude bigger) due to the use of 
extrusion methods. Little consideration has previously been given to the control of the particle size 
distribution, the phage loading per particle and the resulting heterogeneity of the release kinetics 
from each particle (S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012, Tang et al., 2013, 2014). A 
key advantage of the microfluidic microcapsule fabrication process used here is the precision with 
which uniform small microparticles (mean size 10 ~ 100 µm) containing encapsulated phage may be 
prepared under low shear conditions. 
Droplet generation in the microfluidic device established using a stable dripping regime resulted in 
each droplet being produced at the same position; disruptive forces of the same magnitude acted on 
each individual droplet and these forces became negligible after pinch-off. In conventional bulk 
emulsification systems, the droplets are continuously being subjected to shear which typically varies 
widely across the emulsification or homogenisation unit (Jain et al., 2005; Sağlam et al., 2011; Un & 
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Lements, 2007). Continuous excessive exposure to shear results in the droplets breaking further into 
smaller droplets resulting in emulsions with a high degree of polydispersity (Kong et al., 2012). The 
microfluidic fabrication process provides a highly controlled uniform shear environment resulting in 
microparticles with low polydispersity demonstrated here. 
Phages are sensitive to physical and chemical stresses including shear (S. S. Y. Leung et al., 2016; 
Vandenheuvel et al., 2013a), temperature (Vandenheuvel et al., 2013), pH (Briers et al., 2008), ionic 
strength (Knezevic et al., 2011), exposure to organic solvents (Lee and Belcher, 2004; Puapermpoonsiri 
et al., 2009). Overcoming phage instability to gastric acid is a major concern in oral phage delivery; it 
has been addressed in some studies through administration of antacids e.g. sodium bicarbonate prior 
to oral phage treatment or co-encapsulation of calcium carbonate (Jamalludeen et al., 2009). 
Formulations used for phage encapsulation require careful selection of constituents and 
encapsulation conditions to ensure phages remain viable and to prevent titre loss during processing 
and storage. Previous efforts targeting Salmonella in the food chain have attributed poor phage 
stability in the gastrointestinal tract for insufficient in vivo efficacy (Wall et al., 2010). Salmonella Felix 
O1 phage (belonging to the Myoviridae family) was shown here to be highly sensitive to acidic pH. 
Similar results have been reported previously for phage Felix O1, other Salmonella phages as well as 
staphylococcus aureus bacteriophage K (also a myovirus) and for E. coli specific phages (Albino et al., 
2014; S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012; Saez et al., 2011). This loss of phage 
activity highlights the need to protect the phage from the harsh acidic environment of the stomach if 
controlled doses of phage are to be reliably delivered to treat salmonellosis in the infected gut. Our 
results show that phage Felix O1 titre is stable in a formulation of dissolved ES100 10 % (w/v) 
containing variable alginate amounts over the range 0.5 % - 2 % (w/v). Microencapsulated Felix O1 
formulated using 1 % (w/v) alginate in large 100 µm microparticles was shown to survive 2h exposure 
to SGF at pH values as low as pH 1 without loss of phage titre. Felix O1 microencapsulated in alginate 
beads has previously been shown to survive and amplify in the gastrointestinal tract of pigs (Wall et 
al., 2010). In vitro results reported here suggest that high Salmonella phage titres could be delivered 
to the gastrointestinal tract, subsequently released there using a pH trigger and should remain viable 
thereafter. The pH of the colon can fall during bacterial infection to around or just below pH 7; in such 
a case, the released phage should remain viable and capable of lysing the infecting Salmonella bacteria 
present in the gut (McConnell et al., 2008). 
Alginate hydrogel pores tend to be in the 5-200 nm range depending on the degree of crosslinking 
(George & Abraham, 2006). The porosity of the alginate gel microparticles affects phage viability upon 
exposure to the acidic stomach environment. A number of previous studies have used alginate as the 
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main encapsulating agent either on its own or in combination with whey protein or chitosan to 
improve acid stability (Colom et al., 2017a; S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012; 
Samtlebe et al., 2016; Tang et al., 2013, 2014; Wall et al., 2010) Phages encapsulated in crosslinked 
pure alginate microparticles were found to be susceptible to acid damage following exposure to 
simulated gastric fluid (C Dini et al., 2012; Yongsheng Ma et al., 2008, 2012; Soto et al., 2018). 
Previously researchers have co-encapsulated CaCO3 within the microparticles to protect phage from 
acid damage (Colom et al., 2017a; Yongsheng Ma et al., 2012). We have shown that microparticle size 
and alginate composition are important in ensuring acid protection for encapsulated phage. The pH 
responsive character of Eudragit S100 results in phage readily released upon exposure to pH 7. The 
microparticles were stable upon storage under refrigerated conditions for up to 4 weeks. The 
combination of small microparticle size and pH responsive character of the microparticles resulted in 
rapid release of phage within the first two hours upon exposure to SIF at pH 7. Previous studies on 
encapsulated phage in large microparticles (~ 1mm) have reported slower sustained release kinetics 
for alginate encapsulated phage however acid protection was poor (S. Kim et al., 2015a; Yongsheng 
Ma et al., 2008). Faster release from small alginate microparticles (mean size ~ 100 µm) containing 
CaCO3 as antacid was recently reported (Colom et al., 2017a). However, exposure to simulated gastric 
fluid (pH 2.8 for 60 min) resulted in between 2 log and 3 log reduction in Salmonella phage titre 
suggesting that even with the addition of CaCO3, phage were highly susceptible to SGF. Particle size 
was previously shown to be an important factor influencing phage protection from SGF for acid 
permeable beads (Tang et al., 2014). Alginate-whey protein microparticles having the same 
composition but different mean sizes showed larger particles protected phage better compared with 
smaller microparticles (Tang et al., 2014). The acid diffusion path length increases with particle size 
thereby affording protection to phage further away from the bead surface. We have shown that 
encapsulation of phage in Eudragit/alginate microparticles with different mean sizes (50 ~ 100 µm) 
may permit control over the release rate with small particles showing rapid burst release of phage 
cargo whilst larger beads showed an initial burst and then slower sustained release over 2 hours. 
A number of in vivo animal studies have shown dose dependent phage therapy outcomes, with high 
doses of phage resulting in better clinical results (Smith et al., 1987; Biswas et al., 2002; Cerveny et al., 
2002; Wills et al., 2005). Accurate control over the phage dose delivered at the site of infection and 
the timing of the delivery are important considerations (R. J. Atterbury et al., 2007; Malik et al., 2017; 
Sarker et al., 2016). Using in vitro experiments, we have shown that loss in phage titre upon acid 
exposure to SGF may result in a significant delay in phage amplification and this would potentially 
allow bacteria to attain much higher bacterial cell numbers in an in vivo setting with adverse treatment 
outcomes. Failure of a recently concluded phage therapy trial for the treatment of E coli diarrhoea in 
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children was attributed to the lack of in situ phage amplification due low host cell numbers which were 
nevertheless susceptible to the phage cocktail administered (Sarker et al., 2016). Lack of phage 
formulation, no antacid administration and subsequent drop in phage titre due to phage exposure to 
stomach acidity may have been a factor in the consequent lack of in situ phage amplification (Sarker 
et al., 2016). These issues may be addressed through proper formulation development and 
microfluidic encapsulation of high phage titres for targeted delivery and controlled release of phages 
at the site of infection coupled with a better understanding of phage-bacterium population dynamics 
in vivo (C. Y. (Joey); Leung & Weitz, 2016; Levin & Bull, 2004). These aspects have thus far received 
little attention in the published literature. We have demonstrated here that even after exposure of 
phage encapsulated microparticles to simulated gastric fluid at pH 1 for 2 hours, the released phage 
dose was unaffected and corresponded to ~ 1 x 108 PFU g-1. The dose was sufficient to prevent rapid 
bacterial growth in vitro and resulted in rapid phage amplification from an initial titre of 1 x 106 PFU 
ml-1 to ~ 1 x 109 PFU ml-1 within 3 hours of addition of microencapsulated phage. In small animal 
studies (e.g. mice) typical dose via oral gavage is around 100 µl which would allow dosing of around 
0.1 g of microparticles containing around ~ 108 PFU or higher through phage stock concentration. Such 
a dose is indeed typical of many animal studies in literature (Abdulamir et al., 2014; Barrow & Lovell, 
1998; Chibani-chennoufi et al., 2004; Malik et al., 2017; J. Y. Nale, Spencer, et al., 2016; Smith et al., 
1987; Yen et al., 2017). Bacterial killing by phage is dependent on phage particles adsorbing to the 
target bacteria (Cairns et al., 2009). Phage-bacterium binding kinetics may be modelled as a simple 
first order process with respect to the concentrations of bacteria and phage populations respectively 
(Levin & Bull, 2004; Payne & Jansen, 2001). High phage densities are needed in order to arrest the 
growth of phage susceptible bacteria (Malik et al., 2017). Adsorption of phage to bacteria results in an 
initial drop in phage concentration (Cairns et al., 2009). The timing of rapid in situ phage amplification 
is highly dependent on the concentration of the bacteria (Cairns et al., 2009). Successful amplification 
of phage is dependent on high bacterial concentration hence efficient killing is not achieved until both 
phage and bacteria concentrations are high. Resistant bacteria quickly become the dominant 
population unless a phage mixture (cocktail) is used containing high doses of the different phage 
strains capable of killing the resistant mutant population. It is known that phage clearance 
mechanisms rapidly reduce the phage concentration in the absence of host bacteria (Yen et al., 2017). 
We have shown here that a high phage dose is quickly able to arrest the rise of bacterial growth. Tanji 
et al., (2005) showed similar results for E. coli using an in vitro chemostat experimental system. 
However, if low starting concentrations of bacteria are present, phage concentrations in vivo may 
decay significantly due to host clearance mechanisms and phage may be unable to amplify and achieve 
a sufficiently high concentration to eradicate the infecting bacteria until the bacteria have had time to 
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grow bacterial numbers substantially (Malik et al., 2017). In such circumstances it takes time for the 
bacterial population to grow before phage are able to adequately multiply in situ and then arrest 
bacterial growth (Cairns et al., 2009). During this delay in bacterial concentration growth, phage 
concentrations may decay significantly thereby resulting in poor phage therapy outcomes. If phages 
are administered prophylactically too early prior to infection or at the early onset of infection (when 
the bacteria concentration is low), clearance of phage by the host immune system or by other 
mechanisms (e.g. dilution or shortening of intestinal transit times during diarrhoea) may result in 
lowering of the in situ phage concentration resulting in poor phage therapy outcomes (Malik et al., 
2017). Under such conditions mucoadhesion of phage trapped in microparticles and slow sustained 
phage release may be a good strategy. Encapsulation of phage and their slow controlled release may 
help in ensuring that the in situ phage concentration remains at a therapeutically effective level (over 
a realistic time period) allowing phage to amplify once the bacteria concentration increases to levels 
sufficient for in situ phage amplification (Malik et al., 2017). 
Previous phage therapy studies in animals and recent human trials have paid scant attention to phage 
delivery systems and their formulation with little consideration to the bioavailabity of the active agent 
at the site of infection. The size of microparticles may play an important role by ensuring they are 
minimally affected by the conditions of the diseased state. Salmonella is typically found infecting the 
ileum and caecum e.g. in chickens and pigs. Solid dosage forms need to be designed to deliver their 
phage cargo at the site of infection. Gastrointestinal infections can affect different parts of the gut. In 
future different phage fomulations may need to be developed targeting phage release in the 
appropriate intestinal region perhaps using more specific infection related triggers e.g. enzymes or 
toxins released by the bacterium causing the infection (Bean et al., 2014). Other considerations for 
targeted delivery of phage include the changes in transit times during infection. Increased loss of fluid 
from the colon due to symptoms such as diarrhoea result in observed shortened mean transit times. 
Dilution of phage due to the high fluid environment may be a particular challenge. Larger particles (~ 
mm size range) may be more prone to the influence of short transit times. Smaller particles may be 
predisposed to non-specific mucoadhesion (Alhnan et al., 2010; Kietzmann et al., 2010) which may aid 
in phage retention and sustained release over a signficant time period. Colom et al., (2017a) showed 
better phage retention (for animals treated with encapsulated phage versus those treated with free 
phage) in the caecum of chickens and a significant reduction in Salmonella colonisation, attributing 
these results to the mucoadhesiveness of the small alginate microparticles (~ 100 µm) used for 
encapsulating phage. Wittaya-areekul et al ., (2006) showed differences in mucoadhesion properties 
of chitosan coated alginate microparticles using an in vitro assay using porcine gut tissue samples. 
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A limitation of phages for therapeutic use is their narrow host range. Most phages only infect a small 
number of prevalent strains necessitating the use of phage cocktails to provide adequate therapeutic 
coverage. Phages incorporated in the cocktail may require tailored formulations to ensure adequate 
stability (Malik et al., 2017). 
Microfluidic encapsulation technologies have the potential to enable precise control over phage 
loading and production of highly uniform microparticles produced using many different polymer 
formulations enabling high level of innovation using a multitude of different triggers including light, 
temperature, pH, enzymes etc (Malik et al., 2017). Furthermore, the fabrication of structured mutliple 
emulsions e.g. composed of concentric onion-like shells around the core drop may allow production 
of complex microcapsules for co-encapsulation and simultaneous or sequential release of several 
different phages encapsulated in individually optimised formulations (Malik et al., 2017). Multiple 
shells would allow tailored formulations within a single microcapsule e.g. an outer acid stable shell 
may protect phage cargo from the stomach acid, an inner burst release shell containing a phage 
cocktail providing broad host range coverage for typical infection causing serovars and an innermost 
core for perhaps a later burst release or slower sustained release of a different cocktail to target any 
mutants that may give a delayed surge of infection causing bacteria. 
Here, we have demonstrated proof-of-concept in vitro data in support of microfluidic production of 
encapsulated Salmonella Felix O1 phage in a pH responsive polymer suitable for targeted intestinal 
phage delivery. 
4.5 Conclusions 
 
We have demonstrated the controlled production of highly uniform small composite microcapsules 
(using commercially available microfluidic droplet generation chips) with mean size 50 ~ 100 µm 
composed of Eudragit S100 and with varying alginate amounts. Highly uniform microparticles were 
produced with low polydispersity enabling control over phage loading, acid stability upon exposure to 
SGF and their subsequent pH triggered release in SIF. Phage encapsulation and subsequent release 
kinetics revealed that microparticle size and alginate composition are factors affecting the pH stability 
and release profile of encapsulated phages. 100 µm beads prepared from 10 % (w/v) ES100 and with 
1 % (w/v) alginate afforded phage excellent pH protection upon exposure to SGF (for 2 hours at pH 1) 
with no loss in phage titre. The microparticles released all their phage cargo within 2 hours upon 
subsequent exposure to SIF making them suitable solid dosage forms for gastrointestinal delivery of 
phages. We have also demonstrated the storage stability of the encapsulated phage under 
refrigerated conditions over a 4-week storage period. Furthermore, we demonstrated the effect of 
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acid stability and high phage dose delivery on the attenuation of bacterial growth upon release of 
encapsulated phage after exposure of microbeads to SGF at pH 1. Future work will investigate the 
spatial and temporal delivery of encapsulated phage in a relevant small animal model and the 
suitability of these solid dosage forms to target Salmonella infections in vivo. 
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Chapter 5: Microencapsulation of enteric bacteriophages in pH responsive 
microparticles using microfluidic membrane microarray-based emulsification 
for oral delivery 
Abstract 
 
Phage encapsulation for site-specific release was previously studied by Vinner et al., (2017). The use 
of commercially available polymer Eudragit S100 and alginate was used for protection against acid at 
pH 2. Here, we report the scale-up of this system using membrane emulsification technology to 
produce large volumes of encapsulated phage in composite microparticles. Investigation of process 
parameters to determine the effect on droplet diameter was studied and reported. Impact of dose 
was probed in this study by performing a phage -bacterial killing assay. A three-way interaction 
between phage, bacteria and epithelial cells was also investigated. Changes in epithelial cells showed 
bacterial infection however after introducing phage, bacterial growth was arrested, and epithelial cell 
damage rescued. Both free and encapsulated phage showed comparable results indicating that 
microparticles were able to dissolve and unload phage to effectively reduce bacterial growth. For the 
first time, this study has shown process scale-up for phage encapsulation which can successfully target 
enteric pathogen in vitro. 
5.1 Introduction to membrane emulsification 
 
Chapters 3 and 4 have investigated the use of microfluidic platforms for phage encapsulation. 
Optimisation and fine-tuning the production of uniform droplet size and therefore the release kinetics 
of phage in vitro was demonstrated. When considering the use of encapsulated phage for phage 
therapy, large scale production is required. Microfluidic platforms lack the ability to produce large 
volumes of material but are an excellent tool for formulation development and optimisation. Up-
scaling this process can be challenging since conventional methods lack the ability to produce uniform 
droplets, introduce high mechanical stress and insufficient batch-to-batch reproducibility 
(Spyropoulosa et al., 2011).  
Membrane emulsification (ME) overcomes some of the afore mentioned disadvantages. Emulsions 
are produced by injecting the dispersed phase through defined pores of a membrane into the 
continuous phase. The resulting emulsions have uniform droplets with CV below 20 % whilst 
permitting large volume production (Vladisavljević et al., 2012). ME is suitable for large-scale 
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production due to the simplicity of adding more membrane area to increase the throughput of 
emulsion formation. Furthermore, versatility of the system is demonstrated in its ability to produce 
both batch and continuous production as shown by Peng and Williams, (1998) on a pilot scale. 
Membrane emulsification consumes low energy between 104- 106 J m-3 in comparison to 106- 108 J m-
3 consumed by conventional methods (Joscelyne & Trägårdh, 2000).  
Injection of one non-miscible fluid into another is termed direct membrane emulsification whereas a 
premade emulsion injected into another immiscible fluid is termed premix membrane emulsification 
(C. Charcosset et al., 2004). The type of emulsion produced is dependent on the membrane type, a 
hydrophobic membrane produces water-in-oil emulsion whereas a hydrophilic membrane produces 
an oil-in-water emulsion. In both cases, the dispersed phase must not wet the surface of the 
membrane where droplet detachment takes place (Nakashima et al., 2000). Droplet detachment is 
aided by shear applied above the membrane e.g. via a paddle stirrer connected to a pump (Williams 
& Vladisavljevic, 2005).  
Droplet size is affected by several parameters such as shear, membrane type, membrane pore size, 
dispersed phase flux, emulsifier, viscosity of both phases (Catherine Charcosset, 2009; Joscelyne & 
Trägårdh, 2000; Nazir et al., 2010; Spyropoulos et al., 2014; Williams & Vladisavljevic, 2005). 
5.1.1 Membrane type 
 
There are several types of membranes available for ME which contribute to the production of stable 
emulsions. The type of membrane used depends on whether a water-in-oil or oil-in-water emulsion is 
required. Shirasu porous glass (SPG) membranes were initially used for membrane emulsification. 
Available in different pore sizes varying between 0.05 to 20 µm, these membranes have a high porosity 
(50-60 %) (Catherine Charcosset, 2009). Naturally used as a hydrophilic membrane through chemical 
modification the surface can be made hydrophobic to cater for water-in-oil emulsions (Kukizaki, 2009). 
Microsieve membranes made from ultra-thin foils are an alternative to SPG (R. G. Holdich et al., 2013). 
An advantage of these membranes is that they have the capacity to reach high transmembrane flux 
at a low transmembrane pressure (Wagdare et al., 2010) and are less likely to foul. Examples of 
microsieve membranes include silicon nitride Aquamaijn™, nickel produced by Micropore Technology 
Ltd (Egidi et al., 2008) as well as aluminium and stainless steel foil (Williams & Vladisavljevic, 2005). 
Microsieve membranes offer the flexibility to produce pores with varying geometry such as slotted 
pores (R. Holdich et al., 2006). Pore size is an important parameter as a direct linear correlation is 
observed between the pore diameter and the size of the droplet produced (Williams & Vladisavljevic, 
2005).  
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5.1.2 Role of emulsifier in drop production 
 
The role of the emulsifier to prevent coalescence is well known, however in membrane emulsification 
it plays a significant role in droplet detachment from the membrane surface. The emulsifier stabilises 
the water- oil interface by reducing the interfacial tension between the two immiscible phases and 
therefore facilitates droplet detachment (Goran T. Vladisavljević et al., 2012). A critical amount of 
emulsifier needs to be used so as to prevent lowering of the interfacial tension to the point where the 
dispersed phase jets into the continuous phase without forming droplets (Goran T. Vladisavljević et 
al., 2012). Membrane fouling by surfactant can occur if these molecules adhere to the membrane 
surface and allow the dispersed phase to spread across the membrane (Vladisavljevic, 2015). 
Katoh et al., (1996) investigated the effect of different emulsifiers on the effect of stable droplet 
generation in an oil in water emulsion between water phase and a mixture of corn oil and kerosene. 
They observed that each emulsifier produced monodispersed droplet once the interfacial tension was 
reduced to a constant minimum value which differed for each emulsifier (Katoh et al., 1996).  
 
Figure 5.1 Schematic representation of the membrane emulsification system used for 
microencapsulation of bacteriophages. 
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5.1.3 Effect of shear on drop production  
 
In a stirred membrane emulsification system (Figure 5.1), the shear produced by the moving 
continuous phase of the membrane surface aids droplet detachment (Joscelyne & Trägårdh, 2000; 
Nakashima et al., 2000). Alternate arrangements have been used to provide surface shear including 
pulsing membrane emulsification systems and utilising crossflow in combination with the pulsing 
membrane for droplet detachment (R. G. Holdich et al., 2013). Similarly, vibrating or rotating 
membrane systems produce shear by vibrating and rotating the membrane respectively allowing for 
droplet detachment (R. G. Holdich et al., 2010; Williams & Vladisavljevic, 2005). Also, a cylindrical 
membrane which oscillates back and forth to produce shear for droplet detachment is termed 
Azimuthallly oscillating membrane system (P. S. Silva et al., 2015). These different membrane systems 
demonstrate that the shear influences the droplet size and monodispersity.  
5.1.4 Flux and viscosity of the dispersed phase on droplet production 
 
The dispersed phase is pumped through the membrane pores to form droplets. Higher 
transmembrane fluxes allow more filling before the droplet is detached however other parameters 
influence the transmembrane flux. Egidi et al., (2008) investigated the effect of membrane flux on 
droplet production with two pore sized membranes (80 and 200 µm). The study found that droplet 
size increased as the dispersed phase injection rate increased for a 200 µm pore sized membrane and 
decreased with increasing shear. However, only at low flux the most monodispersed droplets were 
achieved with a CV of 18 %. The opposite was true for the 80 µm pore size, where CV of less than 10 
% was achieved for high transmembrane fluxes. Generally, at low shear stresses with a high flux rate, 
decrease in droplet size was observed (Egidi et al., 2008).  
The effect of increasing continuous phase viscosity on droplet size has been reported to decrease the 
average droplet size. However, depending on other process parameters the uniformity of the droplets 
may be better at low continuous phase viscosity (Goran T. Vladisavljević et al., 2006). Another study 
by Liu et al., (2002) found that viscosity of alginate affected the uniformity of droplet size with 
concentrations of 2 % (w/v) alginate producing droplets with average diameter of 97µm and CV of 82 
%. Production of monodispersed droplets is dependent on several factors and optimisation of the 
various process parameters are necessary to achieve control over drop size and uniformity of the 
emulsion.  
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5.1.5 Phage bacterium kinetics 
 
Phage therapy effectiveness in reducing bacterial load requires high phage dose to lyse bacteria. 
Hence, delivering of a high dose of phage at the site of infection can prove to be an effective strategy 
in arresting bacterial growth and clearing infection (Tangi et al., 2013). At present, limited work has 
been published to address the problem of acid inactivation of phages in the stomach when phages are 
delivered orally. Several studies have shown that phage are rendered unviable if the pH is acidic 
(typically below pH 3) and demonstrated possible routes to protect them (Colom et al., 2015, 2017b; 
Cecilia Dini et al., 2012; Yongsheng Ma et al., 2012; Stanford et al., 2010a; Tang et al., 2013, 2014; 
Yongsheng et al., 2008).  
However, so far protection against pH 2 for 2 hours has been demonstrated in vitro (Yongsheng Ma et 
al., 2012; Tang et al., 2013, 2014; Yongsheng et al., 2008). Targeting phage encapsulation for 
biocontrol applications e.g. in poultry and swine may justify the reason for studying phage protection 
at pH 2. Human phage therapy however needs protection at pH values lower than pH 2 due to the 
variation in stomach pH depending on fed or non-fed state (McConnell et al., 2008). Chapter 2 
addresses this, showing that the combination of Eudragit and alginate can be used to protect phage 
from pH as low as pH 1. This is key in delivering the correct dose of phages to the site of infection. The 
rate of mutation in actively growing bacteria was reported to be 10-5 h-1 (Cairns et al., 2009), which is 
fast and necessitates rapid phage killing to prevent increase in bacterial concentration. In addition, 
scale-up issues around encapsulated phage need to be addressed. 
Ex vivo experiments showing a three-way interaction of phage, bacteria and epithelial cells may prove 
beneficial in understanding infection dynamics. Stressed mammalian cells in the presence of bacteria 
may offer insights into an in vivo scenario. Addition of phages in a cell culture model useful insights 
into understanding of phage-bacterial inhibitions and the impact of this on mammalian cells (Shan et 
al., 2018). Further analysis will prove beneficial, when encapsulated phage are introduced and results 
can be compared and evaluated to show the equally beneficial effect of encapsulated phage. 
 
Aims and objectives 
 
The aim of this work was to demonstrate scale-up of phage encapsulation using membrane 
emulsification technology. Formulation development and optimisation performed in chapters 3 and 4 
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were transferred to produce larger quantities of encapsulated phage. Optimisation using membrane 
emulsification was performed to achieve encapsulated phage microparticles capable of acid 
protection. Control over droplet size was investigated by controlling various experimental parameters. 
Arresting growth of actively growing bacteria with both free phage and encapsulated phage was 
investigated, evaluating the effect of dose on bacterial lysis in vitro. The potential of encapsulated 
phage in arresting bacterial growth and infection of mammalian cells was studied in an ex vivo model. 
Overall, the potential of using ME to up-scale the process of phage encapsulation and application was 
investigated.  
 
5.2 Materials and Methods 
 
5.2.1 Chemical reagents 
 
Eudragit S100 was purchased from Evonik Germany. Medium viscosity alginate was purchased from 
Sigma Aldrich, UK. Miglyol 840, a propylene glycol diester of caprylic/capric acid, was obtained from 
Sasol Germany. Food grade Castor oil was purchased from Elf Foods, Loughborough U.K. both of which 
made the continuous oil phase. Polyglycerol polyricinoleate (PGPR) soluble surfactant was purchased 
from Abitek USA. Tween 20, p-toluenesulfonic acid, sodium chloride and calcium chloride (Acros 
Organics, UK) were purchased from Fisher Scientific, UK. Ultrapure water was obtained from Millipore 
185 Milli-Q Plus water filtration system. Sorensen’s buffer 0.2 M was used as a dissolution media for 
the microparticles and was prepared by mixing sodium phosphate monobasic (NaH2PO4) (for pH 7, 39 
ml) with sodium phosphate dibasic (Na2HPO4) (for pH 7 61 ml) (Fisher Scientific UK). Pancreatin and 
pepsin added to simulated intestinal fluid and simulated gastric fluid respectively were purchased 
from Sigma Aldrich, U.K. McCoys medium, Leibovitz supplemented with CO2, Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and Fetal bovine serum (FBS) were purchased from Sigma Aldrich UK.  
5.2.2 Culturing EV36 and phage propagation 
 
E. coli strain EV36 and phage K1F were obtained from collaborator Dr Antonia Sagona, University of 
Warwick, U.K. EV36 is a K-12 and K1 hybrid which is susceptible to K1 specific phages including K1F 
and K1-5 (Scholl et al., 2005). Phage K1F is a T7-like phage first isolated from sewage in 1984 (Scholl & 
Merril, 2005).  
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EV36 was genetically modified to express red fluorescent protein (RFP) by Dr Antonia Sagona 
(University of Warwick, UK). The procedure for this cannot be disclosed here due to copyright 
protection. RFP-EV36 was cultured in Luria-Bertani (LB) medium (Oxoid, Ltd., UK) with the addition of 
0.5 mM IPTG and 10mg/ml Ampicillin sodium salt, (Sigma Aldrich U.K) (Figure 9.11 appendix).  
Phage K1F was propagated on RFP-EV36. Phage stocks were prepared by growing a fresh culture of 
RFP-EV36, shaking at 37˚C until the O.D.550 reached 0.2. Then phage K1F was added at a MOI of 0.01. 
Once complete lysis of bacteria was observed (as seen by a clear solution of LB broth) the culture was 
centrifuged for 15 mins at 2,000 x g, and filtered through a 0.2 µm filter (Millipore, USA). The stock 
was stored at 4˚C until further use.  
Plaque assays were carried out using the double layer agar method as described by Mahony et al., 
(1985) and Goh et al., (2005). Briefly, 10 µl of overnight culture of RFP-EV36 was added to a 50:50 
mixture of LB semi-solid agar and salt mixture (0.4 M MgCl2 and 0.1 M CaCl2, Oxoid Ltd. UK). This was 
poured onto LB agar plates and set under a laminar flow hood. 10 µl of phage solution was spotted on 
the plate (in triplicate), left to dry and incubated at 37˚C overnight. The following day the resulting 
number of phage plaques was enumerated. 
The phage titre was determined by carrying out serial dilutions from the phage collected and each 
dilution (in triplicate) was spotted on host lawn. Phage titre was determined by counting plaques and 
expressed as plaque forming units (PFU) per ml. Similarly, for bacterial growth serial dilutions of 
bacterial culture were spotted on LB agar in triplicate and incubated overnight at 37˚C. Bacteria 
concentration was determined by counting colonies and expressed as colony forming unit (CFU). 
5.2.3 Phage sensitivity assay 
 
Phage inactivation (sensitivity) to different pH was assessed as follows. 0.2 M NaCl was pH adjusted 
with HCl to achieve pH 2, 2.5 and 3. 0.05 M of KH2PO4 was pH adjusted with NaOH to achieve pH 4, 5, 
6 and 7. To analyse the survival of phage in each parameter 270 µl of each solution was added to a 96 
well plate (in triplicate), with LB broth as positive control, 30 µl of phage stock (~108 PFU/ml) was 
added to each well. At time points 0 h, 0.5h, 1h, 3h, 6 h and 24 h serial dilutions in LB broth (270 µl) 
were performed for each test and spotted (10 µl x 3) on host lawn (prepared as described in the plaque 
assay section previously). The spotted plates were dried for 5 min and then incubated at 37 ˚C 
overnight. The following day, plaques were counted, and PFU/ml calculated. 
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5.2.4 Preparation of W/O emulsions 
 
The dispersed (aqueous) phase was prepared by dissolving Eudragit S100 powder (final working 
concentration of 10 % w/v) in ultrapure water. 10 M NaOH solution was added dropwise until the 
solution turned clear and colourless indicating complete dissolution of Eudragit S100 polymer. Next, 
2 % (w/v) alginate was dissolved with Eudragit S100 over heat (~60 °C) stirring overnight. 50ml of 
phage was concentrated in 50K Amicon Ultra centrifuge tubes, Millipore U.K. 10 % (v/v) of 
concentrated phage was added to a cooled Eudragit and alginate solution with a final working solution 
of 109 PFU/ml. The continuous (oil) phase was prepared by dissolving 2 % (w/v) of PGPR in a mixture 
of miglyol 840 and castor oil (9:1).  
A dispersion cell from Micropore Technologies Ltd. (Teesside, U.K.) was used for the emulsification 
process. Figure 5.1 shows the setup of the equipment, the base holding the glass cylinder cell is made 
of poly(tetrafluoroethylene) (PTFE). The dispersed phase was introduced via a syringe mounted on the 
syringe pump into this base through a nickel membrane of a specified pore size (20 µm) (Figure 9.13 
appendix). The glass cell carried the continuous phase which was screwed into the base of the above 
the membrane. The shear stress was provided by a paddle-blade stirrer operated by a 24 V DC motor, 
rpm was converted to rads-1 (Figure 9.8 appendix) necessary for droplet detachment. The dispersed 
phase enters the glass cell through uniformly spaced pores of the membrane and the shear allows 
detachment of the droplets forming an emulsion. The nickel membranes also purchased from 
Micropore Technologies Ltd. (Teesside, U.K.) were pre-treated with 1H, 1H, 2H, 2H- 
Perfluorodecyletriethoxysilane (Sigma Aldrich U.K.) as per the manufacturer’s instructions (Method 
9.1 appendix). They were stored in the continuous phase when not in use. The use of membrane 
emulsification to produce uniform droplets by changing various parameters was well studied by 
(Kosvintsev et al., 2008; Stillwell et al., 2007).  
For this work, phage encapsulation was studied by producing polymer droplets which were cross-
linked post droplet production for 1 h. The stirrer speed setting used for all experiments was 62 rad s-
1. The nickel membrane with pore size 20 µm had an effective surface area of 8.54 cm2 (Hanga et al 
2014), with pore spacing distance of 200 µm. The dispersed phase was pumped by a Harvard syringe 
pump (Harvard Apparatus U.K.) with an injection rate of 4.68 Lm-2h-1. The continuous phase volume 
was 50 ml for every 15 ml of dispersed phase that was introduced into the glass cell.  
5.2.5 Preparation and characterisation of Eudragit and alginate particles 
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Once the emulsion was formed, it was transferred into a sterile tube. The droplets were settled by 
centrifuging at 500 x g for 3 mins. The droplets were re-suspended in acidified oil phase consisting of 
a 9:1 mixture of miglyol to castor oil with 2 % (v/v) PGPR) and 0.05 M toluenesulfonic acid. The droplets 
were left to crosslink for 1h, then they were centrifuged at 500 x g for 3 mins to pellet the semi-
crosslinked droplets. After discarding the supernatant, the pellet was re-suspended in 0.1 M calcium 
chloride (CaCl2) with 1 % (v/v) Tween 20 and left to further crosslink for 2h. The crosslinked particles 
were centrifuged at 2, 000 x g for 5 minutes to remove CaCl2 solution. Particles were stored at 4˚C in 
sealed tubes. 
Photographs of the droplets and particles were taken with an optical microscope (Nikon Eclipse E200, 
U.K.). For SEM images the gelled particles were firstly freeze dried (VirTis Wizard 2.0) for 24 hours at 
1 bar pressure at -20°C. The dried particles were mounted on stubs and sputter coated with gold and 
viewed using a benchtop Scanning Electron Microscope (Hitachi TM3030 Table-top Microscope). 
5.2.6 Cell culture and imaging 
 
For cell culture T24 (ATCC® HTB-4™) urinary bladder epithelial cells were used. To obtain a confluent 
culture of epithelial cells, McCoys medium was added to tissue culture flasks with 1 % streptomycin 
(Sigma Aldrich, UK) and seed with frozen stocks of cells. Epithelial cells were grown in Leibovitz 
medium supplemented with 10 % FBS when grown in parallel with bacteria. NucBlue (Thermofisher 
U.K.) 1 drop/ml was added to epithelial cells and left to incubate for 15 mins before imaging changes 
in the nucleus.  
Epithelial cells were inoculated with 10 µl of bacteria and incubated for 2 hours for infection to begin. 
After which in control flasks bacteria were left to grow with addition of LB (20 µl) without phage. Free 
phage at different titres (102, 104, 106, 108 PFU/ml) (volume 20 µl) was added to the positive control 
flasks. Microparticles with phage K1F were exposed to pH 2 for 2 hours before they (20 µl) were added 
to infected epithelial cells. Imaging was taken at hourly intervals (each flask was staggered accordingly). 
During imaging the temperature was maintained at 37°C. 
For imaging Zeiss LSM 880 confocal microscope was used at University of Warwick (U.K.) with multi-
channel spectral imaging and ultra-sensitive GASP detector. Images were analysed on Zen2.3 Lite 
software. 
5.2.7 Dissolution of microparticles 
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1 g of particles were suspended in prewarmed 10 ml simulated intestinal fluid, 10 mg/ml pancreatin 
in 0.05mM KH2PO4 at pH 7 (Sigma Aldrich, UK) under agitation conditions at 37°C. For acid exposure 1 
g of washed particles were suspended in prewarmed 10 ml simulated gastric fluid, 3.2 mg/ml pepsin 
in 0.2 M NaCl at pH 2 (Sigma Aldrich, UK) for an exposure period of 2 h, under shaking at 37°C. Particles 
were subsequently centrifuged at 2,000 g for 15 min and re-suspended in simulated intestinal fluid 
(pH 7, 6, or 5) under agitation conditions at 37°C until complete dissolution of particles. For 
enumeration of phage released, plaque assays were used (as described previously) by removing 10 µl 
of sample at hourly intervals, serially diluting in LB broth and spotting on a host bacterial lawn. The 
PFU/ml was determined the following day. For the co-encapsulation assay each phage was spotted on 
its respective host for titre. 
For storage tests,1 g of particles was weighed and exposed to SGF (pH 2) for 2 hours, then centrifuged 
at 2,000 g for 15 mins and resuspended in SIF (pH 7) at 37°C until complete dissolution of particles. 
Phage release was enumerate as described above. 
5.2.8 Coulter particle size analysis 
 
A Coulter LS 130 (Beckman Coulter Inc.) (Figure 9.7 appendix) was used to determine the droplet and 
particle size distribution. The device is laser modulated and uses the optical model Fraunhofer, to 
detect laser diffraction caused by droplets and particles (appendix). The equipment feeds the 
information to a computer where data is collated via the LS software program. Droplets or particles 
were loaded into the sample cell containing the continuous phase and directly placed inside the 
coulter equipment to carry out the measurements.  
5.2.9 In vitro phage bacteria dynamics 
 
The effect of free phage and encapsulated phage in arresting bacterial growth was investigated. 
Firstly, bacteria were grown until log phase was reached, at 0.2 (O.D. 550) (approximately 108 CFU/ml). 
The assay was performed in LB and cell culture media, (Leibovitz). Each well contained 2 ml of bacteria 
to which 20 µl of free phage was added at different concentrations (102, 104, 106, 108 PFU/ml), 20 µl 
of encapsulated phage (Ephage) was also added to 2 ml of bacterial culture with and without pH 2 
exposure for 2 hours. Separately, a negative control contained 20 µl of Ephage in LB media or cell 
culture media without bacteria and the positive control contained bacteria only. After phage addition, 
the infection was allowed for one hour before samples were taken at hourly intervals up to 5 hours.  
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Upon sample collection, 1 ml was removed to record the O.D.550 and 1 ml was centrifuged, and plaque 
assay carried out (as per the procedure above). For the positive control, bacterial counts were 
determined by spotting 10 µl of sample on LB agar plates. The following day the plates were counted 
and CFU determined.  
5.2.10 Statistical analysis of results 
 
Comparison of sample means using 2 sample t-tests and evaluation of 95 % confidence intervals for 
data was carried out using the statistical software Minitab 18. 
 
5.3 Results  
 
5.3.1 Acid sensitivity of free phage 
 
Model phages against enteric pathogens such as Salmonella and E. coli were analysed for their 
sensitivity to different pH. The results for each phage, demonstrates susceptibility to low acidic pH 
and highlights the need for encapsulation. In the case of phage K1F, all phages were inactivated after 
merely 10 secs of pH 2 exposure whereas Felix O1 showed more resilience as viable phage were 
detectable after 10 mins of exposure. Nevertheless, in both cases no detectable phages were 
measured after the initial 10 minutes of exposure time. The results underpin the motivation behind 
this study which is to encapsulate and protect the phages from acid damage. 
The pH sensitivity of K1F to low pH was evident even at pH 2.5, the phage was completely inactivated 
after 10 minutes of exposure. On the other hand, Felix O1 showed more tolerance at this pH, with 
viable phage measured up to 3 hours (Figure 4.3). However, the titre of the phage significantly 
dropped indicating a clear need for encapsulation. The stomach pH of some animals may be as high 
as pH 3, therefore it is important to consider the phage viability at this pH.  Phage K1F showed more 
tolerance at this pH but there was over a log reduction in titre whereas Felix 01 showed greater 
stability over time (Figure 5.2). In either case, phages were stable over 24 hours as the pH increased, 
this is important when using pH responsive polymers such as Eudragit S100, because to dissolve this 
polymer the pH needs to be neutral or alkaline.  
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Figure 5.2 Effect of pH on free phage K1F viability in 0.2 M NaCl solution pH 2 not shown since no 
detectable phage was recovered at time point 0. * indicates significantly different phage titres using 
a 2-sample t-test at each condition compared with phage exposed to pH 7 at the corresponding time 
point. Time point 0 hours denotes time between 0-10 minutes for phages exposed to all pH values 
except pH 2.5 where phage titre reduced rapidly, and data are plotted 10 seconds post exposure. P-
values can be found in Table 9.1 (appendix). 
 
5.3.2 Effect of stirrer speed on droplet diameter 
 
 
  
 
 
 
 
 
Figure 5.3 Effect of stirrer speed on the mean droplet size (300 droplets analysed) composed of 5 % 
(w/v) ES100 with infusion rate of 100 mlh-1, membrane pore size 20 µm. * indicates significantly 
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different droplet sizes when comparing the mean sizes of each parameter for each time point (p < 
0.05). 
Shear is an important parameter when determining the size of droplets in membrane emulsification. 
Hence, the influence of shear rate on droplet size was investigated using 5 % (w/v) Eudragit S100 in 
the dispersed phase. A total of 300 droplets were measured for each parameter investigated. Uniform 
droplets were measured ranging between 10 to 30 µm (Figure 5.3). With increasing shear the average 
droplet diameter reduced. However, this was not necessarily linear. It was found that further 
increasing the shear did not result in smaller droplets but rather the C.V. was compromised. The 
influence of droplet size on phage loading was also analysed (Figure 5.4). There was a slight decrease 
in phage loading observed when the droplet size was reduced from 27 µm to 10 µm. This may be 
attributable to the shear stress; by increasing the frequency of droplet breakup at the membrane 
interface the resulting droplets were smaller in size. This translated to smaller particles, the larger 
surface area to volume ratio increased the likelihood of phages encountering acid during crosslinking 
in acidified oil. This may be attributable to the decrease in phage loading in smaller particles. These 
findings formed the basis for further work, which included increasing polymer concentration and 
introducing alginate as a co-polymer. Changing the dispersed phase composition also meant changing 
the viscosity which influenced the droplet size.  
 
 
 
 
 
 
 
 
Figure 5.4 Effect of droplet size on phage encapsulation. Phage released in pH 7 (without acid exposure) 
and titre measured after 5 hours. * indicates the significance mean was compared (p < 0.05) using a 
2-sampel t-test. All measurements were done in triplicate (n=3) 
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5.3.3 Effect of alginate concentration on drop diameter 
 
 
Figure 5.5 Effect of alginate concentration on droplet size, all other parameters were kept constant at, 
10 % ES100, 40 mlh-1, 62 rads-1, 20 µm pore nickel hydrophobic membrane a) 0.5 % (w/v) alginate, b) 
1 % (w/v) alginate c) 2 % (w/v) alginate. 
Changes in droplet size were investigated through changing alginate concentration whilst keeping 
Eudragit S100 concentration constant at 10 % (w/v). In comparison to Eudragit droplets alone the 
average droplet size increased (Figure 5.5). The viscous nature of the alginate meant the infusion rate 
was increased to allow for enough dispersed phase to enter the pore to form a droplet. Droplets were 
bigger for 0.5 % (w/v) alginate formulation (Figure 5.5a) in comparison to other formulations. As the 
concentration of alginate increased so did the viscosity. Therefore, at the same infusion rate the 
lowest concentration of alginate (0.5 % (w/v)) caused an increase in the dispersed phase flux. As 
viscosity increases with higher alginate concentration, the dispersed phase flux decreased resulting in 
smaller droplets. 
The most uniform droplets were observed with the 1 % (w/v) alginate formulation, due to better 
balance between viscosity and interfacial tension. With increasing viscosity, the interfacial tension also 
increases which theoretically should result in larger droplets due to instability of droplets, and their 
tendency to coalesce. The amount of surfactant required to overcome interfacial tension was higher 
therefore the variation in droplet size was observed at higher concentration of alginate (Figure 5.5c). 
The formulation prepared with 2 % (w/v) alginate gave the best results during acid exposure of phage 
therefore, this was taken forward for further analysis. 
5.3.4 Effect of membrane pore size and flow rate on droplet diameter 
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Figure 5.6 Effect of membrane pore size and dispersed phase flow rate on drop size. ai) 40 µm pore 
membrane with 10 mlh-1 aii) 40 µm pore membrane with 40 mlh-1 aiii) 40 µm pore membrane with 50 
mlh-1 bi) 20 µm pore membrane with 10 mlh-1 bii) 20 µm pore membrane with 40 mlh-1 biii) 20 µm 
pore membrane with 50 mlh-1. 
Another set of parameters that can affect the size of the droplets is the membrane pore size. The 
influence of a 20 µm and 40 µm pore size nickel membrane was investigated with formulations 
containing 2 % (w/v) alginate and 10 % (w/v) ES100 as the dispersed phase (Figure 5.6). The shear was 
kept constant, but the dispersed phase the flow rates were changed to observe changes in drop size. 
Droplets produced using the 40 µm membrane produced larger droplets for the respective flow rates 
in comparison to the 20 µm membrane. For both membranes the uniformity of the droplets was 
compromised due to the viscous nature of the dispersed phase. As the flow rate was increased the 
droplet size was also seen to increase. Droplets as large as 1 mm were produced at the highest 
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flowrate (Figure 5.6 aiii and biii). Desired droplet size could be achieved by either membrane by 
changing the dispersed phase flux.  
5.3.5 Effect of continuous phase on droplet diameter 
 
 
Figure 5.7 Effect of continuous phase viscosity on droplet size and particle size. Miglyol and castor oil 
(M:C) were mixed in varying ratios to alter viscosity ai) M:C 9:1 droplets aii) M:C 9:1 particles bi) M:C 
4:1 droplets bii) M:C 4:1 particles ci) M:C 2:3 droplets cii) M:C 2:3 particles. 
Typically, in literature on emulsions the dispersed phase viscosity tends to be less than that of the 
continuous phase, however the present case, dispersed phase viscosity was higher. Therefore, to gain 
further control over droplet size in the membrane emulsification process, the continuous phase 
viscosity was changed. Viscosity of the continuous phase was increased by adding castor oil at 
different ratios to miglyol whilst keeping PGPR concentration the same at 2 % (w/v). Figure 5.7 shows 
the droplets produced with the corresponding particles. With increasing viscosity, the droplet size 
decreased (Figure 5.7). The coulter analyses put into perspective the average droplet size for each 
parameter showing as the viscosity of the continuous phase was increased, the mean droplet size 
increased (Table 5.1). Droplets were also crosslinked with TSA and CaCl2 and the size was analysed for 
any changes. Shrinkage of the particles was observed in all cases, with approximately 50 % reduction 
in the mean droplet to particle size.  
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Table 5.1 Cumulative size distribution by volume of (10 %, 50 %, 90 %) droplets and particle with 
changing miglyol to castor oil ratios with 10 % (w/v) Eudragit and 2 % (w/v) alginate as aqueous phase. 
Droplet/ particle size in µm 
 
M:C 
D10 D50 D90 
Droplets Particles Droplets Particles Droplets Particles 
9:1 8 6 54 24 64 59 
4:1 8 3 49 24 111 70 
2:3 5 1 16 10 54 31 
 
 
 
 
 
 
 
Figure 5.8 Coulter analysis of a) drops and b) particles produced by varying miglyol to castor oil ratios 
(M:C 9:1, 4:1, 2:3). ai) volume percentage of droplets aii) cumulative volume percentage of drops bi) 
volume percentage of particles bii) cumulative volume percentage of particles. 
Coulter volume distribution analysis showed the bulk of the volume consisted of bigger drops/particles 
as opposed to the smaller drops/particles. The graph shifted to the left as the continuous phase 
viscosity was increased, showing that the average drop or particle size by volume decreased (Figure 
5.8a). Bulk of the volume was carried by the bigger drops for each parameter even though the smaller 
drops/particles may be higher in number. The phages are carried in the bulk volume therefore the 
release profile will be largely influenced by the larger droplets. Figure 5.8b shows the cumulative 
volume for each parameter with drop/ particle size varying between 10 to 100 µm. A shift is noticeable 
ai) 
aii
) 
bi) 
bii 
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as the continuous phase viscosity rises and can be a useful tool to manipulate the production of a 
certain range of drop/particle sizes.  
5.3.6 Effect of dispersed phase flow rate on droplet diameter 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Effect of flow rate on droplet diameter a) optical images ai) 10 mlh-1 aii) 40 mlh-1 aiii) 50 
mlh-1 b) coulter analysis bi) 10 mlh-1 bii) 40 mlh-1 biii) 50 mlh-1 c) phage encapsulation with release in 
pH 7 Sorensen’s buffer with no acid exposure. 
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Flow rate plays an important part when manipulating droplet size. The dispersed phase flux controls 
the amount of liquid flowing through the pores before shear breaks them away from the membrane 
surface. Low dispersed phase flux results in smaller droplets in comparison to high fluxes (Figure 5.9 
ia-c). Although the size is also influenced by continuous phase viscosity, in this case this parameter 
was kept constant to observe the impact of dispersed phase flux.  
The change in droplet size was further confirmed by coulter analysis (Figure 5.9ii). There was a clear 
shift in the average droplet diameter towards the right (bigger drops) as the dispersed phase flux 
increased. This is a key factor when using membrane emulsification to control drop size. The smallest 
droplets were produced at the lowest flux with a high proportion of drops in the 10 µm region. This 
increased for 40 mlh-1 and 50 mlh-1 to below and above 100 µm. 
For all three parameters, the effect on phage encapsulation was analysed (Figure 5.9c). Phages were 
present in all samples and were protected at pH 2 (exposure for 2 hours). For further experiments, 40 
mlh-1 was used due to the narrow distribution of drop size in coulter and phage loading. 10 mlh-1 was 
not chosen due to increased length of time required to run the experiments and 50mlh-1 was not 
chosen due to a broader distribution of drop size in coulter. The experiment was then repeated with 
the following parameters, dispersed phase flux 40 mlh-1, shear rate 62 rads-1 and 9:1 ratio of Miglyol 
to castor oil with 2 (w/v) alginate. Figure 5.10 shows the results for phage encapsulation in these 
particles. The optical images are presented at different magnification for droplets Figure 5.10a and 
particles Figure 5.10b). The coulter sheds light into the droplet and particle size distribution where 
there is a slight shift of particle size to the left (smaller size) in comparison to droplets. The particles 
were then freeze dried and viewed under SEM (Figure 5.11). Here the morphology of the particles 
shows that they are non-porous, smooth and spherical. 
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Figure 5.10 Optical microphotographs of w/o emulsion droplets, crosslinked particles, and size 
distribution of phage containing emulsion droplets and particles. (a) emulsion produced using 
dispersed phase flow rate of 40 mlhr-1 and paddle rotation speed of 62 rads-1at different 
magnifications. Dispersed phase composition: Eudragit S100 10 % (w/v), Alginate 2 % (w/v). 
Continuous phase composition: M:C ratio 9:1, with 2 % (w/v) PGPR. (b) Microparticles produced from 
emulsions following TSA and CaCl2 crosslinking at different magnifications. (c)  Droplet and particle 
size distribution, solid lines – droplets; dashed lines – particles. 
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Figure 5.11 SEM image of particles produced by membrane emulsification (phage K1F) from 10 % (w/v) 
ES100, 2 % (w/v) alginate.  
5.3.7 Effect of crosslinking parameters on phage encapsulation.  
 
 
 
 
 
 
 
 
 
Figure 5.12 Effect of Tween concentration and crosslinking time on phage viability (10 % (w/v) ES100, 
2 % (w/v) alginate at 62 rads-1, 20 µm mem, M:C 9:1 Felix 01). 1 % and 2 % (v/v) of Tween 20 was 
added to CaCl2 for crosslinking composite particles. After crosslinking the particles were release in SIF 
for 6 hours. The plotted results are mean of 3 repeats. *indicates a significance difference between 
the mean PFU/ml for each parameter comparedto the mean of every other parameter within each 
time point (p<0.05). 
The effect of crosslinking times and surfactant concentration in the crosslinking solution was 
investigated. The influence of Tween concentration was studied because the pH of the solution 
changes with the addition of surfactant. With higher Tween concentrations the pH of CaCl2 falls, so at 
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2 % tween the pH was 3 and at 1 % tween the pH was 4. The effect was further examined by allowing 
different crosslinking times (2 hours and 24 hours). Figure 5.12 shows that there was no significant 
difference in each of the parameters investigated. Phage titre was unaffected by tween concentration 
and crosslinking time.  
 
 
 
 
 
 
 
 
 
Figure 5.13 Phage Felix 01 and K1F encapsulated together in 10 % (w/v) ES100, 2 % (w/v) alginate at 
62 rads-1, 20 µm membrane, M:C 9:1. The plotted results are mean of 3 repeats. *indicated a  statistical 
difference for the PFU/gram at each time point in comparison to the final value at 6 h (p<0.05) 
Since the formulation was used for more than one phage against enteric pathogens, both Felix O1 and 
K1F were encapsulated together. This was to observe any interactions between the phages that may 
affect the encapsulation process.  Figure 5.13 shows the results for the two phages encapsulated 
together and their release profile at pH 7 (plaque assay carried on the appropriate host). The 
encapsulation showed 100 % efficiency with the titre remaining ~ 109 PFU/ml for both phages. The 
release profiles also showed similarities with a burst release within the first hour and slow increase 
thereafter. The two phages did not have a negative effect on the encapsulation of the other, the 
formulation was suitable for co-encapsulation of more than one phage. Both phages belong to the 
myoviridae family and are in similar in size, therefore they occupy a similar spatial area.  
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5.3.8 Encapsulation of phage K1F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Release of encapsulated phage from 10 % (w/v) ES100, 2 % (w/v) alginate at 62 rads-1, 20 
µm mem, M:C 9:1 microparticles. (a) Total phage release from ES100/Alg microparticles after 6 h 
exposure to SIF at pH 7 with and without exposure to SGF at pH 2 and pH 2.5 (exposure to SGF for 3h). 
* 
* 
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(b) Phage release kinetics from ES100/Alg microparticles over a 6 h exposure period to SIF at pH 7 
without (K1F pH 7) and with exposure to SGF at pH 2 (K1F pH 2) and pH 2.5 (K1F pH 2.5). *indicates a 
statistical difference between the average mean of each parameter in comparison to pH 7 within each 
time point in a two-sample t-test (p<0.05). 
Phage K1F was encapsulated and exposed to SGF pH 2 and 2.5 for 2 hours, after which phage was 
released at pH 7 SIF Figure 5.14a. Over 70 % of the encapsulated phages were released after 2 hours 
exposure to pH 2, this was comparable to pH 7 as there was less than 1-log reduction in phage titre. 
The release profile showed a burst release of the phages with most of the phages being released within 
the first hour and then slowly rising over five hours to complete full release (Figure 5.14b). For pH 2 
and 2.5 the phage titre after complete release was of the same order and statistically indifferent to 
pH 7 as shown by the error bars.  
 
 
 
 
 
 
 
 
Figure 5.15 Release of encapsulated phage from 10 % (w/v) ES100, 2 % (w/v) alginate at 62 rads-1, 20 
µm mem, M:C 9:1 microparticles. Phage release (PFU g-1) after 5h from ES100/Alg microparticles in 
SIF at different pH values following prior exposure of microparticles to SGF at pH 2 (3 h exposure to 
SGF). Black squares represent the % phage release. * indicates significantly different phage titres (p < 
0.05) for a 2-sample t-test with each sample compared with phage release from ES100/Alg exposed 
to pH 7. 
The phage was further investigated for its release kinetics at pH 5 and 6 (Figure 5.15). The pH in the 
lower gastrointestinal tract rises slowly therefore release of phage at these pH was a crucial factor to 
consider. Post pH 2 exposure encapsulated phage K1F microparticles were added to pH 5, 6 and 7 
(Figure 5.15). Less than 40 %/ 106 PFU/ml of phages were released at pH 5 and approximately 60 %/ 1 
151 
 
x 109 PFU/ml were released at pH 6. This phenomenon was observed due to the hydrolysis of the 
carboxylate groups on the Eudragit polymer which are present at pH 5 and these begin to increase as 
the pH rises to pH 6 and 7 hence increase in phage release. Similarly, with increasing pH alginate also 
begins to swell and dissolve.  Upon a 5-hour exposure to pH 5 and 6 the particles were then suspended 
in pH 7 solution to complete the dissolution and release of the remaining encapsulated phage which 
corresponded the phage titre at pH 7 only. 
5.3.8 Kinetics of bacterial lysis by encapsulated phage 
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Figure 5.16 Dynamics of phage killing of E. coli EV36 bacteria with K1F bacteriophages. (a) Optical 
density curves showing bacteria killing in the presence of different concentrations of added phage. 
*indicates significance difference in comparison to the control (p< 0.05) n=3 (b) Phage amplification 
in the presence of E. coli EV36. *indicates significance difference between all parameters within each 
time point (p<0.05) n=3 (c) Comparison of phage amplification of EK1F phages encapsulated in 
microparticles with and without exposure to SGF (3 hours). *indicates the significance difference in 
the mean PFU/ml between pH 2 exposed K1F and EK1F within each time point in a two-sample t-test 
(p < 0.05) n=3. 
Encapsulated phage killing of bacteria in comparison to free phage was examined in a series of 
experiments. The control which monitored the growth of bacteria over the course of the experiment 
showed exponential growth Figure 5.16a as shown by the optical density. Different concentrations of 
free phage were added to an exponentially growing culture of bacteria. High concentration of free 
phage (106 PFU/ml and 108 PFU/ml) were able to arrest bacterial growth early on approximately within 
the first hour the O.D. of the bacteria dropped significantly. Low free phage concentrations such as 
102 PFU/ml and 104 PFU/ml were also able to arrest bacterial growth however this took longer around 
3 hours post phage infection. 
Ephage pre-exposed to pH 2 showed similar killing profile to the low pH phage concentrations. Ephage 
was also able to arrest bacterial growth but 3 hours post infection. Low phage concentration lags due 
to the time required for phage amplification. Phage amplification catches up to the growing bacterial 
population however there was a time delay in comparison to a high titre phage Figure 5.16b. Ephage 
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and 104 PFU/ml showed similar phage amplification Figure 5.16b meaning the phage released from 
the ephage was of the same order (104 PFU/ml). All phage was amplified by hour 3 Figure 5.16b 
meaning low titre phage can catch up due to amplification.  
Figure 5.16c demonstrates the comparison between ephage with and without exposure to SGF and 
release of ephage in the absence of bacteria. Ephage with and without SGF exposure showed similar 
amplification profiles, meaning the exposure to SGF did not affect the phage titre. Encapsulation 
enabled the phage to stay viable even after pH 2 exposure which was an important finding since free 
phages alone were not able to survive pH 2 exposure. 
5.3.9 Three-way interaction of phage, bacteria and epithelial cells 
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Figure 5.17 Confocal microscopy images of RFP E. coli EV36 cells (red) treated with microencapsulated 
EK1F in the presence of epithelial cells (blue). (a) controls without phage: (i) 2 h, (ii) 3 h, (iii) 3.5 h and 
(iv) 5 hours following incubation of epithelial cells with EV36; (v) image showing damage to actin (using 
phalloidin staining) – inset showing control epithelial cells not exposed to EV36. (b) (i) Phage 
amplification of free phage and microencapsulated phage in the presence of EV36; Confocal images 
of EK1F treated sample: (ii) 3 h, (iii) 3.5 h and (iv) 5 hours following incubation of epithelial cells with 
EV36; (v) image showing condition of actin of epithelial cells exposed to EV36 and treated with phage 
K1F. 
A cell culture assay was carried out to investigate the arresting potential of ephage of the bacteria in 
situ. Mammalian cells were grown until confluent, to which bacteria EV36 (host for phage K1F) was 
added and allowed to grow and infect for 2 hours. After which ephage was added to one culture, 
whilst one was used as a control. Figure 5.17ai-iv shows the epithelial cells and the growth of bacteria. 
It was evident the bacteria had actively grown in the presence of epithelial cells as shown in Figure 
5.17ai-iv highlighted by the pink/red fluorescence rods. Confocal imaging showed stressed epithelial 
cells in the presence of growing number of bacteria as shown by the blue fluorescent dye. This was 
evident due to the shrinking cell morphology Figure 5.17aiv and damaged actin cytoskeleton found 
around the cell structures Figure 5.17av actin provides support for cell shape, cell division and other 
cellular processes). The cell morphology deteriorated over time due to the presence of growing 
number of bacteria.  
On the other hand, cells treated with phage after SGF exposure showed a different profile Figure 5.17b. 
Upon release phage amplification took place in the presence or bacteria, lysing them and preventing 
further cell damage. In comparison to the control the number of bacterial cells at each time point 
were seen to be reduced Figure 5.17biii the morphology of the mammalian cells was showed some 
recovery and further damage was prevented Figure 5.17biv-v. The actin cytoskeleton also showed 
better morphology with taut microtubules rather than collapsed ones seen with the control.  
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5.3.10 Storage stability of Ephage 
 
Figure 5.18 Storage stability of encapsulated K1F phage in 10 % (w/v) ES100, 2 % (w/v) alginate at 62 
rads-1, 20 µm mem, M:C 9:1 microparticles refrigerated at 4C. Phage titre was evaluated by exposing 
microparticles to simulated intestinal fluid. Absence of * indicates sample means were not significantly 
different as compared with sample at week 0 (p < 0.05) using a 2-sample t-test. 
Table 5.2 Summary of microencapsulated EKF1 storage results from Figure 5.18. 
Storage period / 
weeks 
Mean / PFU 
g-1 
Lower 95% CI Upper 95% CI 
0 a 1.8 x108 8.9 x107 2.8 x108 
1 a 1.1 x 108 8.4 x 107 1.3 x 108 
2 a 1.1 x 108 8.4 x 107 1.3 x 108 
3 a 8.3 x 107 5.0 x 107 1.2 x 108 
4 a 8.8 x 107 6.0 x 107 1.1 x 108 
 
Notes: CI = confidence interval; different superscripts in the same column indicate significantly 
different mean values at p < 0.05 (2-sample t-test) comparison with storage period 0 weeks. 
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Ephage was stored at 4˚C for 6 months (Figure 5.18) The results indicate that there was no significant 
drop in titre of the phage over this period. There was an initial significant drop in titre after 1 week 
however this seemed to have stabilised for the remaining storage period. This could be due to the 
phage adjusting to the unfamiliar environment otherwise kept at room temperature of 37˚C for all 
experimental work. The confidence intervals shown in Table 5.2 are evidence to the results in Figure 
that the titre of the phage remained unchanged over the storage period. This concluded that the 
phage was not affected by the formulation or process parameters of encapsulation.  
 
5.4 Discussion 
 
Phage encapsulation is an integral part of phage therapy. Limited studies on phage encapsulation 
demonstrate that much is yet to be done to develop formulations and techniques to enhance the 
efficacy of phage therapy. A key motivation for this piece of work was to demonstrate the route to 
scale-up phage encapsulation using a pH trigger responsive polymer system. Also, to show the 
transferability of the system to phages of different enteric pathogens. Previously, focus has been on 
developing the formulation with precise control of droplets and protection against acidic pH. Phage 
are sensitive to acidic pH to a different degree as demonstrated in this study, nevertheless this raises 
an important question regarding the development of cocktails against enteric pathogens. With the 
intention of delivering an equal titre of phage in a cocktail or alone, acid inactivation may disable the 
desired effect of phage. Hence, it is imperative to study the resilience of each phage to pH and ensure 
that sufficient protection is provided to deliver an expected dose to the site of infection. 
Membrane emulsification was found to be a suitable method for scale-up since large scale production 
can be achieved through adding more membrane area. The narrow droplet size distribution achieved 
via microfluidics can be difficult to replicate during scale-up. However, with membrane emulsification 
droplet size distribution is homogenous in comparison to conventional shear dependent methods. 
Hanga & Holdich, (2014) found that despite the high viscosity of alginate, droplets size ranged from 
0.2 to 1.5 µm where span less than 1 is considered as monodispersed. In this study this was difficult 
to achieve since coefficient of variance was observed to be at 60 %. Usually, CV values below 20 % are 
considered monodispersed. Droplet size is said to be influenced largely by the choice of membrane 
and not by the shear in the dispersion cell (Charcosset et al., 2004). Many studies have however, 
shown the influence of shear in the dispersion cell on droplet size. Here, we demonstrated that shear 
influenced droplets size to a small degree and therefore the phage loading.  
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Size analysis revealed that particles at D50 ranged from 10 to 24 µm for different continuous phase 
viscosities. Previously, we have reported particle size ranging around 100 µm (Vinner et al., 2017) with 
others reporting particle size as big as 900 µm (Yongsheng Ma et al., 2012). Bigger microparticles have 
shown to have better acid protection and slower release kinetics (Yongsheng Ma et al., 2012; 
Yongsheng et al., 2008) whereas release in this study displayed a burst release with up to 90 % of 
phage being release within the first hour. Although a burst release was observed during dissolution in 
SIF, phages were protected after a two-hour pH 2 SGF exposure. This observation indicated that the 
formulation was a crucial factor in determining acid protection in addition to the physical parameters 
of the microparticles produced. Incorporating properties from a combination of polymers ensures that 
the microparticles produced as a result can protect phage from hostile environment.  
A combination of parameters was investigated to better understand and optimise the production of 
monodispersed droplets and hence particles using membrane emulsification. This did however prove 
challenging in that up-scaling from microfluidic platforms where fine-tuned uniform droplets were 
produced (chapters 3 and 4), the same could not be replicated with membrane emulsification. There 
are several factors which contributed to this, the change in geometry of the emulsification played a 
crucial role. In comparison to microfluidics, where a single capillary was used to produce droplets, and 
every single drop was subjected to the same fluid dynamic forces, in membrane emulsification this 
drastically changed. Here, formation of a droplet was dependent on the flow rate, membrane pore 
diameter, membrane type and coating, the shear applied by the paddle stirrer, viscosities of both 
phases and the presence of surfactant. The majority of these parameters played a role in determining 
the droplet size in microfluidics; however, the major difference with membrane emulsification was 
the emphasis on the membrane and the shear applied. As the droplet grew whilst entering through 
the membrane pore it was continuously subjected to shear which was heterogenous throughout the 
dispersion cell. Hence, depending on the formulation droplets were further broken into smaller 
droplets producing polydisperse droplets. 
In the presence of these parameters, monodispersed droplets were successfully been produced with 
a low coefficient of variance even in the case of high viscosity alginate (Hanga & Holdich, 2014; Liu, 
Bao, et al., 2002). Despite the change in droplet diameters for each parameter the phage loading was 
not significantly affected. Microparticle produced showed smooth non-porous solid surface 
confirming the microparticles were sufficiently crosslinked. Crosslinking of microparticles was further 
investigated by looking at the influence of Tween (emulsifier) on phage titre due to pH of the solution 
being acidic (pH 3). Results showed there was no impact of the acidic solution on phage viability which 
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also confirmed acid protection at pH 3 after a 24-hour exposure where otherwise phage sensitivity to 
pH 3 has previously been reported (Yongsheng Ma et al., 2012; Yongsheng et al., 2008).  
Precision control of droplet size can help predict the release profile of the microparticles hence the 
production of monodispersed microparticles is highly desirable. Microparticles produced via 
membrane emulsification showed an average droplet diameter of 50 µm going up to of 100 µm and 
lows of 5 µm. Phage release kinetics demonstrated that despite there being an initial burst release as 
previously seen, a slower sustained release was observed after 1- hour which may be attributed to the 
presence of poly-size microparticles. The initial burst from smaller microparticles in the first hour 
changes the solution properties, slowing the rate of diffusion of hydroxyl ions which then prolonged 
the release of the larger microparticles.  
Encapsulation of phage was a crucial step in ensuring a known dosage was delivered to the site of 
infection to eradicate the pathogen. Studies have shown phage cocktails with broad host ranges were 
better at targeting bacteria (Connerton et al., 2011; Nale et al., 2016; Nale et al., 2018). Therefore, 
every formulation must be tailored for each phage to be encapsulated and address possible 
interactions between different phage. Phage K1F and Felix O1 were co-encapsulated and subsequently 
released in SIF, the results revealed no effect on phage viability in either case. This was a crucial first 
step in devising formulations and platforms for phage encapsulation engineered for phage therapy.  
A high phage dose was required to arrest bacterial growth (Malik et al., 2017; Y. Tanji et al., 2004) 
hence when designing formulations, release profiles need to be carefully considered. In this study, the 
release of composite Eudragit and alginate microparticles was studied at different pH which may be 
encountered during transit through the digestive system. This has not previously been reported and 
therefore not taken into consideration when calculating phage dosages. Up to 10 % and 50 % phage 
was released at pH 5 and 6 respectively, demonstrating that although polymers maybe pH responsive 
at neutral to alkaline pH their release starts prematurely. Presence of hydroxyl ions start to increase 
as the pH values increase which initiate the dissolution or swelling of polymer resulting in release of 
phage. In certain circumstances, this can be a useful occurrence where the infection has spread over 
a large area such as colon or the pH has changed due to infection (McConnell et al., 2008; Lalezari, 
2012). The premature release may help prevent the spread of bacteria to other sites. It is however 
important to account for the premature release of phage during transit to better understand dosing 
during phage therapy. 
Further investigation led us to conclude that even very low amount of phage has the capacity to arrest 
bacterial growth with a short delay given that bacteria are actively growing. These findings confirm 
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phage-bacterial infection mathematical models (Malik et al., 2017; Payne & Jansen, 2001; Y. Tanji et 
al., 2004).  In situ analysis of phage killing of bacteria showed a positive arrest of mammalian cell 
deterioration and rescue of the actin cytoskeleton. Bacterial lysis was observed with both free and 
encapsulated phage. These findings provide a useful insight into how not only free phage work in vivo 
but also how encapsulated phage may behave. Phage in the presence of human cell lines predicts the 
response of the bacteria and cells to phage which potentially could have adverse effects on 
mammalian cells (Mirzaei et al., 2016). Phage have reported to respond well in lysing bacterial cells in 
the presence of epithelial cells as found to be the case against P. aeruginosa  (Debebe Alemayehu et 
al., 2012).  
For encapsulated phage, polymer safety and toxicity need to be evaluated. Eudragit is FDA approved 
and considered safe for use in biological applications, its use in commercially available medicine is 
evidence of its low toxicity. A study by Coco et al., (2013) also showed very low toxicity of Eudragit 
nanoparticles on Caco-2 intestinal epithelium cells mimicking the inflamed epithelium. A study by Shan 
et al., (2018) showed a three-way interaction between phage, bacteria and epithelial cells. HT-29 cell 
line was used to mimic the colon environment to investigate the C. difficile infection and the effect of 
introducing phage. Bacterial killing by phage was shown to be more effective in comparison to in vitro 
assays thought to be due to phage adherence to epithelial cells which increased phage-bacteria 
interactions (Shan et al., 2018). pH 2-exposed microparticles carrying phage which were successfully 
able to lyse bacteria in the presence of epithelial cells demonstrate that the interaction of phage with 
cells and bacteria is not hindered by encapsulation.  
Phage stability is important to ensure the titre does not drop during storage which can alter the phage 
dosage. Polymer properties impact phage viability during long-term storage and this study 
demonstrated that phage was well protected in composite particles over a 4-week period with no 
significant drop in titre. Composite microparticles produced via membrane emulsification showed 
phage encapsulation can be scaled-up to produce larger quantities without compromising on 
optimised properties of the formulation.  
5.5 Conclusions 
 
Membrane emulsification technique was used to scale up the process of phage encapsulation in 
composite, Eudragit and alginate microparticles. Experimental parameters affected the droplet 
diameter which ranged on average from 10 to 50 µm at D50 with the lowest CV achieved at 57 %. 
Phage was encapsulated at a high yield and showed protection from SGF (pH2 for 2 hours) with less 
than 0.5 log reduction in phage titre. Premature release of phage was also observed at pH 5 and 6 
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with up to 10 % and 50 % phage unloaded respectively. Further investigation of different phage titres 
in reducing bacterial concentration showed higher phage titres to arrest bacterial growth faster than 
low phage titres. Addition of epithelial cells demonstrated that encapsulated phage was released from 
microparticles and lyse bacteria. Overtime, bacterial concentration decreased and an improvement in 
epithelial cell morphology was observed. Phage was stable for up to 4 weeks in microparticles at 4°C. 
The study demonstrated that membrane emulsification is a viable technique for scale-up which can 
successfully produce microparticles for phage encapsulation. Further work is required to better 
control droplet size and test this formulation for a more diverse set of phages to ensure its efficacy.   
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Chapter 6: Microencapsulation of Felix O1 in pH responsive polymers using 
spray drying for tableting and improved storage. 
 
Abstract 
 
Treatment of enteric infections can be challenging since the harsh stomach environment (acidic pH) 
can render phages inactive during transit. Therefore, site-specific delivery and stability of phage over 
prolonged periods is essential for phage therapy. Spray drying is a conventional technique used 
industrially to produce encapsulated drugs, respiratory powders and even vaccines. Phage Felix O1 
was used as a model phage to be spray dried in pH responsive polymer Eudragit and/or alginate. 
Phages are also prone to damage from desiccation and elevated temperatures usually encountered 
during spray drying. To further protect phage from environmental stresses trehalose was used in 
addition to polymers to protect phage and prolong storage stability. Spray dried powder entrapping 
phage was compressed into tablets with a 1 mm diameter, these were tested for dissolution, 
disintegration, friability and storage under different conditions. Results showed a high encapsulation 
yield of phage Felix O1 with stable storage at 4°C. 
6.1 Introduction 
 
Spray drying is a popular technique to produce dry powder forms carrying bioactive agents such as 
proteins, peptides, attenuated antibodies and phages (Ameri & Maa, 2006). Previously, spray drying 
has been used for the encapsulation of phages to produce powders for respirable use (S. S. Y. Leung 
et al., 2016; Matinkhoo et al., 2011; Vandenheuvel et al., 2013b). Dry powder forms are favoured due 
to their ease of handling and long-term storage stability e.g. at ambient temperatures avoiding the 
need for a cold supply chain for storage. Encapsulating phages in a dry powder form opens possibilities 
for their use in dry powder inhalers and oral solid dosage forms e.g. tablets for enteric delivery. This 
chapter investigates the use of spray drying for phage microencapsulation in multicomponent 
formulations using the following combination of excipients: the pH responsive polymer Eudragit S100, 
the disaccharide trehalose and the biopolymer alginate. This chapter presents results investigating the 
use of these excipients to produce pH responsive microparticles using a one-step method for phage 
microencapsulation such that the particles have high phage loading and good storage stability. The 
best formulations were processed further into compressed tablets suitable for blister packaging. The 
work reported here allows evaluation of the suitability of these methods for phage encapsulation 
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using highly scalable manufacturing processes that would facilitate translation of phages from bench 
to bedside for phage therapy in both humans and animals. 
6.1.1 Excipients for spray drying phage 
 
Phage Felix O1 belongs to the Myoviridae family, first isolated by Felix and Callow in 1943. Since then, 
it has been studied for various applications including incorporation in phage cocktail for phage therapy 
to treat Salmonella contamination in pig skin (Hooton et al., 2011). The effect of temperature on phage 
is better understood in the dairy industry where phages can cause problems with cheese making by 
killing bacteria that initiate the fermentation process. These phages however are found to be prone 
to thermal stresses showing all or partial loss of activity at temperatures above 60°C (Capra et al., 
2004; Jończyk et al., 2011; Müller-Merbach et al., 2005). It is common practice to store phages in at 
4°C, in liquid nitrogen or -80°C with 50 % glycerol, these conditions keep phage relatively stable over 
several years (Ackermann et al., 2004). Phages are essentially vehicles which carry genetic material in 
the form of DNA or RNA hence elevated temperatures can cause protein denaturing rendering phage 
incapable of binding/ adsorbing onto the host.  
6.1.1.1. Trehalose 
 
In contrast to lyophilization which often uses low temperatures, spray drying can expose active agents 
to temperatures as high as 100°C, which can be detrimental for temperature labile active agents such 
as phage. To overcome this, phages are often spray dried with excipients or bulking agents to provide 
protection from elevated temperatures. Good excipients prevent or minimise the effect of thermal 
stress on the active agent, some examples include sugars i.e. trehalose and sucrose etc. These sugars 
act as water-replacing agents, in other words active agents such as phage and proteins which undergo 
irreversible damage due to the removal of water (essential for the maintenance of the hydrogen bonds 
necessary to stabilise the secondary structure of the proteins) are protected by these sugars (Arakawa 
& Timasheff, 1982). Sugar acts to replace the hydrogen bonds which otherwise would be lost due to 
evaporation under higher temperatures.  
Trehalose structure is made of two α-glucose units and naturally occurs as a disaccharide, it is the 
glycosidic linkage that makes it resistant to hydrolysis. In its amorphous form, trehalose exhibits a high 
glass transition temperature- around 117°C which gives it exceptional lyoprotectant properties (Miller 
& de Pablo, 2000). High glass transition temperature means the ability to form a glassy matrix in the 
amorphous form which averts the structural transformation of the active agent under higher 
temperatures. Therefore, under humid conditions trehalose picks up the moisture, changes in part to 
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its crystallisation form preventing hydrolysis- this in turn reduces the glass transition temperature. As 
the moisture is removed by drying, the sugar can return to its amorphous state. The instability of 
amorphous trehalose can be measured by Gibbs free energies of the amorphous and crystallization 
states at constant heat and pressure. The decrease in Gibbs free energy of changing from amorphous 
to crystalline equals the enthalpy minus the entropy of the system and surroundings. A bigger 
thermodynamic driving force for crystallisation is observed when the Gibbs free energy is high. As 
investigated by  Miller & de Pablo, (2000) the Gibbs free energy for trehalose was found to be -17 
kJ/mol which is the highest amongst sugars compared with maltose (-7.4 kJ/mol) and sucrose (-9.6 
kJ/mol). This indicated that trehalose makes a good excipient for protecting active agents which are 
prone to environmental changes during long-term storage.  
Trehalose has been used to spray dry phages to produce stable powder for applications such as dry 
powder inhalers. A Podoviridae phage LUZ19, was spray dried with trehalose, lactose and dextran 35 
by Vandenheuvel et al., (2013) for use against respiratory infections caused by Pseudomonas 
aeruginosa. Trehalose was found to be the best excipient in protecting phage from temperature and 
shear stress caused during the spray drying process, less than 1-log reduction in phage titre was 
observed. Similarly, Leung et al., (2016) also spray dried an anti-Pseudomonal Podoviridae phage with 
mannitol, trehalose and leucine however, failed to achieve less than 1-log reduction in titre but 
showed overall better phage viability when compared to spray freeze drying. In contrast, a collection 
of Myoviridae phages was spray dried with trehalose, leucine and a surfactant by Matinkhoo et al., 
(2011) showed less than 1-log reduction in phage titre. In addition to that enhanced performance of 
the spray dried powder was observed in comparison to commercial dry powder inhalers.  
6.1.1.2 Eudragit S100 
 
Application of spray dried phage has largely been for combating pulmonary infection or to increase 
the long-term storage stability of phages for better preservation. To date, limited work has been done 
to exploit the use of spray dried phage for oral dosage form to address enteric infections. Stanford et 
al., (2010) encapsulated four anti-E. coli phages in a pH responsive polymer using spray drying, 1-log 
reduction in phage titre was observed. Due to the intended enteric delivery, the encapsulated phage 
was exposed to pH 3 for 20 mins to mimic the stomach acidic environment in cattle. Protection against 
pH 3 was observed for all four phages with the highest survivability at 13 %. This study demonstrated 
the use of spray dried powder containing phage for use in oral dosage forms to treat enteric infections. 
pH responsive Eudragit S100 a methyl-methacrylate copolymer ensures the stability of the phage upon 
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exposure to low pH. This opens the possibilities of spray drying phage with excipients other than sugar 
or lyoprotectants to produce tailored release powder properties of Ephage.  
Eudragit S100 and its analogue copolymers such as Eudragit L100 and RS have been used for 
encapsulation and coating active agents in various pharmaceutical applications. Examples of 
commercially available products containing these polymers include Dulcolux and coated Naproxen 
tablets. Several patents have also been setup which have included the use of Eudragit in application 
for colon drug delivery (Basit & Ibekwe, 2007) and also for encapsulating phage in Eudragit copolymers 
(Waddell et al., 2013). Further studies have focussed on using the pH responsive behaviour of this 
polymer to encapsulate probiotics for delivery to the colon (Govender et al., 2015), where the 
commensal flora can be repopulated after infection. Eudragit is a popular enteric coating for delivery 
to the lower gastrointestinal tract, however it can also be used for micro and nano encapsulation with 
other polymers (Collnot et al., 2012). 
6.1.1.3 Alginate 
 
Alginate is naturally occurring anionic polymers extracted from brown seaweed and has been 
extensively used in biomedical applications due to its bioavailability and desirable physical and 
chemical properties. It is a non-toxic copolymer, generally regarded as safe under the FDA 
classification (George & Abraham, 2006) and readily dissolves in water making it highly useful when 
working with active agents sensitive to solvents such as ethanol. To crosslink alginate addition of 
multivalent cations such as calcium can be added to form a hydrogel matric which dissolves in neutral 
to high pH. Under acidic conditions alginate tends to contract which is desirable since the porosity of 
the alginate matrix is reduced, entrapping and protecting the active agents inside the hydrogel.  
Alginate has already proven to be a popular choice for the encapsulation of bacteriophages (Colom et 
al., 2017a; Yongsheng Ma et al., 2008, 2012; Stanford et al., 2010b; Tang et al., 2013, 2014) mainly 
due to its biocompatibility and ease of use. Using alginate for phage encapsulation has shown some 
promise, however in light of its porous structure when exposed to SGF at pH 2 or 2.5 the acid was able 
to penetrate the gel matrix and reduce phage viability (C Dini et al., 2012; Yongsheng Ma et al., 2008, 
2012). Therefore, some studies have proposed the use of alginate in combination with other 
copolymers such as chitosan (C Dini et al., 2012; S. Kim et al., 2015a; Yongsheng Ma et al., 2008, 2012), 
guar gum, pectin (C Dini et al., 2012), whey protein (Samtlebe et al., 2016; Tang et al., 2013, 2014) and 
Eudragit (Jain et al., 2005; Stanford et al., 2010b). This highlighted that when used in combination with 
another polymer better phage protection maybe achieved against SGF 
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6.1.2 Tableting spray dried powder 
 
6.1.2.1 Benefits of tabletting 
 
Tableting bioactive agents has several advantages, it is the preferred dosage form in the 
pharmaceutical industry due to its accurate dosing, ease of manufacture at low cost and stable long-
term storage stability. The ease of use and dosage is pre-empted by the uniformity and reproducibility 
of each tablet in the blister pack, which ensures patient compliance to the prescribed medicine. 
Several phage products are available on the market around the globe targeting the spread of bacteria 
through food, veterinary applications and environmental sanitation- many of these products offered 
by Intralytics Inc. (USA). However, tableted phage is manufactured by Biochimpharm, under 
Septaphage®. This product contains several phages against bacteria such as Shigella, Salmonella, E. 
coli, Proteus, Staphylococcus, Pseudomonas and Enterococcus. The commercial availability of this 
tablet highlights the possibility of using other formulations to produce encapsulated phage in a tablet 
form, with enhanced properties in terms of targeted release.  
6.1.2.2 Examples of tableting by direct compression 
 
Typically, tableting is carried out using wet or dry granulation however, an increased interest in direct 
compression is observed due to the simplicity of the method and by-passing many steps involved in 
granulation (Jivraj et al., 2000). There are several ideal requirements of the powder for direct 
compression technique to be employed for tableting. Ensuring homogenous and quick flow of the 
powder for filling the punch chamber in high speed tableting machines is an important consideration. 
Similarly, the compressibility of the powder is also important, as the mass compressed into a tablet 
must remain compact once the compression force is removed. The tapped bulk density of the powder 
can be a good indicator of whether powder has the potential to be directly compressed, external 
factors can also influence the bulk density of a powder such as segregation of particles and moisture 
(Jallo et al., 2012).  
Spray dried powders followed by direct compression that are commercially available include Lactose-
316 Fast Flo®, Avicel PH, Karion Instant, TRI-CFOS S and Advantose 100. Powder produced via spray 
drying has good flowability and retains the uniform spherical shape of particles which is advantageous 
for direct compression (Marwaha et al., 2010). Excipients such as sugar i.e. trehalose may be used for 
direct compression to form tablets carrying phage- since phage has proven to be stable when spray 
dried with trehalose. However, without triggered release properties trehalose tablets alone do not 
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serve purpose for enteric delivery- adding a copolymer such as Eudragit and/or alginate can help 
enhance tableting potential for site specific delivery.  
Enteric coating of tablets with the Eudragit series have shown their potential in site specific targeting 
of the active agent. Govender et al., (2015) showed encapsulation of a model probiotic bacteria, 
Lactobacillus acidophilus in ovalbumin to create mini-tablets after 24-hour lyophilization (~1.87 mm). 
These were then separately coated with either lactose or Eudragit S100 to create a tablet in tablet 
system with the aim of targeting release in the upper and lower GI tract. Results revealed successful 
protection of the bacteria from acidic stomach environment and pH dependent release in the colon. 
A separate study Souza et al., (2013) investigated the release of minitablets composed of Polyox®WSR 
1105 carrying model drug mesalamine using dry granulation which were further coated using a 
fluidized bed with Eudragit L30D55. The results showed a prolonged drug release at pH 6 and 7.2 
showing zero-order release kinetics.  
Risedronate, an antiresorptive drug for GI tract injuries was encapsulated in pullulan (polysaccharide) 
and Eudragit S100 using spray drying to produce dry powder, which was directly compressed into 
tablets. Upon exposure to pH 1.2 the formulation containing the highest amount of Eudragit 
concentration showed the highest gastro-resistance with only 10 % drug release. Further release in 
SIF revealed a prolonged release of the drug over 4 hours (De Arce Velasquez et al., 2014). The 
potential of using spray dried powder for tableting though direct compression has shown potential 
when using Eudragit and sugars as excipients. Similarly, when considering the use of Eudragit 
encapsulated phage in dry powder form, tableting can improve the dosage and ease of use for therapy 
applications.  
Aims and Objectives 
 
Previous chapters have shown and optimised the use of Eudragit and alginate in phage encapsulation 
using different encapsulation techniques. This study investigated the versatility of the formulation 
when applied to well established industrial spray drying technique. A bench-top spray dryer was used 
to produce phage encapsulated powder. An additional excipient, trehalose was incorporated into the 
process due to its protective properties of phage demonstrated in literature. Effect of each excipient 
on phage viability during spray drying was investigated as well in combination to produce an optimised 
recipe suitable for phage encapsulation. Parameters such as temperature, yield, moisture content and 
encapsulation efficiency were evaluated. The optimised formulation was further explored by 
tableting. Tablets were examined for their disintegration, dissolution and friability capabilities. For 
both powder and tablets the effect of long-term storage under various conditions was studied for its 
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effect of phage viability. Shift in glass transition temperatures for each sample was analysed and will 
be discussed. Conclusions, regarding the potential use of powder and tableted form for animal and 
human therapy will be discussed.  
 
6.2 Materials and Methods 
 
6.2.1 Model bacterium and phage  
 
All work carried out for both bacteria and phage was carried out according to the method in chapter 
4 section 4.2.2, salmonella strain and bacteriophage Felix O1. 
To test the effect of temperature on phage viability phage in BHI broth was incubated at temperatures 
40°C, 50°C, 60°C for 60 minutes. 10 µl was removed at 10-minute intervals for the first 30 mins and 
then at 60 minutes, which was then diluted 10-fold to 10-8 and spotted in triplicate on a double layer 
agar plate containing Salmonella. The plate was dried an incubated overnight at 37°C and plaques 
counted the following day to determine phage viability.  
 
6.2.2 Spray drying phage Felix O1 
 
Eudragit S100 was purchased from Evonik Germany. D- (+)-Trehalose, Dihydrate was purchased from 
Fisher Scientific (U.K.). Alginate was purchased from Sigma Aldrich (U.K.). Solutions containing 
different excipient concentrations (table 6.1) were dissolved in 500 ml of dH2O. For Eudragit pH of the 
water was changed to alkaline to allow polymer dissolution. To dissolve alginate, the temperature was 
raised to 60°C and left stirring until full dissolution was observed. For each formulation 1 % (v/v) high 
titre phage Felix O1 was added. The phage solution was spray dried using a two-fluid nozzle Labplant 
spray dryer SD-06 (Labplant UK limited) (Figure 9.14 appendix). The diameter of the nozzle used 
throughout the work was 0.5 mm with liquid flow rate at 280 mlh-1 and air speed at 4.3 ms-1. 
Temperature was controlled by changing the inlet temperature (table 6.2) with corresponding outlet 
temperature Table (6.2) which varied by 2°C between runs.  
Once the dry powder was collected, it was stored at 4°C in sealed tubes unless storage conditions 
were changed. For storage analysis, powder was stored at 4°C and at 23°C for a period of up to 3 
months. At timely intervals 0.1 g of powder was removed and dissolved in simulated intestinal fluid 
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(SIF) (composition 10 mg/ml of pancreatin in 0.5mM KH2PO4 pH 7) and phage titre enumerated using 
a plaque assay (described above). To ascertain the phage encapsulated in each excipient, 0.1 g of 
powder was removed and dissolved in SIF, 10 µl of sample was removed and plaque assay performed 
to enumerate phage. Similarly, simulated gastric fluid (SGF) (composition 3.2 mg/ml of pepsin in 0.2 
M NaCl pH 2) exposure was carried out for 2 hours for each formulation after which release kinetics 
were analysed in SIF. At timely intervals (30 mins) up to 3 hours, 10 µl of sample was removed and 
plaque assay performed to observe phage release. 
 
Table 6.1 Formulations used for spray drying phage Felix O1 
 
 
Table 6.2 Spray drying inlet temperature with corresponding outlet temperatures. 
Inlet temperature Outlet temperature 
180°C 96°C ± 2°C 
150°C 82°C ± 2°C 
120°C 66°C ± 2°C 
100°C 56°C ± 2°C 
 
6.2.3 Powder characterisation 
 
6.2.3.1. Scanning electron microscope (SEM) 
 
To analyse the morphology of spray dried powder, a representative sample from formulation 
containing 2 % (w/v) Eudragit and 1 % (w/v) trehalose spray dried at inlet temperature 150 °C was 
Excipient Concentration (w/v) 
 F1 F2 F3 F4 F5 F6 F7 
Eudragit S100   3 % 3 % 2 % 2 % 2 % 
Trehalose  4 %  2 % 1 % 1 % 4 % 
Alginate 1 %     0.5 %  
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taken and mounted on double sided carbon stickers. The sample was gold-sputter coated ready to be 
viewed using a benchtop SEM (Hitachi TM3030 Tabletop Microscope Europe).  
6.2.3.2 Coulter size analysis 
Coulter LS 130 (Beckman Coulter Inc.) (Figure 9.7 appendix) was used to determine the particle size 
distribution of the spray dried powder. The device is laser modulated and uses the optical model 
Fraunhofer, to detect laser diffraction caused by particles. A representative sample from formulation 
2 % (w/v) ES100 and 1 % (w/v) trehalose was taken for each temperature tested and loaded into the 
glass sample cell containing n-hexane (Sigma Aldrich U.K.). The volume size and cumulative 
distribution were measured and reported. 
6.2.3.3 Different scanning calorimetry (DSC) 
Eudragit and trehalose powders were taken before and after spray drying at 150°C inlet temperature 
for differential scanning calorimetry (DSC). 10 mg of powder was weighed into aluminium pans for 
analysis with an empty pan for reference. The analysis was performed for temperatures 25°C to 120°C 
with a ramp rate of 5°C a minute. The thermographs were recorded and analysed for glass transition 
temperature.  
6.2.4 Tableting  
 
Spray dried powders from formulation 7 and 5 spray dried at inlet temperature of 150°C were used 
for tableting using Riva Minipress MII (U.K.) machine (Figure 9.15 appendix). Each powder sample was 
mixed with varying amount of magnesium stearate (Sigma Aldrich U.K.) (0.5 %, 1 %, 1.5 % w/v). 
Approximately 0.3 g of powder was loaded into the punch hole and compressed at a force of 13.5 kN. 
The produced tablets were weighed and stored in sealed tubes for further analysis.  
6.2.4.1 Friability 
 
Six tablets were used to test for friability using Erweka friability tester (U.K.) (Figure 9.17 appendix), 
and the weight of each tablet was recorded prior to the start of the analysis. Every 20-drum rotations 
the weight of each tablet was recorded and reported at percentage (%) loss.  
6.2.4.2 Disintegration 
 
Tablet disintegration was evaluated using Erweka ZT31 (U.K.) disintegration machine (Figure 9.16 
appendix). Six tablets from each formulation were used to test for tablet disintegration in SGF pH 2 
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for a period of 2 hours. The weight of the tablets was recorded and subsequent release in SIF 
performed. At timely intervals of 30 mins 10 µl of sample was removed and plaque assay performed 
to ascertain the amount of phage present, for a total period of 3 hours.  
6.2.4.3 Tablet storage 
 
Tablets were stored in glass universals at 4°C tightly sealed and at 30°C with 65 % relative humidity 
(RH) with lids removed in a humidity chamber. Tablets were stored for 6 weeks, a tablet for each 
parameter was removed at 1 week, 2 weeks, 4 weeks and 6 weeks to test for phage viability. The 
tablets were exposed to SGF pH 2 for two hours in the disintegrator before being dissolved in SIF. The 
phage titre was evaluated use plaque described above.  
6.3 Results 
 
 
Figure 6.1. Temperature stability of free phage Felix O1 in BHI broth over a period of 1 hour. 
*indicates the significance difference between the PFU/ml of each parameter in comparison to 0 h in 
a two-sample t-test (p < 0.05). 
Effect of temperature on phage Felix O1 was investigated by exposing the phages in BHI broth to 
temperatures typically encountered during the spray drying process. The phage was unaffected by 
temperatures below 50°C but 1-log reduction after 60 mins exposure was observed at 60°C Figure 6.1. 
Phage was also exposed to 90°C (data not shown) however no phage was recovered after 10 mins of 
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exposure. Continued exposure to all temperatures for 24 hours showed no further loss at 
temperatures 40°C and 50°C but a further 1-log loss was observed for exposure to 60°C. 
6.3.1 Phage encapsulation using different excipients and experimental parameters 
 
Figure 6.2. Felix O1 encapsulated at 4 temperatures and its release from each excipient in PFU/gram. 
* indicates significance means were compared across all temperatures to 100°C inlet temperature (p 
< 0.05) using a 2-sample t-test. All measurements were done in triplicate (n = 3). 
Phage Felix O1 was spray dried with each excipient used in this study separately to observe effects on 
encapsulation. For each excipient different inlet temperatures were studied to observe the effect of 
temperature. Trehalose was found to be a good excipient, with phage encapsulated at high titres at 
all temperatures Figure 6.2. Whilst alginate and Eudragit alone showed less promise in retaining phage 
viability after spray drying Figure 6.2. The phage titre dropped by an average of 3-log for alginate and 
4-log for Eudragit. This may be attributed to the lack of protection from desiccation and heat provided 
by the two excipients in comparison to trehalose which is known be an excellent excipient for the 
protection of bioactive agents due to its high glass transition temperature. 
Effect of temperature on phage viability however was less obvious as the phage titre did not change 
with decreasing temperature with trehalose and Eudragit. In the case of alginate however, better 
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phage viability was observed with lower temperatures (120°C and 100°C) Figure 6.2. The influence of 
temperature on phage viability therefore may be dependent on the excipient used.  
 
Figure 6.3. Felix O1 encapsulated in 3 % (w/v) Eudragit and 2 % (w/v) trehalose at different 
temperatures, with subsequent release in SIF for 5 hours. No statistical difference was found between 
the mean of each temperature. No statistical difference was found between the means. 
Felix O1 was encapsulated with Eudragit S100 and trehalose to combine the benefits of both 
excipients, one being the pH responsive behaviour of the polymer and second the potential to protect 
phage from thermal stress and desiccation provided by trehalose. Taking forward the formulation 
from previous chapters, the viscosity of solutions containing between 5 % to 10 % (w/v) Eudragit was 
found to be too high for the peristaltic pump supplying the atomiser in the spray dryer. Therefore, the 
concentration of Eudragit was lowered to 3 % (w/v) (with a viscosity of 20 mPa) which was then mixed 
with 2 % (w/v) trehalose. The reason for using 2 % (w/v) trehalose as opposed to 4 % (w/v) as 
previously investigated Figure 6.2 was to prevent premature dissolution of particles in aqueous 
solutions. The concentration of trehalose had to be lower than Eudragit otherwise the higher solids 
fraction of the sugar excipient was found to dominate dissolution characteristics over the pH 
responsive effect of Eudragit, nullifying the encapsulation properties of the formulation.   
The phage viability after spray drying remained high with virtually no loss in phage titre (Figure 6.3). 
The amount of phage being encapsulated (added to polymer and sugar solution before spray drying) 
was 5 x 109 PFU/ml. Encapsulated phage was released in SIF for 3 hours, until complete dissolution of 
powder. Despite the change in temperature during spray drying, the phage was unaffected, showing 
a similar profile to when encapsulated with trehalose alone Figure 6.2. By incorporating lesser (1 % 
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w/v) amounts of trehalose it was possible to retain a high phage titre which otherwise was not possible 
if encapsulating phage in Eudragit alone (Figure 6.4). Encapsulated phage was also exposed to SGF, pH 
2 for 2 hours before releasing in SIF. However, only 2 x 107 PFU/gram viable phage was recovered after 
acid exposure. This may be explained by the concentration of trehalose which may have caused a 
premature loss of phage during SGF exposure. Trehalose was added to yield a high titre of phage 
during encapsulation, perhaps adding lesser amounts where up to 95 % of the microparticles are 
composed of Eudragit, trehalose can still exhibit its benefits. However, reducing trehalose 
concentration too much may result in a low glass transition temperature meaning that phage is not 
able to resist the effects of desiccation and high temperatures which can also affect storage stability.  
 
Figure 6.4. Release kinetics of encapsulated Felix O1 in 2 % (w/v) Eudragit S100 and 1 % (w/v) 
trehalose prepared using different spray drying temperatures. Time zero corresponds to 5 mins of 
microparticles release. *indicates the significance difference between the mean values for each 
parameter when compared within each time point (p < 0.05) (n = 3). 
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Figure 6.5. Release of Felix O1 from spray dried microparticles (2 % (w/v) Eudragit and 1 % (w/v) 
trehalose) after exposure to SGF (pH2) for 2 hours and subsequent release in SIF for 5 hours. * 
indicates significance means were compared across all temperatures (p < 0.05) using a 2-sample t-
test. All measurements were done in triplicate (n = 3). 
The concentration of trehalose was lowered to 1 % (w/v) due to the lack of phage protection from 
SGF. Unlike other solutions such as trehalose and alginate alone, 3 % (w/v) Eudragit was the limit in 
terms of how well the pump was able to function and how effective the nozzle deblocker was able to 
keep the spray nozzle unclogged. Therefore, the concentration of Eudragit was lowered to 2 % (w/v), 
still maintaining the trehalose concentration low at 50 % from 67 % previously. Once again phage was 
encapsulated at varying temperatures to investigate any effect of temperature on phage 
encapsulation.  
The initial titre of phage in the solution was 1 x109 PFU/gram. Figure 6.4 shows the phage release 
kinetics in SIF over a period of 3 hours for samples spray dried at each temperature. In all cases there 
was burst release of phage, unloading on average 50 % of encapsulated phage in the first hour and 
releasing the remainder of the phage thereafter. For all spray dried temperatures, the release profile 
was similar with slight differences in the measured phage titre. 10-20 % less phage was encapsulated 
and therefore released for phage encapsulated at an elevated inlet temperature 180°C (Figure 6.4). A 
significant difference was found after performing a 2-sample t-test (p < 0.05) comparing values for 
180°C to all the other inlet temperatures. Here, it may be possible to relate the effect of increased 
temperature on the concentration of viable phage encapsulated.  Encapsulated phage particles were 
further investigated by exposing them to SGF for 2 hours and subsequently releasing in SIF for 3 hours 
(Figure 6.5). Viable phages were recovered in all cases, with the best results noted for the inlet 
temperature 120°C with a phage titre of 8.5 x 108 PFU/gram indicating a 15 % overall phage reduction. 
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The remaining inlet temperatures presented phage titres around 2 x108 PFU/gram, showing just under 
a log reduction after SGF (pH 2) exposure.  
 
 
 
 
 
 
 
 
 
Figure 6.6 Release profile in SIF of 2 % (w/v) Eudragit, 1 % (w/v) trehalose, 0.5 % (w/v) alginate 
encapsulated phage Felix O1 under different spray drying temperatures in SIF for 6 hours. *indicates 
the significance difference between the mean values within each time point (p < 0.05) n=3.  
 
 
 
 
 
 
 
 
 
Figure 6.7. Release of Felix O1 from spray dried microparticles using formulation with 2 % (w/v) 
Eudragit, 1 % (w/v) trehalose, 0.5 % (w/) alginate prepared using different spray drying temperatures 
(release after a 2-hour SGF exposure with subsequent release in SIF for 6 hours). * indicates 
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significance means were compared across all temperatures (p < 0.05) using a 2-sample t-test. All 
measurements were done in triplicate (n = 3). 
Alginate was incorporated in previous chapters to improve acid protection in hydrogel dosage forms. 
In the case of spray drying, the effect of alginate in phage encapsulation was also investigated by 
incorporating 0.5 % (w/v) in the formulation. Due to the high viscosity of alginate solutions, only a 
small amount was added thereby allowing the spray dryer to pump the solution through the nozzle 
without blocking. Unlike the phage yield for spray dried alginate alone, higher phage titres were 
observed for phages encapsulated in formulations containing alginate in combination with trehalose 
and Eudragit (Figure 6.6). Encapsulated phage was released completely in SIF for 3 hours with full 
dissolution of particles. Titres of 2 x 108 PFU/ml were observed after complete release, somewhat 
lower than the formulation containing no alginate (Figure 6.5). No statistical difference in phage 
viability was observed across the varying inlet temperatures. All samples showed phage protection 
against pH 2 (Figure 6.7) after 2 h exposure to SGF followed by release in SIF. Less than 1-log reduction 
was observed for all samples in comparison to phage release at SIF alone Figure 6.7. Although the loss 
of phage during the spray drying process was higher in comparison to formulation without alginate, 
the overall acid protection was better. The loss of phage viability during the spray drying process can 
be explained by the low titres observed during phage encapsulation in each excipient alone where 
alginate and Eudragit show higher loss of phage Figure 6.2.  
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6.3.2 Characterisation of spray dried powder 
 
 
Figure 6.8 Percentage (%) moisture content of spray dried powders produced using four inlet 
temperatures with different excipients. * indicates significance difference between means which were 
compared across and within all temperatures (p < 0.05) using a 2-sample t-test. All measurements 
were done in triplicate (n = 3). 
For each excipient examined the moisture content was analysed at each temperature Figure 6.8. The 
amount of moisture in the sample impacts the properties of the powder as well storage stability. So, 
for each sample a representative amount of powder was weighed and left in an oven overnight to 
remove any residual water. Highest level of moisture was found with Eudragit alone reaching 26 % 
moisture content at inlet temp of 100°C. For all other excipients the moisture content of the spray 
dried samples was 15 % or below. The second excipient with the highest moisture content was for 
formulations containing alginate alone. Formulation with 2 % (w/v) trehalose with 3 % (w/v) Eudragit 
in comparison to 1 % (w/v) trehalose with 2 % (w/v) Eudragit displayed low moisture content, 
indicating the influence of trehalose in sequestering moisture with increasing concentration. The 
general trend across all formulations was that as the temperature decreases the level moisture 
increases Figure 6.8. Moisture content related to storage stability, higher moisture content equally 
lowering of the glass transition temperature. Low glass transition temperature powder recrystalizes 
at low storage temperatures which can destroy the encapsulated phage.  
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Figure 6.9. Percentage (%) yield (weight of solids collected in comparison to solid weight spray dried) 
of excipients used to produce spray dried powder. * indicates significant difference between the 
means which were compared across all formulations (p < 0.05) using a 2-sample t-test. All 
measurements were done in triplicate (n = 3). 
The yield of powders following spray drying was evaluated for every formulation.  The amount of 
powder produced was compared to the amount of solids dissolved in solution before spray drying. 
There were several challenges when the yield of excipients such as alginate and trehalose was low at 
20 to 30 % (Figure 6.9) which meant several runs were required to obtain enough material for analysis. 
This was due to the powder being carried away through the cyclone which was unable to remain in 
the collection bottle. Usually, the finer microparticles are not effectively trapped in the cyclone which 
causes a high loss of powder during production. The yield was highest for formulations containing 
Eudragit (Figure 6.9) with 3 % (w/v) Eudragit showing the highest yield at 50 %. Combining Eudragit, 
trehalose and alginate the yield decreased in comparison to Eudragit and trehalose. On average the 
yield remained higher for comibined excipients when compared to spray drying these excipients 
alone, indicating the influence of Eudragit overall remains high.  
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Figure 6.10. Coulter analysis on particles from spray dried 2 % (w/v) ES100 and 1 % (w/v) trehalose 
powder using different inlet temperatures a) differential volume distribution of particles b) cumulative 
volume distribution. 
The two-fluid nozzle diameter used for spray drying powders was 0.5 mm, the microparticles produced 
from this nozzle are affected by the formulation viscosity and the spray drying conditions 
(temperature). Therefore, the size of microparticles was analysed using the coulter size analyser for 2 
% ES100 and 1 % trehalose. Figure 6.10a shows the % differential volume distribution of all the inlet 
temperature according particle diameter. Multiple peaks demonstrate polydispersity of the 
microparticles which range from 1 to 100 µm. Marginal difference can be seen for each temperature 
with 180°C showing smaller particle size and 100°C showing the biggest particle diameter. This trend 
was further demonstrated in the % cumulative volume as shown in Figure 6.10b, where 50 % of the 
particle at inlet temperature 180°C were below 5 µm whereas for 100°C inlet temperature, 50 % of 
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particles are below 25 µm. For inlet temperatures 150°C and 120°C, 50 % of the particle are below 6 
µm and 7 µm respectively.  
The particles were also examined under the scanning electron microscope for morphological 
characterisation Figure 6.11. The particles were spherical in shape with a smooth outer surface, size 
range between a few microns to tens of microns. Panel one of Figure 6.11 shows the makeup of the 
powder from these small microparticles which were smooth in texture and the powder was flowable 
without course aggregated particles.  
  
Figure 6.11. SEM of spray dried 2 % (w/v) ES100 and 1 % (w/v) trehalose powder at inlet 
temperature 150°C. 
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6.3.3. Storage of phage encapsulated spray dried powder 
 
 
 
 
 
 
 
 
 
Figure 6.12. Storage results of 4 % (w/v) trehalose spray dried powder encapsulated Felix O1 under 
4°C and 23°C (RT). * indicates significance mean was compared to 0 month for all parameters tested 
(p < 0.05) using a 2-sample t-test. All measurements were done in triplicate (n = 3). 
 
 
 
 
 
 
 
 
 
Figure 6.13. Storage results of 3 % (w/v) Eudragit spray dried powder encapsulated Felix O1 under 4°C 
and 23°C. * indicates significance mean was compared to 0 month for all parameters tested (p < 0.05) 
using a 2-sample t-test. All measurements were done in triplicate (n = 3). 
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Figure 6.14. Storage results of 2 % (w/v) Eudragit, 1 % (w/v) trehalose spray dried powder 
encapsulated Felix O1 under 4°C and 23°C. * indicates significance mean was compared to 0 month 
for all parameters tested (p < 0.05) using a 2-sample t-test. All measurements were done in triplicate 
(n = 3). 
 
 
 
 
 
 
 
 
 
 
Figure 6.15. Storage results of 2 % (w/v) Eudragit, 1 % (w/v) trehalose 0.5 % (w/v) alginate spray dried 
powder encapsulated Felix O1 under 4°C and 23°C. * indicates significance mean was compared to 0 
month for all parameters tested (p < 0.05) using a 2-sample t-test. All measurements were done in 
triplicate (n = 3). 
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Spray dried phage in all excipients were stored at room temperature (23°C) in sealed tubes and in the 
fridge at 4°C for a period of 3 months. A sample was removed from each tube and tested for phage up 
to a period of 3 months (Figure 6.12-15). Trehalose encapsulated phage showed good stability over 
the storage period, with minimal drop in titre at 4°C for all samples (Figure 6.12). Samples stored at 
room temperature showed just under a log decrease in the phage titre. Similarly, phage encapsulated 
in 3 % (w/v) Eudragit showed good stability after 3 months storage with little to no phage reduction 
in all storage conditions Figure 6.13. The formulation containing trehalose and Eudragit, Figure 6.14 
displayed good stability over 3 months. No change in phage titre was detected for the first month and 
this remained the same for 4°C at 3 months however the titre of phage dropped by a log for all samples 
at RT.  For the formulation containing all three excipients together (trehalose, Eudragit and alginate) 
Figure 6.15 phage titre was affected the most in terms of viability. The phage titre dropped by a log at 
4°C after 3 months and up to 2-logs at 23°C after 3 months. The Tg may be the reason for this, 
crystallization of trehalose under humid condition can affect phage viability.  
 
6.3.4 Tableting spray dried phage 
 
 
 
 
 
 
 
 
 
Figure 6.16. Image of tablets produced using Minipress tableting machine. 
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Figure 6.17. Encapsulated Felix O1 release in SIF for 5 hours from powder and tablet form using two 
different concentrations of excipients. * indicates significance mean was compared to tablet and 
powder in SIF for all parameters tested (p < 0.05) using a 2-sample t-test. All measurements were done 
in triplicate (n = 3). 
Spray dried phage containing powders were compressed into solid round tablets which can be blister 
packed for ease of use and transfer Figure 6.16. The formulation used throughout this piece of work 
was the combination of 1 % (w/v) trehalose and 2 % (w/v) Eudragit. This formulation gave the best 
overall results in terms of encapsulation, yield of powder and acid protection and storage. In addition 
to this, 4 % (w/v) trehalose and 2 % (w/v) Eudragit was also tableted and tested- with the intention 
that tableting compression may halt premature dissolution of the tablet and offer protection against 
SGF. Increasing trehalose concentration also meant long-term storage maybe improved.  
The inlet temperature used for further experiments was 150°C which was due to minor differences in 
encapsulation efficiency at all temperatures. 180°C showed modest adverse effect of temperature on 
phage viability therefore the next lower temperature (150°C) was carried forward. Industrial scale 
spray dryers operate at much higher temperatures, therefore the higher the temperature the easier 
feasibility of future to scale up of the operating at 150°C proven, hence temperatures 100°C and 120°C 
were not used as they were statistically no different.  
As mentioned in section 6.2 (material and methods) tablets were produced using a small scale 
Minipress® machine and subsequent analysis was carried out using pharmaceutical grade equipment 
for disintegration, friability and dissolution (appendix). The spray dried powder was loaded into the 
tableting machine and tablets weighing at 0.3 g ± 0.5 were produced. The variation in tablet weight 
was due to a low bulk density of the spray dried powder largely attributed to Eudragit. A total of 6 
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tablets were exposed to SGF in the disintegration apparatus for 3 hours, following which each tablet 
was collected and dried, the weight of the tablet was measured before and after to account for any 
erosion during disintegration. 6 representative tablets were not exposed to SGF and were directly 
dissolved in SIF (Figure 6.17).  
Along with the tablets the powder used to produce the tablets was tested in the same way (2-hour 
acid exposure under agitation conditions at 37°C and directly in SIF). The results for both powder and 
tableted phage are shown in Figure 6.17. Where there was release of phage in SIF without SGF 
exposure the phage from powder and tablets show no statistical difference and the titre was high at 
109 PFU/gram. SGF exposure (pH 2) for 2 hours with subsequent SIF exposure showed protection in 
both formulations for both powder and tablet form. In the case of powder, the formulation containing 
4 % (w/v) trehalose showed significant lost in phage viability. For both formulations, phage exposure 
to SGF and release thereafter from tablets showed similar protection with just over a log loss in titre- 
higher than in the powder form. A significant difference was observed in phage loss after SGF exposure 
in powder form for in comparison to tablet form.  
Figure 6.18. Powder release profile of 2 % (w/v) Eudragit 1 % (w/v) trehalose encapsulated phage Felix 
O1 using 150°C inlet temperature for spray drying with and without the addition of magnesium 
stearate, after 2 hours SGF exposure and subsequent release in SIF over 3 hours. *indicates a 
significance difference between the mean of each parameter in comparison to 0 % MgSt within each 
time point (p < 0.05) n=3. 
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Figure 6.19. Tablet release profile of 2 % (w/v) Eudragit 1 % (w/v) trehalose encapsulated phage Felix 
O1 using 150°C inlet temperature for spray drying, with and without the addition of magnesium 
stearate, after 2 hours SGF exposure and subsequent release in SIF over 3 hours. *indicates a 
significance difference between the mean of each parameter in comparison to the mean of every 
other parameter within a timepoint (p < 0.05) n=3. 
Tablets and powder were analysed with different concentration of magnesium stearate and exposed 
to SGF (pH 2) for 2 hours before release in SIF Figure 6.18 and 6.19. The titre of phage in the 
microparticles was 5 x109 PFU/gram (without SGF exposure). Release was followed for 3 hours for all 
samples, the release profile in all cases showed similar kinetics. A common trend was observed with 
an initial burst release of phage, up to 50 % phage released within minutes of SIF exposure. For all 
samples, the majority of the phage were released within the first hour. No influence of magnesium 
stearate concentration on phage yield was observed.  
Release profiles of the powders at different concentrations Figure 6.18 show a gradual release of 
phage. Sample without magnesium stearate showed the highest loss in phage titre (1-log) after SGF 
exposure in comparison to the other samples. All the other samples containing various amounts of 
magnesium stearate showed similar release kinetics and protection against low pH. There was a 
notable improvement in phage titre with magnesium stearate, with losses of less than a log with final 
titre of the phage at 6 x 108 PFU/gram. For both the powder and tablet form, a further improvement 
on acid protection was seen after 2-hour SGF exposure and subsequent release. 
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Tableted phage displayed a low initial release at t=0 with a maximum of 20 % phage being unloaded. 
Prolonged release of phage over the 3 hours was observed for all parameters. Sample with no 
magnesium stearate yielded 7 x 108 PFU/gram phage, showing the most loss in phage viability after 
SGF exposure. For samples, with 1 %, 1.5 % and 2 % magnesium stearate, approximately 109 PFU/gram 
was released at the end of the 3 hours. Specifically, 1 % magnesium stearate sample release 9 x 109 
PFU/gram which was the highest titre of phage released at the end of 3 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.20. Tablet storage results with varying concentrations of magnesium stearate under a) 4°C b) 
30°C, 65 % RH for 6 weeks. * indicates significance mean was compared to 0 month for all parameters 
tested (p < 0.05) using a 2-sample t-test. All measurements were done in triplicate (n = 3). 
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Encapsulation of phages in tablet form was further examined in terms of achieving viable phages after 
storage at two different conditions. Tablets were kept in glass vials with the lid finger-tight in the fridge 
at 4°C and at 30°C with RH of 65 %. At regular intervals of 1, 4 and 6 weeks a tablet was removed from 
each condition and exposed to SGF for 2 hours before releasing the phage in SIF. The results after 
complete release of phage are shown in Figure 6.20a and b. Approximately 1-log loss was seen for 
samples stored at 4°C throughout the 6-week storage, this remained the same for every sample 
containing a different amount of magnesium stearate. Phages were unaffected by the formulation 
parameters as noted in previous chapters. Phage stocks were also stored at 4°C and were stable for 
up to a year. A similar effect can be seen for tablets stored at 4°C since no phage loss was observed.  
In contrast to the results for 4°C storage, samples stored at 30°C with 65 % RH, Figure 6.20b showed 
loss in phage titre over a period of 6 weeks.  After just 1-week storage, with a 2-hour exposure to SGF, 
phage titre decreased by just under 2-logs. For the weeks following, a further 2 to 3-log reduction in 
phage titre was observed giving final titres around 1 x 105 - 1 x 106 PFU/gram.  
 
 
 
 
 
 
 
 
 
  
Figure 6.21. Friability of tablets produced with the addition of different magnesium stearate 
concentrations over 100 drum rotations. *indicates a significance difference between each parameter 
in comparison to the mean of every other parameter (p < 0.05) n=3. 
Tablets were tested for robustness using a friability tester to test its compliance to British 
Pharmacopeia (BP) standards, 100 drum rotations were carried out and tablet weight recorded after 
every 20 rotations to observe loss of tablet weight. The results are shown in Figure 6.21, by 20 
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rotations 60 % tablet weight was lost for 1 % magnesium stearate compared with 10 % loss for 1.5 and 
2 % magnesium stearate. By 100 rotations, 80 % of tablet weight was lost for 1 % magnesium stearate 
and 50 % and 22 % for 1.5 % and 2 % magnesium stearate respectively.  
 
Figure 6.22. DSC thermograph of Eudragit and trehalose powder before spray drying. 
Figure 6.23. DSC thermograph of Eudragit and Trehalose after spray drying at 200°C (trehalose) and 
150°C (Eudragit) inlet temperature. 
Glass transition temperature was measured for Trehalose and Eudragit in the form supplied by the 
manufacturer (powder taken directly from the bottle). Figure 6.22 shows the DSC analysis for both 
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excipients, with glass transition of 55°C and 66°C respectively. Trehalose is manufactured in dihydrate 
form which indicates crystallisation is likely due to the presence of water molecules. However, since a 
glass transition temperature was recorded, this indicated that trehalose was partially crystalline. A 
study by Vandenheuvel et al., (2014) also showed the presence of Bragg peaks demonstrating the 
presence of crystallinity typically found in dihydrate trehalose. A substantial exothermic peak was 
observed from 100°C to 120°C for trehalose where heat was released to the surroundings, 
demonstrating crystallisation. A smaller peak was also observed at 68°C which may be due to 
evaporation of residual moisture. Once trehalose was spray dried, the thermograph revealed a lower 
heat capacity of the initially observed peak from 2.2 to 0.3 W/g, showing a shift in the glass transition 
of trehalose Figure 6.23. In amorphous state, trehalose is known to exhibits a higher glass transition 
temperature. 
DSC for Eudragit did not display a glass tranistion temperature but rather a wide peak spanning from 
30°C to 120°C (Figure 6.22), although the reason for this is unclear but evaporation of residual 
moisture may be a reason. After spray drying Eudragit no significant difference was observed (Figure 
6.23) in the thermograph, implying that since the state of Eudragit remains unchanged, it is 
manufactured in its amorphous form. According to the manufacturer the glass transition temperature 
of Eudragit S100 is 130 ± 5°C. The thermal profile of each excipient was not studied beyond 120°C due 
to irrelevance on storage stability of the powder.  
 
6.4 Discussion 
 
This study has investigated the encapsulation of phage Felix O1 using the method of spray drying. 
Encapsulation was carried out in different excipients or bulking agents to obtain the optimal 
formulation for this technique. Effect of each excipient on phage titre was investigated along with the 
effect of temperature. Formulation which gave SGF protection and contained stable phage after 
storage was carried forward for further work. Optimised conditions uncovered from investigating the 
phage encapsulation efficiency in the powdered form were used for tableting. Tableting required the 
solid dosage form to be robust enough to survive disintegration for 2 hours at SGF with subsequent 
dissolution. A binder was added to the tablets post spray drying of phage and the effect of binder 
concentration was tested. Binder was added post spray drying due to the hydrophobic nature of 
mageniusm stearate which does not dissolve in water. Further to this, the stability of the powder and 
tablet was examined for storage under different conditions. It will be discussed in this section the 
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findings from the study and the possible reasons why one formulation worked better than others and 
if spray drying and tableting is a viable way of phage encapsulation.  
6.4.1 Phage encapsulation using different excipients and experimental parameters 
 
Phage Felix O1 was used as a model phage for encapsulation using the method of spray drying which 
has been previously studied (Yongsheng Ma et al., 2008; Tang et al., 2013). Based on the findings from 
previous chapters, Eudragit and alginate have proven to contribute towards a stable encapsulation of 
phage using other advanced encapsulation techniques. Spray drying is a well characterised technique; 
therefore, the formulation was implemented to elucidate the role of each excipient under different 
encapsulation conditions. Non-encapsulated Felix O1 was subjected to different temperatures 
representative of the outlet spray drying temperatures. Felix O1 showed resilience to temperature 
below 50°C however as the temperature rose to 60°C the phage titre began to drop after 60 minute 
exposure, correlating with the findings by Jończyk et al., (2011). The ability of phage to survive 
elevated temperatures is a pre-requisite for high encapsulation efficiency during encapsulation via 
spray drying.  
With the aid of trehalose as the preservative Felix O1 was found to be stable under both high and low 
temperatures as otherwise with outlet temperatures ranging between 80°C to 90°C, phage cannot 
survive the thermal stress which was found to be the case with free phage. Eudragit and alginate 
alone, did not provide sufficient protection from both high and low temperatures as several log 
reductions in the phage titre was observed. Despite the phage being resilient to temperatures up to 
60°C, the added desiccation stress also has an impact. Unlike trehalose, Eudragit and alginate have 
different chemical properties- amorphous trehalose can interact with the phage by replacing the 
hydrogen bonds lost due to thermal stress and dehydration. Vitrifying phages in glass during 
dehydration prevents structural and conformation changes which can render them inactive (Chang et 
al., 2017b).  
No phage was detectable after SGF (pH 2 for 2 hours) exposure for 3 % (w/v) Eudragit and 2 % (w/v) 
trehalose microparticles. Trehalose is water soluble and therefore upon exposure to aqueous 
solutions it readily dissolves creating pores in the composite spray dried microparticles. Phage release 
in SIF occurs without a drop in titre however when microparticles were exposed to SGF no phage were 
recovered. This was due to premature phage release and the penetration of SGF into the 
microparticles leading to loss in phage activity as found during free phage exposure to low pH. Hence, 
reconsidering the concentration of trehalose was an important step by lowering the concentration of 
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trehalsoe to 1 % (w/v) led to phage protection during acid exposure, further improvement to acid 
exposure was observed by addition of 0.5 % alginate.  
Protection against SGF (pH 2) was observed with formulation, 2 % (w/v) Eudragit and 1 % (w/v) 
trehalose with approximately 1-log titre reduction after two-hour exposure. Addition of 0.5 % (w/v) 
alginate also showed SGF protection across all samples with less than 1-log reduction in phage titre. 
Standford et al., (2010) encapsulated four E. coli specific phages in Eudragit (unspecified 
concentration) using spray drying, after 30 min pH 3 exposure 2.71 x 109 PFU/gram (13.6 %) of phages 
were recovered when compared to results from this study, 2-hour pH 2 exposure resulted in less than 
1-log reduction (90 % recovery). An Initial 1-log reduction in phage titre occured during spray drying 
(Stanford et al., 2010) however only 10 % phage loss was observed when spray drying Felix O1 with 
Eudragit and trehalose. This suggests that by incorporating trehalose, protection against elevated 
outlet temperatures encountered during spray drying can be achieved preventing loss of phage 
viability. Incorporation of alginate showed better acid protection but loss of phage titre during spray 
drying meant no further work was done alginate. Formulation containing Eudragit and trehalose only 
were carried forward for further work. 
Moisture content of the spray dried powder influences the stability of the phage during storage. 
Excipients such as trehalose are well known for their ability to sequester moisture, although this 
results in a lowering of the glass transition temperature. This prevents moisture causing 
conformational and activity changes of the active encapsulated agent. Spray dried Eudragit powders 
were found to have a high moisture content (~25 %), when spray dried with trehalose the moisture 
content was lowered significantly. In terms of stability during storage low moisture prevents 
crystalizing of trehalose which may affect phage viability. Crystallisation of trehalose may change the 
flowability of the powder, bonds are formed between the microparticles preventing them from 
dispersing easily (Chang et al., 2017a). Low moisture content was seen with higher spray drying 
temperatures for all formulations as the driving force for drying air was higher.  
Powder yield was significantly affected by the type of excipient, Eudragit showed the highest yield 
similar to results obtained by de Arce Velasquez et al., (2014) when compared to alginate and 
trehalose alone. When combined with Eudragit the yield was significantly increased, for blends with 
trehalose and alginate. Laser diffraction analysis revealed that microparticles they ranged between 1 
to 20 µm. Lower temperatures 100°C and 120°C displaying some bigger particles too, between 20 µm 
to 100 µm. It is generally recommended to produce particles below 200 µm for oral consumption to 
mask the granular powder. Particles showed a smooth non-porous surface composed of Eudragit and 
trehalose under the SEM, typical of Eudragit particles. Low spray drying temperatures (i.e. 60°C) may 
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sometimes produce fractured and inflated microparticles, which was not observed in this study. SEM 
imaging revealed that all formulations produced spherical microparticles ranging from a few to tens 
of microns. The concentration of both polymer and sugar was low and despite this particle morphology 
did not display any cracking or blowholes. Particle merging due to a high concentration of amorphous 
excipients can also be an issue as observed by Leung et al., (2017) with trehalose concentrations of 40 
%, however this was not observed in this study. 
Storage in the presence of trehalose showed that the phage titre dropped the least in comparison to 
Eudragit and alginate. The presence of trehalose reduced the negative effect of storage temperature 
and humidity from affecting the phage viability. Around 1-log reduction in phage titre was observed 
by Stanford et al., (2010) after 1 year storage of Eudragit microparticles at 20°C. In this study, a lower 
encapsulation efficiency of phage Felix O1 was observed however, storage results showed a similar 
trend in that negligible effect on phage titre was observed over 3 months. With the addition of 
trehalose, phage titre was preserved better as reported by Leung et al., (2017), only ~ 1.4 log titre 
drop was observed as opposed to 5.1 log without any trehalose. Similar report with Felix O1 was 
observed in that less than a log titre reduction was seen after 3 months storage at 4°C. Storage at 22°C 
showed the most reduction in phage titres across all samples, highlighting the onset of temperature 
and humidity fluctuations when stored at room temperature. Recrystallisation of trehalose during 
storage affected the phage survivability resulting in several logs drop in titre across all samples. 
 
6.4.2 Direct compression tableting of spray dried phage 
 
Tableting reduces the frequency of dosage by effectively increasing the localization of the active 
ingredient at the site of infection due to their bound conformation which ameliorates the chance of 
the active encapsulated agents being inactivated during transit. Incorporating, functionalised pH 
responsive microparticles carrying phage into tablet systems enhances their efficacy by being 
delivered at high titres. There are several advantages of using direct compression tableting since many 
processes are by-passed to avoid affecting the encapsulated phage. This study has combined the 
benefits of different excipients to produce powdered encapsulated phage for ease of use. 
The first half of the study focused on producing powder with stable phage in excipients which provide 
both acid protection and sustain phage titre during storage. Tableting this powder via direct 
compression demonstrated the ease of use and possible scale up for producing oral dosage forms of 
phages. Enteric coating is usually used to coat tablets to protect active ingredients from disintegrating 
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in the stomach (Waddell et al., 2013) and this may involve processing steps which introduce changes 
in temperature and expose the active ingredient to further shear. The formulation investigated here 
requires no further coating since the enteric element was incorporated during the spray drying 
process. The phages were shown to remain viable with each excipient and during the spray drying 
process, further investigation highlighted the powder prevents acid damage.  
The effect of compression during tableting on phage viability was examined by taking six tablets for 
each formulation and analysing the phage titre with and without SGF exposure. Tablets as well as 
powder were analysed to compare the effect of tableting on phage survivability under SGF and SIF. 
The results revealed that there was no detrimental effect on phage during tableting since the titre 
showed no significant difference to powder. Similarly, exposure to SGF did not show any negative 
effect on phage viability and the results once again were comparable to powder. In fact, previously it 
was observed the use of high concentration of trehalose (2 %) resulted in 2-log titre drop after acid 
exposure, here equivalent results were obtained with 4 % trehalose. However, some improvement 
was observed with tableting with approximately a log reduction in phage titre after acid exposure. 
This may be explained by the structure of the tablet where only the outer layer was exposed to SGF- 
in the case of powder the surface area was much larger and all microparticles encounter SGF. 
Pharmaceutical grade dissolution apparatus was used for SGF exposure, tablets were exposed for a 
period of two hours. During this time, erosion and disintegration of tablets was observed since 
trehalose is water soluble. To improve the tablet integrity during disintegration, magnesium stearate 
was added to the spray dried powder before tableting. Magnesium stearate is used in tableting to act 
as a lubricant or an anti-adherent to prevent powders sticking to machinery during the manufacturing 
process. The hydrophobic nature of magnesium stearate contributes to slow dissolution of tablet in 
the dissolution apparatus (Ariyasu et al., 2016). It has low toxicity and is approved by the FDA in the 
list of pharmaceutical ingredients. Concentration of lubricants added needs to be carefully considered 
since too much lubricant can result in a laxative effect reducing residence times, preventing effective 
dissolution of the tablet at the desired site. Incorporating various concentrations of magnesium 
stearate to powder before tableting was to observe the effect on dissolution, tablet disintegration, 
effect on phage viability and friability. Higher concentrations of magnesium stearate showed 
improved tablet integrity with no effect on phage viability. 
Phage release kinetics were examined for both powder and tablets with and without magnesium 
stearate after SGF exposure. Improvement in phage viability in the presence of magnesium stearate 
was observed for both powder and tablets, although this was more apparent in the case of powder 
with approximately 50 % less phage release from sample without magnesium stearate. The 
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hydrophobic nature of magnesium stearate shields microparticles and protects them from acid. A 
difference between powder and tablets also showed improved phage survival in the tablet form with 
approximately 70 % more phage release at the end of the 3-hour dissolution period for tablets (2.4 x 
109 PFU/gram) in comparison to powder (6 x108 PFU/gram). Differences between samples with varying 
magnesium stearate concentration were less obvious, all samples showed similar release profiles 
achieving titres of 109 PFU/ gram for tablets.  
Relative to the initial titre of phage in the microparticles, 0.3-log titre reduction was observed for 
tableted form (1.5 % Mg-St) and 0.9-log for powder form (1 % Mg-St) when exposed to SGF (pH 2 for 
2 hours). A 13 % loss in phage titre was observed by Stanford et al., (2010) after Eudragit spray dried 
phage was exposed to pH 3 for 30 min, showing a significant improvement in phage protection against 
low pH. Phage encapsulated powders have been prepared for pulmonary applications without the use 
of functionalised polymer for oral delivery (S. S. Y. Leung et al., 2017; Matinkhoo et al., 2011; 
Vandenheuvel et al., 2013a). However, other encapsulation techniques have been used for phage 
encapsulation for oral delivery by incorporating biopolymers such as alginate, whey protein and 
chitosan (Colom et al., 2017b; C Dini et al., 2012; Yongsheng Ma et al., 2012; Tang et al., 2013; 
Yongsheng et al., 2008).  
Tang et al., (2014) encapsulated phage K in alginate and whey protein microsphere with additional 
protective agents to improve phage stability during thermal stress. Wet microspheres showed good 
phage viability after exposure to pH 2.5 for two hours without titre reduction for all formulations. 
Exposure to pH 2 however, showed phage viability was reduced across formulations, highest 
concentration of whey protein showing the least titre reduction. Phage viability for dried microspheres 
was improved which included maltose upon exposure to pH 2.5 only. The study demonstrated like the 
one investigated here the use of polymers with protective agents in combating the harsh 
gastrointestinal conditions found in the stomach. Improving the phage viability during acid exposure 
is a crucial factor when considering formulations for oral delivery.  
Tablets were stored at two different temperatures (25°C and 4°C). The phage viability showed 
significant reduction for samples stored at 25°C. No reduction in phage titre was observed for tablets 
stored at 4°C across all samples over a period of 6 weeks. On the other hand, phage titre dropped by 
a log every week for the first 4 weeks losing up to 4-logs by the end of 6 weeks for samples stored at 
25°C with 65 % RH. This reduction may be attributed largely to the high relative humidity (65 %) during 
storage. Temperature has previously shown not to influence phage since free phage stayed viable at 
temperatures up to 50°C. The high humidity during storage was a key factor since conditions during 
transit as well as delivery to low-income countries without refrigeration facilities may be required. 
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Hence, testing the formulation in extreme conditions to probe the ability of the formulation in 
protecting phage was insightful.  
The role of trehalose in protecting phage from desiccation and thermal stress is widely known, 
however during high humidity conditions, trehalose can crystallize which can be detrimental for the 
phages inside the polymer matrix (Vandenheuvel et al., 2013a). Post spray drying, trehalose was in its 
amorphous state meaning the glass transition temperature was high. Upon storage under humid 
conditions trehalose sequesters moisture, inevitably crystallises which lowers the glass transition 
temperature. Phages are protected from these adverse conditions by the presence of trehalose, 
however once trehalose fully crystallises phage are prone to environmental stresses and damage. This 
was shown by storage data, demonstrating in the presence of high humidity and temperature the 
phage titre falls significantly. One factor which is important to consider is the optimum concentration 
of trehalose to avert the effect of temperature, humidity and desiccation. Studies about freeze drying 
with sugars have recommended concentrations of 20 % (w/w) for good freeze-drying results. At this 
concentration the water activity is 0.987 which does not produce osmotic stress in the freeze-drying 
process. Another study presented good bacterial cell protection, prolonged shelf life and stability after 
spray drying L. acidophilus in 20 % (w/v) of excipient (Pehkonen et al., 2008; R. Zhao et al., 2008).  
 
6.5 Conclusions 
 
This study demonstratesd the use of conventional spray dryer method for spray drying phage Felix O1 
in pH responsive polymer Eudragit in combination with trehalose. Spray dried powder showed 
approximate average diameter of microparticles was 7 µm across all inlet temperatures. Encapsulated 
phage was sufficiently protected from SGF (pH 2 for 2 hours) with 0.5-log reduction in phage titre. 
Spray dried phage was then tableted where no effect of compression force was observed on phage 
viability. SGF (pH 2 for 2 hours) exposure showed once again less than 0.5-log reduction in phage titre. 
Addition of magnesium stearate improved tablet disintegration and friability. Release profile in SIF 
with magnesium stearate showed a prolonged phage release over a period of 3 hours. Phage storage 
at 4°C remained stable without loss in titre however at higher temperature and humidity the phage 
significantly dropped in titre. This study demonstrates the use of dry powder phage with pH responsive 
characteristics for enteric delivery. For ease of dosage and use, the study demonstrated that tableting 
is a feasible method. 
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Chapter 7: Electrospinning bacteriophage K in Eudragit composite fibres.  
Abstract 
 
The prevalence of multi-drug resistant (MDR) bacterial species, as seen in methicillin-resistant 
Staphylococcus aureus (MRSA) pose a serious healthcare challenge in wound infections making 
antibiotic-based treatment limited. Application of bacteriophages for the treatment of wound 
infections shows promise and is a viable alternative to the use of antibiotics. In this study, two 
emulsion formulations were prepared for the encapsulation of phage K in core-shell fibres using 
water-in-oil emulsion electrospinning. Biocompatible, pH-responsive Eudragit S100 (ES100) was used 
as the organic phase (forming 99% bulk of the fibre shell), and poly (vinyl alcohol) (PVA) or sodium 
alginate as the aqueous phase (carrying the phage). Defect-free, continuous fibres with large 
diameters were fabricated and their morphology was optimised to facilitate the encapsulation of 
phage K, serving as a proof-of-concept study for novel wound dressing applications. SEM analysis 
revealed that for both emulsions, fibre diameters and diameter distributions were influenced by 
changes to the applied voltage. Infusion rate only influenced the mean fibre diameter. Optimal 
electrospinning conditions for both emulsions were found to be at 15 kV and 1 ml h-1. Increasing the 
concentration of either the organic phase or aqueous phase, which subsequently increased the 
viscosity and conductivity of the emulsions, had the most influence on fibre diameters. Phages were 
successfully encapsulated by suspending them in the aqueous phase of ES100-PVA fibres fabricated 
at different parameters. Phage plaque assay revealed that fibres with larger diameters and fabricated 
at lower applied voltages (10 and 12.5 kV) offered the best phage viability, as only a two-log reduction 
in phage viability was observed. Increasing the concentration of ES100 from 7 % (w/v) to 15 % (w/v) 
resulted in a three-log reduction in phage viability. Increasing ES100 concentration demonstrated 
enhanced viability compared to fibres fabricated at 15 kV applied voltage but with a lower ES100 
concentration. 
7.1 Introduction 
 
7.1.1 Wound infections 
 
199 
 
Human pathogenic bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa pose a 
serious healthcare challenge in wound infections. With the emergence of antibiotic resistance as seen 
in methicillin-resistant S. aureus (MRSA), treatment options are limited (Kelly et al., 2016). Phage 
therapy offers a promising alternative in combating antibiotic resistance against pathogens which 
have already evolved resistance. Phages are protein shells, which package genetic information, they 
are prone to environmental stresses which can damage their structural characteristics rendering them 
inactive. When considering the use of phages against infectious bacteria whether that be for enteric, 
pulmonary or wound infections it is important to consider the dosage. Phages are prone to damage 
when kept under conditions outside their optimal environment, this can be in the form of thermal 
stress as discussed in the previous chapter 6, solvents, desiccation, humidity and low pH (Malik et al., 
2017). It is therefore important to address these factors during the application of phages for therapy. 
Use of phages to combat bacterial contamination of food products has been well investigated and 
approved for use which can be used as a basis to study phage therapy for wounds. Commercially 
available products for such applications include EcoShield™ and SalmoFresh™ (Intralytics Ltd.). They 
are delivered and applied in liquid format and often require transportation under refrigeration which 
can be costly and may be detrimental to the stability of the phages. Maintaining phage viability whilst 
reducing operations/transportation cost requires alternative ways of delivering and applying phage.  
Dry phage products offer several advantages in addressing this issue, since the costs related to volume, 
shipment and storage conditions can be eradicated (Koo et al., 2016). To produce dry carrier of phage 
with high infectivity, lypholization is often considered a viable option (Puapermpoonsiri et al., 2009). 
It is an excellent way to preserve phage at high titres for extended periods of time, but the method 
remains costly and time consuming. Therefore, electrospinning phages in fibres has the potential to 
both reduce bacterial load in food packaging materials as well as treat infected wounds. 
Global healthcare issue of wound treatment is a growing concern, acute and chronic wounds prone to 
infection have delayed healing due to ineffective treatment. Sizable portion of wound infections are 
related to diabetic ulcers which comprise 600,000 hospitalisations related specifically to diabetic foot 
ulcers (Sen et al., 2009). Commercially available wound dressings cater for various conditions, basic 
dressings usually protect from external biological contaminants and absorb exudates from the wound. 
Advanced dressings allow for air circulation, provide moisture to prevent dehydration whilst 
incorporating an anti-microbial agent to heal the wound (Mele, 2016). 
7.1.2 Electrospinning fibres for wound dressings 
 
Electrospinning is a growing technology which produces polymer nanofibers which can be 
biodegradable, biocompatible and have a high surface-to-volume ratio (A. Haider et al., 2015). Ideally, 
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fabricated nanofibers should be uniform, continuous and bead-free; a phenomenon achieved when 
the experimental conditions are set to accommodate the production of ideal fibres for a specific 
polymer system. These conditions are classified as the electrospinning, solution and environmental 
parameters (A. Haider et al., 2015), as summarised in Table 7.1. 
 Table 7.1 Process conditions influencing the fabrication of electrospun nanofibers (Haider et al., 
2015) 
 
Electrospun fibres have a large surface area to volume ratio which is why they form good delivery 
systems for surface applications (Reza Korehei & Kadla, 2014). Furthermore, they have been used for 
a range of applications including wound dressings (Zahedi et al., 2010) and drug delivery systems (Sill 
& von Recum, 2008). Encapsulation of phages in electrospun fibres offers dimensional stability, 
improves storage and allows release of phage near the infected wound and host. Spraying phage 
directly onto the surface of the wound does not ensure targeted dose delivery, amount of phage 
delivered also depends on the spray technique and the distance from which it is sprayed. Reproducible 
application therefore is difficult, by ensuring phages entrapped in wound dressings and covering the 
infected area, one can ensure the prolonged and sustained release of phage. There is a higher chance 
of targeting the host bacteria if release is continuous and diffusion related, otherwise sprayed phage 
is prone to dehydration and therefore inactivation if host is not encountered. 
Previous studies have investigated the encapsulation of phages in electrospun fibres using water 
soluble polymers, which show burst release of phage. M13 was encapsulated in polyvinyl pyrrolidone 
(PVP) by Lee & Belcher (2004) into nanofibers which showed instant release when suspended in 
buffer. Other phages encapsulated in water soluble PVA include T4, T7 and lambda (Salalha et al., 
2006) which were electrospun into nanofibers and maintained a high viability. These studies 
Electrospinning parameters Solution parameters Environmental parameters 
Applied electric field Solvent Relative humidity 
Distance between spinneret and 
collector plate 
Polymer concentration Temperature 
Infusion rate Viscosity  
Spinneret diameter Conductivity  
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demonstrate that encapsulating phages using electrospinning is a viable option for producing wound 
dressing with tailored released properties.   
A drawback of encapsulation via electrospinning is that the phages would be exposed to high electric 
voltage which could be detrimental to the phages and therefore make it difficult to encapsulate phage 
at higher titres (Dai et al., 2014; Drees et al., 2003). Low concentration of viable phages in electrospun 
fibres may delay efficacy of phage therapy for wounds since the incidence of phage encountering host 
may lessen and the efficiency with which bacteria can be lysed be decreased. To minimise the loss of 
phage viability during the electrospinning process, magnesium salt has shown to be an effective 
additive, similarly trehalose has been shown to improve storage stability in fibres (Dai et al., 2014; Koo 
et al., 2016). Other methods to improve survival of phages during electrospinning is to change the 
geometry of the nozzle to produce core-shell nanofibers. Co-axial electrospinning produces fibres 
ensuring the inner phase has minimal exposure to current and effects of dehydration (Reza Korehei & 
Kadla, 2014). Table 7.2 provides a summary of published research on phage encapsulation using 
electrospun nanofibers.  
7.1.3 Formulating for electrospinning phages 
 
So far, electrospinning for phage encapsulation has involved the use of salts, sugars, water soluble 
polymers and for application in food packaging polymers dissolved in solvents. Little consideration has 
been given to the use of stimuli responsive polymers in encapsulating phages. Encapsulation of other 
active agents has been well documented with the use of polymers for therapeutic applications (Mele, 
2016). Fibrous wound scaffolds produced from natural polymers via electrospinning can aid wound 
healing through their natural anti-microbial properties. Utilisation of natural material for creating 
scaffolds ensures that they are biocompatible, biodegradable and are sometimes naturally anti-
bacterial or anti-inflammatory. Extracellular matrix is a complex network of proteins and cells which 
helps maintain the natural processes of the skin. Healthy skin has an acidic pH ranging between pH 4-
6; when the skin is damaged this environment changes to alkaline above pH 7 (Dargaville et al., 2013; 
Ehlers et al., 2001). This is also the reason why some wounds become infected and prolong the healing 
process. Physiochemical changes in wounds can be exploited for preparing wound dressings which 
can be used to trigger release and efficiently eradicate the bacteria causing infection. 
Alginate, is a natural biocompatible polysaccharide, previously utilised for wound dressings (T. 
Hashimoto et al., 2004) and drug delivery systems (Augst et al., 2006). It can effectively protect phages 
from harsh environmental conditions such as acidic pH without causing loss of phage viability (Colom 
et al., 2017a). Several studies have concluded its inability to form continuous fibres due to its lack of 
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chain entanglements without the addition of a carrier polymer, which enhances the chain elasticity of 
the system (Yu et al., 2006). Poly(vinyl alcohol) (PVA), a non-toxic polymer, has demonstrated to 
provide some protection to phages during  encapsulation (Salalha et al., 2006) but may offer enhanced 
protection when incorporated with different polymers and fabricated at different process conditions.  
Eudragit S100 (ES100), a pH- responsive polymer has previously been electrospun to incorporate drugs 
targeted delivery (She et al., 2015). Since it is soluble at pH ≥ 7, it has the potential to enable a 
controlled release of phages in wounds, which become alkaline during bacterial infection, thereby 
making it a promising material for wound dressings. There have been no previous published studies 
on the encapsulation of phages for wound dressing applications using Eudragit, making it a novel 
material for this research 
The lack of previous research on phage encapsulation in electrospun fibres for wound dressing 
applications means there are several combinations of polymers can be exploited. Generally, the use 
of organic solvent systems is ideal however, the lack of chain entanglement for continuous fibre 
production is a challenge. Korehei and Kalda (2014) investigated water-in-oil (w/o) emulsion 
electrospinning to enhance phage protection from harsh electrospinning conditions by pre-
encapsulating the phages in core-shell fibres. Entrapping the phages in an aqueous core, coated with 
an oil-phase shell (polymer dissolved in organic water-immiscible solvent) produced a promising 
delivery system for phages which retained phage viability and released phages in a sustained fashion. 
Similarly, modifying the spinneret to produce co-axial electrospun fibres ensured the morphology of 
the fibres was continuous and smooth whilst minimising the exposure of phage to solvents which can 
affect phage viability.  
 
Aims and objectives 
 
In this work, two different w/o emulsion formulations were prepared for the encapsulation of phage 
K in core-shell fibres using emulsion electrospinning for wound dressing applications. Phage K specific 
against model bacterium, Staphylococcus aureus ATCC 6358 were used as model organisms. 
Biocompatible, pH responsive ES100 was used as the organic phase (forming the fibre shell) with PVA 
or sodium alginate as the aqueous phase (forming the fibre core) for the emulsions. Sorbitan 
monooleate (Span 80) was used as a non-ionic surfactant due to its low HLB value of 4.3, making it 
suitable for water-in-oil emulsions. This was added to the organic phase. The effects of applied voltage 
and infusion rate on fibre morphology were tested to determine the optimal electrospinning 
conditions for each emulsion formulation. Emulsion formulations were then developed by increasing 
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the concentration of the organic phase or aqueous phase and characterising the fibre morphology, 
rheology, and conductivity for each emulsion. The fabricated fibres were then screened for fibres 
which were continuous, defect-free and had a large mean diameter suitable for wound dressings. 
Phage K was encapsulated by suspension in the aqueous phase and phage viability determined by 
plaque assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.2 Summary of literature on phage encapsulation using electrospun nanofibers.  
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Ref Phage Carrier 
system 
Encapsulation 
method 
Additives Target 
application 
Fibre 
diameter 
Advantages Limitations 
(S. W. 
Lee & 
Belcher, 
2004) 
M13 Polyvinyl 
pyrrolidine 
(PVP) 
Wet spinning 
and 
electrospinning 
Water Biosensor 10–20 µm Uniform PVP fibres may 
provide catalytic 
capabilities to be utilised in 
biomedical applications. 
Viability of phages was 
undetermined 
(Salalha 
et al., 
2006) 
T7, T4 
and λ 
PVA Electrospinning Water Non-specific 250–400 
nm 
Some phage viability is 
retained after three 
months of storage at -20 
and -55 °C. 
Only 1% of T4 phages 
remained viable 
immediately after 
electrospinning, which is 
attributed to the rapid 
dehydration of the 
phages during fibre 
formation. 
(R. 
Korehei 
& 
Kadla, 
2013) 
T4 Polyethylene 
oxide (PEO)-
alginate 
Emulsion and 
coaxial 
electrospinning 
Chloroform Food 
packaging 
1 µm 
(emulsion) 
and 2 µm 
(coaxial) 
Core-shell fibre formation 
(emulsion and coaxial). 
Coaxial electrospinning 
encapsulated phages with 
a long storage time, high 
Phage activity dropped 
from 108 to 106 PFU ml-1 
for emulsion 
electrospinning. 
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loading capacity and full 
viability. 
(Reza 
Korehei 
& 
Kadla, 
2014) 
T4 PEO-
cellulose 
diacetate 
Coaxial 
electrospinning 
Chloroform 
and 
methanol 
Food 
packaging 
1.35-2.48 
µm 
Core-shell fibre formation. 
PEO-CDA blends 
suppressed burst release 
of phages. 
Phage activity dropped 
by 106 PFU ml-1 after four 
weeks storage. 
(Koo et 
al., 
2016) 
T7 Polyvinyl 
pyrrolidine 
(PVP) 
Electrospinning Water Various 100-200 
nm 
Preservation of phages in 
dry form, storage stability  
Loss of phage viability at 
high humidity (33 % and 
75 %) 
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7.2 Material and Methods 
7.2.1 Materials 
 
ES100 (Mw = 34 kDa), PVA (Mw = 13-23 kDa, partially hydrolysed 87%-89%), low viscosity sodium 
alginate (100-300 cP), trehalose (Mw = 378.33) and Span-80 were purchased from Sigma Aldrich 
Corporation. Chloroform (Mw = 119.38 Da), 1-Butanol (Mw = 74.12 Da) and calcium chloride (CaCl2) were 
purchased from Fisher Scientific, UK. Magnesium chloride (MgCl2) was purchased form Acros Ogranics, 
UK. BHI broth and Bacteriological Agar were obtained from Oxoid, UK. Phage K obtained from ATCC. 
Deionised water (DI) was obtained from the laboratory in the Department of Chemical Engineering at 
Loughborough University. All reagents were used as received. 
7.2.2 Preparation of emulsions 
 
The organic phase for the emulsion was prepared by dissolving a pre-weighed mass of ES100 (7, 10 or 
15% w/v) and Span-80 (5% w/v) in chloroform and 1-butanol, at a ratio of 50% v/v.  The solution was 
then sonicated for 30 minutes then stirred magnetically overnight at room temperature (16-24°C). 
The aqueous phase was prepared by dissolving a pre-weighed mass of PVA (5% w/v) or sodium 
alginate alginate (1, 3 or 5% w/v) in trehalose. The solution was then heated at 80°C and stirred, after 
which it was left to stir magnetically overnight at room temperature. Phage K was added to the 
aqueous phase the following day at a ratio of 1:1 (phage K to aqueous phase). The emulsion was 
prepared by adding dropwise the aqueous phase (with added phage K) to the organic phase at a ratio 
of 9:2 (organic to aqueous phase), at consistent intervals over the span of 12 minutes whilst 
simultaneously mixed at 1000 rpm using an overhead stirrer. 
7.2.3 Culturing bacteria and phage K for release assay 
 
7.2.3.1 Culturing of Staphylococcus aureus ATCC 6358 
 
Approximately, 17.25 g BHI broth was dissolved in 500 ml of DI, autoclaved at 121˚C for 15 minutes 
and stored at room temperature. Double layer agar procedure was used as previously performed by 
Goh et al. (Goh et al., 2005) and Mahony et al. (Og, Af, Sygdomme, Henrik, & Epidemiologisk, 2009) 
 
S. aureus strain was maintained in cryopreservation at -80˚C. Sterile 5 μl inoculation loops were used 
to streak the strain on a BHI agar plate. The plate was incubated for 24 hours at 37˚C. A single colony 
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of S. aureus was transferred via a sterile inoculation loop BHI broth and grown shaking at 37 ˚C 
overnight. The turbidity of the culture is indicative in liquid culture growth. Upon successful growth of 
culture, it was centrifuged at 13,000 x g (Beckham Coulter, UK) at 20˚C for 15 minutes. The supernatant 
was decanted, and the pellet re-suspended in 5 ml of SM buffer and stored in fridge.  
 
7.2.3.2. Culturing of bacteriophage K 
 
Isolated phage K can infect strain S. aureus ATCC 6358, therefore host is used to propagate phage for 
making stocks and analysis. Phage infection and replication was observed by plaque assays and spot 
tests using the double agar layer method. Phage propagation for developing stock was done in liquid 
culture. All work carried out was in aseptic conditions near a Bunsen flame or the laminar fume hood.  
  
A freshly growing culture of S. aureus in BHI broth was checked for logarithmic growth by taking the 
optical density (OD550 nm at hourly intervals until it reached 0.2, after which (dependent on phage 
titre of stock) phage was added at a MOI of 0.01. The 50 ml tube was incubated shaking overnight at 
37˚C for infection to occur. The following day the tube was removed and centrifuged at 4, 500 x g for 
10 minutes. The supernatant was filtered using a 0.2 μm pore size filter (Millipore, USA) and a 25 ml 
syringe (BD Plastipak) into a new tube. The phage stock was stored at 4˚C until use.  
 
The titre of phage stocks was determined by mixing soft agar and salt in a 50 ml tube in a 1:1 ratio and 
to make sloppy. Approximately, 10 µl of overnight S. aureus culture was mixed in 8 ml of sloppy and 
poured onto 1% BHI agar plates and left to set for 5 minutes under the laminar flow hood. To 
enumerate the phage titre, serial dilutions from 10-1 to 10-7, 10 μl from each dilution (in triplicate) was 
spotted on host lawn. Dilutions were made of 90 μl of BHI broth and 10 μl of phage stock. The plates 
were incubated overnight at 37˚C. The following day, phage titre was determined by counting plaques 
and expressed as plaque forming unit PFU g-1. The following equation was used to calculate the PFU 
g-1, where 𝑃 is the PFU g-1, 𝑁 is the number of plaques, 𝐷𝑓 is the dilution factor and 𝑀 (g) is the weight 
of the polymer. 
 
    
                                                           𝑃 =  
𝑁 × 𝐷𝑓
𝑀
                                                   (1) 
7.2.3.3. Phage release assay 
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For phage release assay, 10 μl of dissolved electrospun fibres in 10 ml SM buffer pH 7 was serially 
diluted in 96-well plate (as described in section 7.2.3.2) and was spotted on the gridded area on the 
agar in triplicate, left to evaporate and incubated at 37˚C overnight. The following day the plates were 
observed for clearance in form of lysis or plaques to indicate phage infection of bacteria and PFU g-1 
calculated (equation 1). 
 
7.2.4 Characterisation of emulsions 
 
Rheology was characterised using the HAAKE Viscotester 550 Rotational Viscometer, equipped with a 
coaxial cylinder and kept at constant temperature (25 ˚C). The shear viscosity (η) was determined as 
a function of the shear rate (γ) from 10 to 200 s-1. Conductivity of PVA and alginate were measured a 
using a conductivity meter (Omega CDH222) with an accuracy of (±3%) full scale.  
 
7.2.5 Electrospinning process 
Emulsions were added to 12 ml plastic syringe (Luer Lock syringe, Sigma Aldrich) and attached to a 
pump system (PHD ULTRA, Harvard Apparatus) in a horizontal setup. Emulsions were injected through 
a spinneret (inner diameter 0.5 mm) at a constant infusion rate (1-3 ml hr-1) for a set duration (60 
minutes) within a sealed chamber where the temperature (17-23 ˚C) and relative humidity (50-70%) 
were measured using a probe. A high-power voltage supply was used to generate an electric field (10-
15 kV) inside the sealed chamber. Fibrous mats were collected on an oppositely charged rectangular 
copper plate, wrapped in aluminium foil and placed 15 cm from the spinneret tip (Figure 7.1). Three 
repeats were conducted for each sample fabricated. Fibre morphology was analysed using scanning 
electron microscopy (FEG-SEM, Zeiss 1530VP) by taking three images at different magnifications. 
Mean fibre diameters were calculated by measuring 30 individual fibres using NIH-ImageJ software. 
7.2.6 Fourier transform infrared spectroscopy  
 
Fourier transform infrared (FTIR) spectra of 3 samples of electrospun fibres were recorded using FTIR 
spectrophotometer (Model 20DXC, Nicolet Instrument Corp., Madison, WI. USA). 
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7.2.7 Statistical analysis 
 Statistical analysis was performed using a two-tailed unpaired Student’s t-test (Excel, Microsoft 2010) 
to determine any statistical difference (P < 0.05) between data sets. Data was presented by giving the 
mean ± standard deviation. 
 
 
 
 
 
 
Figure 7.1 Schematic of emulsion electrospinning process for phage encapsulation. 
7.3 Results  
7.3.1. Determination of optimal electrospinning conditions for ES100 composite fibres 
 
The influence of electrospinning parameters on fibre morphology have been reported for different 
polymer formulations. Since the fabrication of ES100-PVA and ES100-alginate fibres is novel, there 
were no previous reports on the influence of electrospinning parameters on the fibre morphology. 
Optimal conditions for producing continuous fibres was determined by testing the effect of applied 
voltage and infusion rate on the morphology of the fibres (Figure 7.2). The strength of the applied 
electric field has been reported to influence the formation of various size fibres for different polymer 
formulations (Sill & von Recum, 2008). Critical values for field strength varies for different polymer 
systems and failure in stable jet formation during electrospinning could be attributed to suboptimal 
field strengths (A. Haider et al., 2015). By increasing the voltage, the strength of the electric field at 
the spinneret is also increased which subsequently affects the whipping stability during 
electrospinning (C. Wang et al., 2009). Stronger electric fields have been demonstrated to produce 
smaller diameter nanofibers due to increased stretching of the fibres during whipping of the charged 
jet in correlation with the charge repulsion within the jet (Lv et al., 2017). 
210 
 
7.3.1.1 ES100 and PVA for phage K encapsulation in electrospun fibres 
 
Figure 7.2 shows the change in nanofiber diameter with varying voltages (10, 12.5 and 15 kV) and 
infusion rates (1, 2 and 3 ml hr-1) for the ES100-PVA (7% w/v ES100) emulsion. The use of a two-tailed 
t-test (of 3 replicates) verifies that the difference in fibre diameter from 10 to 15 kV across all three 
infusion rates (1, 2 and 3 ml hr-1) was significant (P < 0.05). Lower voltages result in larger fibre 
diameters, which is desirable as operating at lower voltages would decrease the likelihood of loss of 
phage viability. However, it was observed that electrospinning at 10 and 12.5 kV caused dripping of 
the polymer fluid from the spinneret tip. This was thought to be due to an insufficient voltage required 
to form a stabilised charged jet. Despite the increase in fibre diameter, operating at a voltage below 
15 kV across all three flowrates was suboptimal, as there was significant 50 % loss of material due to 
partial electrospinning of the polymer solution. 
             
 
 
 
 
 
 
 
 
Figure 7.2 SEM micrographs of ES100-PVA (7% w/v ES100) fibres fabricated at different applied 
voltages (10, 12 and 15 kV) and different infusion rates (1, 2 and 3 ml hr-1). Shown at magnification 
x15,000. 
1 ml hr-1 2 ml hr-1 3 ml hr-1 
10.0 kV 
12.5 kV 
15.0 kV 
311 ± 83 nm 222 ± 61 nm 351 ± 96 nm 
226 ± 67 nm 215 ± 55 nm 216 ± 67 nm 
147 ± 43 nm 192 ± 42 nm 209 ± 44 nm 
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The effect of applied voltage on fibre diameter distribution was investigated for the ES100-PVA (7% 
w/v ES100) emulsion, (Figure 7.3). It was observed that a higher voltage produced a narrower 
distribution of fibre diameters across all three infusion rates (1, 2 and 3 ml hr-1), which was desirable. 
Similar results were obtained by Huan et al., (2015) which could be explained by the imbalances of 
the three major forces influencing fibre diameter: Coulombic, surface tension and viscoelastic force. 
Lower applied voltages cause the surface tension to dominate over the Coulombic force, resulting in 
fibres with a broader diameter distribution. The three forces become balanced when the applied 
voltage is increased and closer to that of the optimal threshold, resulting in a narrower fibre 
distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Distribution of ES100-PVA (7% w/v ES100) fibre diameters fabricated at 1 ml hr-1 with 
applied voltage of a) 10 kV and b) 15 kV. Fibres fabricated at 3 ml hr-1 with applied voltage of c) 10 kV 
and d) 15 kV. 
7.3.1.2 Effect of voltage on ES100 and Alginate fibres 
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The effect of applied voltage on fibre diameter was investigated for the ES100-alginate (3% w/v 
alginate) emulsion, (Figure 7.4). Unlike the ES100-PVA fibres, the ES100-alginate fibres showed a 
significant (P < 0.05) increase in fibre diameter as the voltage was increased from 10 to 15 kV, across 
all three infusion rates (1,2 and 3 ml hr-1). Whilst it has been discussed why an increase in voltage 
results in fibres with smaller diameters, it should be noted that the effect of applied voltage on fibre 
diameter remains unclear, with some studies reporting that an increase in voltage results in an 
increase in fibre diameter, for example Zhang & Yuan, (2005) showed the increase in average fibre 
diameter of PVA fibres with increasing voltage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 SEM micrographs of ES100-alginate (3% w/v alginate) fibres fabricated at different applied 
voltages (10, 12 and 15 kV) and different infusion rates (1, 2 and 3 ml hr-1). Shown at magnification 
x10,000. 
In contrast with the results obtained for the effects of applied voltage on fibre diameter distribution 
for the ES100-PVA fibres, it was observed that an increase in voltage resulted in a wider fibre diameter 
distribution for the ES100-alginate (3% w/v alginate) fibres, (Figure 7.5). Since the effect of applied 
voltage is determined by the three major forces, it is argued that higher applied voltages cause the 
584 ± 112 nm  656 ± 137 nm 641 ± 139 nm 
513 ± 118 nm 497 ± 108 nm 691 ± 194 nm 
1671 ± 467 nm 1548 ± 414 nm 1286 ± 379 nm 
1 ml hr-1 2 ml hr-1 3 ml hr-1 
10.0 kV 
12.5 kV 
15.0 kV 
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Coulombic force to dominate over the viscoelastic force. This culminates in a broader distribution of 
fibres, which is attributed to breakage from an over-stretched charged jet (Huan et al., 2015).  
 
 
 
Figure 7.5 Distribution of ES100-alginate (3% w/v alginate) fibre diameters fabricated at 1 ml hr-1 
with applied voltage of a) 10 and b) 15 kV. Fibres fabricated at 3 ml hr-1 with applied voltage of c) 10 
kV and d) 15 kV.  
Figure 7.2 illustrated that an increase in infusion rate significantly (P < 0.05) increases the fibre 
diameter for the ES100-PVA (7% w/v ES100) emulsion when operating at an applied voltage of 15 kV, 
but inconclusive (P > 0.05) when operating at 10 and 12.5 kV. It can be hypothesised that the jet was 
more stable when operating at 15 kV for this polymer system. This allowed for the effect of infusion 
rate on fibre morphology to become more apparent. It was observed that whilst operating at flowrates 
of 2 and 3 ml hr-1, dripping of polymer fluid from the spinneret tip occurred. This may be attributed to 
the incomplete drying of charged jet. 
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The ES100-alginate (3% w/v alginate) fibres were observed to significantly increase (P < 0.05) in fibre 
diameter as the infusion rate increased from 1 ml hr-1 to 3 ml hr-1, across all three applied voltages (10, 
12.5 and 15 kV), (Figure 7.5). This indicated that the morphology of the ES100-alginate fibres was more 
influenced by infusion rate across a wider range of investigated applied voltages, compared to the 
ES100-PVA fibres. The effect of fibre diameter distribution was investigated for both polymeric 
emulsions, but it was concluded that the infusion rate had a minor impact on narrow fibre diameter 
distribution. High flowrates may cause the charged jet to become unstable and electrospray due to 
the pull of gravitational force, leading to a wider fibre diameter distribution (Zargham et al., 2012).  
Like the ES100-PVA fibres, operating at an infusion rate of 2 ml hr-1 or 3 ml hr-1 led to dripping of the 
polymeric fluid from the spinneret tip. This indicated that for both systems, operating at these two 
flowrates was suboptimal and lead to a loss of material. It was thought that a low infusion rate was 
generally preferred for polymer systems to sustain a balance  between the withdrawing polymer fluid 
and the substitution of that fluid with fresh fluid during formation of the charged jet (Zeleny, 1935). 
7.3.2. Development and characterisation of emulsion formulations 
To observe the effects of viscosity on the production of fibres, concentrations of alginate and ES100 
were changed and the effect on fibre diameter observed (Figure 7.6 and 7.7).  
 
7.3.2.1 ES100 and alginate for phage K encapsulation in electrospun fibres 
 
Alginate has been utilised for a range of biomedical applications and it is one of the most common 
materials used in microencapsulation (Colom et al., 2017a), making it a promising material for this 
work. The charge repulsions among the alginate chain debilitates the ability to electrospin pure 
alginate in water unless it is blended with a co-polymer such as PEO (Bhattarai et al., 2006), thereby 
alleviating the charge repulsions and enhancing chain flexibility (Bonino et al., 2011). ES100-alginate 
emulsions with different concentrations of alginate (1, 3 and 5 % w/v) were electrospun to observe 
what effects the concentration will have on the emulsion viscosity and subsequent fibre diameter, 
(Figure 7.6). An increase in viscosity accompanied an increase in alginate concentration across all three 
concentrations. The mean fibre diameter increased from (588 ± 190 nm) (1 % w/v) to (1548 ± 414 nm) 
(3 % w/v), which was thought to be due to the increase in viscosity leading to an enhanced chain 
flexibility for electrospinning. Contrastingly, the mean fibre diameter decreases with an increasing 
alginate concentration from 3 % w/v (1286 ± 379 nm) to 5 % w/v (839 ± 250 nm). This may be due to 
the viscosity beyond the optimal threshold of the polymer system. It was observed that during 
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electrospinning of the 5 % w/v alginate and ES100 emulsion, the fluid started to dry at the spinneret 
tip, indicating that the viscosity was too high. 
 
 
 
  
 
 
 
 
 
 
Figure 7.6 Effect of alginate concentration on viscosity and fibre diameter for ES100-alginate (3% w/v 
alginate) fibres fabricated at 1 ml hr-1 and 15 kV. 
 
7.3.2.2 ES100 and PVA for phage K encapsulation in electrospun fibres 
Similarly, the concentration of ES100 was increased to observe what effects it will have on fibre 
morphology. Upon increasing the ES100 concentration from 7 % w/v to 10 % w/v, the ES100-alginate 
emulsion (3 % w/v alginate) fails to electrospin due to the fluid drying off at the spinneret tip, 
suspected to be to a viscosity far exceeding the optimal threshold of the system. In contrast, the 
ES100-PVA fibres experience an increase in fibre diameter upon increasing ES100 concentration, 
(Figure 7.7). The ES100 concentration has the greatest impact on fibre diameter when compared to 
the effects of applied voltage and infusion rate as the fibre diameter increases almost 20-fold when 
increasing the ES100 concentration from 7 % w/v (147 ± 43 nm) to 15 % w/v (2914 ± 935 nm). Notably, 
the largest incremental increase of fibre diameter occurs from 10 % w/v (525 ± 123 nm) to 15 % w/v 
(2914 ± 935 nm), where the largest increase in viscosity also occurs (115 to 518.5 cP) (Figure 7.2). 
However, it was observed that some drying of the jet occurred at 15 % w/v ES100, once again 
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suspected to be because of high viscosity. This also affected the stability of the jet, as the relative 
standard deviation of fibre diameters was highest for the 15 % w/v ES100 emulsion, whereas the 
lowest relative standard deviation was for the 10 % w/v ES100 emulsion, indicating enhanced jet 
stability at that viscosity. 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Effect of ES100 concentration on emulsion viscosity and fibre diameter for ES100-PVA 
fabricated at 1 ml hr-1 and 15 kV. 
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7.3.2.3 Polymer conductivity 
Table 7.3 Conductivity of PVA and different alginate concentrations in DI.    
 
The conductivity of different alginate concentrations (1, 3 and 5 % w/v) and 5 % w/v PVA solution were 
compared to determine how the fibre morphology was influenced. Data in Table 7.3 illustrates that 
an increase in alginate concentration accompanies an increase in conductivity. Notably, the 
conductivity of alginate across all three concentrations was higher than PVA, which was thought to be 
a contributing factor to why the ES100-alginate fibres have a larger diameter than the ES100-PVA 
fibres. This may be because the higher conductivity expressed in the alginate solutions are closer to 
the optimal conductivity of the emulsion system; allowing for greater polymer surface charges for 
Coulombic forces to dominate leading to enhanced stretching of the fibres. This was only true to a 
certain extent, as when the alginate concentration was increased from 3 to 5 % w/v, the mean fibre 
diameter experiences a decrease, as previously shown in Figure 7.6. This could be explained by the 
large conductivity value at 5 % w/v (8.95 ± 0.60 mS cm-1), which was hypothesised to be at a critical 
value which increases the surface charge on the polymer droplet to such an extent that it decreases 
the tangential electric field which weakens the electrostatic force on the surface of the polymer fluid 
(A. Haider et al., 2015). As a result, formation of the Taylor cone was affected, and thinner fibres are 
formed. 
 
 
Material Concentration (% w/v) Conductivity (mS cm-1) 
 
Alginate 
1 2.39 ± 0.60 
3 6.21 ± 0.60 
5 8.95 ± 0.60 
PVA 5 0.37 ± 0.06 
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Figure 7.8 FTIR analysis of Eudragit and PVA electrospun fibres with varying Eudragit concentrations 
(7 %, 10 %, 15 %). Eudragit functional groups (O-H, C=O, CH3, C-O) are labelled. 
Fourier-transform infrared spectroscopy (FTIR) spectra of the ES100 and PVA fibres is presented in 
Figure 7.8. Due to the very low concentration of PVA in comparison to ES100, the FTIR spectrum can 
be attributed to the functional groups found in the ES100 structure. Fibres produced from emulsion 
with varying concentrations of ES100 were analysed. The spectra for all concentrations showed a 
similar profile confirming the presence of ES100, however the transmittance levels differ slightly which 
is due to higher density of polymer made with emulsion containing higher ES100 concentration. Fibres 
produced from the lowest ES100 concentration (7% w/v) showed a broad peak between 3000 and 
3700 cm-1 this is explained by exchangeable protons; a compound contains many hydrogen bonds 
which are bonded to a different extent. Therefore, when IR absorption is acquired, varying frequencies 
for this bond will occur.  
Peak at 2925 cm-1 demonstrated the presence of carboxylic acid (O-H), at 1720 cm-1 showed the 
presence of ester bond (C=O). In the fingerprint region, at 1149 cm-1 carbonyl group (C-O) stretch was 
observed as well as a methyl group bend at 1440 cm-1. The FTIR analysis concluded that fibres are 
largely made of ES100 with concentrations of PVA being negligible and phage showing no structural 
impact on fibres.  
7.3.3. Encapsulation and release of phage K in ES100 and PVA fibres 
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Having optimised the fibre morphology by testing a range of different electrospinning and developing 
the emulsion formulations, phage K was encapsulated in ES100-PVA fibres to determine the viability 
of the phages before and after electrospinning. Encapsulation of phage K was not pursued for ES100-
alginate fibres for this report. This was attributed to poor reproducibility of the ES100-alginate fibres, 
as on occasions during repeats of the experiment, the thickness and distribution of the fibres varied 
significantly from the previous results. 
7.3.3.1 Effect of applied voltage on phage viability during encapsulation 
Phage K was encapsulated in three different ES100-PVA (7 % w/v ES100) fibrous mats, fabricated at 
three different electrospinning conditions. Mat 1, fabricated at 3 mlh-1 and 10 kV was selected for 
encapsulation because it produced fibres with the largest mean diameter (351 ± 96 nm), as previously 
shown in Figure 7.2. Mat 2 fabricated at 2 ml hr-1 and 12.5 kV (215 ± 44 nm) was selected to serve as 
an intermediate between the two extreme electrospinning parameters for comparative purposes. Mat 
3, which previously produced the thinnest fibres (147 ± 43 nm) and fabricated at optimal 
electrospinning conditions of 1 ml hr-1 and 15 kV was used to compare phage viability between the 
thickest and thinnest fibres. Figure 7.9 shows the phage release viability for the ES100-PVA (7% w/v 
ES100) fibres by comparing the initial titre with the release titre after encapsulation. Mat 1 yields the 
highest phage viability after release, as there was only a two-log reduction in phage viability. This was 
likely attributed to the large diameters of the fibres offering enhanced phage protection from the 
harsh electrospinning conditions.  
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Figure 7.9 Viability of phages before and after 24 hours of encapsulation for ES100-PVA (7%w/v ES100) 
fibres fabricated at different electrospinning parameters. * indicates significantly different phage 
titres (p < 0.05) for a 2-sample t-test with each sample compared with initial titre released in pH 7 for 
each parameter. 
7.3.3.2 Effect of polymer concentration on phage viability in electrospun fibres 
 
The phage viability was assessed for ES100-PVA fibres fabricated using different ES100 concentrations 
(7, 10 and 15 % w/v) at optimal electrospinning conditions of 15 kV and 1 ml hr-1. Figure 7.10 illustrates 
the phage viability for the different ES100 concentrations before and after electrospinning. Fibres 
fabricated using 15 % w/v ES100 (2914 ± 935 nm) yield a four-log reduction in phage viability and 
therefore did not offer improved phage protection when compared to fibres fabricated at 7 % w/v 
ES100 (147 ± 43 nm). This is thought to be attributed to the drying of the jet at the spinneret tip arising 
from the emulsion’s high viscosity, thereby affecting the extent of successful encapsulation. The 
phages ability to lyse bacteria may also have been hindered at such a high viscosity. Fibres fabricated 
at 10% w/v ES100 (525 ± 123 nm) offered the most promising results, as it produces a three-log 
reduction in phage viability. This could be to an amalgamation of effects arising from the thickness of 
the fibres, offering improved protection, and the stability of the jet at that concentration, offering 
improved encapsulation.  However, it does not offer improved protection compared to the ES100-PVA 
(7 % w/v ES100) fibres fabricated at 10 kV and 3 ml hr-1, therefore inferring that the fibres’ large 
diameters do not completely mitigate the harmful effects of a higher applied voltage on phage 
viability. Whilst the phage viability is not as high as the viability reported by Korehei and Kadla [18], it 
still offered a higher viability compared to previous work by Salalha et al., (2006), where 1% of phages 
remained viable after encapsulation.  
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Figure 7.10 Viability of phages before and after 24 hours of encapsulation for ES100-PVA fibres 
fabricated at different ES100 concentrations. * indicates significantly different phage titres (p < 0.05) 
for a 2-sample t-test with each sample compared with initial titre released in pH 7 for each parameter. 
7.4 Discussion 
 
Defect-free, continuous fibres with large diameters are desired for phage encapsulation as they allow 
for a slower release rate of phages by hindering polymer chain unfolding and disentanglement (Reza 
Korehei & Kadla, 2014), thereby improving phage viability. A narrow fibre diameter distribution is also 
preferred as it promotes a controlled release rate of phages because each fibre would take 
approximately the same amount of time to dissolve. Electrospinning parameters, including applied 
voltage and infusion rate have been previously reported to influence electrospun nanofiber 
morphology. In addition to electrospinning parameters, solution parameters, including viscosity and 
conductivity, which are dependent on the polymeric concentration have also been reported to 
influence fibre morphology (Fong et al., 2001). In this work, different process conditions were tested 
using the ES100-PVA and ES100-alginate emulsions to determine the optimal conditions to achieve 
defect-free, continuous fibres with large diameters to facilitate the encapsulation of phage K.  After 
encapsulation, the release of phage K was evaluated using plaque assays. 
 
The variations in fibre diameter could be attributed to the use of different polymer and solvent 
systems, which respond differently to each parameter. Baumgartner et al., (1971) reported an 
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increase in fibre diameter with increasing voltage, which was thought to be due to a longer charged 
jet length. The increase in fibre diameter has also been reported to be attributed to an increase in jet 
velocity for the same infusion rate, due to a decrease in the size of the Taylor cone (A. Haider et al., 
2015). 
Similar to applied voltage, the infusion rate has also been reported to influence the fibre diameter and 
porosity of electrospun nanofibers. Megelski, (2002) reported an increase in fibre diameter with 
increasing flowrate, which was thought to be due to incomplete drying of the charged jet during flight 
to the collector plate. Wang et al., (2009) attributed the increase in fibre diameter with increasing 
infusion rate to the expansion of the Taylor cone which produced a longer and wider charged jet. 
Like the ES100-PVA fibres, ES100-alginate operating at an infusion rate of 2 ml hr-1 or 3 ml hr-1 led to 
dripping of the polymeric fluid from the spinneret tip. This indicated that for both systems, operating 
at these two flowrates was suboptimal and lead to a loss of material. It was thought that a low infusion 
rate was generally preferred for polymer systems to sustain a balance  between the withdrawing 
polymer fluid and the substitution of that fluid with fresh fluid during formation of the charged jet 
(Zeleny, 1935). 
 
Having established the effects of the electrospinning parameters on fibre morphology, the next stage 
was to develop and characterise the emulsion formulations that could enhance phage K viability by 
changing the concentration of the organic and aqueous phase. Phage K was stored in buffer or broth 
which was not miscible with solvents therefore when producing an emulsion for electrospinning, 
phage K was added to the aqueous phase.  
 
It has been previously reported that increasing the concentration of polymer in a polymer solution will 
also increase the viscosity of that system, leading to a greater number of chain entanglements in the 
polymer chains (A. Haider et al., 2015). The fabrication of defect-free, continuous fibres is determined 
by the number of chain entanglements in polymer systems, which are required to overcome the 
surface tension of the fluid. Polymer systems with dilute concentrations, low viscoelasticity or with a 
low molecular weight will have insufficient entanglements and therefore not meet the critical chain 
entanglement threshold required for the production of continuous fibres (Yu et al., 2006). Like the 
applied voltage and infusion rate, exceeding the concentration beyond a critical value could result in 
the fabrication of defective fibres. This is because the polymer fluid dries off at the spinneret tip, which 
restricts the flow of the fluid and extent of subsequent whipping (S. Haider et al., 2013). 
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Whilst an increase in viscosity is generally preferred as it leads to thicker fibres, it has also been 
reported that the ability for phages to lyse bacteria declines with increasing solution viscosity (Hanlon 
et al., 2001). Fabricating thicker fibres for phage encapsulation should therefore not rely solely on 
increasing the concentration of the polymer system, as the viscosity increase may hinder phage 
viability. 
 
Phage encapsulation results agree with those reported by Korehei and Kadla (2014), who also reported 
a two-log reduction in phage viability using emulsion electrospinning. In contrast, Mat 3 exhibited a 
four-log reduction in phage viability, which could be attributed to smaller fibre diameters offering less 
phage protection. Another factor for consideration was that phages are approximately 200 nm in 
length from head to tail; therefore, the decrease in viability may also be attributed to the fibres being 
insufficient in size to accommodate the encapsulation of phages. Finally, Mat 2 yielded a three-log 
reduction in phage viability after release, which was expected because it was fabricated at 
intermediate electrospinning parameters. 
 
7.5. Conclusions 
 
This data serves as proof-of-concept study for the encapsulation of phage K in core-shell emulsion 
electrospun fibres for novel wound dressing applications. Two different w/o emulsion formulations 
were prepared using pH-responsive ES100 as the organic phase (forming the fibre shell) and PVA or 
alginate as the aqueous phase (forming the fibre core). Defect-free, continuous nanofibers with large 
diameters were fabricated by determining the optimal electrospinning parameters for each 
emulsion, followed by development and characterisation of each emulsion formulation to facilitate 
encapsulation and viability of phage K.  
 
SEM micrographs revealed that changes in applied voltage and changes in infusion rate had a 
significant effect (P < 0.05) on fibre morphology for both emulsions. Higher applied voltages resulted 
in a wider fibre diameter distribution for the ES100-alginate fibres, and a lower distribution for the 
ES100-PVA fibres. Observations during the electrospinning process revealed that operating at an 
applied voltage below 15 kV and at an infusion rate greater than 1 ml hr-1 led to dripping of the polymer 
fluid from the spinneret tip rendering these conditions as suboptimal. Rheology and conductivity 
characterisation revealed that an increase in ES100 or alginate concentration resulted in a higher 
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viscosity and conductivity, ultimately yielding thicker fibres. Increasing the alginate concentration only 
increased the diameter of ES100-alginate fibres up to a critical threshold. Fabrication of ES100-alginate 
fibres led to poor reproducibility, therefore phage K encapsulation was done using ES100-PVA fibres.  
 
Phage K was successfully encapsulated by suspension in the aqueous phase in different ES100-PVA 
fibres fabricated at a range of process conditions. Phage viability assays revealed that larger diameter 
fibres and lower applied voltages offered improved phage viability as reported for fibres with a mean 
diameter of 351 ± 96 nm (fabricated at 10 kV) which resulted in a two-log reduction in phage viability, 
whilst fibres with a smaller mean diameter of 147 ± 43 nm (fabricated at 15 kV) resulted in a four-log 
reduction in phage viability. Phage viability was improved whilst operating at 15 kV by increasing the 
ES100 concentration from 7 to 10% w/v, as this resulted in a three-log reduction in phage viability. 
The improved phage viability may be attributed to an increase in fibre diameter (525 ± 123 nm) and 
enhanced jet stability. However, it does not completely mitigate the harmful effects of the higher 
applied voltage on phage viability.  Future work should focus on further optimising the ES100-alginate 
fibres so that good reproducibility can be established for encapsulation work. 
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Chapter 8: Conclusions 
 
8.1 Key motivations 
 
This work aimed to develop a novel formulation for the application of phage therapy. Use of phages 
has been active since its discovery in 1915 (Abedon et al., 2016). However, little work has been done 
to develop formulations and techniques which can help protect phage from biological and 
environmental stresses during its administration. More specifically, phage therapy against enteric 
pathogens remains challenging due to transit through the GI-tract to reach the small and large 
intestine. Several factors impact on phage survival through the digestive tract, a key one being the 
acidity of the stomach which can range from pH 1-2.5 depending on fed or fasted state in humans 
(McConnell et al., 2008). In animals on the other hand, the pH of the stomach is around pH 2.5 which 
has been the focus of many studies to date for phage encapsulation that mainly focus on biocontrol 
in animals.  
8.1.1 Formulation development for targeted delivery of phage 
 
This study has focused on developing a novel formulation for phage encapsulation and protection 
against stomach acid ranging from pH 1-2.5. A commercially available polymer, Eudragit S100 and 
alginate were used for their pH responsive properties and bio-compatibility. Both alginate (Colom et 
al., 2017b; S. Kim et al., 2015b; Yongsheng Ma et al., 2008, 2012) and Eudragit (Stanford et al., 2010a) 
have previously been used for phage encapsulation and demonstrated protection at pH 2.5 however 
little work has been done to study both together.  
The technique used for encapsulation plays a key part in how effectively the phage is protected from 
acidic pH (usually below pH 3). In all studies reported so far, despite some degree of acid protection a 
significant loss (more than 1-log) in phage titre was observed at pH 2 (Ma et al., 2008, 2012; Kim, Jo 
and Ahn, 2015b). Microfluidics was used for the development of uniform droplets containing phage 
in composite polymers blends. This technique allowed exquisite control over droplet production, by 
varying experimental parameters immediate change in drop diameter was observed. The resulting 
particles showed excellent monodispersity with CV below 1 %. Through developing this process and 
formulation, phage encapsulation could be fine-tuned to produce microparticles varying in size which 
may be targeted for specific sites of the intestines. Size can also effect the residence time in the GI-
tract, where shortened transit times are observed during infection due to the onset of diarrhoea.   
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The combination of Eudragit and alginate was investigated further to provide phage protection at pH 
1 for up to 2 hours without the aid of antacids. Here, the size of the microparticles influenced the level 
of acid protection which previously has not been reported. This highlighted the need for better control 
over particle size to provide the optimum protection against stomach acid. Smaller particles were 
more prone to acid attack; conventional techniques used for particle production offer little control 
over size which can result in a low phage yield post acid exposure. Therefore, a balance needs to be 
achieved between delivering a high phage dose and remaining at the site of infection long-enough to 
induce a positive effect. 
Transferability of phage encapsulation from the in-house fabricated device to a commercial chip was 
demonstrated. This enables reproducibility of the system in most commercially available chips 
showing that the process was well-defined and controlled as opposed to dependent on mechanical 
processes with little control and no standardisation. 
8.1.2 Scaling up phage encapsulation process 
 
When considering phage therapy, multiple dosing (taking phage more than once), transportation, 
long-term storage and reproducibility are all factors which need to be considered. pH-responsive 
microparticles produced via microfluidic devices showed the potential use of the process in phage 
therapy of enteric infections. However, a key concern would be the production volume of 
encapsulated phage which was considerably low using microfluidic platforms. Multiple capillaries 
running parallel are a possible route for process scale-up. However, the material used (quartz glass) 
to produce these chips, can quickly add to the up-scale cost. Therefore, alternative methods were 
exploited, one being membrane emulsification which has the ability to produce material in litres as 
opposed to millilitres with capillary devices. A combination of both Eudragit and alginate were still 
used to produce water-in-oil droplets. A larger volume (50 ml) of encapsulated phage was produced 
which also presented the acid protection as seen with the microfluidic technique.  
Less than 0.5-log loss in phage titre upon exposure to pH 2 and 2.5 was observed, phage release in SIF 
(pH 7) and pH 5 and 6 were also investigated. To date no reports have shown the release of 
encapsulated phage at pH lower than 7. This is an important consideration when aiming at site-specific 
delivery of encapsulated phage. In addition to loss in titre during exposure to stomach acid, phage is 
prone to release during transit through the GI-tract. Transcending through the digestive tract, pH 
begins to rise reaching neutral or pH 7.4 in the colon (Evans et al., 1988). At sites where the pH is 5 or 
6, the pH responsive properties of polymers begin to engage, slowly dissolving due to the presence of 
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hydroxyl ions. This releases the phage prematurely, an important parameter which needs further 
investigation.  
Although phage amplify in the presence of their host, they have been shown to arrest bacterial growth 
more effectively if the initial phage titre is high. Results demonstrated the effect of phage titre on 
arresting actively growing bacteria, initial low titre (102 PFU/ml) phages were able to catch up with 
bacterial killing as seen with a high titre of phage (108 PFU/ml). Despite this, the state of bacterial 
growth during infection may be different, actively growing bacteria as found in vitro may not 
necessarily translate to the in vivo setting. Therefore, phage-bacterium killing during various stages of 
bacterial growth are necessary to test the effect of encapsulation and dosing for phage therapy. 
An ex vivo model was used to examine the three-way interaction of epithelial cells, bacteria and phage. 
Bacterial killing by encapsulated phage previously exposed to pH 2 for 2 hours showed growth arrest 
and prevented further damage to epithelial cells. The results were comparable to free phage which 
was used as the positive control. Complete loss of actin cytoskeleton and nuclei shrinkage was 
observed where no phage was added. Studying phage in the presence of epithelial cells, to observe 
any interaction which may prevent phage-bacterial killing or cause further distress to epithelial cells 
is key. Phages have previously been reported to elicit an immune response (Loc-Carrillo & Abedon, 
2011) therefore evaluating its response in an ex vivo model is a useful tool in determining the best 
phage for therapy.  
8.1.3 Encapsulating phage for long-term storage and ease of manufacture 
 
A second method for scaling-up the production of encapsulated phage, commonly used in industry is 
spray drying. Production of dry powder phage products can be a useful tool in by-passing several 
downstream processing steps such as freeze drying. Phage has been reported to be spray dried in 
several sugar excipients aimed for pulmonary delivery (Vandenheuvel et al., 2013; Leung, et al., 2017). 
However, only one study has reported the use of Eudragit polymer for phage encapsulation (Stanford 
et al., 2010) where Ephage was exposed to pH 3 for 20 mins. Phage encapsulation in Eudragit and 
alginate were investigated here with added trehalose for preservation of phage during storage. Acid 
exposure to pH 2 for 2 hours showed phage survival with less than 0.5-log reduction in titre. 
Addition of alginate improved phage survivability during acid exposure but the increased loss during 
the spray drying process led to Eudragit and trehalose being used in combination only. Powder 
production yields during spray drying were improved with the addition of Eudragit which showed yield 
of 50 % on its own. For large scale production, product loss can be costly however in this case Eudragit 
shows promise in mass producing encapsulated phage. Trehalose provided sufficient phage protection 
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from desiccation and elevated temperatures encountered during spray drying. Without the addition 
of trehalose, phage yields were significantly low indicating there is a need to combine excipients for 
optimum dry powder phage production. A downside to the use of spray drying as opposed to other 
techniques is the need for high temperatures, which need to be tackled by careful formulation. 
Powders are susceptible to environmental changes and can quickly change state depending on 
moisture and temperature which can damage the entrapped phage. Trehalose has a high glass 
transition temperature in its amorphous form, therefore it was a good excipient to use for phage 
encapsulation. For ease of consumption in phage therapy, tablets were produced from dry powder 
phage. Addition of lubricating and binding agents is common practice in tablet production therefore; 
magnesium stearate was added to improve tablet disintegration and friability. No effect of magnesium 
stearate on phage viability was observed indicating that dry powder phage products can be tableted, 
and blister packed for manufacture and shipment. Although further work to improve tablet friability 
is required, this study marked an important first-step towards designing a process for phage-tablet 
production. Similarly, dry powder phage may be added to animal feed to reduce bacterial loads in 
swine and poultry. Previously, free phage has been reported to reduce bacterial load in farm animals 
(R. J. Atterbury et al., 2007; Robert J. Atterbury et al., 2005) however by administering encapsulated 
phage a higher phage titre will be delivered to the lower GI-tract allowing for better biocontrol (Yin-
hing Ma et al., 2014). 
Long-term phage storage was aided by the presence of trehalose in the formulation, no loss in phage 
was observed for powders stored at 4°C but at 30°C with 65 % RH significant loss in phage titre was 
observed. Transportation of phage products to developing countries may result in exposure to 
elevated temperatures and humidity which can affect phage viability and dosing. To avoid significant 
losses in phage titre, concentration of excipients such trehalose need to be evaluated to improve 
survivability in more realistic conditions.  
8.1.4 pH responsive delivery of phage in smart wound dressings 
 
Use of Eudragit as a phage carrier was further probed by producing phage encapsulated fibres for 
wound dressings. Chronic wounds require multiple dressings to aid healing or to treat infections 
caused by pathogenic bacteria (Mele, 2016). Phage therapy to treat wound infections has been 
reported (Rose et al., 2014). Previous attempts at electrospinning phage have used polymers such as 
PVP and PVA which exhibit a non-specific release (Koo et al., 2016; R. Korehei & Kadla, 2013; Reza 
Korehei & Kadla, 2014; Salalha et al., 2006). Eudragit fibres encapsulating phage were produced in an 
emulsion electrospinning process using phage K.  
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pH-triggered release of Eudragit fibres ensures that the phage is released in the presence of infection, 
when the pH of infected wound changes from slightly acidic (pH 5.5) (healthy skin) to neutral or even 
alkaline. To ensure a high titre of phage is directly delivered in proximity to the pathogen, fibres with 
large diameter were produced (up to 1 µm) to improve phage encapsulation. Nano-fibres in the region 
of 200 nm expose phage to environmental stresses during encapsulation which can result in low phage 
yield. Morphology of the phage can play a crucial role in determining effective encapsulation since 
tailed phage equal the size of the nano-fibre diameter and cannot be effectively encapsulated. 
The conventional method of directly spraying phage for biocontrol as reviewed by Hussain et al., 
(2017) can have a limited effect. Loss of phage during spraying onto the target area can lessen the 
effect of phage in reducing bacterial load. Similarly, soaking scaffolds in phage suspensions before 
application on wounds can potentially lower phage dosing due to the random distribution of phage, 
leading to ineffective wound healing with possibility of bacteria developing resistance. Targeting 
phage close to the pathogenic bacteria in a wound can help decrease the need for changing dressings 
which can be costly. Phage encapsulation in Eudragit fibres is a promising step forward in exploring 
effective application of phage treatment in wounds.  
 
8.1.5 Contribution to knowledge 
 
This work has formed the first steps in engineering the effective application of phage therapy of 
humans and animals. The formulations explored here are transferable to diverse types of phage, 
although each phage needs to be tested individually for its suitability to the polymers. Encapsulation 
of phage using various techniques has shown the potential use of available technologies in phage 
encapsulation which previously had not been explored. Protection from acidic pH as low as pH 1 has 
been reported for the first time for a period of 2 hours; a crucial step in ensuring phage is protected 
during exposure to stomach pH. Consideration of particle size has been reported and its impact on 
phage protection and release kinetics. Additionally, Ephage-bacterial killing in the presence of 
epithelial cells demonstrated that encapsulation was as effective as free phage in vitro. This study 
forms the basis of several exciting future projects which can enhance the application of phage in 
biocontrol and therapy.  
8.2 Future work 
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This section provides recommendations for future work based on the results obtained in the PhD 
research. 
8.2.1 Microfluidic platforms for phage encapsulation 
 
Further development of the formulation researched here can incorporate the encapsulation of SYBR-
gold labelled phage. This can be a useful tool in studying the distribution of phage in microparticles. 
Release of phage from microparticles during dissolution could be followed using labelled or 
fluorescent phage to gain a better insight into release kinetics. Changing from a 2-phase capillary 
system to a 3-phase may be beneficial as the phage can be introduced through the most inner capillary 
whilst the polymer solutions engulfs this phase during drop formation in oil phase. This method will 
ensure the phage does not get exposure to any acid in the oil phase and avoid the loss of any phage 
viability during this process. Furthermore, phage will be entrapped within the core of the microparticle 
which can improve the acid protection in SGF.  
To test the versatility of the process, multiple phages against different pathogenic strains can be 
encapsulated together. This way compatibility of each phage to the formulation can easily be tested 
and changed. Multi-shell microparticles can also be fabricated by producing drop-in-drop emulsions 
where each layer can be stripped off at various stages of the GI-tract. This is especially useful in broilers 
where the pH of the crop is pH 4. Therefore, to prevent dissolution, a sacrificial shell may be 
introduced to avoid premature release. Similarly, alternate polymer drops containing different phage 
may be encapsulated at the same time since each phage may behave differently to the same 
formulation. 
8.2.2 Scale-up of phage encapsulation 
 
To further improve and develop the current ME process, different ME systems can be used such as 
oscillating membrane. Using an oscillating ME system can help gain better control over droplet size by 
avoiding the use of paddle stirrers. Although changes to the current system can also be made by using 
a different metal-film membrane which can offer better surface properties and porosity that may aid 
in the development of monodispersed droplets. Changes to the continuous phase may also prove 
beneficial since the viscosity of the current oil phase is lower than the dispersed phase.  
A continuous ME system may also help in controlling droplet size by shortening the exposure time to 
shear and wetting the membrane surface. In situ crosslinking of droplets can also help achieve better 
control over drop size by preventing the effect of shear breaking droplets further. A drop-in-drop 
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system can also be developed by pre-encapsulation in a primary emulsion which can then be 
emulsified further in a pre-mix membrane procedure. This way protection of phage from acid can 
further be improved since antacid can be co-encapsulated or develop a prolonged release profile by 
incorporating multi-shells.  
8.2.3 Phage release from microparticles 
 
Currently, pH 5, 6 and pH 7 (SIF) have been reported for phage release, this can be further studied by 
testing exposure of phage for various times to better understand the properties of microparticle 
dissolution. Similarly, pH 3, 4 can also be tested since in vivo there is a gradual rise in pH. Overall, a 
gut model with varying pH compartments in the presence of pathogenic bacteria and microflora will 
prove beneficial in understand the effects of phage encapsulation on phage therapy. This will offer a 
useful insight into further improvements needed to deliver the correct dose of phage at the correct 
time to effectively arrest bacterial growth.  
Ex vivo models such as the one studied here, could be probed further in exploring the release of 
inflammatory cytokines in the presence of bacteria and phage. This will ensure there are no side 
effects and toxicity from both the phage and the poylymer used for encapsulation. Animal studies as 
the next step could be used to study the transit and deposition of these particles in vivo, which can 
provide information for further improvement in specifically targeting encapsulated phage at the site 
of infection. This could mean incorporating mucoadhesive properties of microparticles to help retain 
them at specific site for longer periods. 
8.2.4 Storage of encapsulated phage 
 
Current results show that Ephage is stable for long periods at 4˚C as opposed to elevated 
temperatures. Incorporation of trehalose has aided this however further investigation is required to 
improve storage stability of phage at higher relative humidity’s. To investigate this, dry phage powder 
can be stored at varying degrees of temperature and humidity to identify the threshold of trehalose 
as a protective agent. This will enable for a better formulation development during spray drying of 
phage and tableting. Different types of binder could be used to improve the disintegration and 
friability of the tablets so as to meet he British Pharmacopeia (BP) standard or solid dosage forms. 
8.2.5 Electrospinning phage 
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Production of defect-free Eudragit fibres encapsulating phage K was demonstrated in this work. The 
use of emulsion electrospinning proved to be a successful method for the production of Eudragit 
fibres. To further improve upon this strategy, co-axial electrospinning can be used to avoid the need 
for emulsion where phage is suspended in an organic solvent. Fibres produced via electrospinning 
offer a further advantage since the phage will be introduced in the core of the fibre, preventing 
exposure to high voltage.  
Cryo-TEM can be a useful tool in determining the deposition of encapsulated phage in both fibres 
and microparticles.  This enables, evaluation of the current encapsulation system which can be 
improved for better phage encapsulation.  
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c) Or Termination 
 
 
 
 
Figure 9.1. Chemical reactions that occur during formation of polymer, polyethylene. During initiation 
(a) a hydrogen peroxide free radical activated a monomer (ethane) by opening the double bond 
between two carbons. This triggers the propagating step (b) an unstable monomer activates other 
monomers forming a chain of saturated polymer. Termination is when the reaction stops (c) by coming 
together of two unstable monomers. The two radicals react with each other and form a stable subunit 
and no further reaction takes place.   
 
 
 
 
 
Figure 9.2. Chitosan chemical structure 
 
 
 
 
 
Figure 9.3. Pectin chemical structure 
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Figure 9.4 Guar gum chemical structure 
 
 
 
 
 
Figure 9.5 Alginate chemical structure 
 
 
 
 
 
 
Figure 9.6 Poly lactic-co-glycolic acid chemical structure 
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Figure 9.7 Coulter LS series instrument set up 
 
Method 9.1 FAS Coating  
 
Procedure 
(Using chloroform as solvent) 
“FAS coating solution” 
To prepare this solution prior to start clean procedure in order to give time for the diffusion of FAS. 
To add 1 mL of FAS in 114 mL of chloroform. 10-2 M FAS 
Clean the membrane according to the following steps: 
1. Alkali clean (4M NaOH), 1 minutes in US bath with 5 minutes soak 
2. Tap water rinse, place into distilled water, 1 minute in US bath 
3. Acid clean (10% HCl), 1 minutes in US bath with 5 minutes soak 
4. Tap water rinse, place into distilled water, 1 minute in US bath 
5. Dry 
Coating the membrane according to the following steps: 
1. To put about 40 mL of FAS solution into a beaker of 100 mL. 
2. To place the cleaned membrane into the beaker. (Check if there are no air bubbles, at the 
membrane surface). 
3. A total soaking of at least 2 days is recommended plus 3 minutes initially in the US bath. 
4. Seal the beakers with (kitchen) plastic film. 
5. Dry and then ready to use. 
(It was observed that is possible to reuse the FAS solution at least 1 time) 
The FAS used is: 1H, 1H, 2H, 2H-Perfluorodecyltriethoxysilane. This chemical was purchased from 
Fluorochem®. 
Procedure 
(Using undecane as solvent) 
“FAS coating solution” 
To prepare this solution prior to start clean procedure in order to give time for the diffusion of FAS. 
To add 1 mL of FAS in 114 mL of undecane. 10-2 M FAS 
Clean the membrane according to the following steps: 
1. Alkali clean (4M NaOH), 1 minutes in US bath with 5 minutes soak 
2. Tap water rinse, place into distilled water, 1 minute in US bath 
3. Acid clean (10% HCl), 1 minutes in US bath with 5 minutes soak 
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4. Tap water rinse, place into distilled water, 1 minute in US bath 
5. Dry 
Coating the membrane according to the following steps: 
1. To put about 40 mL of FAS solution into a beaker of 100 mL. 
2. To place the cleaned membrane into the beaker. (Check if there is no air bubbles, at the 
membrane surface). 
3. Seal the beakers with (kitchen) plastic film. 
4. Ultra-sonication for (min) 3 minutes. 
5. Place the beaker in a bath at 45 degrees for at least 16 hours. 
6. Rinse the membrane with acetone. 
7. Dry and then ready to use. 
(It was observed that is possible to reuse the FAS solution at least 2 times) 
The FAS used is: 1H, 1H, 2H, 2H-Perfluorodecyltriethoxysilane. This chemical was purchased from 
Fluorochem®. 
 
 
Figure 9.8 Conversion from volts to rad s-1 for paddle stirrer in dispersion cell obtained using 
Tachometer readings. 
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Figure 9.9 Salmonella enteric ATCC 19585 growth curve. 
 
 
Figure 9.10 Phage growth curve with CFU counts (file name- 2 Felix 01 adsorption for 8 hours with 
CFU counts 14th Nov 16) 
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Figure. 9.11 Felix 01 phage adsorption assay 
 
 
 
Figure 9.12 EV36 growth curve, OD and CFU counts over 9 hours. 
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Figure 9.13 SEM of nickel 20 µm pore size membrane. 
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Figure 9.14 Spray drying equipment for Felix O1 encapsulation in different excipients. The polymer 
solution with phage is delivered from the container via a peristaltic pump to an inlet at the top of the 
spray dryer (blue arrows). The liquid feed travelled through a small diameter nozzle which was 
surrounded by an outer tube delivering compressed air causing the liquid feed to be atomised into 
the drying chamber. The liquid evaporates, leaving powder which is flown (red arrows) by the cyclone 
and collected in a bottle.  
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Table 9.1. Summary of p-values (2-sample t-test for means) for free phage K1F exposure to different 
pH 
Time / hrs pH2.5 pH3 pH4 pH5 pH6 
0 0.007 0.012* 0.667 0.139 0.338 
0.5 - 0.034* 0.184 0.116 0.111 
1 - 0.004* 0.007* 0.646 0.219 
3 - 0.022* 0.070 1.000 1.000 
6 - 0.026* 0.070 0.800 1.000 
24 - 0.021* 0.114 0.159 1.000 
Notes: * indicates reported mean values at time point are different compared with pH7 sample are 
different p < 0.05 indicates rejection of null hypothesis;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.15 Minipress MII for tableting spray dried powder. 
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Figure 9.16 Erweka tablet disintegration system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.17 Erweka tablet friability tester 
 
